drug_ID	drug_Name	drug_Name_Show	Drug_Type	Synonym	Therapeutic_target_ID	drug_target_name	drug_target_Uniprot_ID	PubChem_CID	ttd_id	drugbank_id	chemble_id
DRG00001	Brimonidine	Brimonidine	Eye pressure lowering drugs	"brimonidine; 59803-98-4; UK 14,304; Bromoxidine; 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine; 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine; brimonidinum; 5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline; UK-14304; 6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-; brimonidina; AGN 190342; E6GNX3HHTE; UNII-E6GNX3HHTE; UK 14304; NSC-318825; BRN 0751629; CHEBI:3175; MLS000069370; AGN-190342 FREE BASE; LK 14304-18; UK-1430418 FREE BASE; MFCD00153878; CHEMBL844; SMR000058355; DTXSID3045221; Brimonidine (INN); NSC 318825; NCGC00016069-09; UK14,304; UK 14304;AGN190342; BRIMONIDINE [INN]; UK 14304 (tartrate);AGN190342 (tartrate); 5-Bromo-N-(2-imidazolin-2-yl)-6-quinoxalinamine; DTXCID1025221; Brimonidine [INN:BAN]; 6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-, (S-(R*,R*))-2,3-dihydroxybutanedioate (1:1); CAS-59803-98-4; SR-01000000023; AGN-190342; Brimodine; 5-bromo-6-(imidazolidinylideneamino)quinoxaline; UK14304; Tocris-0425; [3H]-UK14304; Opera_ID_612; Lopac-U-104; BRIMONIDINE [MI]; brimonidine (UK14304); BRIMONIDINE [VANDF]; cid_2435; Lopac0_001216; SCHEMBL24670; BRIMONIDINE [WHO-DD]; GTPL520; MLS001076349; BIDD:GT0649; GTPL5386; BDBM34572; [3H]brimonidine (UK14304); D11AX21; S01EA05; XYLJNLCSTIOKRM-UHFFFAOYSA-N; HMS3259P09; HMS3263D14; HMS3266O03; HMS3411K05; HMS3675K05; HMS3887K07; AMY22318; BCP12632; EX-A5415; HY-B0659; Tox21_110299; Tox21_501216; AC-162; NSC318825; PDSP1_000640; PDSP2_000635; s9508; AKOS005267239; Brimonidine;AGN190342;UK14304; Tox21_110299_1; CCG-205290; DB00484; GS-3236; LP01216; NC00638; SDCCGSBI-0051183.P002; MRF-0000657; NCGC00016069-01; NCGC00016069-02; NCGC00016069-03; NCGC00016069-04; NCGC00016069-05; NCGC00016069-06; NCGC00016069-07; NCGC00016069-08; NCGC00016069-10; NCGC00016069-11; NCGC00016069-12; NCGC00016069-13; NCGC00016069-24; NCGC00023468-02; NCGC00023468-04; NCGC00023468-05; NCGC00023468-06; NCGC00023468-07; NCGC00261901-01; SY053060; Brimonidine 100 microg/mL in Acetonitrile; B4132; EU-0101216; FT-0650586; NS00006954; EN300-50880; UK 14304-18; C07886; C75796; D07540; 5-bromo-6-(2-imidazolidinylidenamino)quinoxaline; 5-bromo-6-(2-imidazolin-2-ylamino) quinoxaline; 5-Bromo-6-(2-imidazolin-2-ylamino)-quinoxaline; 6-Quinoxalinamine,5-dihydro-1H-imidazol-2-yl)-; A832477; L000615; Q577377; SR-01000000023-2; SR-01000000023-4; BRD-K68264559-001-10-0; 5-Bromo-N-(4,5-dihydro-2-imidazolyl)quinoxalin-6-amine; Z608061562; (5-Bromo-quinoxalin-6-yl)-(4,5-dihydro-1H-imidazol-2-yl)-amine; 5-bromanyl-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine; 5-BROMO-6-(2-IMIDAZOLIN-2-YLAMINO)QUINOXALINE D-TARTRATE (1:1).; 6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)- (9CI)"	TAR10001	Alpha-2A adrenergic receptor (ADRA2A)	P08913	2435	D0AE3X	DB00484	CHEMBL844
DRG00002	Chlorambucil	Chlorambucil	Cytotoxic drugs	"chlorambucil; 305-03-3; Ambochlorin; Leukeran; Chloroambucil; Chloraminophen; Chlorbutin; Chloraminophene; Chlorobutine; Amboclorin; Ecloril; Chlorbutine; Chlorobutin; Lympholysin; Chlocambucil; Linfolizin; Linfolysin; Elcoril; Phenylbutyric acid nitrogen mustard; Leukersan; Leukoran; Chlorambucilum; NSC-3088; 4-{4-[bis(2-chloroethyl)amino]phenyl}butanoic acid; Benzenebutanoic acid, 4-[bis(2-chloroethyl)amino]-; Cb l348; CB 1348; Phenylbuttersaeure-lost; 4-(4-(Bis(2-chloroethyl)amino)phenyl)butanoic acid; NSC 3088; Rcra waste number U035; NCI-C03485; 4-[p-[Bis(2-chloroethyl)amino]phenyl]butyric acid; N,N-Di-2-chloroethyl-gamma-p-aminophenylbutyric acid; CB-1348; 4-[4-[bis(2-chloroethyl)amino]phenyl]butanoic acid; 4-(Bis(2-chloroethyl)amino)benzenebutanoic acid; p-(N,N-Di-2-chloroethyl)aminophenyl butyric acid; 4-(p-Bis(beta-chloroethyl)aminophenyl)butyric acid; Benzenebutanoic acid, 4-(bis(2-chloroethyl)amino)-; CHEBI:28830; NSC3088; 4-[Bis(2-chloroethyl)aminophenyl]butyric acid; 4-[Bis(2-chloroethyl)amino]benzenebutyric acid; MFCD00021783; 4-[Bis(2-chloroethyl)amino]benzenebutanoic acid; CHEMBL515; 4-(p-(Bis(2-chloroethyl)amino)phenyl)butyric acid; gamma-[p-Di(2-chloroethyl)aminophenyl]butyric acid; MLS000028443; Chloorambucol; Chlorbutinum; DTXSID7020263; Elcorin; 4-(Bis(2-chloroethyl)amino)phenylbutyric acid; NCI-3088; gamma-(p-Di(2-chloroethyl)aminophenyl)butyric acid; Butyric acid, 4-(p-bis(2-chloroethyl)aminophenyl)-; 18D0SL7309; Kyselina 4-(N,N-bis-(2-chlorethyl)-p-aminofenyl)maselna; NCGC00015199-08; Clorambucile; Clorambucilo; CAS-305-03-3; SMR000058372; Clorambucile [DCIT]; Leukeran tablets; 4-[Bis(2-chloroethyl)amino]phenylbutyric acid; DTXCID30263; 4-(4-[Bis(2-chloroethyl)amino]phenyl)butyric acid; .gamma.-[p-Di(2-chloroethyl)aminophenyl]butyric acid; Butyric acid, 4-[p-[bis(2-chloroethyl)amino]phenyl]-; Chlorambucilum [INN-Latin]; Clorambucilo [INN-Spanish]; p-N,N-Di-(.beta.-chloroethyl)aminophenyl butyric acid; N,N-Di-2-chloroethyl-.gamma.-p-aminophenylbutyric acid; C14H19Cl2NO2; CCRIS 126; Phenylbuttersaeure-lost [German]; HSDB 3026; SR-01000000062; LEUKERAN (TN); 4-[4-[Bis(2-chloroethyl)amino]phenyl]butyric Acid; EINECS 206-162-0; .gamma.-(p-bis(2-chloroethyl)aminophenyl)butyric acid; .gamma.-[p-bis(2-chloroethyl)aminophenyl]butyric acid; 4-(p-Bis(.beta.-chloroethyl)aminophenyl)butyric acid; 4-[p-Bis(.beta.-chloroethyl)aminophenyl]butyric acid; RCRA waste no. U035; Butyric acid, 4-(p-[bis(2-chloroethyl)amino]phenyl)-; BRN 0999011; chlorambucilddv; gamma-(p-Bis(2-chloroethyl)aminophenyl)butyric acid; Chlorambucil [USP:INN:BAN]; AI3-26083; UNII-18D0SL7309; p-(N,N-Di-2-chlorethylaminophenyl)butyric acid; para-(Di(2-chloroethyl)aminophenyl)butyric acid; Chlorambucil,(S); gamma-(p-bis(2-chloroethyl)aminophenyl)butyricacid; Butanoic acid, 4-(bis(2-chloroethyl)amino) benzene; phenyl)butanoic acid; p-N,N-Di-(beta-chloroethyl)aminophenyl butyric acid; Butyric acid, 4-(p-(bis(2-chloroethyl)amino)phenyl); para-N,N-Di(beta-chloroethyl)aminophenyl butyric acid; N,N-Di-2-chloroethyl-gamma-para-aminophenyl butyric acid; Opera_ID_51; Spectrum_000118; Kyselina 4-(N,N-bis-(2-chlorethyl)-p-aminofenyl)maselna [Czech]; Prestwick0_001079; Prestwick1_001079; Prestwick2_001079; Prestwick3_001079; Spectrum2_000065; Spectrum3_000336; Spectrum4_000273; Spectrum5_000677; CHLORAMBUCIL [MI]; Lopac-C-0253; CHLORAMBUCIL [INN]; CHLORAMBUCIL [JAN]; Epitope ID:139977; CHLORAMBUCIL [HSDB]; CHLORAMBUCIL [IARC]; SCHEMBL4308; CHLORAMBUCIL [VANDF]; Chlorambucil with impurity G; Lopac0_000227; WLN: QV3R DN2G2G; BSPBio_001098; BSPBio_001971; CHLORAMBUCIL [MART.]; KBioGR_000766; KBioSS_000558; 4-14-00-01715 (Beilstein Handbook Reference); MLS001076130; CHLORAMBUCIL [USP-RS]; CHLORAMBUCIL [WHO-DD]; CHLORAMBUCIL [WHO-IP]; DivK1c_000688; SPECTRUM1500171; Chlorambucil (JAN/USP/INN); SPBio_000249; SPBio_002999; BPBio1_001208; GTPL7143; HMS502C10; KBio1_000688; KBio2_000558; KBio2_003126; KBio2_005694; KBio3_001191; NINDS_000688; CHLORAMBUCIL [ORANGE BOOK]; Chlorambucil for system suitability; HMS1571G20; HMS1920M15; HMS2090M19; HMS2091A22; HMS2098G20; HMS2235A04; HMS3259I10; HMS3372O04; HMS3652P08; Pharmakon1600-01500171; 4-(4-(bis(2-chloroethyl)amino); CHLORAMBUCIL [EP MONOGRAPH]; AMY33445; BCP28394; CHLORAMBUCIL [USP MONOGRAPH]; Tox21_110096; Tox21_201390; Tox21_302996; BDBM50003677; CCG-39872; NSC756674; s4288; CHLORAMBUCILUM [WHO-IP LATIN]; AKOS024319346; Tox21_110096_1; Chlorambucil, purum, >=98.0% (T); CS-3118; DB00291; GS-6200; LP00227; NC00555; NSC-756674; SDCCGSBI-0050215.P005; IDI1_000688; NCGC00015199-01; NCGC00015199-02; NCGC00015199-03; NCGC00015199-04; NCGC00015199-05; NCGC00015199-06; NCGC00015199-07; NCGC00015199-09; NCGC00015199-10; NCGC00015199-11; NCGC00015199-12; NCGC00015199-13; NCGC00015199-14; NCGC00015199-15; NCGC00015199-16; NCGC00015199-17; NCGC00015199-19; NCGC00015199-20; NCGC00023250-00; NCGC00023250-03; NCGC00023250-04; NCGC00023250-05; NCGC00023250-06; NCGC00023250-07; NCGC00023250-08; NCGC00023250-09; NCGC00023250-10; NCGC00256464-01; NCGC00258941-01; BP-24028; HY-13593; NCI60_002639; SY031075; SBI-0050215.P004; DB-047794; AB00051938; C2939; EU-0100227; FT-0617365; NS00009960; SW197258-4; A18607; C 0253; C06900; D00266; EN300-123640; H10484; AB00051938-14; AB00051938-15; AB00051938_16; Q415939; 4-(4-(Bis(2-chloroethyl)amino)phenyl)butanoicacid; 4[p-Bis(.beta.-chloroethyl)aminophenyl]butyric acid; Butanoic acid, 4-(bis(2-chloroethyl)amino)benzene-; SR-01000000062-2; SR-01000000062-4; SR-01000000062-7; W-106940; .gamma.-(p-bis(2-chloroethyl)aminophenyl)butyricacid; BRD-K29458283-001-04-2; BRD-K29458283-001-05-9; BRD-K29458283-001-17-4; 4-(4-[Bis(2-chloroethyl)amino]phenyl)butanoic acid #; Z1552153009; 4-[4-(N,N-bis(2-chloroethyl)-amino]phenyl)butanoic acid; Chlorambucil, European Pharmacopoeia (EP) Reference Standard; Chlorambucil, United States Pharmacopeia (USP) Reference Standard; Chlorambucil for system suitability, European Pharmacopoeia (EP) Reference Standard"	TAR10002	DNA topoisomerase 2-alpha (TOP2A)	P11388	2708	D0V8QT	DB00291	.
DRG00003	Fluorouracil	Fluorouracil	Cytotoxic drugs	"5-Fluorouracil; fluorouracil; 51-21-8; 5-FU; Fluoroplex; Efudex; Adrucil; Carac; Fluracil; Fluoroblastin; Queroplex; 5-fluoropyrimidine-2,4(1H,3H)-dione; Phthoruracil; Carzonal; Kecimeton; Fluril; Fluracilum; Timazin; Arumel; Efudix; Ulup; 5-Fluoracil; Fluorouracilum; Fluro Uracil; 5 Fluorouracil; 5-Fluoruracil; 5-fluoro-1H-pyrimidine-2,4-dione; Ftoruracil; Fluri; 5-Fluoro-2,4(1H,3H)-pyrimidinedione; Effluderm (free base); Fluorouracilo; Fluroblastin; 5-Fluoropyrimidine-2,4-dione; Efurix; Fluoro-uracile; Fluoro-uracilo; Uracil, 5-fluoro-; Ro 2-9757; 5-Faracil; Cinco FU; Fluorouracile; 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-; 2,4-Dihydroxy-5-fluoropyrimidine; 5-fluoro-uracil; 5-Fluor-2,4-pyrimidindiol; 5-fluoropyrimidine-2,4-diol; 2,4-Dioxo-5-fluoropyrimidine; Fluorouricil; NSC-19893; 5-Fluoropyrimidin-2,4-diol; 5-fluoro uracil; 5-Ftouracyl; 5-Fluoro-2,4-pyrimidinedione; NSC 19893; Fluorouracil Cream; 5-Fluor-2,4-dihydroxypyrimidin; Fluorouracil, 5-; Ro-2-9757; U-8953; Fluorouracilum [INN-Latin]; Fluorouracilo [INN-Spanish]; Fluouracil; CCRIS 2582; Tolak; 191047-65-1; Fluoro Uracil; HSDB 3228; 5-Fluracil; EINECS 200-085-6; FU; 5-Fluor-2,4(1H,3H)-pyrimidindion; UNII-U3P01618RT; 5 FU; 5-fluoro-1,2,3,4-tetrahydropyrimidine-2,4-dione; DTXSID2020634; CHEBI:46345; AI3-25297; U3P01618RT; NSC19893; Ro-29757; 5FU; CHEMBL185; 2,4-Pyrimidinediol, 5-fluoro- (9CI); DTXCID40634; MLS000069498; 191047-64-0; 191115-88-5; Phtoruracil; EC 200-085-6; MFCD00006018; URF; Fluorouracil [USAN:USP:INN:BAN:JAN]; NCGC00015442-02; Effluderm; SMR000038082; Fluorouracile [DCIT]; 5-Fluoracil [German]; 5-Fluoracyl; 5-Fluoruracil [German]; Fluorouracilum (INN-Latin); Fluorouracilo (INN-Spanish); FLUOROURACIL (MART.); FLUOROURACIL [MART.]; 1004-03-1; FLUOROURACIL (USP-RS); FLUOROURACIL [USP-RS]; 5-FLUOROURACIL (IARC); 5-FLUOROURACIL [IARC]; Flurablastin; FLUOROURACIL (EP MONOGRAPH); FLUOROURACIL [EP MONOGRAPH]; FLUOROURACIL (USP MONOGRAPH); FLUOROURACIL [USP MONOGRAPH]; CAS-51-21-8; Fluoroplex (TN); 5-Fluor-2,4-pyrimidindiol [Czech]; Fluorouracil (USAN:USP:INN:BAN:JAN); Adrucil (TN); Carac (TN); FLUCYTOSINE IMPURITY A (EP IMPURITY); FLUCYTOSINE IMPURITY A [EP IMPURITY]; 5-Fluor-2,4-dihydroxypyrimidin [Czech]; SR-01000075881; 5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]; inhibits thymilidate synthetase; AccuSite; 2,4-Dioxo-5-fluoropryimidine; 5-fluorourasil; 5-florouracil; 5-fluorouacil; 5 Fluorouracilum; 5-FU (TN); 1upf; 5F-uracil; U 8953; Fluorouracil; 5-Fluoropyrimidine-2,4(1H,3H)-dione; Flucytosine Imp. A (EP); Flucytosine Impurity A; Adrucil (ICN); 23935-92-4; 2794-13-0; Adrucil (Fluorouracil); Spectrum_000841; Opera_ID_134; 5-Fluorouracil, 99%; Spectrum2_000076; Spectrum3_000434; Spectrum4_000557; Spectrum5_000718; WLN: T6MVMVJ EF; FLUOROURACIL [MI]; Lopac-F-6627; F0151; 5-Fluorouracil (5-FU); FLUOROURACIL [INN]; FLUOROURACIL [JAN]; UPCMLD-DP130; F 6627; FLUOROURACIL [HSDB]; FLUOROURACIL [USAN]; SCHEMBL3646; 5-fluorpyrimidin-2,4-diol; FLUOROURACIL [VANDF]; Folfox component fluorouracil; Lopac0_000536; BSPBio_002048; FLUCYTOSINE IMPURITY A; KBioGR_001253; KBioSS_001321; 2(1H)-Pyrimidinone, 5-fluoro-4-hydroxy- (9CI); 4(3H)-Pyrimidinone, 5-fluoro-2-hydroxy- (9CI); MLS002415705; DivK1c_000054; FLUOROURACIL [WHO-DD]; FLUOROURACIL [WHO-IP]; SPECTRUM1500305; SPBio_000291; EMTRICITABINE IMPURITY F; 5-fluoro-2,4-dioxo-pyrimidin; 5-fluoro-pyrimidine-2,4-diol; GTPL4789; UPCMLD-DP130:001; Fluorouracil (JP17/USP/INN); HMS500C16; KBio1_000054; KBio2_001321; KBio2_003889; KBio2_006457; KBio3_001268; 5-Fluoro-2,3H)-pyrimidinedione; 5-FLUOROURACIL [WHO-IP]; L01BC02; 2,4-Pyrimidinedione, 5-fluoro-; NINDS_000054; BCPP000428; FLUOROURACIL [ORANGE BOOK]; HMS1920O18; HMS2090I04; HMS2091F19; HMS3259O03; HMS3261L13; HMS3654K22; HMS3715H03; HMS3865L03; Pharmakon1600-01500305; 5-Fluorouracil, analytical standard; BCP02083; 2,3H)-Pyrimidinedione, 5-fluoro-; Fluorouracil (5-Fluoracil, 5-FU); Fluorouracil (5-Fluoracil; 5-FU); Tox21_110150; Tox21_202335; Tox21_300112; Tox21_500536; BDBM50340677; CCG-39879; DL-399; NSC757036; NSC816997; s1209; STK297802; STL367375; 5-FLUOROURACIL, [2-14C]; 5-FLUOROURACIL, [6-3H]-; FLUOROURACILUM [WHO-IP LATIN]; AKOS000119162; AKOS003237897; AKOS008044307; Tox21_110150_1; BCP9000239; CS-0993; DB00544; KS-5129; LP00536; NC00454; NSC-757036; NSC-816997; SDCCGSBI-0050519.P005; FLUCYTOSINE IMPURITY A [WHO-IP]; IDI1_000054; NCGC00015442-01; NCGC00015442-03; NCGC00015442-04; NCGC00015442-05; NCGC00015442-06; NCGC00015442-07; NCGC00015442-08; NCGC00015442-09; NCGC00015442-10; NCGC00015442-11; NCGC00015442-12; NCGC00015442-15; NCGC00015442-16; NCGC00015442-24; NCGC00015442-30; NCGC00091349-01; NCGC00091349-02; NCGC00091349-03; NCGC00091349-04; NCGC00091349-05; NCGC00091349-07; NCGC00091349-08; NCGC00254023-01; NCGC00259884-01; NCGC00261221-01; 5-Fluoro-2,4(1H, 3H)-pyrimidinedione; 5-Fluoropyrimidine-2,4-(1H,3H)-dione; AC-11201; BF166014; EMTRICITABINE IMPURITY F [WHO-IP]; HY-90006; NCI60_001652; SRI-10792-04; SRI-10792-05; SRI-10792-06; SRI-10792_07; SRI-10792_08; 5-Fluoro-1H-pyrimidine-2,4-dione(5FU); 5-Fluorouracil, >=99% (HPLC), powder; SBI-0050519.P004; 2(1H)-Pyrimidinone, 5-fluoro-4-hydroxy-; 4(3H)-Pyrimidinone, 5-fluoro-2-hydroxy-; 5-Fluoro-1H-pyrimidine-2,4-dione(5-FU); DB-051923; DB-065735; DB-268958; DB-272209; DB-297613; pyrimidine-2,4(1H,3H)-dione, 5-fluoro-; 5-Fluoro-1H-pyrimidine-2,4-dione (5-FU); A7567; AM20100252; EU-0100536; FT-0601511; FT-0668745; FT-0695666; FT-0695667; FT-0707652; NS00000337; SW199617-3; 5-Fluoro-1H-pyrimidine-2,4-dione(5-FUra); 5-FLUOROPYRIMIDIN-2,4(1H,3H)-DIONE; EN300-33909; Fluorouracil, meets USP testing specifications; C07649; D00584; 5-Fluorouracil, Vetec(TM) reagent grade, >=99%; Q238512; W-60379; (5-fluorouracil)5-Fluoro-1H-pyrimidine-2,4-dione; 5-Fluoro-1H-pyrimidine-2,4-dione(5-fluoro uracil); SR-01000075881-1; SR-01000075881-3; SR-01000075881-5; W-202929; 5-Fluoro-1H-pyrimidine-2,4-dione (5-Fluorouracil); BRD-K24844714-001-02-1; 5-FLUOROPYRIMIDIN-2,4(1H,3H)-DIONE [WHO-IP]; Z275128052; 5-Fluoro-1H-pyrimidine-2,4-dione(5-fluorouracil)(5-FU); 5-Fluorouracil, certified reference material, TraceCERT(R); Fluorouracil, British Pharmacopoeia (BP) Reference Standard; Fluorouracil, European Pharmacopoeia (EP) Reference Standard; Fluorouracil, United States Pharmacopeia (USP) Reference Standard; pyrimidine antimetabolite: inhibits nucleic acid replication; tetratogen; Fluorouracil, Pharmaceutical Secondary Standard; Certified Reference Material; InChI=1/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9"	TAR10006	Thymidylate synthase (TYMS)	P04818	3385	D05LEO	DB00544	CHEMBL185
DRG00004	Gemfibrozil	Gemfibrozil	Blood liquid regulation drugs	"gemfibrozil; 25812-30-0; 5-(2,5-Dimethylphenoxy)-2,2-dimethylpentanoic acid; Lopid; Jezil; Lipur; Cholespid; Fibratol; Fibrocit; Gemfibril; Gemfibromax; Gemlipid; Hipolixan; CI-719; Gemfibrozilo; Gemfibrozilum; Renabrazin; Clearol; Elmogan; Fetinor; Gemnpid; Innogen; Ipolipid; Lanaterom; Lifibron; Lipigem; Lipizyl; Micolip; Normolip; Progemzal; Reducel; Regulip; Sinelip; Synbrozil; Taborcil; Tentroc; Brozil; Gozid; Hidil; Lipira; Gemd; Gevilon Uno; WL-Gemfibrozil; Gen-Fibro; Pentanoic acid, 5-(2,5-dimethylphenoxy)-2,2-dimethyl-; Low-Lip; Gem-S; Lipozid; 2,2-Dimethyl-5-(2,5-xylyloxy)valeric acid; 2,2-Dimethyl-5-(2,5-xylyloxy)valeriansaeure; Gemfibrozilum [INN-Latin]; Gemfibrozilo [INN-Spanish]; CCRIS 318; 2,2-Dimethyl-5-(2,5-dimethylphenoxy)valeriansaeure; Decrelip; EINECS 247-280-2; NSC-757024; BRN 1881200; Gemfibrozil (Lopid); Valeric acid, 2,2-dimethyl-5-(2,5-xylyloxy)-; Bolutol; CHEBI:5296; Apo-Gemfibrozil; DTXSID0020652; UNII-Q8X02027X3; HSDB 7735; Gemfibrozil (Standard); Gemfibrosil; Lipazil; Litarek; MFCD00079335; Trialmin; Ausgem; Pilder; CHEMBL457; Q8X02027X3; DTXCID20652; MLS000028421; Gemfibrozil [USAN:USP:INN:BAN]; 2,2-Dimethyl-5-(2,5-dimethylphenoxy)pentanoic acid; 5-(2,5-dimethylphenoxy)-2,2-dimethyl-pentanoic acid; NSC 757024; 5-[(2,5-dimethylphenyl)oxy]-2,2-dimethylpentanoic acid; NCGC00016794-09; SMR000058393; Genlip; CAS-25812-30-0; GEMFIBROZIL (IARC); GEMFIBROZIL [IARC]; Gemfibrozilum (INN-Latin); Gemfibrozilo (INN-Spanish); GEMFIBROZIL (MART.); GEMFIBROZIL [MART.]; GEMFIBROZIL (USP-RS); GEMFIBROZIL [USP-RS]; 2,2-DIMETHYL-5-(2,5-XYLYLOXY) VALERIC ACID; GEMFIBROZIL (EP MONOGRAPH); GEMFIBROZIL [EP MONOGRAPH]; Innogem; Gemcor; GEMFIBROZIL (USP MONOGRAPH); GEMFIBROZIL [USP MONOGRAPH]; Gemfibrozil (USAN:USP:INN:BAN); CI 719; Lopid (TN); TEVA-A; SR-01000000056; Gemfibrozil (JAN/USP/INN); Gemfibrozil,(S); 4TX; Prestwick_637; dimethylpentanoic acid; Spectrum_000825; CPD000058393; GEMFIBROZIL [MI]; 114413-98-8; Opera_ID_1658; Prestwick0_000214; Prestwick1_000214; Prestwick2_000214; Prestwick3_000214; Spectrum2_001097; Spectrum3_000440; Spectrum4_000562; Spectrum5_000750; Spectrum5_001991; GEMFIBROZIL [INN]; GEMFIBROZIL [JAN]; GEMFIBROZIL [HSDB]; GEMFIBROZIL [USAN]; GEMFIBROZIL [VANDF]; SCHEMBL4813; BSPBio_000227; BSPBio_002060; GEMFIBROZIL [WHO-DD]; KBioGR_000964; KBioSS_001305; MLS001055364; MLS006011850; DivK1c_000138; SPECTRUM1500313; SPBio_001174; SPBio_002148; BPBio1_000251; GTPL3439; YSSJ5501; Gemfibrozil, analytical standard; Cl-719; HMS500G20; HY-B0258R; KBio1_000138; KBio2_001305; KBio2_003873; KBio2_006441; KBio3_001280; C10AB04; GEMFIBROZIL [ORANGE BOOK]; Gemfibrozil for system suitability; NINDS_000138; HMS1568L09; HMS1920B07; HMS2090K14; HMS2091H11; HMS2095L09; HMS2230H24; HMS3259M12; HMS3655C06; HMS3712L09; Pharmakon1600-10500313; 5-(2,5-dimethylphenoxy)-2,2-; BCP08437; HY-B0258; Tox21_110613; Tox21_201997; Tox21_302784; BBL010807; BDBM50110590; CCG-40111; DL-414; NSC757024; s1729; STK618740; AKOS001606691; Tox21_110613_1; AB03034; AC-4225; DB01241; KS-5192; NC00565; IDI1_000138; NCGC00016794-01; NCGC00016794-02; NCGC00016794-03; NCGC00016794-04; NCGC00016794-05; NCGC00016794-06; NCGC00016794-07; NCGC00016794-08; NCGC00016794-10; NCGC00016794-11; NCGC00016794-13; NCGC00016794-14; NCGC00022722-03; NCGC00022722-04; NCGC00022722-05; NCGC00022722-06; NCGC00022722-07; NCGC00256601-01; NCGC00259546-01; SY052512; Gemfibrozil 100 microg/mL in Acetonitrile; SBI-0051391.P003; 2,2-Dimethyl-5-(2,5-zlyloxy)valeric acid; AB00052003; CS-0694895; FT-0626641; FT-0700924; G0368; NS00010281; SW196802-3; 2,2-Dimethyl-5-(2,5-xylyloxy)valeriansaure; EN300-97098; C07020; D00334; D83091; AB00052003-15; AB00052003-16; AB00052003_17; AB00052003_18; A818037; Q384295; 2,2-Dimethyl-5-(2,5-dimethylphenoxy)valeriansaure; 2,2-Dimethyl-5-(2,5-dimethylphenoxy)valeric Acid; 5-(2,5-dimethyphenoxy)-2,2-dimethylpentanoic acid; SR-01000000056-3; SR-01000000056-4; SR-01000000056-6; SR-01000000056-7; W-107216; 2,2-Dimethyl-5-(2,5-dimethylphenoxy)-pentanoic acid; BRD-K11129031-001-05-1; Z1259021151; Gemfibrozil, British Pharmacopoeia (BP) Reference Standard; Gemfibrozil, European Pharmacopoeia (EP) Reference Standard; Gemfibrozil, United States Pharmacopeia (USP) Reference Standard; Gemfibrozil, Pharmaceutical Secondary Standard; Certified Reference Material; Gemfibrozil for system suitability, European Pharmacopoeia (EP) Reference Standard; 2,2-Dimethyl-5-(2,5-dimethylphenoxy)pentanoic acid, 2,2-Dimethyl-5-(2,5-xylyloxy)valeric acid, 5-(2,5-Dimethylphenoxy)-2,2-dimethylpentanoic aci"	TAR10007	Lipoprotein lipase (LPL)	P06858	3463	D05VIX	DB01241	CHEMBL457
DRG00005	Primaquine	Primaquine	Antimalarial drug	"PRIMAQUINE; 90-34-6; Primachin; Neo-Quipenyl; 8-(4-Amino-1-methylbutylamino)-6-methoxyquinoline; Primaquin; Primachinum; Primaquinum; Primaquina; Kanaprim; Primachina; (+/-)-Primaquine; 1,4-Pentanediamine, N4-(6-methoxy-8-quinolinyl)-; Maliride; SN 13,272; 6-Methoxy-8-(4-amino-1-methylbutylamino)quinoline; Primaquinum [INN-Latin]; Primaquina [INN-Spanish]; 4-N-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; N-(5-aminopentan-2-yl)-6-methoxyquinolin-8-amine; NSC 27296; CCRIS 4109; CHEBI:8405; S. N. 13272; HSDB 6516; 8-((4-Amino-1-methylbutyl)amino)-6-methoxyquinoline; EINECS 201-987-2; UNII-MVR3634GX1; NSC-27296; Primaquine (INN); WR 2975; MVR3634GX1; N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine; Quinoline, 8-(4-amino-1-methylbutylamino)-6-methoxy; WR-2975; SN-13272; DTXSID8023509; N-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; (+)-Primaquine; (-)-Primaquine; NSC27296; N(4)-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; 1,4-Pentanediamine, N(4)-(6-methoxy-8-quinolinyl)-; 8-[(4-Amino-1-methylbutyl)amino]-6-methoxyquinoline; Quinoline, 8-(4-amino-1-methylbutylamino)-6-methoxy-; N-[(S)-4-Amino-1-methylbutyl]-6-methoxy-8-quinolinamine; Quinoline, 8-((4-amino-1-methylbutyl)amino)-6-methoxy-; Primachina [DCIT]; dl-Primaquine; PRIMAQUINE [INN]; Primaquinum (INN-Latin); Primaquina (INN-Spanish); Primaquine [INN:BAN]; BRN 0019337; Maliride; NSC 27296; Neo-Quipenyl; Primachin; N4-(6-methoxy-8-quinolyl)pentane-1,4-diamine; 6-Methoxy-8-[(4-amino-1-methylbutyl)amino]quinoline; N~4~-[6-(methyloxy)quinolin-8-yl]pentane-1,4-diamine; CHEMBL506; MLS001334045; Kanaprim (TN); n4-[6-methoxy-8-quinolinyl]-1,4-pentanediamine; 4-22-00-05817 (Beilstein Handbook Reference); NCGC00178754-06; N~4~-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; SMR000875314; 6-Methoxy-8-((4-amino-1-methylbutyl)amino)quinoline; Quinoline, 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-; (RS)-primaquine; TG1-296; TG1-297; Spectrum_000830; PRIMAQUINE [MI]; Prestwick0_000476; Prestwick1_000476; Prestwick2_000476; Prestwick3_000476; Spectrum2_000887; Spectrum3_000552; Spectrum4_000484; Spectrum5_001363; PRIMAQUINE [VANDF]; Epitope ID:131792; PRIMAQUINE [WHO-DD]; Oprea1_546209; SCHEMBL22207; BSPBio_000612; BSPBio_002223; KBioGR_000967; KBioSS_001310; 4-amino-1-methylbutyl(6-methoxy-8-quinolyl)amine; DivK1c_000806; SPBio_000674; SPBio_002551; (+)-N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine; (-)-N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine; BPBio1_000674; cid_359247; DTXCID903509; GTPL9952; BDBM71542; KBio1_000806; KBio2_001310; KBio2_003878; KBio2_006446; KBio3_001723; P01BA03; NINDS_000806; HMS2090J17; BCP29271; BBL011330; HY-12651A; MFCD00598906; STL146416; 1, N4-(6-methoxy-8-quinolinyl)-; AKOS005721199; DB01087; WLN: T66 BNJ HO1 JMY1&3Z; IDI1_000806; SMP1_000263; NCGC00178754-01; NCGC00178754-02; NCGC00178754-03; AC-23007; AS-30679; NCI60_001035; NCI60_005887; SBI-0051491.P003; AB00053529; CS-0013754; NS00000469; C07627; D08420; EN300-144245; AB00053529-11; AB00053529_12; AB00053529_14; N-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine; A843518; N4-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; Q419834; BRD-A55913614-316-06-2; SR-05000001864-11; N4-(6-methoxy-8-quinolyl)pentane-1,4-diamine;Primaquine; N4-(6-Methoxyquinolin-8-yl)pentane-1,4-diamine (2 H3PO4); N4-(6-methoxy-8-quinolinyl)pentane-1,4-diamine;phosphoric acid; N4-(6-methoxyquinolin-8-yl)pentane-1,4-diamine;phosphoric acid; (4-amino-1-methyl-butyl)-(6-methoxy-8-quinolyl)amine;phosphoric acid"	TAR10015	Plasmodium Deoxyribonucleic acid (Malaria DNA)	.	4908	D0T1LK	DB01087	CHEMBL506
DRG00006	Protoporphyrin IX	Protoporphyrin IX	Antiviral drugs	"protoporphyrin IX; protoporphyrin; 553-12-8; Ooporphyrin; Protoporpyrin IX; Protoporphyrin IX disodium; Porphyrinogen IX; Kammerer's prophyrin; H2ppIX; Kammerer's porphyrin; MLS001074731; 3-[18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid; CHEBI:15430; NSC2632; NSC-2632; 3,7,12,17-Tetramethyl-8,13-divinyl-2,18-porphinedipropionic acid; SMR000127405; 21H,23H-Porphine-2,18-dipropanoic acid, 7,12-diethenyl-3,8,13,17-tetramethyl-; CHEMBL267548; 21H,23H-Porphine-2,18-dipropanoic acid,7,12-diethenyl-3,8,13,17-tetramethyl-; 3,3'-(3,7,12,17-Tetramethyl-8,13-divinylporphine-2,18-diyl)di(propionic acid); protoporphyrin ix containing fe; C2K325S808; 2,18-Porphinedipropionic acid, 3,8,13,17-tetramethyl-7,12-divinyl-; 3,3'-(3,7,12,17-tetramethyl-8,13-divinyl-21H,23H-porphine-2,18-diyl)-bis-propionic acid; ProtoporphyrinIX; 3,7,12,17-tetramethyl-8,13-divinylporphyrin-2,18-dipropanoic acid; 7,12-diethenyl-3,8,13,17-tetramethylporphyrin-2,18-dipropanoic acid; 3,3'-(3,8,13,17-tetramethyl-7,12-divinylporphyrin-2,18-diyl)dipropionic acid; SR-01000076084; NSC 2632; EINECS 209-033-7; UNII-C2K325S808; protoporphyrin-'IX'; Spectrum_001300; Hem; Spectrum2_001016; Spectrum3_001440; Spectrum4_000419; Spectrum5_001303; cid_4971; Lopac0_000973; SCHEMBL25719; BSPBio_003180; KBioGR_000718; KBioSS_001780; Protoporphyrin IX, >=95%; DivK1c_000074; SCHEMBL805850; SPECTRUM1501111; SPBio_001171; PROTOPORPHYRIN IX [MI]; SCHEMBL3287054; PROTOPORPHYRIN [WHO-DD]; CHEMBL1325592; CHEMBL1618319; CHEMBL1907972; CHEMBL1907974; CHEMBL4463327; DTXSID4048353; SCHEMBL14552654; BDBM51757; HMS500D16; KBio1_000074; KBio2_001780; KBio2_004348; KBio2_006916; KBio3_002400; FEDYMSUPMFCVOD-UHFFFAOYSA-N; KSFOVUSSGSKXFI-UHFFFAOYSA-N; KSFOVUSSGSKXFI-UJJXFSCMSA-N; NINDS_000074; OXTIQTUKEUGAPP-UJJXFSCMSA-N; ZCFFYALKHPIRKJ-UHFFFAOYSA-N; HMS1921F05; HMS2271B12; HMS3263C07; Pharmakon1600-01501111; HY-B1247; Tox21_500973; BDBM50523755; CCG-39673; NSC757839; AKOS027320494; CS-4849; DB02285; LP00973; NSC-757839; SDCCGMLS-0066712.P001; SDCCGSBI-0050946.P004; IDI1_000074; NCGC00015844-01; NCGC00015844-02; NCGC00015844-03; NCGC00015844-04; NCGC00015844-05; NCGC00015844-07; NCGC00015844-08; NCGC00015844-12; NCGC00094273-01; NCGC00094273-02; NCGC00094273-03; NCGC00162303-01; NCGC00185010-01; NCGC00261658-01; AS-17461; SBI-0050946.P003; EU-0100973; FT-0696783; protoporphyrin IX [MeSH: protoporphyrin IX]; 2, 3,8,13,17-tetramethyl-7,12-divinyl-; C02191; C75594; P 8293; AB00052204_02; A870226; Q619815; SR-01000763747; SR-01000076084-1; SR-01000076084-4; SR-01000076084-5; SR-01000763747-3; BRD-K26813314-001-04-4; 1,3,5,8-TETRAMETHYL-2,4-DIVINYLPORPHINE-6,7-DIPROPIONATE; 21H,18-dipropanoic acid, 7,12-diethenyl-3,8,13,17-tetramethyl-; 3,3'-(3,7,12,17-tetramethyl-8,13-divinylporphine-2,18-diyl)di; 2,18-Porphinedipropionic acid, 3,8,13,17-tetramethyl-7,12-divinyl- (8CI); 3,3'-(3,7,12,17-tetramethyl-8,13-divinyl-21H,23H-porphine-2,18-diyl)-bis-propionate; 3,3'-(7,12-diethenyl-3,8,13,17-tetramethylporphyrin-2,18-diyl)dipropanoic acid; 3-[(1Z,4Z,9Z,15Z)-18-(2-Carboxy-ethyl)-3,7,12,17-tetramethyl-8,13-divinyl-porphyrin-2-yl]-propionic acid; 3-[(1Z,4Z,9Z,15Z)-18-(2-carboxyethyl)-3,7,12,17-tetramethyl-8,13-divinyl-21,23-dihydroporphyrin-2-yl]propanoic acid; 3-[18-(2-carboxyethyl)-3,7,12,17-tetramethyl-8,13-divinyl-22,23-dihydroporphin-2-yl]propionic acid; 3-[18-(2-carboxyethyl)-3,8,13,17-tetramethyl-7,12-divinyl-21,23-dihydroporphyrin-2-yl]propanoic acid; 3-[8,13-bis(ethenyl)-18-(3-hydroxy-3-oxopropyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid"	TAR10003	Hematopoietic prostaglandin D synthase (HPGDS)	O60760	4971	D0AF3A	DB02285	.
DRG00007	Temozolomide	Temozolomide	Cytotoxic drugs	"temozolomide; 85622-93-1; Methazolastone; Temodar; Temodal; 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; Temozolamide; Sch 52365; CCRG-81045; Temozolomidum [Latin]; Temozolodida [Spanish]; Temozolomidum; CCRG 81045; Sch-52365; NSC 362856; M&B 39831; M&B-39831; NSC-362856; CCRIS 8996; MB 39831; 8-Carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one; M & B 39831; BRN 5547136; M-39831; 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide; 3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide; NSC362856; CHEMBL810; 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide; 3-methyl-4-oxo-3H,4H-imidazo[4,3-d][1,2,3,5]tetrazine-8-carboxamide; MLS002701861; YF1K15M17Y; DTXSID5043714; CHEBI:72564; Mk-7365; 3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide; Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo-; MFCD00866492; TMZ; NCGC00167429-01; Temozolodida; 8-CARBAMOYL-3-METHYLIMIDAZO[5,1-D]-1,2,3,5-TETRAZIN-4(3H)-ONE; DTXCID3023714; C6H6N6O2; 3,4-Dihydro-3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide.; 3-Methyl-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid amide; SMR000466338; Temodal (TN); Temodar (TN); CAS-85622-93-1; Temozolomide, VETRANAL(TM), analytical standard; SR-01000759347; temozolomida; UNII-YF1K15M17Y; Temozolomide (JAN/USAN/INN); Temozolomide [USAN:INN:BAN]; 3,4-Dihydro-3-methyl-4-oxoimidazo[5,1-d]-as-tetrazine-8-carboxamide; 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; IMIDAZO(5,1-D)-1,2,3,5-TETRAZINE-8-CARBOXAMIDE, 3,4-DIHYDRO-3-METHYL-4-OXO-; TEMOZOLIMIDE; Temozolomide- Bio-X; TEMOZOLOMIDE [MI]; TEMOZOLOMIDE [INN]; TEMOZOLOMIDE [JAN]; Temodar (TN) (Schering); TEMOZOLOMIDE [USAN]; SCHEMBL3739; 4-methyl-5-oxo-2,3,4,6,8-pentazabicyclo[4.3.0]nona-2,7,9-triene-9-carboxamide; TEMOZOLOMIDE [VANDF]; TEMOZOLOMIDE [MART.]; MLS000759447; MLS001424028; BIDD:GT0204; TEMOZOLOMIDE [USP-RS]; TEMOZOLOMIDE [WHO-DD]; GTPL7301; TEMOZOLOMIDE [EMA EPAR]; Temozolomide, >=98% (HPLC); GLXC-02560; HMS2051O12; HMS2090B08; HMS2232N13; HMS3264I14; HMS3269P05; HMS3372K13; HMS3393O12; HMS3413D06; HMS3654N05; HMS3677D06; HMS3713H16; Pharmakon1600-01502289; TEMOZOLOMIDE [ORANGE BOOK]; TEMOZOLOMIDE [EP MONOGRAPH]; 3-methyl-4-oxo-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; ALBB-021358; BCP03692; TEMOZOLOMIDE [USP MONOGRAPH]; Tox21_112433; AC-758; BDBM50034562; DL-190; NSC759883; s1237; STK623541; 3-Methyl-4-oxo-3,4-dihydroimidazo-[5,1-d][1,2,3,5]tetrazine-8-carboxamide; 3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide; AKOS005557098; Tox21_112433_1; CCG-100870; CS-0943; DB00853; KS-1216; NC00120; NSC-759883; Imidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo-; NCGC00167429-02; NCGC00167429-04; NCGC00167429-05; BP-25388; BT164447; HY-17364; NCI60_003316; BCP0726000154; Temozolomide 100 microg/mL in Acetonitrile; AM20110227; FT-0630936; FT-0674845; NS00004198; SW197500-4; T2744; D06067; EN300-122324; AB00639915-06; AB00639915-08; AB00639915-09; AB00639915_10; AB00639915_11; A841386; Q425088; Q-201786; SR-01000759347-4; SR-01000759347-5; BRD-K32107296-001-04-5; Z1201620684; 3-methyl-4-oxo-8-imidazo[5,1-d][1,2,3,5]tetrazinecarboxamide; Temozolomide, United States Pharmacopeia (USP) Reference Standard; 3-methyl-4-oxidanylidene-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; 3-METHYL-4-OXO-8-IMIDAZOLO[5,1-D][1,2,3,5]TETRAZINECARBOXAMIDE; 3-Methyl-8-aminocarbonyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one; Imidazo[5,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo-; {Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide,} 3, 4-dihydro-3-methyl-4-oxo-; Temozolomide, Pharmaceutical Secondary Standard; Certified Reference Material; 3-Methyl-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid amide (Temozolomide); 3-Methyl-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid amide(Temozolomide)"	TAR10016	Human Deoxyribonucleic acid (hDNA)	.	5394	D0C8EU	DB00853	.
DRG00008	Dexamethasone	Dexamethasone	Glucocorticoids	"dexamethasone; 50-02-2; Decadron; Maxidex; Dexamethazone; Hexadecadrol; Dexasone; Hexadrol; Aeroseb-Dex; Fluormethylprednisolone; Desametasone; Superprednol; Visumetazone; Cortisumman; Decaderm; Decaspray; Dexacortal; Dexacortin; Gammacorten; Millicorten; Oradexon; Auxiron; Calonat; Dexason; Dexone; Dectancyl; Deltafluorene; Desamethasone; Desameton; Fortecortin; Mediamethasone; Mymethasone; Decalix; Dekacort; Dexacort; Dexameth; Dinormon; Loverine; Luxazone; Azium; Dexa-Scheroson; Prednisolone F; Dexa-sine; Isopto-Dex; Aeroseb-D; Anaflogistico; Aphtasolon; Decacortin; Decasone; Dergramin; Desadrene; Deseronil; Dexadeltone; Dexafarma; Dexalona; Dexapolcort; Dexinolon; Dexinoral; Dextelan; Policort; Spoloven; Corsone; Deronil; Dexapos; Mexidex; Sunia Sol D; Bisu DS; Dexa Mamallet; Dexa-Cortidelt; Dexa-Cortisyl; Prednisolon F; Lokalison F; Ocu-trol; Dex-ide; SK-Dexamethasone; Dexamethasonum; Dexaprol; Fluormone; Decagel; Dexone 4; Hexadrol Elixir; Pet Derm III; Dexamethasone Intensol; Hl-dex; Methylfluorprednisolone; Dexone 0.5; Dexone 1.5; Dexametasona; Fluorocort; Decaject; Decameth; Dexone 0.75; Dexpak; Dxms; Dexamethasone alcohol; Hexadrol Tablets; Desametasone [DCIT]; Decacort; Dexamonozon; Dextenza; Turbinaire; Ozurdex; 9alpha-Fluoro-16alpha-methylprednisolone; Dexametasona [INN-Spanish]; Dexamethasonum [INN-Latin]; Dezone; Decadron Tablets, Elixir; Azium (Veterinary); Dexametasone; Dexamethansone; Adexone; Osurdex; Posurdex; Dexycu; DexaSite; OTO-104; Corson; 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol; 16alpha-Methyl-9alpha-fluoroprednisolone; (3H)-Dexamethasone; Azimycin (Veterinary); delta1-9alpha-Fluoro-16alpha-methylcortisol; MK 125; NSC 34521; 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone; Naquasone (Veterinary); Tresaderm (Veterinary); CCRIS 7067; Diodex; DTXSID3020384; HSDB 3053; ISV-305; (11beta,16alpha)-9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; Zema-Pak; 16-alpha-Methyl-9-alpha-fluoroprednisolone; 9-alpha-Fluoro-16-alpha-methylprednisolone; UNII-7S5I7G3JQL; 16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone; EINECS 200-003-9; 7S5I7G3JQL; MFCD00064136; NSC-34521; 16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone; DXM [Steroid]; 16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone; HEMADY; 16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol; Dexamethasone (GMP); Dexamethasone, topical; CHEBI:41879; AI3-50934; delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol; 9A-FLUORO-16BETA-METHYLPREDNISOLONE; Prednisolone, 9alpha-fluoro-16alpha-methyl-; DTXCID10384; MLS001332507; 16.alpha.-Methyl-9.alpha.-fluoroprednisolone; Dexamethasone [USP:INN:BAN:JAN]; DXM (Steroid); 9-Fluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione; [3H]-dexamethasone; DEXA; [3H]dexamethasone; CIPRODEX COMPONENT DEXAMETHASONE; Decaject-L.A.; MAXITROL COMPONENT DEXAMETHASONE; TOBRADEX COMPONENT DEXAMETHASONE; (1R,2S,10S,11S,13R,14R,15S,17S)-1-fluoro-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-5-one; DEXACIDIN COMPONENT DEXAMETHASONE; DEXASPORIN COMPONENT DEXAMETHASONE; Aphthasolone; TOBRADEX ST COMPONENT DEXAMETHASONE; Dexa-Mamallet; 9.alpha.-Fluoro-16.alpha.-methylprednisolone; Dexametasona (INN-Spanish); Dexamethasonum (INN-Latin); (8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one; C22H29FO5; DEXAMETHASONE (MART.); DEXAMETHASONE [MART.]; 16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol; DEXAMETHASONE (USP-RS); DEXAMETHASONE [USP-RS]; 1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone; Dexamethasone (USP:INN:BAN:JAN); DEXAMETHASONE (EP MONOGRAPH); DEXAMETHASONE [EP MONOGRAPH]; DEXAMETHASONE (USP MONOGRAPH); DEXAMETHASONE [USP MONOGRAPH]; Dexamethasone Base; Decadron (TN); (8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; SMR000857119; BETAMETHASONE IMPURITY A (EP IMPURITY); BETAMETHASONE IMPURITY A [EP IMPURITY]; dexamethasone (tetramethyl-rhodamine conjugated ); Prednisolone, 9.alpha.-fluoro-16.alpha.-methyl-; alin; Amplidermis; Cortidexason; Dexafluorene; Dexamecortin; Dexamethsone; Fluorodelta; Aacidexam; Baycadron; Decadrol; Dexabliss; Dexachel; Dexalocal; Dexasine; Spersadex; .delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol; 16.alpha.-Methyl-9.alpha.-fluoro-.delta.(sup1)-hydrocortisone; Dxevo; NSC34521; TaperDex; Aknichthol Dexa; Alin Oftalmico; Anemul mono; Azium Solution; Dexium Tablets; Azium Powder; Dexa-Rhinosan; .gamma.corten; ZoDex; 9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; Alin Depot; Baycuten N; Lokalison-F; Apo-dexamethasone; Decadron DP; Dexasone 4mg; Alba-Dex; Zonometh Solution; Dexameth-A-Vet; PHL-dexamethasone; PMS-dexamethasone; TaperDex 6-day; TaperDex 7-day; Decasone R.p.; Dexamethasone-omega; NCGC00091019-08; Dexasone 0.5mg; TaperDex 12-day; HiDex 6-day; Dexasone 0.75mg; Sandoz Dexamethasone; Dexamethasone1.5 mg; Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11beta,16alpha)-; Dexamethasone Solution; Dexamethasone Injection; DEXYCU KIT; Maxidex Ont 0.1%; Maxidex Sus 0.1%; Azium Boluses 10 mg; Dexamethasone 1.5 mg; Pet Derm III Tablets; Dexameth-A-Vet Injection; Spectrum5_002019; Azium Tablets 0.25 mg; DEXAMETHASONE 6-Day; Azium Oral Solution 2 mg; DEXAMETHASONE [MI]; MolMap_000018; (9R,14S)-Dexamethasone; DEXAMETHASONE [INN]; DEXAMETHASONE [JAN]; SCHEMBL3774; 16-alpha-Methyl-9-alpha-fluoro-1,4-pregnadiene-11-beta,17-alpha,21-triol-3,20-dione; 16-alpha-Methyl-9-alpha-fluoro-11-beta,17-alpha,21-trihydroxypregna-1,4-diene-3,20-dione; 4-alpha-Fluoro-16-alpha-methyl-11-beta,17,21-trihydroxypregna-1,4-diene-3,20-dione; 9-alpha-Fluoro-16-alpha-methyl-1,4-pregnadiene-11-beta,17-alpha,21-triol-3,20-dione; DEXAMETHASONE [HSDB]; BIDD:PXR0060; BSPBio_000995; DEXAMETHASONE [VANDF]; MLS001055412; MLS001332508; BIDD:ER0494; Dexamethasone Sterile Solution; sustained-release dexamethasone; DEXAMETHASONE [WHO-DD]; DEXAMETHASONE [WHO-IP]; CHEMBL384467; GTPL2768; GTPL3447; SGCUT00126; 9-Fluoro-16-methylprednisolone; Ak Dex Oph Otic Soln 0.1%; DEXAMETHASONE [EMA EPAR]; BDBM18207; Dexamethasone (anti-inflammatory); Dexamethasone (JP17/USP/INN); 1p93; DEXAMETHASONE [GREEN BOOK]; HMS1792A17; HMS1990A17; HMS2089N13; HMS2235F08; HMS3039L11; HMS3259N11; HMS3403A17; Azium Aqueous Suspension Veterinary; DEXAMETHASONE [ORANGE BOOK]; AMY28815; to_000038; Tox21_200122; Dexamethasone, >=97.0% (HPLC); HB2521; HY-14648G; IBI-10090; MK-125; s1322; Dexamethasone 1.0 mg/ml in Methanol; DEXAMETHASONUM [WHO-IP LATIN]; PMS Dexamethasone Elixir 0.5mg/5ml; AKOS005259009; AKOS015895509; 1ST2218; CCG-264887; CS-1505; DB01234; KS-1451; NC00645; alpha -Fluoro-16-alpha -methylcortisol; CAS-50-02-2; Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,17,21-trihydroxy-16alpha-methyl-; SMP1_000092; Dexamethasone, >=98% (HPLC), powder; NCGC00091019-01; NCGC00091019-02; NCGC00091019-03; NCGC00091019-04; NCGC00091019-05; NCGC00091019-06; NCGC00091019-07; NCGC00091019-23; NCGC00257676-01; (11beta,16alpha)-9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione labeled with tritium; (8S,9R,10S,11S,13S,14S,16R,17R)-9-Fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]ph; 23495-06-9; 9alpha-fluoro-16alpha-methyl-Prednisolone; AC-11056; DEXAMETHASONE COMPONENT OF CIPRODEX; DEXAMETHASONE COMPONENT OF MAXITROL; DEXAMETHASONE COMPONENT OF TOBRADEX; HY-14648; NCI60_003067; Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, labeled with tritium, (11beta,16alpha)-; SMR001227192; DEXAMETHASONE COMPONENT OF DEXACIDIN; Fluoro-9alpha Methyl-16alpha Prednisolone; 16alpha -Methyl-9alpha -fluoroprednisolone; 9alpha -Fluoro-16alpha -methylprednisolone; DEXAMETHASONE COMPONENT OF DEXASPORIN; Dexamethasone, tested according to Ph.Eur.; CS-0626118; DEXAMETHASONE COMPONENT OF TOBRADEX ST; NS00000344; EN300-52607; D00292; Dexamethasone, meets USP testing specifications; Prednisolone, 9alpha -fluoro-16alpha -methyl-; 9.alpha.-Fluoro-16.alpha.-methyl-1,20-dione; AB00918428-05; AB00918428-08; AB00918428-09; AB00918428_10; 16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol; 16Alpha-methyl-9alpha-fluoro-delta1-hydrocortisone; Dexamethasone, VETRANAL(TM), analytical standard; Q422252; 1-Dehydro-16alpha-methyl-0alpha-fluorohydrocortisone; delta(Sup1)-9-alpha-fluoro-16-alpha-methylcortisol; Q-200939; BRD-K38775274-001-02-3; BRD-K38775274-001-06-4; DEXAMETHASONE ACETATE IMPURITY A [EP IMPURITY]; 1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone; 9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione; Dexamethasone, British Pharmacopoeia (BP) Assay Standard; Z756391748; Pregna-1,4-diene-3,20-dione, 9-fluoro-11alpha -methyl-; Dexamethasone, European Pharmacopoeia (EP) Reference Standard; WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1; Dexamethasone, powder, BioReagent, suitable for cell culture, >=97%; Dexamethasone, United States Pharmacopeia (USP) Reference Standard; 16-.alpha.-Methyl-9-.alpha.-fluoro-1,17-.alpha.,21-triol-3,20-dione; 4.alpha.-Fluoro-16.alpha.-methyl-11.beta.-17,4-diene-3,20-dione; Pregna-1,20-dione, 9-fluoro-11.beta.,17,21-trihydroxy-16.alpha.-methyl-; 16.alpha.-Methyl-9.alpha.-fluoro-11.beta.-17.alpha.-21-trihydroxypregna-1,20-dione; 9-Fluoro-11.beta.,21-trihydroxy-16.alpha.-methylpregna-1,4-diene-3,20-dione; 9-fluoro-16alpha-methyl-11beta,17,21-trihydroxypregna-1,4-diene-3,20-dione; 9.alpha.-Fluoro-11.beta.-17.alpha.- 21-trihydroxy-16.alpha.-methylpregna-1,20-dione; 9alpha-Fluoro-16alpha-methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione; Dexamethasone for peak identification, European Pharmacopoeia (EP) Reference Standard; Dexamethasone for system suitability, European Pharmacopoeia (EP) Reference Standard; Dexamethasone, Pharmaceutical Secondary Standard; Certified Reference Material; Dexamethasone, powder, gamma-irradiated, BioXtra, suitable for cell culture, >=80% (HPLC); Pregna-1,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11.beta.,16.alpha.)-; (11.BETA.,16.ALPHA.)-9-FLUORO-11,17,21-TRIHYDROXY-16-METHYLPREGNA-1,4-DIENE-3,20-DIONE; (11alpha,14beta,16alpha,17alpha)-9-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dion"	TAR10005	Glucocorticoid receptor (NR3C1)	P04150	5743	D0DV8K	DB01234	CHEMBL384467
DRG00009	Camptothecin	Idarubicin	Cytotoxic drugs	"camptothecin; 7689-03-4; Camptothecine; (S)-(+)-Camptothecin; Campathecin; (+)-Camptothecine; d-Camptothecin; (+)-Camptothecin; 20(S)-Camptothecine; 21,22-Secocamptothecin-21-oic acid lactone; NSC94600; Camptothecine (S,+); CHEMBL65; (S)-4-ethyl-4-hydroxy-1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; NSC-94600; (4S)-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; MLS000766223; XT3Z54Z28A; CHEBI:27656; MFCD00081076; (19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione; NSC 100880; (19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione; (S)-Camptothecin; 1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-, (4S)-; 1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-, (S)-; 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-, (4S)-; 20(S)-Camptothecin; 4-ETHYL-4-HYDROXY-1,12-DIHYDRO-4H-2-OXA-6,12A-DIAZA-DIBENZO[B,H]FLUORENE-3,13-DIONE; SR-01000075798; SR-01000597379; d-camptothecine; (s)-camptothecine; Camptothecin,(S); (4S)-4-ETHYL-4-HYDROXY-1H-PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLINE-3,14(4H,12H)-DIONE; (S)-4-ethyl-4-hydroxy-1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-4-Ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14-(4H,12H)-dione; 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-, (S)-; Prestwick_102; (+)-Camptothecin;; Camptothecine (8CI); Spectrum_000299; Tocris-1100; SpecPlus_000712; Prestwick0_000200; Prestwick1_000200; Prestwick2_000200; Prestwick3_000200; Spectrum2_000903; Spectrum3_001203; Spectrum4_000738; Spectrum5_001126; CAMPTOTHECIN [MI]; Lopac-C-9911; SCHEMBL6038; UNII-XT3Z54Z28A; Lopac0_000341; BSPBio_000159; BSPBio_002586; KBioGR_001036; KBioSS_000779; KBioSS_002283; cid_24360; CAMPTOTHECIN [WHO-DD]; DivK1c_000826; DivK1c_006808; SPECTRUM1502232; SPBio_000746; SPBio_002080; BPBio1_000175; CCRIS 8162; DTXSID0030956; HMS502J08; KBio1_000826; KBio1_001752; KBio2_000779; KBio2_003347; KBio2_005915; KBio3_002086; 4-Ethyl-4-hydroxy-1H-pyrano-[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; NINDS_000826; Bio1_000400; Bio1_000889; Bio1_001378; GLXC-10346; HMS1568H21; HMS1921N08; HMS2089F08; HMS2095H21; HMS3261E03; HMS3414J17; HMS3654D13; HMS3678J15; HMS3712H21; BCP02857; Tox21_500341; AC-202; BBL033963; BDBM50008923; CCG-40255; GR-301; NSC 94600; s1288; STK801886; AKOS004119861; CS-1049; DB04690; KS-5235; LP00341; SDCCGMLS-0066688.P001; SDCCGSBI-0050329.P003; BRN 0631069; CAS-2114454; IDI1_000826; NCGC00015290-01; NCGC00016994-01; NCGC00016994-02; NCGC00016994-03; NCGC00016994-04; NCGC00016994-05; NCGC00016994-06; NCGC00016994-07; NCGC00016994-08; NCGC00016994-09; NCGC00016994-10; NCGC00016994-11; NCGC00016994-12; NCGC00016994-16; NCGC00016994-29; NCGC00024997-01; NCGC00024997-02; NCGC00024997-03; NCGC00024997-04; NCGC00024997-05; NCGC00024997-06; NCGC00178592-01; NCGC00178592-02; NCGC00261026-01; 1ST40312; HY-16560; NCI60_042105; SMR000445686; SY010324; AI3-62475; EU-0100341; NS00011856; SW196414-3; C 9911; C01897; M01564; AB00052452-08; AB00052452-09; AB00052452_10; EN300-1725804; (S)-(+)-Camptothecin, >=90% (HPLC), powder; A838882; Q419964; Q-200785; SR-01000075798-1; SR-01000075798-4; SR-01000597379-1; SR-01000597379-3; BRD-K37890730-001-09-4; BRD-K37890730-001-10-2; Z1741982070; (S)-4-ethyl-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]florene-3,13-dione; (S)-4-ethyl-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione; 4-Ethyl-4-hydroxy-1H-pyrano-[3,4:6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 4-Ethyl-4-hydroxy-1H-pyrano-[3[,4[:6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione; (S)-4-Ethyl-4-hydroxy-1H-pyrano-[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione;(S)-(+)-Camptothecin; (S)-4-Ethyl-4-hydroxy-1H-pyrano[3 inverted exclamation mark ,4 inverted exclamation mark :6,7]indolizino[1,2-b]quinoline-3,14-(4H,12H)-dione; 1H-Pyrano[3',7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-, (S)-; 4(S)-Ethyl-4-hydroxy-1H-pyrano-[3',4':6,7]indolizino[1,2-b]quinoline-3,14 (4H,12H)-dione; 4-ethyl-4-hydroxy-(4S)-3,4,12,14-tetrahydro-1H-pyrano[3'',4'':6,7]indolizino[1,2-b]quinoline-3,14-dione; 4-Ethyl-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione (camptothecin or CPT); 4-Ethyl-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione (Camptothecin); 4-Ethyl-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione (CPT, Camptothecin)"	TAR10008	DNA topoisomerase 1 (TOP1)	P11387	24360	D09YDM	DB04690	CHEMBL65
DRG00010	Daunorubicin	Daunorubicin	Cytotoxic drugs	"daunorubicin; Daunomycin; 20830-81-3; Acetyladriamycin; Leukaemomycin C; Rubidomycin; Cerubidine; (+)-Daunomycin; DaunoXome; Daunorubicinum; Daunorubicine; Cerubidin; RP 13057; Rubomycin C; FI 6339; Daunorubicin (INN); NSC-82151; Daunarubicinum; Daunorrubicina; DaunoXome (TN); Daunamycin; FI-6339; FI6339; ZS7284E0ZP; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; DTXSID7022883; CHEBI:41977; RP-13057; 5,12-Naphthacenedione,8-acetyl-10-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-; NCGC00024246-05; Anthracycline; Anthracyline; NDC-0082-4155; DAUNORUBICIN [INN]; Daunorubicinum [INN-Latin]; DTXCID402883; MLS000069508; Daunorubicin [INN:BAN]; NSC-83142; RCRA waste no. U059; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (8S,10S)-8-acetyl-10-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione; (8S,10S)-8-acetyl-10-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione; CAS-20830-81-3; NSC82151; SMR000058559; CCRIS 914; SR-01000000033; SR-05000001600; HSDB 5095; NCI-C04693; EINECS 244-069-7; NSC 83142; VS-103; BRN 1445583; Tocris-1467; Daunorubicin(Daunomycin); AI3-52942; Prestwick3_000487; DAUNOMYCIN [IARC]; DAUNORUBICIN [MI]; CHEMBL178; DAUNORUBICIN [HSDB]; SCHEMBL3041; DAUNORUBICIN [VANDF]; EPIRUBICIN IMPURITY D; UNII-ZS7284E0ZP; BSPBio_000353; DAUNORUBICIN [MART.]; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)-; cid_62770; DAUNORUBICIN [WHO-DD]; BPBio1_000389; GTPL7063; BDBM32017; EX-A1337A; Valrubicin impurity, daunorubicin; Daunomycin;RP 13057;Rubidomycin; DAUNORUBICIN [ORANGE BOOK]; HMS2089H04; HMS2091K06; Pharmakon1600-01500223; VYXEOS COMPONENT DAUNORUBICIN; Tox21_110896; BDBM50368352; GR-318; HY-13062A; LMPK13050002; MFCD00866340; NSC756717; Tox21_110896_1; CCG-212559; CS-2004; DB00694; NSC-756717; NCGC00024246-06; NCGC00024246-07; NCGC00024246-09; NCGC00024246-10; NCGC00024246-12; NCGC00024246-15; NCGC00024246-18; NCGC00025173-01; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)-; SBI-0206677.P002; AB00514669; C01907; D07776; Epirubicin hydrochloride impurity, daunorubicin-; AB00514669-09; AB01644616_09; AB01644616_10; EN300-7479232; A814957; Q411659; SR-01000000033-4; SR-05000001600-1; SR-05000001600-2; BRD-K43389675-001-01-3; BRD-K43389675-003-02-7; BRD-K43389675-003-03-5; BRD-K43389675-003-20-9; EPIRUBICIN HYDROCHLORIDE IMPURITY D [EP IMPURITY]; VALRUBICIN IMPURITY, DAUNORUBICIN [USP IMPURITY]; DOXORUBICIN HYDROCHLORIDE IMPURITY A [EP IMPURITY]; EPIRUBICIN HYDROCHLORIDE IMPURITY, DAUNORUBICIN- [USP IMPURITY]; (1S,3S)-3-ACETYL-1,2,3,4,6,11-HEXAHYDRO-3,5,12-TRIHYDROXY-10-METHOXY-6,11-DIOXO-1-NAPHTHACENYL 3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSIDE; (7S,9S)-7-[(2R,4S,5S,6S)-4-azanyl-6-methyl-5-oxidanyl-oxan-2-yl]oxy-9-ethanoyl-4-methoxy-6,9,11-tris(oxidanyl)-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride; (7S,9S)-9-acetyl-7-(4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl)oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione chloride; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-quinone;hydrochloride; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride; (7S,9S)-9-acetyl-7-[[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-2-oxanyl]oxy]-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride; (8S,10S)-8-ACETYL-10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-6,8,11-TRIHYDROXY-1-METHOXY-7,8,9,10-TETRAHYDROTETRACENE-5,12-DIONE; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro--6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; 5,12-NAPHTHACENEDIONE, 8-ACETYL-10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL))OXY)-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-1-METHOXY-, (8S-CIS)-"	TAR10002	DNA topoisomerase 2-alpha (TOP2A)	P11388	30323	D01XWG	.	CHEMBL178
DRG00011	Doxorubicin	Doxorubicin	Cytotoxic drugs	"doxorubicin; Adriamycin; 23214-92-8; Adriablastin; Doxil; Doxorubicine; Adriblastina; Doxorubicinum; 14-Hydroxydaunomycin; Doxorubicina; 14-Hydroxydaunorubicine; Adriamycin semiquinone; Doxorubicine [INN-French]; Doxorubicinum [INN-Latin]; Doxorubicina [INN-Spanish]; Hydroxydaunorubicin; CCRIS 739; HSDB 3070; NCI-C01514; NDC 38242-874; EINECS 245-495-6; FI 106; NSC 123127; CHEBI:28748; UNII-80168379AG; NSC-759155; CHEMBL53463; Caelyx (liposomal doxorubicin); (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-; 80168379AG; DTXSID8021480; (1S,3S)-3-Glycoloyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl-(3-amino-2,3,6-tridesoxy-alpha-L-lyxo-hexopyranosid); (1S,3S)-3-glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (8S,10S)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; 1,2,3,4,6,11-Hexahydro-4beta,5,12-trihydroxy-4-(hydroxyacetyl)-10-methoxy-6,11-dioxonaphthacen-1beta-yl-3-amino-2,3,6-trideoxy-alpha-L-lyxohexopyranoside; ADR; ADM; Doxorubicine (INN-French); Doxorubicinum (INN-Latin); NSC-123127; Doxorubicina (INN-Spanish); DOXORUBICIN (MART.); DOXORUBICIN [MART.]; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (8S,10S)-10-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione; (8S,10S)-10-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione; (8S-cis)-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione; Doxorubicin [USAN:INN:BAN]; ThermoDox; hydroxydaunomycin; MLS000028393; DM2; Doxorubicin-hLL1; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-; 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)-; Adriblastina (TN); Doxorubicin-P4/D10; Doxorubicin (USAN/INN); VALRUBICIN IMPURITY, DOXORUBICIN (USP IMPURITY); VALRUBICIN IMPURITY, DOXORUBICIN [USP IMPURITY]; Doxorubicin-hLL1 conjugate; doxorrubicina; Doxorubicin-P4/D10 conjugate; Hydroxyldaunorubicin; Hydroxyl Daunorubicin; NSC123127; DOXORUBICIN [MI]; (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride; Prestwick0_000438; Prestwick1_000438; Prestwick2_000438; Prestwick3_000438; DOXORUBICIN [INN]; DOXORUBICIN [HSDB]; DOXORUBICIN [USAN]; Probes1_000151; Probes2_000129; DOXORUBICIN [VANDF]; SCHEMBL3243; BSPBio_000456; BSPBio_001031; DOXORUBICIN [WHO-DD]; 10-((3-Amino-2,3,6-trideoxy-D-lyxohexopyranosyl)oxy)-8-glycolcyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; SPBio_002395; (8S-cis)-10-; BPBio1_000502; cid_443939; DTXCID301480; GTPL7069; Valrubicin impurity, doxorubicin; BDBM22984; BDBM32022; L01DB01; HMS2089H06; (8S,10S)-10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-8-GLYCOLOYL-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-1-METHOXY-5,12-NAPHTHACENEDIONE; 5,12-NAPHTHACENEDIONE, 10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-8-(HYDROXYACETYL)-1-METHOXY-, (8S-CIS)-; GR-319; HY-15142A; LMPK13050001; AKOS015951330; Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74; Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120; DB00997; SMP1_000106; NCGC00024415-35; NCGC00024415-37; NCGC00024415-38; NCGC00024415-40; NCGC00024415-41; NCGC00024415-42; NCGC00024415-61; BP-23114; NS00002473; (8S,10S)-10; (8S,10S)-10-; C01661; D03899; EN300-120698; Epirubicin hydrochloride impurity, doxorubicin-; H11954; Q18936; A816625; BRD-K92093830-003-04-3; BRD-K92093830-003-25-8; EPIRUBICIN HYDROCHLORIDE IMPURITY C [EP IMPURITY]; DAUNORUBICIN HYDROCHLORIDE IMPURITY D [EP IMPURITY]; EPIRUBICIN HYDROCHLORIDE IMPURITY, DOXORUBICIN- [USP IMPURITY]; (7S,9R)-7-[(2S,4S,5S,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-9-glycoloyl-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-quinone;hydrochloride; (7S,9S)-7-[(2R,4S,5S,6S)-4-azanyl-6-methyl-5-oxidanyl-oxan-2-yl]oxy-4-methoxy-6,9,11-tris(oxidanyl)-9-(2-oxidanylethanoyl)-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride; (7S,9S)-7-[(4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-7-[[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-2-oxanyl]oxy]-6,9,11-trihydroxy-9-(2-hydroxy-1-oxoethyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride; (8S,10S)-10-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione;(7S,9S)-7-[(4S,5S,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S,10S)-10-((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione; (8S-cis)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione; (8S-cis)-10-[(3-Amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione; 1,2,3,4,6,11-hexahydro-4beta,5,12-trihydroxy-4-(hydroxyacetyl)-10-methoxy-6, 11-Dioxonaphthacen-1beta-yl-3-amino-2,3,6-trideoxy-alpha-l-lyxohexopyranoside; 1392315-46-6; 5,12-naphthacenedione, 10-((3-Amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro- 6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione"	TAR10002	DNA topoisomerase 2-alpha (TOP2A)	P11388	31703	D07VLY	DB00997	CHEMBL53463
DRG00012	Paclitaxel	Paclitaxel	Cytotoxic drugs	"33069-62-4; P88XT4IS4D; Paclitaxel; Taxol; Taxol A; Yewtaxan; Genaxol; Plaxicel; Abraxane; Ebetaxel; Genetaxyl; Capxol; Paxene; Onxol; Cyclopax; Genexol; Intaxel; Mitotax; TaxAlbin; OncoGel; Pacliex; Paxceed; EmPAC; Onxal; Zisu; Taxus stent; Taxus Liberte; ABI-007; Padexol; EndoTAG 1; LipoPac; Tocosol Paclitaxel; (-)-Paclitaxel; Nanoxel; Paclitaxol; Sindaxel; NSC-125973; Coroflex Please; Cypher select; Taxus Express; LEP-ETU; Genexol-PM; (NAB)-Paclitaxel; MBT 0206; Infinnium; Taxus; HSDB 6839; ABI 007; DHP 107; DHP-107; Abraxane I.V. Suspension; BMS 181339-01; BMS-181339-01; UNII-P88XT4IS4D; DRG-0190; Paclitaxel (Taxol); NK 105; NSC125973; Paclitaxel (taxus canadensis); QW 8184; CCRIS 8143; Liposome-entrapped paclitaxel easy-to-use; DTXSID9023413; CHEBI:45863; ABI-007 COMPONENT PACLITAXEL; IG 001; MFCD00869953; NK-105; 5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine; QW-8184; CHEMBL428647; DTXCID603413; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-9-(((2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl)oxy)-12-(benzoyloxy)-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxete-6,12b-diyl diacetate; nab-paclitaxel; ORAXOL COMPONENT PACLITAXEL; Paclitaxel [USAN:USP:INN:BAN]; Abraxane (albumin-bound suspension); ABRAXANE COMPONENT PACLITAXEL; MBT-0206; ABI 007 COMPONENT PACLITAXEL; (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester; NCGC00164367-01; NAB-PACLITAXEL COMPONENT PACLITAXEL; 7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.; NSC 125973; PACLITAXEL (MART.); PACLITAXEL [MART.]; PACLITAXEL (USP-RS); PACLITAXEL [USP-RS]; (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-1,9-dihydroxy-15-{[(2R,3S)-2-hydroxy-3-phenyl-3-(phenylformamido)propanoyl]oxy}-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2-yl benzoate; PACLITAXEL (EP MONOGRAPH); PACLITAXEL (USP IMPURITY); PACLITAXEL [EP MONOGRAPH]; PACLITAXEL [USP IMPURITY]; Anzatax; Cynviloq; PACLITAXEL (USP MONOGRAPH); PACLITAXEL [USP MONOGRAPH]; Xorane; Paclitaxel (USAN:USP:INN:BAN); Bris Taxol; Taxol, Bris; SMR000857385; EndoTAG-1; SR-01000075350; paclitaxelum; Nanotaxel; Paclical; Pacligel; Paxoral; Paclitaxel?; Paclitaxel,(S); Abraxane (TN); (2alpha,5beta,7beta,10beta,13alpha)-4,10-bis(acetyloxy)-1,7-dihydroxy-13-({(2R,3S)-2-hydroxy-3-phenyl-3-[(phenylcarbonyl)amino]propanoyl}oxy)-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; [diacetoxy-[(2R,3S)-3-benzamido-2-hydroxy-3-phenyl-propanoyl]oxy-dihydroxy-tetramethyl-oxo-[?]yl] benzoate; 4alpha,10beta-bis(acetyloxy)-13alpha-((2S,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyloxy)-1,7beta-dihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate; 4alpha,10beta-bis(acetyloxy)-13alpha-[(2S,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyloxy]-1,7beta-dihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate; Paclitaxel; 5beta,20-Epoxy-1,7beta-dihydroxy-9-oxotax-11-ene-2alpha,4,10beta,13alpha-tetrayl 4,10-diacetate 2-benzoate 13-[(2R,3S)-3-(benzoylamino)-2-hydroxy-3-phenylpropanoate]; Taxol; Docetaxel Anhydrous Impurity F; Docetaxel Impurity F; Taxol (Paclitaxel); CAS-33069-62-4; BMS-181339; Paclitaxel-SSMM-VIP; P-SSMM-VIP; PACLITAXEL [MI]; PACLITAXEL [INN]; PACLITAXEL [JAN]; Prestwick3_000155; PACLITAXEL [HSDB]; PACLITAXEL [USAN]; PACLITAXELPACLITAXEL; TAXOL (TN); PACLITAXEL [VANDF]; SCHEMBL3976; 3PPC5TL76P; Nova-12005; PACLITAXEL [WHO-DD]; Paclitaxel, Taxus brevifolia; BIDD:PXR0046; BSPBio_000290; KBioGR_002509; KBioSS_002517; Paclitaxel (JAN/USP/INN); MLS002154218; MLS002695976; OAS-PAC-100; PACLITAXEL [EMA EPAR]; BPBio1_000320; GTPL2770; MEGxp0_001940; Taxol (TN) (Bristol Meyers); PACLITAXEL [GREEN BOOK]; PACLITAXEL [ORANGE BOOK]; ACon1_002231; KBio2_002509; KBio2_005077; KBio2_007645; KBio3_002987; ANX-513; DHP-208; DTS-301; L01CD01; SDP-013; cMAP_000068; HMS2090D07; HMS2095O12; HMS2231A16; HMS3712O12; HY-B0015; MPI-5018; Tox21_112107; BDBM50001839; NSC745099; AKOS007930675; AKOS015969673; AKOS025312303; CCG-220155; CS-1145; DB01229; GS-6554; NSC-745099; NCGC00164367-02; NCGC00164367-03; NCGC00164367-04; NCGC00164367-05; NCGC00164367-10; Paclitaxel, From Taxus brevifolia, 95%; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-1,2a,3,4,4a,6,9,10,11,12,12a,12b-Dodecahydro-4,6,9,11,12,12b-hexahydroxy-4a,8,13,13-tetramethyl-7,11-methano-5H-cyclodeca(3,4)benz(1,2-b)oxet-5-one 6,12b-diacetate, 12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine; NCI60_000601; Paclitaxel, from Taxus yannanensis, powder; 1ST000431; PACLITAXEL IMPURITY L [EP IMPURITY]; AB00513812; D00491; EN300-117275; M02242; N88686; AB00513812-02; AB00513812-03; Paclitaxel, Antibiotic for Culture Media Use Only; Q423762; 7,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.; Q-201533; SR-01000075350-1; SR-01000075350-3; SR-01000075350-6; SR-01000075350-7; SR-01000075350-9; BRD-K62008436-001-03-1; BRD-K62008436-001-05-6; BRD-K62008436-001-22-1; Paclitaxel, from semisynthetic (from Taxus sp.), >=97%; Paclitaxel, European Pharmacopoeia (EP) Reference Standard; Paclitaxel, from Taxus brevifolia, >=95% (HPLC), powder; Paclitaxel, United States Pharmacopeia (USP) Reference Standard; 12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine; Paclitaxel protein-bound particles for injectable suspension (albumin-bound); Paclitaxel, Pharmaceutical Secondary Standard; Certified Reference Material; Paclitaxel natural for peak identification, European Pharmacopoeia (EP) Reference Standard; (1S,2S,3R,4S,5R,7S,8S,10R,13S)-4,10-Diacetoxy-2-benzoyloxy-5,20-epoxy-1,7-dihydroxy-9-oxotax-11-en-13-yl (2R,3S)-3-benzoylamino-2-hydroxy-3-phenylpropionate; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-1,2a,3,4,4a,6,9,10,11,12,12a,12b-Dodecahydro 4,6,9,11,12,12b-hexahydroxy-4a,8,13,13-tetramethyl-7,11-methano 5Hcyclodeca(3,4)benz(1,2-b)oxet-5-one 6,12b-diacetate,; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-4,6,12b-Tris(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (alphaR,betaS)-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-(benzoylamino)-a-hydroxybenzenepropanoate; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-9-(((2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl)oxy)-12-(benzoyloxy)-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-3,4,4a,5,6,9,10,11,12,12a-decahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxete-6,12b(2aH)-diyl diacetate; (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12; (2beta,5beta,7alpha,8alpha,10alpha,13alpha)-4,10-bis(acetyloxy)-1,7-dihydroxy-13-({(2R,3S)-2-hydroxy-3-phenyl-3-[(phenylcarbonyl)amino]propanoyl}oxy)-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; ,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester; ,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (alphaR,betaS)- (9CI); -cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR-[2aalpha,4beta,4abeta,6beta,9alpha(aR*,betaS*),11alpha,12alpha,12aalpha,12balpha]]-; [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate; [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl]benzoate; 1203669-79-7; 4,7beta,10beta-tris(acetyloxy)-13alpha-[[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy]-1-hydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate; 5-BETA,20-EPOXY-1,2-ALPHA,4,7-BETA,10-BETA,13-ALPHA-HEXAHYDROXY-TAX-11-EN-9-ONE 4,10-DIACETATE 2-BENZOATE 13-ESTER WITH (2R,3S)-N-BENZOYL-3-PHENYL-ISOSERINE; 5beta,20-Epoxy-1,2 alpha, 4,7beta, 10beta, 13alpha-hexahydroxy tax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R, 3S)-N-benzoyl-3-phenylisoserine; BENZENEPROPANOIC ACID, .BETA.-(BENZOYLAMINO)-.ALPHA.-HYDROXY-, (2AR,4S,4AS,6R,9S,11S,12S,12AR,12BS)-6,12B-BIS(ACETYLOXY)-12-(BENZOYLOXY)-2A,3,4,4A,5,6,9,10,11,12,12A,12B-DODECAHYDRO-4,11-DIHYDROXY-4A,8,13,13-TETRAMETHYL-5-OXO-7,11-METHANO-1H-CYCLODECA(3,4)BENZ(1,2-B)OXET-9-YL ESTER, (.ALPHA.R,.BETA.S)-; Benzenepropanoic acid, 6,12b-bis(acetyl oxy)-12-(benzoyloxy)- 2a,3,4,4a,5,6,9,10,11,12,12a,12b,- dodecahydro-4,11- dihydroxy-4a,8,13,13-tetramethyl-5-oxo- 7,11-methano- 1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR- [2a.alpha.,4.beta.,4a.beta.,6.beta.,9.alpha.(alpha. R*,.beta.S*),11.alpha.,12.alpha.,12a.alpha.,12b.alpha.]]-; Benzenepropanoic acid, b-(benzoylamino)-.alpha.-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (aR,bS)-; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-4,6,12b-tris(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (alphaR,betaS)-; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10"	TAR10017	Microtubule (MT)	.	36314	D0C4RB	DB01229	CHEMBL428647
DRG00013	Gemcitabine	Gemcitabine	Cytotoxic drugs	"gemcitabine; 95058-81-4; 2'-Deoxy-2',2'-difluorocytidine; 2',2'-Difluorodeoxycytidine; dFdC; Cytidine, 2'-deoxy-2',2'-difluoro-; Gemcitabine free base; 2',2'-difluoro-2'-deoxycytidine; 103882-84-4; 4-amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydropyrimidin-2-one; LY188011; 4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 95058-81-4 (free base); B76N6SBZ8R; LY 188011; 4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; Gamcitabine; Gemcitabina; CHEBI:175901; DFdCyd; NSC-613327; Gemcitabinum; Folfugem; Gemcel; Zefei; GemLip; 4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; Gemcitabinum [INN-Latin]; Gemcitabina [INN-Spanish]; C9H11F2N3O4; Gemzar (hydrochloride); SR-05000001491; Gemcitabine (USAN/INN); UNII-B76N6SBZ8R; 2',2'-DiF-dC; Gemcitabine [USAN:INN:BAN]; CCRIS 8984; MFCD00869720; HSDB 7567; 2vpp; gemcitabine (Gemzar); NSC 613327; 4pd5; GEMCITABINE [MI]; GEMCITABINE [INN]; 2'-Deoxy-.beta.-D-2',2'-difluorocytidine; GEMCITABINE [HSDB]; GEMCITABINE [USAN]; CHEMBL888; GEMCITABINE [VANDF]; SCHEMBL4295; GEMCITABINE [WHO-DD]; GTPL4793; DTXSID3040487; 2'deoxy-2',2'-difluorocytidine; BCPP000219; BDBM429521; GLXC-04598; HMS2089P10; HMS3715N07; 2`-Deoxy-2`,2`-difluorocytidine; med.21724, Compound Gemcitabine; DL-215; s1714; AKOS015920303; Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine; BCP9000721; CCG-221183; CS-0643; DB00441; GS-3582; 4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one; NCGC00168784-02; NCGC00168784-08; NCGC00168784-12; BP-58640; HY-17026; G0544; NS00000342; SW199649-2; C07650; D02368; EN300-267822; AB01274777-01; AB01274777-02; AB01274777_05; AB01274777_06; Q414143; J-001056; SR-05000001491-1; SR-05000001491-2; BRD-K15108141-001-04-1; Z1741982024; 4-AMINO-1-[(2R,4R,5R)-3,3-DIFLUORO-4-HYDROXY-5-(HYDROXYMETHYL)TETRAHYDRO-2-FURANYL]-2(1H)-PYRIMIDINONE; 4-amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one"	TAR10009	Ribonucleoside-diphosphate reductase subunit M2 (RRM2)	P31350	60750	D0AJ3K	DB00441	CHEMBL888
DRG00014	Baicalin	Baicalin	Anticardiomyopathy drugs	"Baicalin; 21967-41-9; Baicalein 7-O-glucuronide; 7-D-Glucuronic acid-5,6-dihydroxyflavone; Baicalein 7-glucuronide; CHEBI:2981; MFCD00134418; 347Q89U4M5; 5,6-dihydroxy-4-oxo-2-phenyl-4H-chromen-7-yl beta-D-glucopyranosiduronic acid; 7-D-glucuronic acid-5,6-dihydroxy-flavone; CHEMBL485818; UNII-347Q89U4M5; 5,6,7-trihydroxyflavone 7-O-beta-D-glucuronide; Baicalein 7-O-.beta.-D-glucuronide; beta-D-Glucopyranosiduronic acid, 5,6-dihydroxy-4-oxo-2-phenyl-4H-1-benzopyran-7-yl; (2S,3S,4S,5R,6S)-6-[(5,6-dihydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid; BAICALEIN 7-O-BETA-D-GLUCURONIDE; 5,6-dihydroxy-4-oxo-2-phenyl-4H-1-benzopyran-7-yl beta-D-glucopyranosiduronic acid; 5,6-Dihydroxy-4-oxo-2-phenyl-4H-1-benzopyran-7-yl ; A-D-Glucopyranosiduronic Acid; BAICALEIN 7-O-GLUCURONIDE (USP-RS); BAICALEIN 7-O-GLUCURONIDE [USP-RS]; baikalin; Baicalein 7-O-; A-D-glucuronide; Baicalin,(S); (2S,3S,4S,5R,6R)-6-(5,6-dihydroxy-4-oxo-2-phenylchromen-7-yl)oxy-3,4,5-trihydroxyoxane-2-carboxylic acid; (2S,3S,4S,5R,6S)-6-(5,6-dihydroxy-4-oxo-2-phenyl-4H-chromen-7-yloxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid; 0XE; ss-D-Glucopyranosiduronic acid, 5,6-dihydroxy-4-oxo-2-phenyl-4H-1-benzopyran-7-yl; Baicalin (6CI,7CI,8CI); Baicalein 7-O-glucuronide; Baicalein 7-O-ss-D-glucuronide; Baicalein 7-glucuronide; Baicalin, 95%; (2S,3S,4S,5R,6S)-6-((5,6-dihydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid; BAICALIN [VANDF]; Baicalein-7-D-glucuronide; BAICALIN [WHO-DD]; 31564-28-0; SCHEMBL285082; GTPL13076; TJN-151; DTXSID701346569; GLXC-10491; BAICALIN 7-B-D-GLUCURONIDE; Baicalin, >=99.0% (HPLC); HY-N0197; BDBM50242173; AKOS007930529; AKOS015955933; Baicalin 1000 microg/mL in Methanol; AC-7990; AM84780; CCG-214128; CS-5302; Baicalein 7-beta-D-glucopyranosiduronate; compound 15 [PMID: 37666112]; NCGC00386028-03; (2S,3S,4S,5R,6S)-6-(5,6-DIHYDROXY-4-OXO-2-PHENYL-CHROMEN-7-YL)OXY-3,4,5-TRIHYDROXY-OXANE-2-CARBOXYLIC ACID; (2S,3S,4S,5R,6S)-6-(5,6-dihydroxy-4-oxo-2-phenyl-chromen-7-yl)oxy-3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid; (2S,3S,4S,5R,6S)-6-(5,6-dihydroxy-4-oxo-2-phenylchromen-7-yl)oxy-3,4,5-trihydroxyoxane-2-carboxylic acid; 1ST40031; AS-13226; PD132941; NS00097648; A815791; J-013512; Q-100275; Q2879368; BRD-K49962337-001-01-1; Baicalin, European Pharmacopoeia (EP) Reference Standard; 5,6,7-Trihydroxyflavone-7-O-.beta.-D-glucopyranosideuronic acid; (2S,3S,4S,5R,6R)-6-(5,6-dihydroxy-4-oxo-2-phenyl-chromen-7-yl)oxy-3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid; (2S,3S,4S,5R,6S)-6-(5,6-dihydroxy-4-oxo-2-phenyl-4H-chromen-7-yloxy)-3,4,5-trihydroxy-tetrahydro-2H-pyran-2-carboxylic acid; (2S,3S,4S,5R,6S)-6-(5,6-dihydroxy-4-oxo-2-phenylchromen-7-yl)oxy-3,4,5-trihydroxyoxane-2-carboxylicacid; .BETA.-D-GLUCOPYRANOSIDURONIC ACID, 5,6-DIHYDROXY-4-OXO-2-PHENYL-4H-1-BENZOPYRAN-7-YL"	.	.	.	64982	D08PUW	.	CHEMBL485818
DRG00015	Bendamustine	Bendamustine	Cytotoxic drugs	"Bendamustine; 16506-27-7; 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid; Bendamustina; Bendamustinum; Bendamustine [INN]; 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid; Bendamustine free base; Bendamustinum [Latin]; UNII-9266D9P3PQ; DTXSID2046888; HSDB 7763; 9266D9P3PQ; Treanda (TN); SDX 105; DTXCID0026888; NIOSH/DD6304600; 5-(Bis(2-chloroethyl)amino)-1-methyl-2-benzimidazolebutyric acid; 16506-27-7 (free base); 1H-Benzimidazole-2-butanoic acid, 5-(bis(2-chloroethyl)amino)-1-methyl-; Bendamustine (INN); Bendamustinum (Latin); NCGC00181170-01; 2-Benzimidazolebutyric acid, 5-(bis(2-chloroethyl)amino)-1-methyl-; DD63046000; omega-(1-Methyl-5-bis(beta-chloroethyl)aminobenzimidazole-(2)-butyric acid; bendamustin; Bendamustina [Spanish]; 5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzimidazole-2-butanoic acid; 4-(5-(BIS(2-CHLOROETHYL)AMINO)-1-METHYL-1H-BENZIMIDAZOLE-2-YL)BUTANOIC ACID; 4-{5-[bis(2-chloroethyl)amino]-1-methyl-1H-1,3-benzodiazol-2-yl}butanoic acid; CAS-16506-27-7; Bendamustine [INN:BAN]; gamma-; 1H-benzimidazole-2-butanoic acid, 5-[bis(2-chloroethyl)amino]-1-methyl-; SDX-105 free base; BENDAMUSTINE [MI]; BENDAMUSTINE [HSDB]; BENDAMUSTINE [VANDF]; SCHEMBL26319; BENDAMUSTINE [WHO-DD]; CHEMBL487253; GTPL7478; L01AA09; CHEBI:135515; BDBM173621; BCP04111; Tox21_112771; MFCD00866481; s5939; AKOS022181343; Tox21_112771_1; BCP9000389; DB06769; SDCCGSBI-0633739.P001; NCGC00181170-02; NCGC00181170-03; NCGC00181170-10; AC-22488; AS-73546; HY-13567; BCP0726000100; CS-0007192; FT-0742187; NS00007783; D07501; AB01273966-01; AB01273966-02; AB01273966_03; US9096627, CY190602; EN300-26189677; Q425745; J-010179; BRD-K17068645-003-02-6; 4-{5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzimidazol-2-yl}butanoic acid; Bendamustine; 2-Benzimidazolebutyric acid, 5-[bis(2-chloroethyl)amino]-1-methyl- (8CI); 4-[5-[Bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid; Bendamustine; ?-[1-Methyl-5-[bis(ss-chloroethyl)amino]-2-benzimidazolyl]butyric acid; InChI=1/C16H21Cl2N3O2/c1-20-14-6-5-12(21(9-7-17)10-8-18)11-13(14)19-15(20)3-2-4-16(22)23/h5-6,11H,2-4,7-10H2,1H3,(H,22,23"	TAR10016	Human Deoxyribonucleic acid (hDNA)	.	65628	.	DB06769	.
DRG00016	Mesoporphyrin IX	.	Antiviral drugs	"Mesoporphyrin IX; MESOPORPHYRIN; 493-90-3; MPIX; 3-[18-(2-carboxyethyl)-8,13-diethyl-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid; Mesoporphyrin IX, dihydrochloride; 7,12-Diethyl-3,8,13,17-tetramethyl-21H,23H-porphine-2,18-dipropionic acid; 7,12-Diethyl-3,8,13,17-tetramethyl-21H,23H-porphine-2,18-dipropanoic acid; 7,12-diethyl-3,8,13,17-tetramethyl-2,18-Porphinedipropionic acid; di-HCl of mesoporphyrin IX; mesoprotoporphyrin; EINECS 207-782-4; 3,3'-(7,12-diethyl-3,8,13,17-tetramethylporphyrin-2,18-diyl)dipropanoic acid; SCHEMBL314687; CHEMBL276179; SCHEMBL5447002; SCHEMBL18428593; DTXSID10862030; CHEBI:133626; UQVVDGKMSUMXBI-UJJXFSCMSA-N; NSC19665; NSC-19665; NSC409898; Mesoporphyrin IX - reference standard; NSC-409898; 7,12-diethyl-3,8,13,17-tetramethyl-21H,23H-Porphine-2,18-dipropanoate; 21H,23H-Porphine-2,18-dipropanoic acid, 7,12-diethyl-3,8,13,17-tetramethyl-; 3-[(1Z,4Z,9Z,15Z)-18-(2-carboxyethyl)-7,12-diethyl-3,8,13,17-tetramethyl-21,23-dihydroporphyrin-2-yl]propanoic acid; 3-[(1Z,4Z,9Z,15Z)-18-(2-carboxyethyl)-8,13-diethyl-3,7,12,17-tetramethyl-21,23-dihydroporphyrin-2-yl]propanoic acid"	TAR10016	Human Deoxyribonucleic acid (hDNA)	.	72422	.	.	.
DRG00017	Paradol	.	Phosphodiesterase 4 inhibitor	"Paradol; 27113-22-0; 6-Paradol; [6]-Paradol; 1-(4-hydroxy-3-methoxyphenyl)decan-3-one; 5-Paradol; 3-Decanone, 1-(4-hydroxy-3-methoxyphenyl)-; 1-(4-Hydroxy-3-methoxyphenyl)decan-5-one; [6]-Gingerone; 1-(4-Hydroxy-3-methoxyphenyl)-3-decanone; CHEBI:10137; BO24ID7E9U; Heptyl 4-hydroxy-3-methoxyphenethyl ketone; 1-(4-hydroxy-3-methoxyphenyl)-decan-3-one; CHEMBL2071440; 1-(4-hydroxy-3-methoxy-phenyl)decan-3-one; (6)-GINGERONE; (6)-PARADOL; EINECS 248-228-1; UNII-BO24ID7E9U; 6-Gingerone; 1-(4-Hydroxy-3-methylphenol)-3-decanone; BRN 1984119; CCRIS 8519; 6-GINGERONE; 2-08-00-00318 (Beilstein Handbook Reference); SCHEMBL971599; [6]-Gingerone;[6]-Paradol; MEGxp0_001218; FEMA NO. 4665; ACon1_001067; DTXSID90181574; HYDROXYMETHOXYPHENYL DECANONE; BCP24208; EX-A6738; BDBM50237535; MFCD01736103; s5551; AKOS028111088; CCG-267231; CS-0873; NCGC00169709-01; AC-36782; AS-64448; HY-14617; 1ST158272; DS-020237; FT-0775579; NS00021973; 1-(4'-hydroxy-3'-methoxyphenyl)-3-decanone; 1-(4-Hydroxy-3-methoxyphenyl)-3-decanone #; 1-(4'-hydroxy-3'-methoxyphenyl)-decan-3-one; A911271; Q3363309; BRD-K84571636-001-01-4; Paradol[6]-Paradol; 1-(4-hydroxy-3-methoxyphenyl)decan-3-one; 5-Paradol"	TAR10020	Prostaglandin G/H synthase 2 (PTGS2)	.	94378	.	.	.
DRG00018	7-Ethyl-10-hydroxycamptothecin	.	Cytotoxic drugs	"7-Ethyl-10-hydroxycamptothecin; 86639-52-3; SN-38; SN 38 lactone; SN 38; 7-Ethyl-10-hydroxy-camptothecin; (S)-4,11-Diethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 10-Hydroxy-7-ethylcamptothecin; SN38; 7-Ethyl-10-hydroxy-20(S)-camptothecin; NK 012; NK-012; NK012; CHEBI:8988; 113015-38-6; IT-141; NSC673596; 0H43101T0J; (19S)-10,19-diethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione; (4S)-4,11-diethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; CAMPTOTHECIN, 7-ETHYL-10-HYDROXY-; (4S)-4,11-Diethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; 7-ethyl-10-hydroxy-20(s)-campthothecin; LE-SN38; Captothecin, 7-ethyl-10-hydroxy-; MFCD00871873; UNII-0H43101T0J; C22H20N2O5; 110714-48-2; 1H-PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLINE-3,14(4H,12H)-DIONE, 4,11-DIETHYL-4,9-DIHYDROXY-, (4S)-; 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4,11-diethyl-4,9-dihydroxy-, (4S)-; AvaChem1025; (+)-7-ETHYL-10-HYDROXYCAMPTOTHECIN; diethyl(dihydroxy)[?]dione; SN 38- Bio-X; SCHEMBL34018; GTPL6925; SN 38 [WHO-DD]; DTXSID4040399; 10-hydroxy-7-ethyl camptothecin; 10-hydroxy-7-ethyl-camptothecin; EX-A989; HMS3413B12; HMS3652P12; HMS3677B12; BCP01386; 7-Ethyl-10-hydroxy-20(S)-CPT; BDBM50418088; s4908; AKOS015920433; AC-1357; BCP9000200; CCG-264764; CS-1579; DB05482; NSC-673596; SN-38(NK-012)?; NCGC00167831-01; NCGC00167831-05; AS-13533; BE164132; BP-24513; HY-13704; NCI60_026056; 7-Ethyl-10-hydroxy-20-(S)-camptothecine; E0748; FT-0630943; FT-0674607; FT-0674608; NS00069821; SW219948-1; S-(+)-7-ETHYL-10-HYDROXYCAMPOTHECIN; EN300-122379; NK012 , SN 38; A857464; Q-100871; Q1750127; 7-Ethyl-10-hydroxycamptothecin, >=98% (HPLC), powder; Z1541759909; (19S)-10,19-diethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione; (19S)-10,19-diethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione; (4S)-4,11-Diethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)dione, AldrichCPR; (4S)-4,9-Dihydroxy-4,11-diethyl-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione;SN-38; (S)-4,11-Diethyl-4,9-di-OH-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione; 1H-Pyrano[3',7]indolizino[1,2-b]quinoline- 3,14(4H,12H)-dione, 4,11-diethyl-4,9-dihydroxy-, (4S)-; 7-Ethyl-10-hydroxycamptothecin ((S)-4,11-Diethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione); H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4,11-diethyl-4,9-dihydroxy-, (S)-; RS4"	TAR10008	DNA topoisomerase 1 (TOP1)	P11387	104842	D0B6YB	.	CHEMBL837
DRG00019	Methotrexate	Doxorubicin	Cytotoxic drugs	"methotrexate; 59-05-2; Rheumatrex; Amethopterin; Methylaminopterin; Metatrexan; Hdmtx; Abitrexate; Trexall; Mexate; Ledertrexate; Methylaminopterinum; (S)-2-(4-(((2,4-Diaminopteridin-6-yl)methyl)(methyl)amino)benzamido)pentanedioic acid; Methotrexatum; Antifolan; MTX; 4-Amino-10-methylfolic acid; Amethopterine; Metotrexato; Emtexate; Maxtrex; Rasuvo; Methotrexate hydrate; A-Methopterin; L-Amethopterin; A-Methpterin; Amethopterin L-; Folex-Pfs; Methotrexat-Ebewe; NSC-740; Methotrexate, L-; N-Bismethylpteroylglutamic acid; Farmitrexat; Medsatrexate; Methoblastin; Methotextrate; Methotrexat; Metotressato; Brimexate; Emthexat; Emthexate; Fauldexato; Lantarel; Lumexon; Metrotex; Novatrex; Otrexup; Tremetex; Trexeron; Trixilem; Texate; Metex; Mexate-Aq; alpha-Methopterin; CL-14377; Folex; NCI-C04671; JYLAMVO; Methotrexate Lpf; CCRIS 1109; Nordimet; Xatmep; EMT 25,299; 133073-73-1; 4-Aminomethylpteroylglutamic acid; HSDB 3123; NSC 740; CL 14377; UNII-YL5FZ2Y5U1; Methotrexatum [INN-Latin]; Metotrexato [INN-Spanish]; EINECS 200-413-8; YL5FZ2Y5U1; R 9985; REDITREX; NSC740; DTXSID4020822; CHEBI:44185; AI3-25299; TCMDC-125858; X 133; 4-Amino-N(sup 10)-methylpteroylglutamic acid; ADX-2191; MPI-2505; WR-19039; CHEMBL34259; DTXCID80822; (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid; R-9985; Kyselina 4-amino-N(sup 10)-methylpteroylglutamova; N-(p-(((2,4-Diamino-6-pteridyl)methyl)methylamino)benzoyl)glutamic acid; L-(+)-N-(p-(((2,4-Diamino-6-pteridinyl)methyl)methylamino)benzoyl)glutamic acid; N-(4-(((2,4-Diamino-6-pteridinyl)methyl)methylamino)benzoyl)-L-glutamicacid; N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid; N-(p-(((2,4-Diamino-6-pteridinyl)methyl)methylamino)benzoyl)-L-(+)-glutamic acid; N-[(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}phenyl)carbonyl]-L-glutamic acid; Methotrexate [USAN:USP:INN:BAN:JAN]; NCGC00025060-04; 4-amino-N(10)-methylpteroylglutamic acid; MFCD00150847; Kyselina N-(p-((2,4-diamino-6-pteridinylmethyl)methylamino)benzoyl)-L-glutamova; METHOTREXATE (IARC); METHOTREXATE [IARC]; Methotrexatum (INN-Latin); Metotrexato (INN-Spanish); (2S)-2-[(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}phenyl)formamido]pentanedioic acid; Glutamic acid, N-(p-(((2,4-diamino-6-pteridinyl)methyl)methylamino)benzoyl)-, L-; METHOTREXATE (MART.); METHOTREXATE [MART.]; METHOTREXATE (USP-RS); METHOTREXATE [USP-RS]; Metotressato [DCIT]; Methotrexate, d-; METHOTREXATE (EP MONOGRAPH); METHOTREXATE (USP IMPURITY); METHOTREXATE [EP MONOGRAPH]; METHOTREXATE [USP IMPURITY]; METHOTREXATE (USP MONOGRAPH); METHOTREXATE [USP MONOGRAPH]; MLS001401431; [3H]methotrexate; Methotrexate (hydrate); Methotrexate (USAN:USP:INN:BAN:JAN); SMR000112001; [3H]-methotrexate; folic acid antagonist; 4-Amino-10-methylfolic acid hydrate; SR-01000075682; SMR000449324; Methotrexate (1.0mg/mL in Methanol with 0.1N NaOH); TCMDC-125488; Metolate; Antifolan hydrate; Intradose-MTX; MTX hydrate; 1dhi; 1dhj; 2drc; 4ocx; (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methyl-amino]benzoyl]amino]pentanedioic acid; CAS-59-05-2; Prestwick_322; Otrexup (TN); Xatmep (TN); L-METHOTREXATE; OTREXUP PFS; Kyselina 4-amino-N(sup 10)-methylpteroylglutamova [Czech]; Methylaminopterin; MTX; DL-Amethopterin hydrate; Spectrum_001836; Tocris-1230; 4kn0; Methylaminopterin hydrate; Prestwick0_000135; Prestwick1_000135; Prestwick2_000135; Spectrum2_001077; Spectrum3_000497; Spectrum4_000616; Spectrum5_000958; Abitrexate (Methotrexate); METHOTREXATE [MI]; METHOTREXATE [INN]; METHOTREXATE [JAN]; METHOTREXATE [HSDB]; METHOTREXATE [USAN]; NCIMech_000767; SCHEMBL3711; Kyselina N-(p-((2,4-diamino-6-pteridinylmethyl)methylamino)benzoyl)-L-glutamova [Czech]; METHOTREXATE [VANDF]; BIDD:PXR0175; Lopac0_000020; KBioGR_001172; KBioSS_002341; Methotrexate Methylaminopterin; MLS000049968; MLS002154208; DivK1c_000114; METHOTREXATE [WHO-DD]; METHOTREXATE [WHO-IP]; SPBio_001094; SPBio_002149; Amethopterin (hydrate); CL14377 (hydrate); WR19039 (hydrate); AMY235; cid_126941; cid_165528; GTPL4674; GTPL4815; SCHEMBL12421860; SCHEMBL23111732; BDBM18050; BDBM66082; HMS500F16; KBio1_000114; KBio2_002338; KBio2_004906; KBio2_007474; KBio3_001493; Methotrexate (JP17/USP/INN); L01BA01; L04AX03; g301; NINDS_000114; Bio1_000486; Bio1_000975; Bio1_001464; HMS1568K12; HMS2095K12; HMS2233O18; HMS3260C21; HMS3414L09; HMS3678L07; HMS3712K12; METHOTREXATE [ORANGE BOOK]; APC-2002; BCP13701; GLUTAMIC ACID, N-(P-(((2,4-DIAMINO-6-PTERIDINYL)METHYL)METHYLAMINO)BENZOYL)-, L-(+)-; MPI-5004; Tox21_110944; Tox21_300269; Tox21_500020; CCG-35800; EMT-25299; METHOTREXATUM [WHO-IP LATIN]; MFCD00064370; s1210; STL535338; (4-(((2,4-diaminopteridin-6-yl)methyl)(methyl)amino)benzoyl)-L-glutamic acid; AKOS016340329; Tox21_110944_1; CL14377; CS-1732; DB00563; KS-5093; LP00020; SDCCGSBI-0050009.P003; IDI1_000114; SMP2_000020; (methyl)amino)benzamido)pentanedioic acid; NCGC00025060-01; NCGC00025060-02; NCGC00025060-03; NCGC00025060-05; NCGC00025060-06; NCGC00025060-07; NCGC00025060-08; NCGC00025060-09; NCGC00025060-10; NCGC00025060-11; NCGC00025060-12; NCGC00025060-13; NCGC00025060-15; NCGC00025060-16; NCGC00254216-01; NCGC00260705-01; HY-14519; EU-0100020; FT-0601523; FT-0630651; G-301; NS00098764; SW198601-3; Methotrexate 1.0 mg/ml in Dimethyl Sulfoxide; C01937; D00142; EN300-119523; DL-4-Amino-N10-methylpteroylglutamic acid hydrate; Q422232; SR-01000597411; W-60383; (S)-2-(4-(((2,4-diaminopteridin-6-yl)methyl); Q-201366; SR-01000075682-1; SR-01000075682-2; SR-01000075682-6; SR-01000597411-1; W-105347; BRD-K59456551-001-09-3; BRD-K59456551-001-11-9; WLN: T66 BN DN GN JNJ CZ EZ H1N1&R DVMYVQ2VQ; Z1521553982; 4-AMINO-4-DEOXY-N(SUP 10)-METHYLPTEROYLGLUTAMATE; Methotrexate, European Pharmacopoeia (EP) Reference Standard; Methotrexate, United States Pharmacopeia (USP) Reference Standard; Glutamic acid,4-diamino-6-pteridinyl)methyl] methylamino]benzoyl]-, L-(+)-; L-Glutamic acid,4-diamino-6-pteridinyl)methyl]- methylamino]benzoyl]-; (S)-2-(4-(((2,4-Diaminopteridin-6-yl)methyl)-(methyl)amino)benzamido)pentanedioic acid; GLUTAMIC ACID, N-(P-(((2,4-DIAMINO-6-PTERIDINYL)METHYL)METHYLAMINO)BENZOYL)-,L; L-Glutamic acid,N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-,hydrate(9ci); Methotrexate for peak identification, European Pharmacopoeia (EP) Reference Standard; Methotrexate for system suitability, European Pharmacopoeia (EP) Reference Standard; Methotrexate, Pharmaceutical Secondary Standard; Certified Reference Material; N-(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}benzoyl)-L-glutamic acid; N-[4-[[(2,4-Diamino-6-pteridinyl)methyl] methylamino]benzoyl]-L-glutamic acid; (2S)-2-((4-(((2,4-DIAMINOPTERIDIN-6-YL)METHYL)(METHYL)AMINO)BENZOYL)AMINO)PENTANEDIOIC ACID; (2S)-2-[[[4-[(2,4-diamino-6-pteridinyl)methyl-methylamino]phenyl]-oxomethyl]amino]pentanedioic acid;hydrate; (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methyl-amino]benzoyl]amino]glutaric acid;hydrate; (2S)-2-[[4-[[2,4-bis(azanyl)pteridin-6-yl]methyl-methyl-amino]phenyl]carbonylamino]pentanedioic acid;hydrate; 102613-64-9"	TAR10012	Reduced folate transporter (SLC19A1)	P41440	126941	D05TMW	DB00563	CHEMBL34259
DRG00020	Docetaxel	Docetaxel	Cytotoxic drugs	"docetaxel; 114977-28-5; Taxotere; Docetaxel anhydrous; Docetaxel Winthrop; Docetaxol; Docetaxel Kabi; EmDOC; Docetaxolum; Docefrez; Taxoel; Docetaxel Teva; Docetaxel Accord; RP-56976; Docetaxel [INN]; Docetaxel, anhydrous; DOCETAXEL MYLAN; Docecad; NSC-628503; DTXSID0040464; N-debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol; RP 56976; TXL; DOCETAXEL TEVA PHARMA; NSC 628503; UNII-699121PHCA; CHEBI:4672; HSDB 6965; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol; 699121PHCA; Taxotere (TN); RP56976; CABAZITAXEL METABOLITE (RP56976); BIND 014; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel; DTXCID8020464; CKD-810; NSC628503; [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1,9,12-trihydroxy-15-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate; Benzenepropanoic acid, beta-(((1,1-dimethylethoxy)carbonyl)amino)-alpha-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester; Docetaxel, Trihydrate; taxotel; DOCETAXEL (USP-RS); UNII-15H5577CQD; MFCD00800737; Docetaxel (Taxotere); DOCETAXEL (EP MONOGRAPH); DOCETAXEL (USP IMPURITY); DOCETAXEL (USP MONOGRAPH); (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(acetyloxy)-15-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1,9,12-trihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2-yl benzoate; (2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-acetoxy-9-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxet-12-yl benzoate; 4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate; Benzenepropanoic acid, beta-(((1,1-dimethylethoxy)carbonyl)amino)-alpha-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (alphaR,betaS)-; CAS-114977-28-5; NSC 759850; Docetaxolum [INN-Latin]; DOCETAXEL TRIHYDRATE (EP MONOGRAPH); docetaxelum; MFCD00871399; docetaxel 114977-28-5; XRP-6976L; ANX-514; SDP-014; SID 530; Docetaxel (TN); Docetaxel- Bio-X; NCGC00181306-01; NCGC00181306-02; 4-(acetyloxy)-13alpha-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate; Taxotere (Aventis); CID148124; Docetaxolum (Latin); N-debenzoyl-N-Boc-10-deacetyl taxol; bind-014; Docetaxel (JAN/INN); DOCETAXEL [JAN]; DOCETAXEL [MI]; CHEMBL92; DOCETAXEL [HSDB]; Benzenepropanoic acid, beta-(((1,1-dimethylethoxy)carbonyl)amino)-alpha-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,1313-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, trihydrate, (alphaR,betaS)-; SCHEMBL4419; N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol; GTPL6809; BIND 014 [WHO-DD]; BDBM36351; SYP-0704A; ZDZOTLJHXYCWBA-VCVYQWHSSA-; AMY4356; L01CD02; 114977-28-5, Docetaxel; HMS2089K08; 114915-20-7; EX-A1206; HY-B0011; Tox21_112781; Tox21_113088; AC-383; DOCETAXEL ANHYDROUS [WHO-DD]; AKOS015960718; AKOS024457953; Tox21_112781_1; CS-1144; DB01248; KS-1452; Docetaxel, purum, >=97.0% (HPLC); NCGC00181306-04; NCGC00242509-01; BD164373; D4102; FT-0625558; NS00006849; D07866; EN300-123047; AB01273941-01; AB01273941-02; Q420436; SR-01000003023; W-60384; Q-100074; SR-01000003023-5; BRD-K30577245-001-04-3; BRD-K30577245-341-01-9; Z1546621742; Anhydrous Docetaxel, European Pharmacopoeia (EP) Reference Standard; (1S,2S,3R,4S,5R,7S,8S,10R,13S)-4-Acetoxy-2-benzoyloxy-5,20-epoxy-1,7,10-trihydroxy-9-oxotax-11-en-13-yl (2R,3S)-3-(1,1-dimethylethyl)oxycarbonylamino-2-hydroxy-3-phenylpropanoate; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate; (2beta,5beta,7alpha,8alpha,10alpha,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; (2R,3S)-N-CARBOXY-3-PHENYLISOSERINE, N-TERT-BUTYL ESTER, 13-ESTER WITH 5.BETA.,20-EPOXY-1,2.ALPHA.,4,7.BETA.,10.BETA.,13.ALPHA.-HEXAHYDROXYTAX-11-EN-9-ONE 4-ACETATE 2-BENZOATE; (2R,3S)-N-CARBOXY-3-PHENYLISOSERINE, N-TERT-BUTYL ESTER, 13-ESTER WITH 5beta,20-EPOXY-1,2alpha,4,7beta,10beta,13alpha-HEXAHYDROXYTAX-11-EN-9-ONE 4-ACETATE 2-BENZOATE; [acetoxy-[(2R,3S)-3-(tert-butoxycarbonylamino)-2-hydroxy-3-phenyl-propanoyl]oxy-trihydroxy-tetramethyl-oxo-[?]yl] benzoate; Benzenepropanoic acid, beta-(((1,1-dimethylethoxy)carbonyl)amino)-alpha-hydroxy-, (2aR,4S,4aR,6R,9S,11S,12S,12aS,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,4a,6,11-tetrahydroxy-8,12a,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (alphaR)-, hydrate (1:3); Benzenepropanoic acid,1-dimethylethoxy)carbonyl]amino]-.alpha.-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (.alpha.R,.beta.S)"	TAR10017	Microtubule (MT)	.	148124	D0O5WP	DB01248	CHEMBL92
DRG00021	Exatecan	Exatecan	TOP1 inhibitor	"Exatecan; 171335-80-1; Exatecan [INN]; DX-8951; DX-8951f; OC71PP0F89; (1S,9S)-1-Amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-10H,13H-benzo(de)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-10,13-dione; Dx 8951; (10S,23S)-23-amino-10-ethyl-18-fluoro-10-hydroxy-19-methyl-8-oxa-4,15-diazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16,18,20(24)-heptaene-5,9-dione; (1S,9S)-1-amino-9-ethyl-5-fluoro-9-hydroxy-4-methyl-2,3,12,15-tetrahydrobenzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13(1H,9H)-dione; C24H22FN3O4; UNII-OC71PP0F89; exatecan-mesylate; (1s,9s)-1-amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-10h,13h-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13-dione; EXATECAN [MI]; EXATECAN [WHO-DD]; SCHEMBL2512959; CHEMBL1614650; DTXSID60169061; CHEBI:135709; GLXC-27628; EX-A2683; NSC829066; AKOS005146469; AT33978; BCP9000674; DB12185; NSC-829066; 10H,13H-Benzo(de)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-10,13-dione, 1-amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-, (1S,9S)-; 10H,13H-Benzo(de)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-10,13-dione, 1-amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-, (1S-trans)-; AC-32495; BP-27995; BP-27996; HY-13631; TS-07806; DB-064817; NS00069222; J-521361; Q5419343"	TAR10018	DNA topoisomerase 1 (TOP1)	P11387	151115	D01FUC	DB12185	.
DRG00022	Dizocilpine	Dizocilpine	NMDA receptor antagonists	"DIZOCILPINE; 77086-21-6; MK-801; Dizocilpine [INN]; MK 801; Lopac-M-107; Lopac-M-108; MK-801 (Dizocilpine); Prestwick0_000109; (5S,10R)-5-methyl-10,11-dihydro-5H-5,10-epiminodibenzo[a,d][7]annulene; 7PY8KH681I; CHEMBL284237; CHEBI:34725; MK801; (1S,9R)-1-methyl-16-azatetracyclo[7.6.1.02,7.010,15]hexadeca-2,4,6,10,12,14-hexaene; Dizocilpina; Dizocilpinum; (Rac)-Dizocilpine; (Rac)-MK-801; Dizocilpinum [INN-Latin]; Dizocilpina [INN-Spanish]; UNII-7PY8KH681I; HSDB 7641; dizocilpine-(+); (+)MK-801; (-)-MK801; (+)-MK-801; (+/-)-MK801; DIZOCILPINE [MI]; Prestwick1_000109; Prestwick2_000109; Prestwick3_000109; DIZOCILPINE [HSDB]; Biomol-NT_000210; Lopac0_000872; SCHEMBL34528; BSPBio_000098; DIZOCILPINE [WHO-DD]; SPBio_002037; BPBio1_000108; BPBio1_001272; GTPL2403; 10,11-Dihydro-5-methyl-5H-dibenzo[a,d]cyclohepten-5,10-imine.(MK-801); DTXSID3048447; (5S,10R)-(+)-5-methyl-10,11-dihydro-5Hdibenzo[a,d]cyclohepten-5,10-imine; (5S,10S)-(+)-5-methyl-10,11-dihydro-5Hdibenzo[a,d]cyclohepten-5,10-imine; 1-methyl-16-azatetracyclo[7.6.1.02,7.010,15]hexadeca-2(7),3,5,10(15),11,13-hexaene; 1-methyl-16-azatetracyclo[7.6.1.02,7.010,15]hexadeca-2(7),3,5,10,12,14-hexaene; 1-methyl-16-azatetracyclo[7.6.1.02,7.010,15]hexadeca-2,4,6,10(15),11,13-hexaene; CHEBI:132408; LBOJYSIDWZQNJS-CVEARBPZSA-N; HMS3267C15; (+)-1-methyl-16-azatetracyclo[7.6.1.02,7.010,15]hexadeca-2(7),3,5,10(15),11,13-hexaene; (+/-) MK-8011-methyl-(9R,1R)-16-azatetracyclo[7.6.1.02,7.010,15]hexadeca-2(7),3,5,10(15),11,13-hexaene; (+/-)-1-methyl-16-azatetracyclo[7.6.1.02,7.010,15]hexadeca-2(7),3,5,10(15),11,13-hexaene; (-)-1-methyl-16-azatetracyclo[7.6.1.02,7.010,15]hexadeca-2(7),3,5,10(15),11,13-hexaene; (1S,9R)-1-methyl-16-azatetracyclo[7.6.1.0^{2,7}.0^{10,15}]hexadeca-2(7),3,5,10(15),11,13-hexaene; (1S,9R)-1-methyl-16-azatetracyclo[7.6.1.0^{2,7}.0^{10,15}]hexadeca-2,4,6,10(15),11,13-hexaene; (Dizocilpine)1-methyl-16-azatetracyclo[7.6.1.02,7.010,15]hexadeca-2(7),3,5,10(15),11,13-hexaene; (MK-801)1-methyl-16-azatetracyclo[7.6.1.02,7.010,15]hexadeca-2(7),3,5,10(15),11,13-hexaene; 1-methyl-16-azatetracyclo[7.6.1.02,7.010,15]hexadeca-2(7),3,5,10(15),11,13-hexaene(MK-801); CDA08621; EX-A1701; BDBM50030386; BDBM50344263; HY-15084B; PDSP1_000178; PDSP1_001281; PDSP2_000177; PDSP2_001265; AKOS026673945; AT27821; CCG-204954; SDCCGSBI-0050847.P002; NCGC00015627-01; NCGC00015627-02; NCGC00016935-04; NCGC00016935-05; NCGC00016935-06; NCGC00016935-19; NCGC00024876-02; AC-35306; TS-09284; CS-0020032; NS00076277; SW197022-4; Q4386371; BRD-K58930050-001-01-1; BRD-K58930050-050-03-4; (+)-10,11-DIHYDRO-5-METHYL-5H-DIBENZO(A,D)CYCLOHEPTEN-5,10-IMINE; 5H-Dibenzo(a,d)cyclohepten-5,10-imine, 10,11-dihydro-5-methyl-, (5S)-; 5H-DIBENZO(A,D)CYCLOHEPTEN-5,10-IMINE, 10,11-DIHYDRO-5-METHYL-, (+)-; 5H-Dibenzo[a,d]cyclohepten-5,10-imine, 10,11-dihydro-5-methyl-, (5S,10R)-; (1S)-1-methyl-16-azatetracyclo[7.6.1.0^{2,7}.0^{10,15}]hexadeca-2(7),3,5,10,12,14-hexaene; (2Z)-but-2-enedioate; (1S,9R)-1-methyl-16-azatetracyclo[7.6.1.0?,?.0??,??]hexadeca-2,4,6,10,12,14-hexaene; 1-methyl-16-azatetracyclo[7.6.1.02,7.010,15]hexadeca-2(7),3,5,10(15),11,13-hexaene maleate((+)-MK801); 5H-Dibenzo[a,d]cyclohepten-5,10-imine, 10,11-dihydro-5-methyl-, (5S)-, (2Z)-2-butenedioate (1:1)"	TAR10026	"Glutamate receptor ionotropic, NMDA 3A (GRIN3A)"	.	180081	D02KLW	.	.
DRG00023	Tesaglitazar	Tesaglitazar	Hypoglycemic drug	"Tesaglitazar; 251565-85-2; Galida; AZ 242; AZ-242; (S)-2-Ethoxy-3-(4-(4-((methylsulfonyl)oxy)phenethoxy)phenyl)propanoic acid; AR-H039242XX; (S)-2-Ethoxy-3-{4-[2-(4-methanesulfonyloxy-phenyl)-ethoxy]-phenyl}-propionic acid; (S)-2-Ethoxy-3-{4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl}propionic acid; BR-44608; (S)-2-Ethoxy-3-[4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl]propanoic acid; (2S)-2-ETHOXY-3-[4-(2-{4-[(METHYLSULFONYL)OXY]PHENYL}ETHOXY)PHENYL]PROPANOIC ACID; AR-H-039242; 6734037O3L; (2S)-2-Ethoxy-3-(4-(2-(4-((methylsulfonyl)oxy)phenyl)ethoxy)phenyl)propanoic acid; (S)-2-ETHOXY-3-[4-[2-(4-METHANESULFONYLOXY-PHENYL)-ETHOXY]-PHENYL]-PROPIONIC ACID; Benzenepropanoic acid, alpha-ethoxy-4-(2-(4-((methylsulfonyl)oxy)phenyl)ethoxy)-, (alphaS)-; Benzenepropanoic acid, alpha-ethoxy-4-[2-[4-[(methylsulfonyl)oxy]phenyl]ethoxy]-, (alphaS)-; Tesaglitazar [INN]; Tesaglitazar [USAN:INN]; DTXSID4048773; Tesaglitizar; (s)-2-ethoxy-3-(4-(2-(4-methylsulphonyloxyphenyl)ethoxy)phenyl)propanoic acid; C20H24O7S; (2S)-2-Ethoxy-3-[4-[2-[4-[(methylsulfonyl)oxy]phenyl]ethoxy]phenyl]propanoic acid; (s)-2-ethoxy-3-(4-[2-(4-methanesulfonyloxy-phenyl)-ethoxy]-phenyl)-propionic acid; (S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl]propanoic acid; (s)-2-ethoxy-3-[4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl]propionic acid; (S)-2-Ethoxy-3-[4-[4-[(methylsulfonyl)oxy]phenethoxy]phenyl]propanoic Acid; UNII-6734037O3L; NCGC00182082-02; 1i7g; 1i7i; TESAGLITAZAR [MI]; TESAGLITAZAR [JAN]; TESAGLITAZAR [USAN]; SCHEMBL16594; MLS004774044; TESAGLITAZAR [WHO-DD]; CHEMBL282686; Tesaglitazar (JAN/USAN/INN); BDBM28798; Tesaglitazar, >=98% (HPLC); CXGTZJYQWSUFET-IBGZPJMESA-N; GLXC-03119; MFCD07784004; (S)-2-ethoxy-3-(4-((4-(methylsulfonyloxy)phenethyl)oxy)phenyl)propanoic acid; 2-ethoxy-3-(4-((4-(methylsulfonyloxy)phenethyl)oxy)phenyl)propanoic acid; AKOS015920483; AC-6748; DB06536; DB07399; (2S)-2-ethoxy-3-(4-{2-[4-(methanesulfonyloxy)phenyl]ethoxy}phenyl)propanoic acid; AS-35360; HY-17444; SMR003500714; CS-0008240; FT-0674871; NS00068654; T3497; D01274; A817671; J-015842; Q7705411; (S)-2-Ethoxy-3-(4-(4-((methylsulfonyl)oxy)phenethoxy)phenyl)propanoicacid; (S)-2-ethoxy-3-(4-(4-(methylsulfonyloxy)phenethoxy)phenyl)propanoic acid; (2S)-2-Ethoxy-3-(4-(2-(4-((methylsulfonyl)oxy)phenyl)ethoxy)phenyl)propionic acid; (S)-2-ETHOXY-3-(4-(2-(4-METHYLSULFONYLOXYPHENYL)ETHOXY)PHENYL)PROPANOIC ACID; (S)-2-Ethoxy-3-(4-(4-((methylsulfonyl)-oxy)phenethoxy)phenyl)propanoic acid; (S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl} ethoxy)phenyl]propanoic acid; (S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}-ethoxy)phenyl]propanoic acid; (S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy) phenyl]propanoic acid; (S)-2-Ethoxy-3-[4-[[4-(methylsulphonyloxy)phenethyl]oxy]phenyl]propanoic acid; (S)-2-Ethoxy-3-[4-[2-(4-methanesulf onyloxyphenyl)ethoxy]phenyl]propanoic acid; benzenepropanoic acid, a-ethoxy-4-[2-[4-[(methylsulfonyl)oxy]phenyl]ethoxy]-, (as)-; BENZENEPROPANOIC ACID,.ALPHA.-ETHOXY-4-(2-(4-((METHYLSULFONYL)OXY)PHENYL)ETHOXY) ,(.ALPHA.S)-"	TAR10014	Peroxisome proliferator-activated receptor alpha (PPARA)	Q07869	208901	D0H1NL	DB06536	CHEMBL282686
DRG00024	Thapsigargin	.	Cytotoxic drugs	"thapsigargin; 67526-95-8; MFCD00083511; Z96BQ26RZD; CHEMBL96926; CHEBI:9516; (-)-Thapsigargin; (3S,3aR,4S,6S,6aR,7S,8S,9bS)-6-(acetyloxy)-4-(butanoyloxy)-3,3a-dihydroxy-3,6,9-trimethyl-8-{[(2Z)-2-methylbut-2-enoyl]oxy}-2-oxo-2,3,3a,4,5,6,6a,7,8,9b-decahydroazuleno[4,5-b]furan-7-yl octanoate; TG1; SR-01000076181; UNII-Z96BQ26RZD; OCTANOIC ACID [3S-[3ALPHA, 3ABETA, 4ALPHA, 6BETA, 6ABETA, 7BETA, 8ALPHA(Z), 9BALPHA]]-6-(ACETYLOXY)-2,3,-3A,4,5,6,6A,7,8,9B-DECAHYDRO-3,3A-DIHYDROXY-3,6,9-TRIMETHYL-8-[(2-METHYL-1-OXO-2-BUTENYL)OX Y]-2-OXO-4-(1-OXOBUTOXY)-AZULENO[4,5-B]FURAN-7-YL ESTER; -7-yl ester; C34H50O12; Azuleno[4,5-b]furan, octanoic acid deriv.; THAPSIGARGIN [MI]; n-7-yl ester (9CI); Lopac0_001262; SCHEMBL82423; BSPBio_001501; MLS006010944; GTPL5351; CHEBI:93212; IXFPJGBNCFXKPI-FSIHEZPISA-N; HMS1361L03; HMS1791L03; HMS1989L03; HMS3263N06; HMS3402L03; Tox21_501262; BDBM50035612; HB1118; s7895; AKOS024456410; AT23806; CCG-205336; LMPR0103410001; LP01262; SDCCGSBI-0051229.P002; IDI1_033971; NCGC00016060-08; NCGC00162381-05; NCGC00162381-06; NCGC00261947-01; AC-32567; AS-56389; HY-13433; Octanoic acid, 6-(acetyloxy)-2,3,3a,4,5,6,6a,7,8,9b-decahydro-3,3a-dihydroxy-3,6,9-trimethyl-8-((2-methyl-1-oxo-2-butenyl)oxy)-2-oxo-4-(1-oxobutoxy)azuleno(4,5-b)furan-7-yl ester, (3S-(3alpha,3abeta,4alpha,6beta,6abeta,7beta,8alpha(Z),9balpha))-; SMR001456557; Thapsigargin, >=98% (HPLC), solid film; CS-0006886; EU-0101262; C09561; T 9033; alpha,6beta,6abeta,7beta,8alpha(Z),9balpha]]-; Q3981006; SR-01000076181-1; SR-01000076181-5; BRD-K69023402-001-02-5; Y]-2-OXO-4-(1-OXOBUTOXY)-AZULENO[4,5-B]FURAN-7-YL ESTER; OCTANOIC ACID [3S-[3ALPHA, 3ABETA, 4ALPHA, 6BETA, 6ABETA, 7BETA, 8ALPHA(Z),; (3S,3aR,4S,6S,6AR,7S,8S,9bS)-6-(Acetyloxy)-2,3,3a,4,5,6,6a,7,8,9b- decahydro-3,3a-dihydroxy-3,6,9-trimethyl-8-[[(2Z)-2-methyl-1-oxo-2-butenyl]oxy]-2-oxo-4-(1-oxobutoxy)azuleno[4,5-b]furan-7-yl octanoate; (3S,3aR,4S,6S,6aR,7S,8S,9bS)-6-(acetyloxy)-2,3,3a,4,5,6,6a,7,8,9b-decahydro-3,3a-dihydroxy-3,6,9-trimethyl-8-[[(2Z)-2-methyl-1-oxo-2-buten-1-yl]oxy]-2-oxo-4-(1-oxobutoxy)azuleno[4,5-b]f uran-7-yl ester; (3S,3aR,4S,6S,6aR,7S,8S,9bS)-6-(acetyloxy)-4-(butanoyloxy)-3,3a-dihydroxy-3,6,9-trimethyl-8-{[(2Z)-2-methylbut-2-enoyl]oxy}-2-oxo-2H,3H,3aH,4H,5H,6H,6aH,7H,8H,9bH-azuleno[4,5-b]furan-7-yl octanoate; (3S,3aR,4S,6S,6aR,7S,8S,9bS)-6-Acetoxy-4-(butyryloxy)-3,3a-dihydroxy-3,6,9-trimethyl-8-(((Z)-2-methylbut-2-enoyl)oxy)-2-oxo-2,3,3a,4,5,6,6a,7,8,9b-decahydroazuleno[4,5-b]furan-7-yl octanoate; 123269-03-4; 9BALPHA]]-6-(ACETYLOXY)-2,3,-3A,4,5,6,6A,7,8,9B-DECAHYDRO-3,3A-DIHYDROXY-3,6,9-TRIMETHYL-8-[(2-METHYL-1-OXO-2-BUTENYL)OX; octanoic acid {3S-[3alpha,3abeta,4alpha,6beta,6abeta,7beta,8alpha(Z),9balpha]}-6-(acetoxy)-2,3,3a,4,5,6,6a,7,8,9b-decahydro-3,3a-dihydroxy-3,6,9-trimethyl-8-[(2-methyl-1-oxo-2-butenyl)oxy]-2-oxo-4-(1-oxobutoxy)-azuleno[4,5-b]furan-7-yl ester; OCTANOIC ACID, (3S,3AR,4S,6S,6AR,7S,8S,9BS)-6-(ACETYLOXY)-2,3,3A,4,5,6,6A,7,8,9B-DECAHYDRO-3,3A-DIHYDROXY-3,6,9-TRIMETHYL-8-(((2Z)-2-METHYL-1-OXO-2-BUTEN-1-YL)OXY)-2-OXO-4-(1-OXOBUTOXY)AZULENO(4,5-B)FURAN-7-YL ESTER; octanoic acid, (3S,3aR,4S,6S,6aR,7S,8S,9bS)-6-(acetyloxy)-2,3,3a,4,5,6,6a,7,8,9b-decahydro-3,3a-dihydroxy-3,6,9-trimethyl-8-[[(2Z)-2-methyl-1-oxo-2-butenyl]oxy]-2-oxo-4-(-oxobutoxy)azuleno[4,5-b]furan; Octanoic acid, (3S,3aR,4S,6S,6aR,7S,8S,9bS)-6-(acetyloxy)-2,3,3a,4,5,6,6a,7,8,9b-decahydro-3,3a-dihydroxy-3,6,9-trimethyl-8-[[(2Z)-2-methyl-1-oxo-2-butenyl]oxy]-2-oxo-4-(1-oxobutoxy)azuleno[4,5-b]fura; Octanoic acid, 6-(acetyloxy)-2,3,3a,4,5,6,6a,7,8,9b-decahydro-3,3a-dihydroxy-3,6,9-trimethyl-8-[(2-methyl-1-oxo-2-butenyl)oxy]-2-oxo-4-(1-oxobutoxy)azuleno[4,5-b]furan-7-yl ester, [3S-[3alpha,3abeta,4"	TAR10021	Calcium-transporting ATPase type 2C member 1 (ATP2C1)	.	446378	D02KGR	.	CHEMBL96926
DRG00025	Melphalan	Melphalan	Cytotoxic drugs	"melphalan; 148-82-3; Alkeran; Melfalan; L-PAM; Phenylalanine mustard; L-Sarcolysine; L-Phenylalanine mustard; L-Sarcolysin; p-L-Sarcolysin; Levofalan; Levofolan; Levopholan; Melfalano; Melphalanum; L-Sarkolysin; 4-[Bis(2-chloroethyl)amino]-L-phenylalanine; Phenylalanine nitrogen mustard; p-Di-(2-chloroethyl)amino-L-phenylalanine; NCI-C04853; Alanine Nitrogen Mustard; CB 3025; p-Bis(beta-chloroethyl)aminophenylalanine; L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine; 3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine; p-N-Bis(2-chloroethyl)amino-L-phenylalanine; 4-(Bis(2-chloroethyl)amino)-L-phenylalanine; 3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine; Sarcolycin, l-; Melfalano [INN-Spanish]; Melphalanum [INN-Latin]; Rcra waste number U150; CB-3025; (2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid; SK 15673; SK-15673; NSC-8806; CCRIS 374; Phelinun; CHEBI:28876; HSDB 3234; L-Phenylalanine, 4-(bis(2-chloroethyl)amino)-; EINECS 205-726-3; Mephalan; At-290; p-N,N-bis(2-chloroethyl)amino-L-phenylalanine; NSC 241286; UNII-Q41OR9510P; BRN 2816456; DTXSID6020804; L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine; Q41OR9510P; 8057-25-8; CHEMBL852; NSC-241286; Alanine, 3-(p-(bis(2-chloroethyl)amino)phenyl)-, L-; DTXCID00804; 3025 C.B.; ALKERAN (TN); NIOSH/AY3360000; 3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine; L-phenylalanine mustard (L-PAM); NSC8806; 4-14-00-01689 (Beilstein Handbook Reference); Alanine, 3-[p-[bis(2-chloroethyl)amino]phenyl]-, L-; Melphalan [USAN:USP:INN:BAN:JAN]; NCGC00090757-02; MELPHALAN (IARC); MELPHALAN [IARC]; (2S)-2-azaniumyl-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoate; Melfalano (INN-Spanish); Melphalanum (INN-Latin); p-L-sarcolysine; AY33600000; p-N-Di(chloroethyl)aminophenylalanine; MELPHALAN (MART.); MELPHALAN [MART.]; L-Phenylalanine, 4-[bis(2-chloroethyl)amino]-; Alanine, 3-(p-(bis(2-chloroethyl)amino)phenyl)-; MELPHALAN (EP MONOGRAPH); MELPHALAN [EP MONOGRAPH]; MELPHALAN (USP MONOGRAPH); MELPHALAN [USP MONOGRAPH]; (S)-2-amino-3-(4-(bis(2-chloroethyl)amino)phenyl)propanoic acid; CB 3007; (2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid; (2S)-2-amino-3-{4-[bis(2-chloroethyl)amino]phenyl}propanoic acid; (S)-2-Amino-3-{4-[bis-(2-chloro-ethyl)-amino]-phenyl}-propionic acid; Melphalan (USAN:USP:INN:BAN:JAN); CAS-148-82-3; SMR000058720; Mustard, Phenylalanine; RCRA waste no. U150; MFCD00057717; NSC241286; Melphalan, powder; Prestwick_1006; Spectrum_000397; Melphalan USP, 2 mg; MELPHALAN [INN]; MELPHALAN [JAN]; MELPHALAN [MI]; MELPHALAN [HSDB]; MELPHALAN [USAN]; Spectrum2_000074; Spectrum3_000684; Spectrum4_000882; Spectrum5_001601; MELPHALAN [VANDF]; Epitope ID:141802; 4-[Bis-(2-chloroethyl)amino]-L-phenylalanine; MELPHALAN [WHO-DD]; SCHEMBL5872; BSPBio_002407; KBioGR_001284; KBioSS_000877; MLS001333666; MLS002153368; BIDD:GT0044; DivK1c_000653; SPECTRUM1500382; SPBio_000287; Melphalan (JP17/USP/INN); GTPL7620; MELPHALAN [ORANGE BOOK]; HMS502A15; KBio1_000653; KBio2_000877; KBio2_003445; KBio2_006013; KBio3_001627; L01AA03; L-Sarcolysin Phenylalanine mustard; NINDS_000653; HMS2090B09; HMS2091B16; HMS2235D21; Pharmakon1600-01500382; Tox21_111010; Tox21_202522; BDBM50025837; CCG-39704; DL-442; NSC757098; s8266; AKOS015895374; p-di(chloroethyl)amino-L-phenylalanine; Tox21_111010_1; CS-3120; DB01042; NSC-757098; IDI1_000653; Para-di(2-chloroethyl)aminophenylalanine; SMP2_000174; NCGC00090757-01; NCGC00090757-03; NCGC00090757-04; NCGC00090757-05; NCGC00090757-06; NCGC00260071-01; AS-13314; HY-17575; WR-19813; 4-bis(2-chloroethyl)amino-l-phenylalanine; SBI-0052787.P003; Para-di(2-chloroethyl)amino-L-phenylalanine; NS00068077; 4-[bis(2-chloroethyl)-amino]-L-phenylalanine; 4-[bis(2-chloroethyl)-amino]-l-phenyl-alanine; 4-[bis(2-chloroethyl)amino]-(L)-phenylalanine; C07122; D00369; 3(p-(bis(2-chloroethyl)amino)phenyl)-l-alanine; AB00053282-07; AB00053282-08; AB00053282_09; EN300-7479343; P-DI-(2-CHLOROETHYL)AMINO-L-PHENYLALNINE; A808810; SR-05000001667; Q2298283; SR-05000001667-1; W-108096; BRD-K87827419-001-02-8; L-PHENYLALANINE,4-(BIS(2-CHLOROETHYL)AMINO)-; P-N-BIS(2-CHLOROETHYL)AMINO)PHENYL)-L-ALANINE; 2-amino-3-[4-bis(2-chloroethyl)amino]phenylpropanoic acid; (2S)-2-azanyl-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid; 2-Amino-3-{4-[bis-(2-chloro-ethyl)-amino]-phenyl}-propionic acid; 2-Amino-3-{4-[bis-(2-chloro-ethyl)-amino]-phenyl}-propionic acid(L-PAM); 2-Amino-3-{4-[bis-(2-chloro-ethyl)-amino]-phenyl}-propionic acid (Melphalan); 2-Amino-3-{4-[bis-(2-chloro-ethyl)-amino]-phenyl}-propionic acid(Melphalan)"	TAR10016	Human Deoxyribonucleic acid (hDNA)	.	460612	D06XES	DB01042	.
DRG00026	Maytansine	Maytansine	Cytotoxic drugs	"MAYTANSINE; Maitansine; Maytansine [USAN]; Maitansinum; Maitansina; NSC-153858; 35846-53-8; Maitansine [INN]; Maytansin; CHEBI:6701; NSC 153858; Maytansine (USAN); N-Acetyl-N-methyl-L-alanine(1S-(1R*,2S*,3R*,5R*,6R*,16E,18E,20S*,21R*))-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethy-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo(19.3.1.1(sup 10,14).0(sup 3,5))hexacosa-10,12,14(26),16,18-pentaen-6-yl ester; 14083FR882; (3beta,4beta,5beta,10beta,11e,13e)-Maytansine; Maitansinum [INN-Latin]; NSC153858; Maitansina [INN-Spanish]; EINECS 252-754-7; BRN 5417399; UNII-14083FR882; L-Alanine, N-acetyl-N-methyl-, 11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo(19.3.1.110,14.03,5)hexacosa-10,12,14(26),16,18-pentaen-6-yl ester, (1S-(1R*,2S*,3R*,5R*,6R*,16E,18E,20S*,21R*))-; MAYTANSINE [MI]; SCHEMBL61357; CHEMBL292702; DTXSID00879995; BDBM50480257; LMPK04000017; (4beta,5beta,11E,13E)-maytansine; HY-13674; CS-0007711; NS00057900; D04864; Q6720157; 3GT"	TAR10017	Microtubule (MT)	.	5281828	.	.	.
DRG00027	Indium-111	Indium-111	Imaging agents	"Indium-111; Indium In-111; 15750-15-9; 111In; 111In radioisotope; Indium, isotope of mass 111; Indium (111 In); E9NGC49E0T; UNII-E9NGC49E0T; In-111 radioisotope; INDIUM IN 111; INDIUM (111IN); INDIUM, IN-111; ISOTOPE OF MASS 111; INDIUM IN 111 [VANDF]; DB11916; INDIUM (111 IN) [WHO-DD]; Q6025171"	TAR10052	Human Deoxyribonucleic acid (hDNA)	P00533	5462099	.	DB11916	.
DRG00028	Gallium-68	.	Radionucleotides	"Gallium-68; Gallium Ga-68; 15757-14-9; Gallium, isotope of mass 68; 98B30EPP5S; 68Ga; UNII-98B30EPP5S; GA 68; Q2516934"	TAR10052	Human Deoxyribonucleic acid (hDNA)	.	5488452	.	.	.
DRG00029	Morphine	Morphine	Analgesics	SCHEMBL4545441	TAR10010	Mu-type opioid receptor (OPRM1)	P35372	9795834	.	DB00295	.
DRG00030	Gambogic acid	.	Cytotoxic drugs	"gambogic acid; 2752-65-0; (-)-Gambogic Acid; Gambogic-acid; R-gambogic acid; beta-Guttiferin; Cambogic acid; B''-Guttiferin; 8N585K83U2; .beta.-Guttiferin; GAMBOGICACID; (Z)-4-((1S,3aR,5S,11R,14aS)-8-hydroxy-2,2,11-trimethyl-13-(3-methylbut-2-en-1-yl)-11-(4-methylpent-3-en-1-yl)-4,7-dioxo-1,2,5,7-tetrahydro-11H-1,5-methanofuro[3,2-g]pyrano[3,2-b]xanthen-3a(4H)-yl)-2-methylbut-2-enoic acid; CHEBI:67521; UNII-8N585K83U2; GAMBOGIC ACID [MI]; CHEMBL555017; CHEMBL5305342; SCHEMBL16160279; GEZHEQNLKAOMCA-RRZNCOCZSA-N; DTXSID101029723; GLXC-02792; BCP21539; HY-N0087; BDBM50366237; MFCD16878985; s2448; AKOS024463359; CCG-270284; CS-1456; AC-34804; BP-22199; Gambogic acid, >=95% (HPLC), powder; H10129; Q5519727; (2Z)-2-METHYL-4-((1R,3AS,5S,11R,14AS)-3A,4,5,7-TETRAHYDRO-8-HYDROXY-3,3,11-TRIMETHYL-13-(3-METHYL-2-BUTEN-1-YL)-11-(4-METHYL-3-PENTEN-1-YL)-7,15-DIOXO-1,5-METHANO-1H,3H,11H-FURO(3,4-G)PYRANO(3,2-B)XANTHEN-1-YL)-2-BUTENOIC ACID; (Z)-4-[(1S,2S,8R,17S,19R)-12-hydroxy-8,21,21-trimethyl-5-(3-methylbut-2-enyl)-8-(4-methylpent-3-enyl)-14,18-dioxo-3,7,20-trioxahexacyclo[15.4.1.02,15.02,19.04,13.06,11]docosa-4(13),5,9,11,15-pentaen-19-yl]-2-methylbut-2-enoic acid; 1,5-Methano-1H,3H,11H-furo(3,4-g)pyrano(3,2-b)xanthene-1-crotonic acid, 3a,4,5,7-tetrahydro-8-hydroxy-alpha,3,3,11-tetramethyl-13-(3-methyl-2-butenyl)-11-(4-methyl-3-pentenyl)-7,15-dioxo-, (Z)-; 2-BUTENOIC ACID, 2-METHYL-4-((1R,3AS,5S,11R,14AS)-3A,4,5,7-TETRAHYDRO-8-HYDROXY-3,3,11-TRIMETHYL-13-(3-METHYL-2-BUTEN-1-YL)-11-(4-METHYL-3-PENTEN-1-YL)-7,15-DIOXO-1,5-METHANO-1H,3H,11H-FURO(3,4-G)PYRANO(3,2-B)XANTHEN-1-YL)-, (2Z)-"	.	.	.	9852185	.	.	.
DRG00031	Mertansine DM1	Mertansine DM1	Cytotoxic drugs	"Mertansine; 139504-50-0; Maytansinoid DM 1; maytansinoid DM1; Mertansine (DM1); N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine; DDZ29HGH0E; DM 1; [(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] (2S)-2-[methyl(3-sulfanylpropanoyl)amino]propanoate; DM1; N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine, L-; Maytansine, N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-; DM1 [Maytansinoid]; DM 1 [Maytansinoid]; UNII-DDZ29HGH0E; Mertasine; MFCD28398157; DM1;Maytansinoid; Maytansinoid DM1; Dm-1; MAYTANSINOID DM1 [MI]; CHEMBL4802230; SCHEMBL13558634; CHEBI:82755; ANZJBCHSOXCCRQ-FKUXLPTCSA-N; DTXSID801026968; DM1 , Maytansinoid DM1; s6773; CS-5804; DA-48536; HY-19792; Q4515649; (1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.1(10,14).0(3,5)]hexacosa-10(26),11,13,16,18-pentaen-6-yl (2S)-2-[methyl(3-sulfanylpropanoyl)amino]propanoate"	TAR10017	Microtubule (MT)	.	11343137	.	.	.
DRG00032	"N1-(7-chloroquinolin-4-yl)butane-1,4-diamine"	.	Antimalarial Drugs	"53186-45-1; 4-(4-Aminobutyl)amino-7-chloroquinoline; N1-(7-CHLOROQUINOLIN-4-YL)BUTANE-1,4-DIAMINE; 1,4-Butanediamine, n1-(7-chloro-4-quinolinyl)-; N'-(7-chloroquinolin-4-yl)butane-1,4-diamine; MFCD07700284; N-(4-aminobutyl)-7-chloroquinolin-4-amine; N-(7-chloroquinolin-4-yl)butane-1,4-diamine; CHEMBL236491; SCHEMBL1147513; DTXSID50472238; FIVQKRXTOFYZCQ-UHFFFAOYSA-N; AKOS010116787; SB71980; AS-53416; CS-0188349; N-(7-chloro-4-quinolyl)-1,4-diaminobutane; N'-(7-chloro-4-quinolyl)butane-1,4-diamine; P16457; N1-(7-Chloro-4-quinolinyl)-1,4-butanediamine"	.	.	.	11770817	.	.	.
DRG00033	Ursodeoxycholic acid	Ursodeoxycholic acid	Cytotoxic drugs	"Cholan-24-oic acid, 3,7-dihydroxy-, (3a,5b,7b)-; (4R)-4-((3S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid; (4R)-4-[(3S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid; SCHEMBL27201; AMY8904; AKOS024462710; DS-9638; CS-0457382; F12824; (3beta,7beta)-3,7-Dihydroxycholan-24-oic acid; (4R)-4-[(1R,3AS,3BR,4S,7S,9AS,9BS,11AR)-4,7-DIHYDROXY-9A,11A-DIMETHYL-TETRADECAHYDRO-1H-CYCLOPENTA[A]PHENANTHREN-1-YL]PENTANOIC ACID; 1229519-10-1"	TAR10013	Biliverdin reductase A (BLVRA)	P53004	13505246	.	.	.
DRG00034	Chlorin e6	.	Cytotoxic drugs	"Chlorin e6 dimethylester; 197444-89-6; (17S,18S)-12-Ethenyl-7-ethyl-20-(2-methoxy-2-oxoethyl)-18-(3-methoxy-3-oxopropyl)-3,8,13,17-tetramethyl-17,18,22,23-tetrahydroporphyrin-2-carboxylic acid; SCHEMBL21184917"	.	.	.	15381804	.	.	.
DRG00035	β-Naloxamine	.	Partial agonist of the KOR	SCHEMBL13416089	TAR10027	Kappa-type opioid receptor (OPRK1)	.	23579705	.	.	.
DRG00036	Cytolysin-dithiopyridine	.	Cytotoxic drugs	.	.	.	.	25058428	.	.	.
DRG00037	TGX-D1	TGX-D1	Cytotoxic drugs	TGX-D1; BL-05; GLXC-01756; 1308384-65-7	TAR10022	Phosphatidylinositol 3-kinase catalytic subunit type 3 (PIK3C3)	.	53232474	.	.	.
DRG00038	Monomethyl auristatin E	Monomethyl auristatin E	Cytotoxic drugs	Monomethyl auristatin E; MMAE; 474645-27-7; Monomethyl auristatin E (vedotin); SCHEMBL16645126; EX-A636; AKOS032947340; D09691	TAR10017	Microtubule (MT)	.	53297465	.	.	.
DRG00039	Morphine-6-glucuronide	.	Analgesics	.	TAR10010	Mu-type opioid receptor (OPRM1)	.	58533559	.	.	.
DRG00040	NLG919	NLG919	Cytotoxic drugs	"NLG919; 1402836-58-1; 1-cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethanol; NLG919 (GDC-0919); 1-Cyclohexyl-2-(5H-imidazo-[5,1-a]isoindol-5-yl)ethanol; CHEMBL3629569; NLG919(GDC-0919,Navoximod); MFCD26142661; 5H-Imidazo[5,1-a]isoindole-5-ethanol, alpha-cyclohexyl-; 1-Cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethan-1-ol; 1-CYCLOHEXYL-2-{5H-IMIDAZO[4,3-A]ISOINDOL-5-YL}ETHANOL; YTRRAUACYORZLX-UHFFFAOYSA-N; GTPL9019; SCHEMBL13280897; DTXSID20735206; EX-A574; HMS3653M05; AMY12328; BCP09887; BDBM50126144; s7111; AKOS025287054; CCG-267268; CS-3512; SB16495; NCGC00386274-04; AC-30124; AS-35112; DA-45347; HY-13983; SY046802; FT-0700192; SW219857-1; A853907; J-690162; Q27087945; 1-cyclohexyl-2-[5H-imidazo[4,3-a]isoindol-5-yl]ethan-1-ol; 5-(2-Cyclohexyl-2-hydroxyethyl)-5H-imidazo[5,1-a]isoindole; 3-(2-Amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione hydrochloride; a-Cyclohexyl-5H-imidazo[5,1-a]isoindole-5-ethanol; 1-Cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethanol; NLG919; alpha-Cyclohexyl-5H-imidazo[5,1-a]isoindole-5-ethanol;1-cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethanol"	TAR10023	"Indoleamine 2,3-dioxygenase 1 (IDO1)"	.	66558287	D06MHZ	.	CHEMBL3629569
DRG00041	12Adt-asp	12Adt-asp	Cytotoxic drugs	12Adt-asp; Aspartyl-12adt; UNII-U4U7MXY86U; U4U7MXY86U; 1172636-20-2; CHEMBL4802225; C21580; Q27290687	TAR10021	Calcium-transporting ATPase type 2C member 1 (ATP2C1)	.	72941986	.	.	.
DRG00042	Tubugis	.	Cytotoxic drugs	.	TAR10017	Microtubule (MT)	.	76013049	.	.	.
DRG00043	JH-VII-139-1	.	Cytotoxic drugs	CHEMBL3747134; SCHEMBL20494794; BDBM50500360	TAR10024	SRSF protein kinase 1 (SRPK1)	.	127041847	.	.	.
DRG00044	AGRO100	.	Anticancer aptamer	AGRO100; DB04998; PD098430	.	.	.	145994598	.	DB04998	.
DRG00045	Duocarmycin Sa	Duocarmycin Sa	Cytotoxic drugs	CHEMBL4443767	TAR10016	Human Deoxyribonucleic acid (hDNA)	.	155516542	.	.	.
DRG00046	Hydroxycamptothecin	Hydroxycamptothecin	Cytotoxic drugs	SCHEMBL24513666	TAR10008	DNA topoisomerase 1 (TOP1)	P11387	167109626	.	.	.
DRG00047	Lutetium-175	Lutetium-175	Stable nuclide	"7439-94-3; Lu; Lutetium; lutecium; lutetium atom; CASSIOPEUM; LUTETIUM, ELEMENTAL; 5H0DOZ21UJ; Lutetium foil; DTXSID5047746; MFCD00011098; Lutetium standard; UNII-5H0DOZ21UJ; Lutetium Standard: Lu @ 1000 microg/mL in 5% HNO3; Lutetium Standard: Lu @ 10000 microg/mL in 5% HNO3; cassiopium; lutecio; Cassiopeium; Lutetium pieces; hydrido lutetium; Lutetium Nanofoil; Lutetium Dihydride; EINECS 231-103-0; Lutetium ingot, 3N; Lutetium powder, 3N; LUTETIUM [MI]; Lutetium (III) Hydride; 71Lu; Lutetium Standard: Lu @ 10 microg/mL in 2% HNO3; DTXCID9027730; CHEBI:33382; OHSVLFRHMCKCQY-UHFFFAOYSA-N; Lutetium Internal Standard: Lu @ 10 microg/mL in 2% HNO3; Lutetium pieces, distilled dendritic; AKOS015902696; Lutetium foil, 0.5mm (0.02in) thick; Lutetium foil, 0.1mm (0.004in) thick; NS00082210; Q1857; Manganese Telluride (MnTe) Sputtering Targets; Lutetium - Lu @ 1000 microg/mL in 5% HNO3; Lutetium, powder, 1g, max. particle size 500 micron, 99.9%; Lutetium, foil, thickness 1.0 mm, size 25 x 25 mm, purity 99%; Lutetium, lump, 25 mm max. lump size, weight 1 g, purity 99.9%; Lutetium, lump, 25 mm max. lump size, weight 2 g, purity 99.9%; Lutetium, foil, thickness 0.025 mm, size 25 x 25 mm, purity 99%; Lutetium, foil, thickness 0.025 mm, size 50 x 50 mm, purity 99%; Lutetium, foil, thickness 0.1 mm, size 25 x 25 mm, tolerance 0.2; Lutetium, foil, thickness 0.125 mm, size 25 x 25 mm, tolerance 0.2; Lutetium, foil, thickness 0.125 mm, size 50 x 50 mm, tolerance 0.2; Lutetium, foil, thickness 0.15 mm, size 25 x 25 mm, tolerance 0.2; Lutetium, dendritic pieces, purified by distillation, 99.99% trace metals basis"	TAR10052	Human Deoxyribonucleic acid (hDNA)	.	23929	.	.	.
DRG00048	Fluorine-18	Fluorine-18	Imaging agents	Fluorine-18; fluorane; 13981-56-1; 18F radioisotope; fluorine-18 atom; 18 Fluorine; CHEMBL1909275; CHEBI:36939; DTXSID00930616; KRHYYFGTRYWZRS-BJUDXGSMSA-N; F-18; (18)F; (18)9F; Q2031969	TAR10052	Human Deoxyribonucleic acid (hDNA)	.	105162	.	DB13134	.
DRG00049	Lutetium-177	Lutetium-177	Radionucleotides	Lutetium-177; Lutetium Lu-177; 14265-75-9; 177Lu; Lu 177; Lu-177; Lutetium Lu 177; Lutetium (Lu 177); BRH40Y9V1Q; DTXSID30931570; Lutetium (Lu 177) [WHO-DD]; DB13982; Q18882670	TAR10052	Human Deoxyribonucleic acid (hDNA)	.	161046	.	DB13982	.
DRG00050	Terbium-159	.	Stable nuclide	.	.	.	.	.	.	.	.
DRG00051	Terbium-161	Terbium-161	Radionucleotides	"Terbium-161; 14391-19-6; 161Tb; Terbium, isotope of mass 161; (~161~Tb)Terbium; DTXSID10932146"	TAR10052	Human Deoxyribonucleic acid (hDNA)	.	177426	.	.	.
DRG00052	Copper-64	Copper-64	Imaging agents	"Copper-64; Copper, isotope of mass 64; Copper Cu-64; 13981-25-4; 2MK2L64N0S; UNII-2MK2L64N0S; 64Cu radioisotope; Copper, Cu-64; (~64~Cu)Copper; DTXSID10930607; Q27254977"	TAR10052	Human Deoxyribonucleic acid (hDNA)	.	105141	.	DB13980	.
DRG00053	Actinium-225	Actinium-225	Radionucleotides	"Actinium-225; E95CP8XCT3; Actinium cation Ac-225; 14265-85-1; UNII-E95CP8XCT3; Actinium +3 cation Ac-225; Actinium, isotope of mass 225 (225Ac3+); 1261243-53-1; Actimab-M; Actinium, isotope of mass 225; Actinium Ac-225; (~225~Ac)Actinium; HI04ACM8I1; DTXSID50931577"	TAR10052	Human Deoxyribonucleic acid (hDNA)	.	167045	D0XE4W	.	.
DRG00054	Yttrium-90	Yttrium-90	Radionucleotides	"Yttrium-90; Yttrium Y-90; 10098-91-6; 90Y radioisotope; Yttrium, isotope of mass 90; Yttrium Y 90; Yttrium (90 Y); Y-90; 1K8M7UR6O1; Yttrium Radioisotopes; 90Y; SIR-Spheres; 90Yttrium; UNII-1K8M7UR6O1; Radioactive Yttrium; Y-90 radioisotope; Yttrium, radioactive; Yttrium (90Y); HSDB 7406; DTXSID40874005; YTTRIUM (90 Y) [WHO-DD]; DB13076; Y 90; Q2650092; D015021000"	TAR10052	Human Deoxyribonucleic acid (hDNA)	.	104760	.	DB13076	.
DRG00055	Technetium-99m	Technetium-99m	Imaging agents	"Technetium-99; Technetium Tc-99m; Technetium-99M; 14133-76-7; Technetium-99mTc; Technetium, isotope of mass 99; CEA-Scan; 99Tc; Arcitumomab technetium-99m; Technetium 99m; Technetium-99m arcitumomab; CEA scan; UNII-029JF1SCU8; Tc 99; Technetium Tc 99m; Tc-99m arcitumomab; Technetium Tc 99m arcitumomab; Technetium (99mTc); Technetium, Tc-99m; Technetium (Tc 99m); Arcitumomab 99mtc-labeled form [MI]; Technetium-99m arcitumomab [WHO-DD]; 029JF1SCU8; Arcitumomab 99MTC-labeled form; Technetium (99mtc) arcitumomab; 6EW75241VU; Arcitumomab, technetium-99m labeled; 154361-49-6; Technegas; UNII-6EW75241VU; 99Tc radioisotope; Technetium,Tc-99m; Technetium 99m metal; (99)Tc; CHEBI:33371; DTXSID00874006; GKLVYJBZJHMRIY-OUBTZVSYSA-N; TECHNETIUM TC 99M [VANDF]; TECHNETIUM,TC-99M [VANDF]; (99)43Tc; TECHNETIUM TC 99M [WHO-DD]; TECHNETIUM (99MTC) TECHNEGAS; DB14227; TECHNETIUM (TC 99M) [VANDF]; Technetium, isotope of mass 99m(6.01 h)"	TAR10052	Human Deoxyribonucleic acid (hDNA)	.	26476	.	DB14227	.
DRG00056	Camptothecin	Camptothecin	Cytotoxic drugs	.	TAR10008	DNA topoisomerase 1 (TOP1)	P11387	.	.	.	.
DRG00057	Chlorambucils; Camptothecins	.	Cytotoxic drugs	.	TAR10019	DNA topoisomerase 1 (TOP1); Human Deoxyribonucleic acid (hDNA)	P11387	.	.	.	.
DRG00058	Cryptophycin analog	.	Cytotoxic drugs	.	TAR10017	Microtubule (MT)	.	.	.	.	.
DRG00059	Sunitinib	Sunitinib	Retinal ganglion cells protection drugs	"Sunitinib; 557795-19-4; Sutent; SU11248; SU-11248; sunitinibum; Su-011248; Sunitinib Base; 342641-94-5; (Z)-N-(2-(Diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-{[(3Z)-5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}-2,4-dimethyl-1H-pyrrole-3-carboxamide; Sunitinib (INN); Sunitinib [INN]; NSC-750690; SU 11248; UNII-V99T50803M; CHEBI:38940; HSDB 7932; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; CHEMBL535; N-(2-(Diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; NSC-736511; V99T50803M; SU011248; NSC750690; Sunitinib, Free base; NSC 736511; NSC 750690; 1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-; n-(2-(diethylamino)ethyl)-5-((z)-(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl)-2,4-dimethyl-1h-pyrrole-3-carboxamide; N-(2-(DIETHYLAMINO)ETHYL)-5-((Z)-(5-FLUORO-2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE; Sunitinib (free base); Sunitinib [INN:BAN]; NCGC00164631-01; MFCD09260778; C22H27FN4O2; (Z)-Sunitinib; 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-; 5-(5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide; 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide; Sutent (free base); KS-5022; SUNITINIB [MI]; 1126641-10-8; SUNITINIB [VANDF]; SCHEMBL8081; SUNITINIB [WHO-DD]; SUNITINIB [EMA EPAR]; BDBM4814; GTPL5713; Sutent, Sunitinib, SU11248; DTXCID9021134; CHEBI:91430; EX-A553; L01XE04; WINHZLLDWRZWRT-ATVHPVEESA-N; BCPP000057; K00588a; (E)-N-[2-(Diethylamono)ethyl]-5-[(5-fluoro-2-oxo-1,2-dihydro-3H-indole-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; HY-10255A; NSC800937; s7781; AKOS015908193; AKOS025312424; CCG-268638; CS-1670; DB01268; NSC-800937; NCGC00164631-02; NCGC00164631-04; 5-(5-fluoro-2-oxo-1,2-dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide; BD164426; 1,2,4,5-tetramethylpyrrole-3-carboxamide; AM20090630; FT-0651493; FT-0659515; NS00004661; D08552; EN300-323230; AB01273976-01; AB01273976-02; AB01273976_04; A822143; A830806; Q417542; SR-00000000005; SR-00000000005-2; Q27163278; Z2568722545; 1H-Pyrrole-3-carboxamide,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-; 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid(2-diethylamino-ethyl)-amide; N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1 pound not2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2 pound not4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carbo"	TAR10011	Vascular endothelial growth factor receptor 2 (KDR)	P35968	5329102	D0YX2B	DB01268	CHEMBL535
DRG00060	Platinum(IV)	Platinum(IV)	Cytotoxic drugs	.	.	.	.	.	.	.	.
DRG00061	KLUKLUKKLUKLUK	.	Lytic peptide	.	.	.	.	.	.	.	.
DRG00063	Pyrrolobenzodiazepine (PBD) dimer	.	Cytotoxic drugs	.	TAR10016	Human Deoxyribonucleic acid (hDNA)	.	.	.	.	.
DRG00064	Choline phosphate	Choline phosphate	Immunomodulatory drugs	"107-73-3; PHOSPHORYLCHOLINE; Phosphorylcholine Chloride; choline phosphate; Choline phosphate chloride; Trimethyl-(2-Phosphonooxyethyl)Azanium Chloride; phosphocholine chloride; N,N,N-trimethyl-2-(phosphonooxy)ethanaminium chloride; Ethanaminium, N,N,N-trimethyl-2-(phosphonooxy)-, chloride; Phosphorylcholine (chloride); trimethyl(2-phosphonooxyethyl)azanium;chloride; 96AN057F7A; [2-(trimethylazaniumyl)ethoxy]phosphonic acid chloride; Trimethyl(2-(phosphonooxy)ethyl)ammonium chloride; UNII-96AN057F7A; Ethanaminium, N,N,N-trimethyl-2-(phosphonooxy)-, chloride (1:1) (ACI); Choline, chloride, dihydrogen phosphate (7CI, 8CI); Ethanaminium, N,N,N-trimethyl-2-(phosphonooxy)-, chloride (9CI); Choline phosphate; Choline phosphate chloride; Choline phosphochlor; EINECS 203-516-6; FOSFORYLCHOLINE; Choline phosphochloride; PC-Cl; SCHEMBL24426; PHOSPHORYLCHOLINE [MI]; FOSFORYLCHOLINE [MART.]; CHEBI:61040; DTXSID90910205; HY-B2233; AKOS027327289; CS-7829; WS-03268; DB-257203; NS00041278; E85458; [2-(phosphonooxy)ethyl]trimethylammonium chloride; (2-HYDROXYETHYL)TRIMETHYLAMMONIUM CHLORIDE DIHYDROGEN PHOSPHATE"	.	.	.	7886	.	.	.
DRG00065	Irinotecan	Irinotecan	Cytotoxic drugs	"irinotecan; 97682-44-5; (+)-Irinotecan; Camptosar; Irinophore C; Irinotecanum; Biotecan; Irinotecan lactone; Irinotecan mylan; Irinotecanum [INN-Latin]; Campto; Irinotecan Free base; CPT-11; (S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl [1,4'-bipiperidine]-1'-carboxylate; HSDB 7607; Irinotecan (INN); NSC-728073; CHEBI:80630; CHEMBL481; UNII-7673326042; DTXSID1041051; 97682-44-5 (Free base); NSC728073; NSC 728073; (4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE; 1,4'-Bipiperidine-1'-carboxylic acid (S)-4,11-diethyl-3,4,12,14- tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester; IRINOTECAN [INN]; Irinotecanum (INN-Latin); Irinotecan [INN:BAN]; (1,4'-Bipiperidine)-1'-carboxylic acid, 4,11-diethyl-3,4,12-14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinolin-9-yl ester, (S)-; CPT-11 hydrochloride;Camptothecin 11 hydrochloride; Irrinotecan; Biotecan (TN); (1,4'-Bipiperidine)-1'-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinolin-9-yl ester; [1,4'-Bipiperidine]-1'-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester; 1,4'-bipiperidine-1'-carboxylic acid (s)-4,11-diethyl-3,4,12,14- tetrahydro-4-hydroxy-3,14-dioxo-1h-pyrano(3',4':6,7)indolizino(1,2-b)quinolin-9-yl ester; Irinotecan?; MFCD00866307; (4S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinolin-9-yl (1,4'-bipiperidine)-1'-carboxylate; (4S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl [1,4'-bipiperidine]-1'-carboxylate; IRINOTECAN [MI]; IRINOTECAN [HSDB]; IRINOTECAN [VANDF]; SCHEMBL4034; IRINOTECAN [WHO-DD]; IRINOTECAN; CPT-11; BSPBio_002346; GTPL6823; DTXCID9021051; AMY4227; L01XX19; 1u65; BCP02860; BDBM50128267; s1198; AKOS015894969; AB07527; AC-7469; BCP9000793; CS-1138; DB00762; NCGC00178697-02; NCGC00178697-05; (4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate; AS-14323; HY-16562; NCI60_005051; NS00004943; D08086; EN300-708800; AB00698464-07; AB00698464-09; AB00698464-10; AB00698464-11; AB00698464_12; AB00698464_13; AB00698464_14; A845740; Q412197; BRD-K08547377-003-02-4; (diethyl-hydroxy-dioxo-[?]yl) 4-(1-piperidyl)piperidine-1-carboxylate; (+)-7-ethyl-10-hydroxycamptothecine 10-(1,4'-bipiperidine)-1'-carboxylate; 2-methoxy-5-[2-(3-sulfophenyl)-5-(4-sulfophenyl)pyrylium-4-yl]benzenesulfonic acid; (+)-(4S)-4,11-diethyl-4-hydroxy-9-((4-piperidino-piperidino)carbonyloxy)-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinol-3,14,(4H,12H)-dione; (1,4'-bipiperidine)-1'-carboxylic acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinolin-9-yl ester; (19S)-10,19-Diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.0[2,11].0[4,9].0[15,20]]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaen-7-yl 4-(piperidin-1-yl)piperidine-1-carboxylate; (19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaen-7-yl [1,4'-bipiperidine]-1'-carboxylate; (19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaen-7-yl 4-(piperidin-1-yl)piperidine-1-carboxylate; (4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3'',4'':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4''-BIPIPERIDINE-1''-CARBOXYLATE; (S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl[1,4'-bipiperidine]-1'-carboxylate; [(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate; [1,4'']bipiperidinyl-1''-carboxylic acid (S)-4,11-diethyl-4-hydroxy-3,13-dioxo-3,4,12,13-tetrahydro-1H-2-oxa-6,12a-diaza-dibenzo[b,h]fluoren-9-yl ester; [1,4'']Bipiperidinyl-1''-carboxylic acid 4,11-diethyl-4-hydroxy-3,13-dioxo-3,4,12,13-tetrahydro-1H-2-oxa-6,12a-diaza-dibenzo[b,h]fluoren-9-yl ester"	TAR10008	DNA topoisomerase 1 (TOP1)	P11387	60838	D07HOB	DB00762	CHEMBL481
DRG00066	5-Carboxyfluorescein	5-Carboxyfluorescein	Fluorescent dye	"5-Carboxyfluorescein; 76823-03-5; 5-FAM; 4-carboxyfluorescein; 4(5)-Carboxyfluorescein; 3',6'-Dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthene]-5-carboxylic acid; MFCD00036874; 3',6'-dihydroxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-carboxylic acid; AB2MM66GSF; 3',6'-dihydroxy-3-oxo-3H-spiro[2-benzofuran-1,9'-xanthene]-5-carboxylic acid; 5-Carboxyfluorescein (Technical Grade); Spiro(isobenzofuran-1(3H),9'-(9H)xanthene)-5-carboxylic acid, 3',6-dihydroxy-3-oxo-; 5-Carboxyfluorescein; 3',6'-Dihydroxy-3-oxo-spiro[isobenzofuran-1(3H),9'-[9H]xanthene]-5-carboxylic acid; UNII-AB2MM66GSF; SCHEMBL20095; BIDD:GT0758; CHEBI:51617; 5 - FAM; DTXSID30227642; GLXC-10846; BCP22613; 5-Carboxyfluorescein, 99% (HPLC); AKOS015901359; 5(6)-carboxyfluorescein, mixed isomers; Spiro[isobenzofuran-1(3H),9'-[9H]xanthene]-5-carboxylicacid, 3',6'-dihydroxy-3-oxo-; AC-32459; AS-32304; BP-30031; HY-66022; PD012213; SY057359; C2477; FT-0620190; J-100059; Q27122687; Z1139186537; 5-Carboxyfluorescein, BioReagent, suitable for fluorescence, >=95% (HPLC); 3',6'-Dihydroxy-3-oxo-spiro[isobenzofuran-1,9'-xanthene]-5-carboxylic acid; 3',6'-DIHYDROXY-3-OXOSPIRO(ISOBENZOFURAN-1(3H),9'-(9H)XANTHENE)-5-CARBOXYLIC ACID; SPIRO(ISOBENZOFURAN-1(3H),9'-(9H)XANTHENE)-5-CARBOXYLIC ACID, 3',6'-DIHYDROXY-3-OXO-"	TAR10028	"Alkaline phosphatase, tissue-nonspecific isozyme (ALPL)"	P05186	123755	.	.	.
DRG00067	P-Coumaric acid	P-Coumaric acid	.	"4-trans-4-Hydroxycinnamic acid; 4-hydroxy cinnamic acid; CHEBI:36090; (Z)-3-(4-hydroxyphenyl)acrylic acid; 2-Propenoic acid, 3-(4-hydroxyphenyl)-, (2Z)-; 4hydroxycinnamic acid; p-hydroxy cinnamic acid; 4- hydroxycinnamic acid; 4-hy droxycinnamic acid; 4-hydroxy-cinnamic acid; Enamine_005378; Epitope ID:116879; DTXSID6064660; NGSWKAQJJWESNS-UHFFFAOYSA-N; 3-(4-hydroxy-phenyl)-acrylic acid; MFCD00064995; AKOS017269003; SY015618; SY020906; SY027398; DB-055828; DB-092338; NS00004354; Q27104329"	.	.	.	322	.	DB04066	.
DRG00068	Vitamin B3 (nicotinic acid)	Vitamin B3 (nicotinic acid)	.	"nicotinic acid; niacin; 59-67-6; Pyridine-3-carboxylic acid; 3-pyridinecarboxylic acid; 3-Carboxypyridine; wampocap; Niaspan; Acidum nicotinicum; nicolar; Apelagrin; Pellagrin; Akotin; Daskil; Efacin; Pelonin; Linic; vitamin B3; nicamin; nicobid; nicocap; Enduracin; Nicodelmine; Niconacid; Nicotinipca; Pellagramin; Direktan; Nicacid; Nicangin; Peviton; Bionic; Diacin; Nicyl; Nyclin; Niac; Vitaplex N; Davitamon PP; Nico-Span; Tega-Span; Nicocidin; Nicocrisina; Niconazid; Nicoside; Nicotamin; Nicotene; Nicovasan; Nicovasen; Nipellen; SK-Niacin; Naotin; Niacor; Nicodon; Niconat; Nicosan 3; Nicosyl; Nicotil; Tinic; 3-Carboxylpyridine; Nicotine acid; nicotinate; Slo-niacin; NICO; 3-Picolinic acid; Nicotinsaure; Nico-400; Acide nicotinique; Pyridine-beta-carboxylic acid; Nicagin; anti-Pellagra vitamin; Caswell No. 598; PP Factor; Kyselina nikotinova; P.P. factor; Pellagra preventive factor; S115; Nicotinsaure [German]; Acido nicotinico; 3-Pyridylcarboxylic acid; m-Pyridinecarboxylic acid; Kyselina nikotinova [Czech]; MFCD00006391; niacine; CCRIS 1902; Pyridine-carboxylique-3; EPA Pesticide Chemical Code 056701; Acide nicotinique [INN-French]; Acido nicotinico [INN-Spanish]; Acidum nicotinicum [INN-Latin]; HSDB 3134; Pyridine-carboxylique-3 [French]; AI3-18994; Pyridinecarboxylic acid, 3-; Niacin [USP]; SR 4390; BRN 0109591; Niacin extended release; Nicotinic acid [INN]; NAH; CHEMBL573; beta-pyridinecarboxylic acid; NSC-169454; MLS000069603; Pyridine-.beta.-carboxylic acid; DTXSID1020932; CHEBI:15940; Niacin (USP); 2679MF687A; P.P. factor-pellagra preventive factor; CAS-59-67-6; pyridine, 3-carboxy-; NCGC00016268-02; SMR000059024; [5, 6-3H]-niacin; DTXCID10932; Niacin [USAN]; Nicotinicacid; NIO; Niacin (nicotinic acid); SR-01000722017; EINECS 200-441-0; NIASPAN TITRATION STARTER PACK; NSC 169454; pellagra; Nikotinsaeure; Ncotnc acd; Nicotinic Acid;; UNII-2679MF687A; preventative factor; antipellagra vitamin; Niaspan (TN); 3-Pyridylcarboxylate; 3PyrCOOH; [3H]nicotinic acid; Niacor (TN); Nicotinic Acid,(S); [3H]-Nicotinic acid; Spectrum_001063; Nicotinic acid, Ph Eur; pyridinium-3-carboxylate; NIACIN [VANDF]; NIACIN [HSDB]; Nicotinic acid (Niacin); 5-pyridinecarboxylic acid; NIACIN [FCC]; NIACIN [USP-RS]; Opera_ID_1346; Prestwick0_000881; Prestwick1_000881; Prestwick2_000881; Prestwick3_000881; Pyridine-3-carbonic acid; Spectrum2_000006; Spectrum3_000515; Spectrum4_000965; Spectrum5_001287; VITAMIN B-3; 3-Pyridyl carboxylic acid; Nicotinic acid-d3(major); WLN: T6NJ CVQ; 3-pyridine carboxylic acid; bmse000104; Nicotinic acid, >=98%; Nicotinic acid, USP grade; EC 200-441-0; SCHEMBL1433; NICOTINIC ACID [MI]; Oprea1_514398; VITAMIN B3 [VANDF]; BSPBio_000662; BSPBio_002069; KBioGR_001309; KBioSS_001543; NIACIN [ORANGE BOOK]; NICOTINIC ACID [JAN]; 5-22-02-00057 (Beilstein Handbook Reference); Nicotinic acid (Vitamin B3); BIDD:GT0644; DivK1c_000695; Nicotinic acid (JP17/INN); SIMCOR COMPONENT NIACIN; SPECTRUM1500430; .beta.-Pyridinecarboxylic acid; SPBio_000011; SPBio_002881; ADVICOR COMPONENT NIACIN; NIACIN [USP MONOGRAPH]; NICOTINIC ACID [VANDF]; BPBio1_000730; GTPL1588; GTPL1594; NICOTINIC ACID [MART.]; NICOTINIC ACID [WHO-DD]; NICOTINIC ACID [WHO-IP]; BDBM23515; HMS502C17; KBio1_000695; KBio2_001543; KBio2_004111; KBio2_006679; KBio3_001569; ABT-919; NICOTINIC ACID [EMA EPAR]; NINDS_000695; HMS1570B04; HMS1920P17; HMS2091H22; HMS2097B04; HMS2236A05; HMS3259K21; HMS3371E07; HMS3655K08; HMS3714B04; Pharmakon1600-01500430; Nicotinic acid, analytical standard; BCP16301; HY-B0143; STR00112; Tox21_110337; Tox21_201420; Tox21_302904; AC8691; BBL037343; CCG-38340; NICOTINIC ACID [EP IMPURITY]; Nicotinic acid, for synthesis, 99%; NSC169454; NSC757241; s1744; STK301803; NICOTINIC ACID [EP MONOGRAPH]; AKOS000118980; Nicotinic acid, >=99.5% (HPLC); Tox21_110337_1; AM81316; CS-1946; DB00627; NC00524; Nicotinic Acid 1.0 mg/ml in Methanol; NSC-757241; PS-4255; SDCCGMLS-0066610.P001; IDI1_000695; NCGC00016268-01; NCGC00016268-03; NCGC00016268-04; NCGC00016268-05; NCGC00016268-08; NCGC00016268-09; NCGC00016268-13; NCGC00094734-01; NCGC00094734-02; NCGC00256537-01; NCGC00258971-01; AC-22484; ACIDUM NICOTINICUM [WHO-IP LATIN]; BP-21419; NCI60_001041; Nicotinic acid, NIST(R) SRM(R) 148; Nicotinic acid, plant cell culture tested; SY011111; SBI-0051456.P003; DB-007765; Nicotinic Acid [Matrix for MALDI-TOF/MS]; AB00052050; FT-0600004; FT-0672715; FT-0672716; FT-0672717; FT-0672718; FT-0773496; N0082; N1103; Nicotinic acid 10 microg/mL in Acetonitrile; Nicotinic acid, purum, >=99.0% (HPLC); NS00003500; SW197229-3; EN300-16693; C00253; D00049; Nicotinic acid, SAJ special grade, >=99.5%; AB00052050-13; AB00052050_14; AB00052050_15; Nicotinic acid, meets USP testing specifications; AC-907/25014105; L001199; METHYL NICOTINATE IMPURITY A [EP IMPURITY]; Nicotinic acid, Vetec(TM) reagent grade, >=98%; Q134658; J-523605; SR-01000722017-2; SR-01000722017-3; SR-01000722017-4; Z56755709; 3DDB011E-F3A6-45B6-A2D2-77B2A6E8936E; F2191-0082; Niacin, United States Pharmacopeia (USP) Reference Standard; Nicotinic acid, certified reference material, TraceCERT(R); Nicotinic acid, European Pharmacopoeia (EP) Reference Standard; Nicotinic acid, matrix substance for MALDI-MS, >=99.5% (HPLC); InChI=1/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9; Nicotinic acid, for inorganic trace analysis, >=99.999% (metals basis); Niacin (Nicotinic Acid), Pharmaceutical Secondary Standard; Certified Reference Material; 101113-41-1; Nicotinic acid, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, >=98%"	TAR10053	Nicotinic acid receptor (HCAR2)	Q8TDS4	938	D0N0ES	DB00627	.
DRG00069	Palmitic acid	Palmitic acid	.	"palmitic acid; Hexadecanoic acid; 57-10-3; Cetylic acid; palmitate; n-Hexadecanoic acid; Hexadecylic acid; 1-Pentadecanecarboxylic acid; Hydrofol; n-Hexadecoic acid; Palmitinic acid; hexaectylic acid; Pentadecanecarboxylic acid; 1-Hexyldecanoic Acid; Industrene 4516; Emersol 140; Emersol 143; Hystrene 8016; Hystrene 9016; hexadecoic acid; Palmitinsaeure; Palmitic acid, pure; Palmitic acid 95%; Kortacid 1698; FEMA No. 2832; Loxiol EP 278; Palmitic acid (natural); Hydrofol Acid 1690; Cetyl acid; Prifac 2960; C16:0; HSDB 5001; Pristerene 4934; Pristerene-4934; Edenor C16; NSC 5030; AI3-01594; Lunac P 95KC; Lunac P 95; Lunac P 98; CCRIS 5443; Prifac-2960; CHEBI:15756; NSC5030; NSC-5030; EINECS 200-312-9; UNII-2V16EO95H1; FA 16:0; BRN 0607489; Palmitic acid (NF); DTXSID2021602; Glycon P-45; IMEX C 1498; Hexadecanoic--d5 Acid; 2V16EO95H1; Hexadecanoic acid (9CI); MFCD00002747; 67701-02-4; Palmitic acid (7CI,8CI); CHEMBL82293; DTXCID101602; 1219802-61-5; CH3-[CH2]14-COOH; EC 200-312-9; 4-02-00-01157 (Beilstein Handbook Reference); n-hexadecoate; LMFA01010001; PA 900; EDENOR C 16-98-100; FA 1695; SURFAXIN COMPONENT PALMITIC ACID; 1-hexyldecanoate; NCGC00164358-01; LUCINACTANT COMPONENT PALMITIC ACID; pentadecanecarboxylate; Hexadecanoic acid 10 microg/mL in Acetonitrile; HEXADECANOIC-11,11,12,12-D4 ACID; PALMITIC ACID (II); PALMITIC ACID [II]; PALMITIC ACID (MART.); PALMITIC ACID [MART.]; CH3-(CH2)14-COOH; Palmitic acid; Hexadecanoic acid; PLM; palmic acid; Hexadecanoate (n-C16:0); PALMITIC ACID (EP MONOGRAPH); PALMITIC ACID [EP MONOGRAPH]; Acid, Palmitic; CAS-57-10-3; Acid, Hexadecanoic; HEXADECANOIC-9,9,10,10,11,11,12,12,13,13,14,14,15,15,16,16,16-D17 ACID; SR-01000944716; Palmitic acid [USAN:NF]; palmitoate; Hexadecoate; Palmitinate; Palmitinsaure; palmitic-acid; palmitoic acid; Hexadecanoicacid; Aethalic acid; Hexadecanoic acid Palmitic acid; 2hmb; 2hnx; Palmitic acid_jeyam; n-Hexadecyclic Acid; fatty acid 16:0; Palmitic Acid, FCC; Kortacid 1695; Palmitic acid_RaGuSa; Univol U332; Prifrac 2960; Hexadecanoic acid anion; 3v2q; Palmitic acid, >=99%; bmse000590; Epitope ID:141181; CETYL ACID [VANDF]; PALMITIC ACID [MI]; SCHEMBL6177; PALMITIC ACID [DSC]; PALMITIC ACID [FCC]; PALMITIC ACID [FHFI]; PALMITIC ACID [HSDB]; PALMITIC ACID [USAN]; FAT; WLN: QV15; 1-MONOPALMITIN_met001; P5585_SIGMA; PALMITIC ACID [VANDF]; GTPL1055; QSPL 166; PALMITIC ACID [USP-RS]; PALMITIC ACID [WHO-DD]; (1(1)(3)C)hexadecanoic acid; 1b56; HMS3649N08; Palmitic acid, analytical standard; Palmitic acid, BioXtra, >=99%; Palmitic acid, Grade II, ~95%; HY-N0830; Palmitic acid, natural, 98%, FG; Tox21_112105; Tox21_201671; Tox21_302966; AC9381; BBL011563; BDBM50152850; s3794; STL146733; Palmitic acid, >=95%, FCC, FG; AKOS005720983; Tox21_112105_1; 1ST1714; CCG-267027; CR-0047; DB03796; Palmitic acid, for synthesis, 98.0%; NCGC00164358-02; NCGC00164358-03; NCGC00256424-01; NCGC00259220-01; BP-27917; Palmitic acid, purum, >=98.0% (GC); SY006518; CS-0009861; FT-0626965; FT-0772579; NS00008548; P0002; P1145; Palmitic acid, SAJ first grade, >=95.0%; EN300-19603; 1ST1714-1000; C00249; D05341; Palmitic acid, Vetec(TM) reagent grade, 98%; PALMITIC ACID (CONSTITUENT OF SPIRULINA); Palmitic acid, >=98% palmitic acid basis (GC); A831313; Q209727; Hexadecanoic acid Solution in Methanol, 1000mug/mL; PALMITIC ACID (CONSTITUENT OF FLAX SEED OIL); PALMITIC ACID (CONSTITUENT OF SAW PALMETTO); SR-01000944716-1; SR-01000944716-2; BA71C79B-C9B1-451A-A5BE-B480B5CC7D0C; PALMITIC ACID (CONSTITUENT OF BORAGE SEED OIL); PALMITIC ACID (CONSTITUENT OF SPIRULINA) [DSC]; F0001-1488; Z104474418; PALMITIC ACID (CONSTITUENT OF EVENING PRIMROSE OIL); PALMITIC ACID (CONSTITUENT OF SAW PALMETTO) [DSC]; Palmitic acid, certified reference material, TraceCERT(R); Palmitic acid, European Pharmacopoeia (EP) Reference Standard; Hexadecoic acid , hexadecanoic acid , Cetylic acid; Palmitic acid, United States Pharmacopeia (USP) Reference Standard; Palmitic acid, Pharmaceutical Secondary Standard; Certified Reference Material; Sodium Palmitate, Palmitic acid sodium salt, Sodium hexadecanoate, Sodium pentadecanecarboxylate, HSDB 759"	TAR10045	Fatty acid-binding protein 5 (FABP5)	Q01469	985	D02TVS	DB03796	.
DRG00070	Pyridoxine	Pyridoxine	.	"pyridoxine; 65-23-6; Pyridoxol; Pyridoxin; 3-hydroxy-4,5-bis(hydroxymethyl)-2-methylpyridine; Adermine; Gravidox; Hydoxin; Pyridoxolum; 3,4-Pyridinedimethanol, 5-hydroxy-6-methyl-; 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol; 5-Hydroxy-6-methyl-3,4-pyridinedimethanol; Pyridoxinum; Piridossina; Piridoxina; Piridossina [DCIT]; 3-Hydroxy-4,5-dimethylol-alpha-picoline; Pyridoxinum [INN-Latin]; 12001-77-3; Piridoxina [INN-Spanish]; Hexabione; (5-Hydroxy-6-methylpyridine-3,4-diyl)dimethanol; 2-Methyl-3-hydroxy-4,5-bis(hydroxymethyl)pyridine; 2-Picoline-4,5-dimethanol, 3-hydroxy-; Pyridoxine [INN:BAN]; 2-Methyl-3-hydroxy-4,5-di(hydroxymethyl)pyridine; 2-Methyl-4,5-bis(hydroxymethyl)-3-hydroxypyridine; CHEBI:16709; EINECS 200-603-0; 4,5-bis(hydroxymethyl)-2-methyl-pyridin-3-ol; UNII-KV2JZ1BI6Z; KV2JZ1BI6Z; VitaminB6; Vitamin V6; Pyridoxin hydrochloride; vitamin B-6; 2-methyl-3-hydroxy-4,5-dihydroxymethylpyridine; NSC-759148; DTXSID4023541; Pyridoxine free base; 2-Methyl-3-hydroxy-4,5-dihydroxymethyl-pyridin [German]; 4,5-Bis(hydroxymethyl)-2-methyl-3-pyridinol; Prestwick0_000623; Prestwick1_000623; Prestwick2_000623; Prestwick3_000623; Adermin hydrochloride; 2-Methyl-3-hydroxy-4,5-dihydroxymethyl-pyridin; TimTec1_000657; Oprea1_061614; BSPBio_000586; CBDivE_015627; SPBio_002805; DTXCID903541; BPBio1_000646; Pyridoxine hydrogen chloride; Pyridoxine (INN); M.V.I.-12; STK177324; 65-23-6 (FREE BASE); 2-methyl-3-hydroxy-4,5-bis(hydroxy-methyl) pyridine; 3-hydroxy-2-Picoline-4,5-dimethanol; NSC 759148; DB00165; CAS-58-56-0; SMP2_000230; NCGC00016261-01; NCGC00016261-03; PYRIDOXINE [INN]; Pyridoxinum (INN-Latin); Piridoxina (INN-Spanish); C00314; AC-907/25014218; Adermin; Bezatin; Pirivitol; Infuvite Pediatric; CAS-65-23-6; PN; NSC36225; Pyridoxine (Vit B6); SR-05000001644; NCGC00164317-01; M.V.I.-12 Lyophilized; pyridoxina; Pridoxine; vitaminum b6; Beesix (Salt/Mix); nchembio.93-comp1; Becilan (Salt/Mix); Benadon (Salt/Mix); Hexobion (Salt/Mix); Vitamin B6 (TN); Pyridoxol; Vitamin B6; Pyridoxine, >=98%; Hexabetalin (Salt/Mix); PYRIDOXINE [MI]; Vitamin b6,hydrochloride; LS-134393; PYRIDOXINE [VANDF]; bmse000288; SCHEMBL3506; CHEMBL1364; PYRIDOXINE [WHO-DD]; BIDD:PXR0180; VITAMIN B6 [VANDF]; P5669_SIGMA; PYRIDOXINE [ORANGE BOOK]; A11HA02; NSC36225 (HCL); Pyridoxol, Vitamin B6, Gravidox; AIDS006784; HMS2093L07; KUC106691N; Pharmakon1600-01505453; AIDS-006784; BCP27975; HY-B1328; Tox21_113644; Tox21_300365; BBL005552; BDBM50103505; c1302; MFCD00006335; NSC759148; s3980; ZINC00049154; AKOS005410791; Tox21_113644_1; CCG-213453; CS-W019950; 2-methyl-4,5-dimethylol-pyridin-3-ol; Vitamin B6 100 microg/mL in Methanol; NCGC00016261-02; NCGC00016261-04; NCGC00016261-05; NCGC00016261-08; NCGC00164317-02; NCGC00254340-01; AC-14512; DS-11013; 58-56-0 (HCL); KSC-11-207-23; SBI-0206844.P001; 3-Hydroxy-4,5-dimethylol-.alpha.-picoline; DB-073595; AM20070169; FT-0631288; FT-0674200; NS00004187; EN300-39851; 4,5-bis(hydroxymethyl)-2-methylpyridine-3-ol; D08454; O10129; 4,5-Bis(hydroxymethyl)-2-methyl-3-pyridinol #; A835033; Q423746; Q-201646; SR-05000001644-1; SR-05000001644-3; 2B3E07D2-E4CC-4CC5-B085-6070BA01F9F0; Z382721012; 2-methyl-3-hydroxy-4-hydroxymethyl-5-hydroxymethyl pyridine; InChI=1/C8H11NO3/c1-5-8(12)7(4-11)6(3-10)2-9-5/h2,10-12H,3-4H2,1H"	TAR10043	Aromatic-L-amino-acid decarboxylase (DDC)	P20711	1054	D07MUN	DB00165	.
DRG00071	Α-Cyano-4-hydroxycinnamic acid	a-Cyano-4-hydroxycinnamic acid	.	"28166-41-8; alpha-Cyano-4-hydroxycinnamate; 2-Cyano-3-(4-hydroxyphenyl)acrylic acid; NL5EEM9E2G; 2-cyano-4-hydroxycinnamate; NSC 173138; a-Cyano-4-hydroxycinnamic acid; 2-cyano-3-(4-hydroxyphenyl)prop-2-enoic acid; Spectrum_001499; 2-Propenoic acid, 2-cyano-3-(4-hydroxyphenyl)-; NSC-173138; 2-Cyano-3-(4-hydroxyphenyl)-2-propenoic Acid; 4-Hydroxy-alpha-cyanocinnamic Acid; NSC 173138; alpha-Cyano-4-hydroxycinnamic Acid;; CHC; EINECS 248-879-1; Spectrum2_001947; Spectrum3_000730; Spectrum4_000334; UNII-NL5EEM9E2G; KBioGR_000707; KBioSS_001979; DivK1c_000219; 4-hydroxy-alpha-cyanocinnamate; SPBio_002013; alpha-cyano4-hydroxycinnamic acid; GTPL11300; KBio1_000219; KBio2_001979; KBio2_004547; KBio2_007115; KBio3_001480; NINDS_000219; 4-hydroxy-alpha-cyanocinnamic acid; DTXSID501018295; HMS3741O15; HMS3867D03; AKOS028110673; 2-cyano-3-(4-hydroxyphenyl) acrylic acid; DB-047349; 2-Cyano-3-(4-hydroxy-phenyl)-acrylic acid; C1768; NS00015227"	.	.	.	2102	.	.	.
DRG00072	Mellitic acid	Mellitic acid	.	"MELLITIC ACID; 517-60-2; Benzenehexacarboxylic acid; benzene-1,2,3,4,5,6-hexacarboxylic acid; Mellic acid; Hexacarboxybenzene; benzene hexacarboxylic acid; 1,2,3,4,5,6-Benzenehexacarboxylic acid; P80QSP14DM; CHEBI:41089; MFCD00002469; NSC-229358; UNII-P80QSP14DM; EINECS 208-243-6; NSC 229358; Mellitic acid, 99%; 1bq4; MELLITIC ACID [MI]; SCHEMBL22971; YSWG055; CHEMBL1231329; DTXSID50199650; NSC229358; AKOS001116892; DB01681; 1,3,4,5,6-Benzenehexacarboxylic acid; AS-64036; B0246; CS-0169857; FT-0622642; NS00032334; EN300-18764; Q734078; Z90123533"	.	.	.	2334	.	.	.
DRG00073	Caffeic acid	Caffeic acid	.	"DTXSID5020231; Caffeic acid 1000 microg/mL in Acetone; 3,4-dihydroxycinnamic acid (caffeic acid); Spectrum_001686; SpecPlus_000528; Prestwick0_000902; Prestwick1_000902; Spectrum2_001612; Spectrum4_001694; 3,4-dihydroxy cinnamic acid; KBioGR_001988; KBioSS_002166; DivK1c_006624; SPBio_001643; SPBio_002943; CHEMBL3181904; KBio1_001568; KBio2_002166; KBio2_004734; KBio2_007302; HMS1570F06; HMS2097F06; HMS3371E09; HMS3655J20; AKOS025243986; 3-(3,4-Dihydroxy-phenyl)-acrylic acid; NCGC00017364-14; NCI60_004400; SY009299; caffeic acid (3,4-dihydroxycinnamic acid); DB-048344; propenoic acid, 3-(3,4-dihydroxyphenyl)-; (E)-3-(3,4-Dihydroxyphenyl) acrylic acid; FT-0614329; Q56231106"	.	.	.	2518	.	.	.
DRG00074	Cyclophosphamide	Cyclophosphamide	.	"cyclophosphamide; 50-18-0; Cytoxan; Cyclophosphamid; Cyclophosphane; Endoxan; Cytophosphan; Procytox; Sendoxan; Clafen; Cyclophosphan; Cyclostin; Cyclophosphamidum; Cytophosphane; Endoxanal; Neosar; Claphene; Endoxana; Genoxal; Endoxan-Asta; Endoxan R; Zyklophosphamid; Mitoxan; Cyclophosphoramide; Cyklofosfamid; Endoxane; (RS)-Cyclophosphamide; Cyclophosphamide anhydrous; Cyclophosphanum; Enduxan; Semdoxan; Senduxan; (+-)-Cyclophosphamide; Ciclophosphamide; ASTA; Lyophilized Cytoxan; Ciclofosfamida; D,L-Cyclophosphamide; Rcra waste number U058; Asta B 518; (-)-Cyclophosphamide; Cycloblastin; NSC-26271; 2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide; Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester; CB 4564; Cyclophosphamide (anhydrous); NCI-C04900; ASTA B518; SK 20501; NSC 26271; CHEBI:4027; B 518; Occupation, cyclophosphamide exposure; CCRIS 188; N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide; 4-Hydroxy-cyclophosphan-mamophosphatide; HSDB 3047; Anhydrous cyclophosphamide; EINECS 200-015-4; Ciclofosfamide; N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide; UNII-6UXW23996M; BRN 0011744; Cyclophosphamide-d4; AI3-26198; 6UXW23996M; Cyclophosphamide (INN); 1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin; NSC26271; Cytoxan (TN); 2-(Bis(2-chloroethyl)amino)-2H-1,3,2-oxazaphosphorine 2-oxide; N,N-Bis(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide; N,N-Di(2-chloroethyl)-N,O-propylene-phosphoric acid ester diamide; 50-18-0 (anhydrous); 2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide; 2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-,2-oxide; Phosphorodiamidic acid, N,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, intramol. ester; CY; DTXSID5020364; CYCLOPHOSPHAMIDE LYOPHILIZED; CYCLOPHOSPHAMIDE, ANHYDROUS; N,N-Bis(beta-chloroethyl)-N',O-propylenephosphoric acid ester diamide; 2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazophosphorine 2-oxide; N,N-Bis(beta-chloroethyl)-N',O-trimethylenephosphoric acid ester diamide; Cyklofosfamid [Czech]; N,N-bis(2-chloroethyl)-2-oxo-1,3,2$l^{5}-oxazaphosphinan-2-amine; N,N-Bis-(beta-chloraethyl)-N',O-propylen-phosphorsaeure-ester-diamid; Ciclophosphamide [INN]; 2-[Bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide; 2H-1,3,2-Oxazaphosphorine, 2-(bis(2-chloroethyl)amino)tetrahydro-, 2-oxide; Zyklophosphamid [German]; NSC-756711; Ciclophosphamide hydrat; Cytoxan (Lyophilized); CYCLOPHOSPHAMIDE [INN]; Ciclofosfamida [INN-Spanish]; Cyclophosphamidum [INN-Latin]; UNII-8N3DW7272P; CYCLOPHOSPHAMIDE (IARC); CCRIS 7469; CYCLOPHOSPHAMIDE (USP-RS); Cyclophosphamide (anhydrous form); Cyclophosphamide (TN); CYCLOPHOSPHAMIDE (EP MONOGRAPH); CYCLOPHOSPHAMIDE (USP MONOGRAPH); SR-01000075737; NCGC00015209-05; RCRA waste no. U058; Cyclophosphamide [USP:INN]; Cycloblastine; Cyclofosphamide; Cyclophospham; Cyclostine; Fosfaseron; Syklofosfamid; Carloxan; Cicloxal; Genuxal; Ledoxina; 2-(Bis(2-chloroethyl)amino)-2H-1,2-oxazaphosphorine 2-oxide; 2-[Bis(2-chloroethyl)amino]-2H-1,2-oxazaphosphorine 2-oxide; 2-(Bis(2-chloroethylamino))-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide; (Bis(chloro-2-ethyl)amino)-2-tetrahydro-3,5,6-oxazaphosphorine-1,3,2-oxide-2 hydrate; [Bis(chloro-2-ethyl)amino]-2-tetrahydro-3,5,6-oxazaphosphorine-1,3,2-oxide-2 hydrate; 2-(BIS(2-CHLOROETHYL)AMINO)TETRAHYDRO-2H-1,3,2-OXAZAPHOSPHORINE 2-OXIDE; CYCLO-cell; N,N-Bis(beta-cloraethyl) N'-O-propylenphosphorildiamid monohydratum; 173547-45-0; bis(2-Chloroethyl)phosphamide cyclic propanolamide ester; CB-4564; Spectrum_000858; CHEMBL88; Spectrum2_001146; Spectrum3_000370; Spectrum4_000304; Spectrum5_000795; Lopac-C-0768; Epitope ID:131782; C 0768; N,N-Bis-(beta-chloraethyl)-N',O-propylen-phosphorsaeure-ester-diamid [German]; SCHEMBL4346; (.+/-.)-Cyclophosphamide; Lopac0_000238; BSPBio_002099; KBioGR_000888; KBioSS_001338; DivK1c_000246; DTXCID70364; SPBio_001071; CYCLOPHOSPHAMIDE [HSDB]; GTPL7154; SCHEMBL4345553; 2-H-1,3,2-Oxazaphosphorinane; SCHEMBL10262910; CMSMOCZEIVJLDB-UHFFFAOYSA-; KBio1_000246; KBio2_001338; KBio2_003906; KBio2_006474; KBio3_001319; CYCLOPHOSPAMIDE MONOHYDRATE; CYCLOPHOSPHAMIDE [WHO-DD]; L01AA01; WLN: T6MPOTJ BO BN2G2G; NINDS_000246; 2-(bis(2-chloroethyl)amino)-1,3,2-oxazaphosphinane 2-oxide; HMS2090A12; HMS3260P17; HMS3715J05; Pharmakon1600-01500213; AMY33449; BCP02139; Tox21_500238; BDBM50237604; N,N-bis(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine; NSC273033; NSC273034; NSC756711; STK177249; AKOS005410738; tetrahydro-N,N-bis(2-chloroethyl)-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide; CS-1425; CYCLOPHOSPHAMIDE ANHYDROUS [MI]; DB00531; LP00238; NSC-273033; NSC-273034; SDCCGSBI-0050226.P004; IDI1_000246; N,3,2-oxazaphosphorin-2-amine-2-oxide; N,O-propylen-phosphorsaeure-ester-diamid; NCGC00015209-01; NCGC00015209-02; NCGC00015209-03; NCGC00015209-04; NCGC00015209-06; NCGC00015209-07; NCGC00015209-08; NCGC00015209-09; NCGC00015209-12; NCGC00015209-28; NCGC00091741-02; NCGC00091741-03; NCGC00260923-01; AS-73255; BP-25411; HY-17420; NCI60_002097; N,O-propylenephosphoric acid ester diamide; SBI-0050226.P003; DB-082057; N,O-propylene-phosphoric acid ester diamide; WR-138719; C2236; EU-0100238; FT-0624276; FT-0665387; N,O-trimethylenephosphoric acid ester diamide; NS00000339; EN300-74526; C07888; D07760; AB00053446-09; AB00053446-11; AB00053446-12; AB00053446_13; AB00053446_14; AB00053446_15; Q408524; W-60377; N,O-propylenephosphoric acid ester amide monohydrate; SR-01000075737-1; SR-01000075737-6; W-105248; BRD-A09722536-002-02-4; Z276509078; 2-(bis(2-chloroethyl)amino)-1,3,2-oxazaphosphinane2-oxide; Bis(2-chloroethyl)phosphoramide-cyclic propanolamide ester; 2-[bis(2-chloroethyl)amino]-1,3,2??-oxazaphosphinan-2-one; 1-BIS(2-CHLOROETHYL)AMINO-1-OXO-2-AZA-5-OXAPHOSPHORIDINE; 2-[bis(2-chloroethyl)amino]-1,3,2$l^{5}-oxazaphosphinan-2-one; 2-[bis(2-chloroethyl)amino]-1,3,2lambda5-oxazaphosphinan-2-one; N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide #; 2-[Bis(2-chloroethyl)amino]tetrahydro-1,3,2-oxazaphosphorin-2-oxide; 2H-1,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide; 2H-1,3,2-Oxazaphosphorine, 2-(bis(2-chloroethyl)amino)tetrahydro-,2-oxide; N,N-Bis(.beta.-chloroethyl)-N',O-trimethylenephosphoric acid ester diamide; N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine-2-oxide; N,N-Bis-(.beta.-chloraethyl)-N',O-propylen-phosphorsaeure-ester-diamid; N,N-DI(2-CHLOROETHYL)-N,O-PROPYLENE PHOSPHORIC ACID ESTER DIAMIDE; (+/-)-2-(BIS(2-CHLOROETHYL)AMINO)TETRAHYDRO-2H-1,3,2-OXAZAPHOSPHORINE 2-OXIDE; 2-(DI(2-CHLOROETHYLAMINO))-1-OXA-3-AZA-2-PHOSPHACYCLOHEXANE 2-OXIDE; 2-Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide; 2H-1,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide; 2H-1,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide, (+)-; 2H-1,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide, (-)-; 2H-1,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate; 2H-1,3,2-oxazaphosphorin-2-amine, N,N-is(2-chloroethyl)tetrahydro-,2-oxide; N,N-bis(2-chloroethyl)-2-oxo-1-oxa-3-aza-2$l^{5}-phosphacyclohexan-2-amine; N,N-BIS(2-CHLOROETHYL)-N'-(3-HYDROXYPROPYL)PHOSPHORODIAMIDIC ACID INTRAMOL.; N,N-BIS(BETA-CHLOROETHYL)N',O-TRIMETHYLENEPHOSPHORIC ACID ESTER DIAMIDE; Phosphorodiamidic acid,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, intramol. ester; InChI=1/C7H15Cl2N2O2P/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14/h1-7H2,(H,10,12)"	TAR10052	Human Deoxyribonucleic acid (hDNA)	.	2907	D0CT9C	DB00531	.
DRG00075	Ibuprofen	Ibuprofen	Anti-infection drug	"ibuprofen; 15687-27-1; 2-(4-Isobutylphenyl)propanoic acid; Motrin; Brufen; Advil; Nurofen; Dolgit; Liptan; Medipren; Nuprin; Anflagen; Buburone; Butylenin; Ibuprocin; Lamidon; Ebufac; Ibumetin; Mynosedin; Roidenin; Andran; Apsifen; Bluton; Epobron; Haltran; Nobfen; Nobgen; Trendar; Adran; PediaProfen; Rufen; 2-[4-(2-methylpropyl)phenyl]propanoic acid; Brufort; Ibuprohm; Inabrin; Nobfelon; Pantrop; Rebugen; Suspren; Tabalon; Burana; Anco; Urem; (RS)-Ibuprofen; Ibu-slo; Brufanic; Napacetin; Ibufen; Ibuprin; Profen; Ibren; Cap-Profen; Tab-Profen; Ibu-Tab; (+/-)-Ibuprofen; Novoprofen; Proartinal; Amersol; Dibufen; Dolgin; Dolocyl; Lidifen; Optifen; Ostofen; Panafen; Paxofen; Proflex; Quadrax; Uprofen; Carol; Midol; Rafen; Cobo; Ifen; 4-Isobutylhydratropic acid; (+-)-Ibuprofen; Artril 300; p-Isobutylhydratropic acid; duralbuprofen; Balkaprofen; Betaprofen; Butacortelone; Daiprophen; Ibuprofeno; Ibuprofenum; Jenaprofen; Algofen; Amelior; Amibufen; Antagil; Antalfene; Antarene; Antiflam; Artofen; Bruflam; Bufigen; Bukrefen; Buracaps; Citalgan; Combiflam; Dansida; Dentigoa; Dignoflex; Dolgirid; Dolmaral; Dolofen; Dolofort; Dologel; Dolomax; Doloren; Doltibil; Dorival; Duobrus; Dysdolen; Easifon; Exneural; Femadon; Femafen; Femapirin; Femidol; Fenspan; Fibraflex; Gelufene; Gynofug; Ibubest; Ibubeta; Ibucasen; Ibudolor; Ibuflamar; Ibugesic; Ibuhexal; Ibulagic; Ibuleve; Ibulgan; Ibumerck; Ibupirac; Junifen; Kratalgin; Lebrufen; Librofem; Malafene; Manypren; Mensoton; Neobrufen; Nerofen; Noalgil; Nobafon; Noritis; Novadol; Novogent; Nuprilan; Opturem; Oralfene; Ostarin; Paduden; Perofen; Ranofen; Relcofen; Rhinadvil; Sadefen; Salivia; Seclodin; Sednafen; Seklodin; Seskafen; Siyafen; Solpaflex; Sugafen; Suprafen; Syntofene; Tatanal; Unipron; Alaxan; Anafen; Artril; Bloom; Brofen; Bufeno; Bupron; Cesra; Cunil; Dalsy; Dolibu; Dolven; Duafen; Emflam; Eputex; Ergix; Faspic; Fendol; Gofen; Grefen; Ibudol; Ibufug; Ibugel; Ibugen; Ibular; Ibulav; Ibumed; Ibusal; Ibutid; Inflam; Inoven; Ipren; Irfen; Isodol; Kesan; Lopane; Melfen; Midol 200; Moment; Narfen; Ozonol; Provon; Rofen; Rufin; Rupan; Stelar; Tempil; Tofen; Tonal; Upfen; Zofen; Drin; Ibol; Pediatric Advil; Apo-Ibuprofen; Brufen Retard; Deep Relief; Dolo-Dolgit; Ibu-Attritin; Neo-Helvagit; Novo-Profen; Ibu-slow; Neo-Mindol; Dolofen-F; Donjust B; Nagifen-D; Dura-Ibu; Children's Advil; Motrin IB; Children's Motrin; Togal N; 4-Isobutyl-alpha-methylphenylacetic acid; ACHES-N-PAIN; Dularbuprofen; Caldolor; Ibu-Tab 200; Ibuprofene; Ibuprophen; Pedea; alpha-(4-Isobutylphenyl)propionic acid; Children's Ibuprofen; IP-82; Kontagripp Mono; Tabalon 400; Novo Dioxadol; Schmerz-Dolgit; Junior Strength Advil; 58560-75-1; Brufen 400; Emflam-200; DOLO PUREN; Hemagene Tailleur; Junior Strength Motrin; Act-3; Ak+C2278tren; Advil Liqui-Gels; Adex 200; Codral Period Pain; Junior Strength Ibuprofen; (+-)-Ibuprophen; Children's Elixsure; RD 13621; Am-Fam 400; IB-100; Alivium; (+-)-p-Isobutylhydratropic acid; Advil migraine; U-18,573; Perrigo ibuprofen; Hydratropic acid, p-isobutyl-; (4-Isobutylphenyl)-alpha-methylacetic acid; VUFB 9649; p-Isobutyl-2-phenylpropionic acid; MOTRIN MIGRAINE PAIN; (+-)-2-(p-Isobutylphenyl)propionic acid; UCB 79171; alpha-(p-isobutylphenyl)propionic acid; CCRIS 3223; CHEBI:5855; rac Ibuprofen; CHILDREN'S ADVIL-FLAVORED; HSDB 3099; UNII-WK2XYI10QM; Ibuprofene [INN-French]; Ibuprofenum [INN-Latin]; Advil Migraine Liqui-Gels; Racemic ibuprofen; WK2XYI10QM; Ibuprofeno [INN-Spanish]; alpha-p-Isobutylphenylpropionic acid; EINECS 239-784-6; Midol Liquid Gels; (+-)-alpha-Methyl-4-(2-methylpropyl)benzeneacetic acid; Benzeneacetic acid, .alpha.-methyl-4-(2-methylpropyl)-; NSC 256857; NSC-256857; BRN 2049713; alpha-Methyl-4-(2-methylpropyl)benzeneacetic acid; Ibuprofen sodium; U 18573; U-18573; DTXSID5020732; Ibu; 2-(4-ISOBUTYLPHENYL)PROPIONIC ACID; M01AE01; (+/-)-p-Isobutylhydratropic acid; 2-(p-Isobutylphenyl)propionic acid; MFCD00010393; NSC256857; CHEMBL521; 2-(4-Isobutyl-phenyl)-propionic acid; Acide (isobutyl-4-phenyl)-2 propionique; Benzeneacetic acid, alpha-methyl-4-(2-methylpropyl)-; DTXCID90732; alpha-Methyl-4-(isobutyl)phenylacetic acid; MLS000069733; (+/-)-2-(4-Isobutylphenyl)Propanoic Acid; Dolofin; Esprenit; R.D. 13621; Fenbid; Zafen; EC 239-784-6; COMBUNOX COMPONENT IBUPROFEN; REPREXAIN COMPONENT IBUPROFEN; VICOPROFEN COMPONENT IBUPROFEN; Ibuprofen [USAN:USP:INN:BAN:JAN]; SINE-AID IB COMPONENT IBUPROFEN; .alpha.-(p-isobutylphenyl)propionic acid; NCGC00015529-09; .alpha.-(4-Isobutylphenyl)propionic acid; Acide (isobutyl-4 phenyl)-2 propionique; SMR000058184; (+/-)-2-(p-isobutylphenyl)propionic acid; 4-Isobutyl-.alpha.-methylphenylacetic acid; Ibuprofene (INN-French); Ibuprofenum (INN-Latin); ADVIL ALLERGY SINUS COMPONENT IBUPROFEN; Ibuprofeno (INN-Spanish); IBUPROFEN (MART.); IBUPROFEN [MART.]; IBUPROFEN (USP-RS); IBUPROFEN [USP-RS]; CHILDREN'S ADVIL COLD COMPONENT IBUPROFEN; ADVIL CONGESTION RELIEF COMPONENT IBUPROFEN; CHILDREN'S MOTRIN COLD COMPONENT IBUPROFEN; Advil, Children's; .alpha.-Methyl-4-(2-methylpropyl)benzeneacetic acid; IBUPROFEN (EP MONOGRAPH); IBUPROFEN (USP IMPURITY); IBUPROFEN [EP MONOGRAPH]; IBUPROFEN [USP IMPURITY]; IBUPROFEN (USP MONOGRAPH); IBUPROFEN [USP MONOGRAPH]; Midol IB Cramp Relief; Bayer Select Pain Relief; Ibuprofen (USAN:USP:INN:BAN:JAN); 2-(4-isobutylphenyl)propanoate; Motrin IB Gelcaps; rac Ibuprofen (1.0 mg/mL in Methanol); alpha-(4-Isobutylphenyl)propionate; CAS-15687-27-1; Motrin (TN); Advil (TN); Children's Elixsure IB; SR-01000000214; Actrogel; Cedaprin; Ibupril; IbuprofenJunior; Ibuprox; Probufen; Proprinal; Aktren; ibuprofeninfants; Ibutab; kidgets infants; MotrinInfants; DragonTabs; Ibux; Advil Liquigels; Childrens Advil; CounterActIB; Dolex Children; Dover Addaprin; Ibuprofen Mini; Ibuprofen Minis; Ibuprofen Oral; ibuprofen tablet; Infants Motrin; profen ibinfants; Uline Ibuprofen; Welby Ibuprofen; Xpect Ibuprofen; Ibuprofen Ib; Infants Advil; Medique Iprin; Flex-prin; CDT-ibuprofen; Childrens Motrin; Dolex Flex; Equate Ibuprofen; IbuprofenSoftgels; Leader Ibuprofen; MFCD00069290; Nurofen Meltlets; Rexall Ibuprofen; Zee Ibutab; Profen Ib; Aramark Ibuprofen; Assured Ibuprofen; Ibuprofen Tablets; IbuprofenChildrens; Infants Ibuprofen; Sunmark Ibuprofen; Topcare Ibuprofen; AeroTab Ibuprofen; CareOne Ibuprofen; IbuprofenDye Free; IbuprofenDye-Free; Fast Pain Relief; Rx Act Ibuprofen; (y)-Ibuprofen; Equaline Ibuprofen; Ibuprofen Migraine; Ibuprofen Softgels; Ibuprofen Thompson; profen IBchildrens; Redicare Ibuprofen; Ibuprofen 200mg; Ibuprofen,(S); (+) ibuprofen; Childrens Ibuprofen; Unishield Ibuprofen; Care One Ibuprofen; Circle K Ibuprofen; Dye Free Ibuprofen; Dye-Free Ibuprofen; IBU Tabs; Ibuprofen (Advil); MoreBrand Ibuprofen; Acide (isobutyl-4-phenyl)-2 propionique [French]; (?)-Ibuprofen; CAREALL Ibuprofen; Ibuprofen 200; Motrin IB Migraine; Dg Health Ibuprofen; Ibuprofen [USAN]; Moorebrand Ibuprofen; dye-free pain relief; Ibuprofen 200 mg; Medi-first Ibuprofen; Basic Care Ibuprofen; EPROBRON; Good Sense Ibuprofen; IBUOROFEN; IBUPAK; IBUPFROFEN; Otis Clapp Ultraprin; Sound Body Ibuprofen; Sunmark Ibuprofen Ib; Caring mill ibuprofen; Ibuprofen (NSAID); Up and Up Ibuprofen; p-Isobutylhydratropate; Health Mart Ibuprofen; Pain Relief Ibuprofen; Combunox (Salt/Mix); I buprofen 200 mg; IBUPROFEN CA; KOSHER MEDS; (A+/-)-Ibuprofen; betr remedies ibuprofen; Clear Choice Ibuprofen; Crane Safety Ibuprofen; Henry Schein Ibuprofen; Medique at Home Iprin; Members Mark Ibuprofen; sunmark ibuprofeninfants; Direct Safety Ibuprofen; Harris Teeter Ibuprofen; INFANT'S ADVIL; Spectrum_000849; leader infants ibuprofen; equate ibuprofenchildrens; IBUPROFEN [INN]; IBUPROFEN [JAN]; Opera_ID_554; care one ibuprofeninfants; IBUPROFEN [MI]; Preferred Plus Ibuprofen; rx act ibuprofenchildrens; Signature Care Ibuprofen; Ibuprofen, Caseys 4good; VALUMEDS IBUPROFEN; Childrens Ibuprofen fruit; Childrens Ibuprofen grape; IBUPROFEN [HSDB]; Ibuprofen Mini 200 mg; Sunmark ibuprofenchildrens; Topcare ibuprofenchildrens; Family Wellness Ibuprofen; First Aid Only Ibuprofen; Handy Solutions Ibuprofen; Health Mart Ibuprofen Ib; IBUPROFEN200 MG; Lil Drug Store Ibuprofen; Physicians Care Ibuprofen; Spectrum2_000129; Spectrum3_000465; Spectrum4_000015; Spectrum5_000862; Topcare Infants Ibuprofen; Welby Childrens Ibuprofen; Childrens Ibuprofen 100; IBUPROFEN [VANDF]; IBUPROFEN Tablet coated; Ibuprofen Tablets, coated; IbuprofenImmediate Release; Dye-Free Ibuprofen 200; Equaline ibuprofenchildrens; Medi-first Plus Ibuprofen; WLN: QVY&R DIY; careone childrens ibuprofen; CBMicro_005634; COMPRESSO IBU 66; Green Guard Ibupro Relief; IBUPROFEN 100; IBUPROFEN 250; Leader Childrens Ibuprofen; Care One ibuprofenchildrens; COMPRESSO IBU 66S; Epitope ID:139973; Good Sense ibuprofeninfants; p-isobutyl-hydratropic acid; Topcare Childrens Ibuprofen; I 4883; basic care infants ibuprofen; Cambridge id 5152402; family wellness ibuprofen ib; IBUPROFEN [WHO-DD]; IBUPROFEN [WHO-IP]; SCHEMBL3001; Equaline Childrens Ibuprofen; Ibuprofen Capsules 200 mg; Kirkland Signature Ibuprofen; 24/7 Life IBUPROFEN; Berkley and Jensen Ibuprofen; McKesson Ibuprofen 200 mg; 365 everday value ibuprofen; Childrens Ibuprofen bubblegum; Dye Free Childrens Ibuprofen; Green Guard Ibuprofen Relief; Isobutylpropanoicphenolic acid; Lopac0_000691; BSPBio_002170; Concentrated ibuprofen infants; Good Sense IbuprofenChildrens; Help I Have An Aching Body; IBUPROFEN [EMA EPAR]; KBioGR_000389; KBioSS_001329; 365 everyday value ibuprofen; APROFENREGULAR STRENGTH; DG Health childrens ibuprofen; Ibuprofen tablet, film-coated; MLS001146965; p-Isobutyl-2-phenylpropionate; Pain Relief Anti Inflammatory; sunmark childrens ibuprofen ib; BIDD:GT0050; COMPRESSO IBU 85 PAR; DivK1c_000887; Harris Teeter IbuprofenInfants; SPECTRUM1500347; Basic Care Childrens Ibuprofen; caring mill childrens ibuprofen; core values childrens ibuprofen; Easy Care First Aid Ibuprofen; Good Sense Childrens Ibuprofen; Ibuprofen, >=98% (GC); Preferred Plus Ibuprofen 200; Quality Choice Ibuprofen 200; Sound Body Childrens Ibuprofen; SPBio_000178; Up and Up Childrens Ibuprofen; Ibuprofen (JP17/USP/INN); Ibuprofen, 1mg/ml in Methanol; Pain Reliever / Fever Reducer; alpha-p-Isobutylphenylpropionate; GTPL2713; Health Mart Childrens Ibuprofen; Kirkland Signature Ibuprofen Ib; Motrin IB Gelcaps (Salt/Mix); Pain Relief-Ibuprofen 200 mg; parents choice infants ibuprofen; IBUPROFEN [ORANGE BOOK]; Ibuprofen Tablets USP, 200mg; 2-p-isobutylphenylpropionic acid; Good Neighbor Pharmacy Ibuprofen; Signature Care Infants Ibuprofen; Toxicology Saliva Collection Kit; HEFN"	TAR10020	Prostaglandin G/H synthase 2 (PTGS2)	P35354	3672	D0R1QE	DB01050	CHEMBL521
DRG00076	Estradiol	Estradiol	.	"estradiol; beta-Estradiol; 17beta-Estradiol; 50-28-2; Oestradiol; Dihydrofolliculin; Estrace; Vivelle; progynon; Diogynets; Ovocyclin; Aquadiol; Climara; Diogyn; Vagifem; Dihydrotheelin; Dihydroxyestrin; Dimenformon; Divigel; Estraderm; Gynergon; Gynoestryl; Oestroglandol; Aerodiol; Corpagen; Estraldine; Estrogel; Estrovite; Femestral; Follicyclin; Ginosedol; Macrodiol; Oestergon; Ovahormon; Ovasterol; Ovastevol; Perlatanol; Primofol; Profoliol; Altrad; Bardiol; Evorel; Femogen; Lamdiol; Syndiol; Dihydromenformon; estradiol-17beta; cis-Estradiol; Estraderm TTS; Estroclim; Trocosone; Estring; Innofem; Menorest; Nordicol; Zumenon; Alora; Systen; 17beta-Oestradiol; D-Oestradiol; D-Estradiol; Progynon DH; Climaderm; Compudose; Dermestril; Estrasorb; Fempatch; Gynodiol; Ovocycline; Ovocylin; Encore; Esclim; Menest; Oesclim; Dihydroxyoestrin; SK-Estrogens; Progynon-DH; Elestrin; Gynestrel; Microdiol; Oestrogynal; Ovociclina; Tradelia; Estroclim 50; Evamist; Macrol; Zerella; Oestradiol R; Estring vaginal ring; Trial SAT; Theelin, dihydro-; Estradot; Menostar; Oestrogel; Compudose 200; Compudose 365; 17 beta-Estradiol; Profoliol B; VIVELLE-DOT; Estradiol-17-beta; Estradiolum; Estrogen; Gelestra; 3,17-Epidihydroxyestratriene; Zesteem; Dihydroxyesterin; cis-Oestradiol; Estraderm TTS 50; Estrogens, esterified; NSC-9895; 17.beta.-Estradiol; 17b-Oestradiol; Epiestriol 50; 17beta oestradiol; Estra-1,3,5(10)-triene-3,17beta-diol; Estradiol Anhydrous; 17-beta-estradiol; Estradiol-17 beta; Amnestrogen; Elestrim; Femanest; Minivelle; (17beta)-Estra-1,3,5(10)-triene-3,17-diol; B-Estradiol; 3,17-Epidihydroxyoestratriene; Sandrena 1; 17b-Estradiol; Estraderm (TN); [3H]-estradiol; 17; A-estradiol; 17; A-Oestradiol; Estrogel (TN); Climara (TN); Divigel (TN); Estrace (TN); Estring (TN); Innofem (TN); Vagifem (TN); Vivelle (TN); 17.beta.-Oestradiol; (8R,9S,13S,14S,17S)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; CHEBI:16469; 3,17.beta.-Estradiol; .beta.-Estradiol; .beta.-Oestradiol; [3H]]estradiol; NSC-20293; Estradiol 17-beta; 17-beta-oestradiol; IMVEXXY; (17beta)-estra-1(10),2,4-triene-3,17-diol; Estradiol (Standard); Estradiol, .beta.-; Estradiol-17.beta.; Estra-1,3,5(10)-triene-3,17-diol (17beta)-; Oestradiol-17.beta.; 17-.beta.-oestradiol; 4TI98Z838E; Oestra-1,3,5(10)-triene-3,17beta-diol; Estrasorb (TN); 17.beta.-OH-estradiol; 17.beta.-OH-oestradiol; 17beta estradiol (E2); Extrasorb; 17beta-Estra-1,3,5(10)-triene-3,17-diol; Estreva; Estrifam; Femtran; Ginedisc; WC3011; C18H24O2; CHEMBL135; GynPolar; Sandrena Gel; D-3,17.beta.-Estradiol; WC-3011; D-3,17.beta.-Oestradiol; Sisare Gel; Estra-1,3,5(10)-triene-3,17-diol, (17beta)-; Estrofem 2; MLS000069494; 3,17b-Dihydroxyestra-1,3,5(10)-triene; (+)-3,17.beta.-Estradiol; 141290-02-0; Oestradiolum; DTXSID0020573; Estradiol valerate metabolite e2; BIJUVA COMPONENT ESTRADIOL; NSC9895; ANGELIQ COMPONENT ESTRADIOL; Climara Forte; ORIAHNN COMPONENT ESTRADIOL; PREFEST COMPONENT ESTRADIOL; Oestradiol Berco; Estraderm MX; ACTIVELLA COMPONENT ESTRADIOL; 1,3,5-Estratriene-3,17beta-diol; COMBIPATCH COMPONENT ESTRADIOL; [3H]E2; CLIMARA PRO COMPONENT ESTRADIOL; Oestradiol-17beta; Estrapak 50; E2; Estradiolum [INN]; Estradiolo [DCIT]; NCGC00091544-04; Oestradiol-17-beta; Estrodiolum; Estradiolo; Femestrol; SMR000059126; Estradiol-3,17beta; 17-beta-OH-estradiol; 3,17-beta-Estradiol; 3,17beta-Dihydroxy-1,3,5(10)-estratriene; 3,17beta-Dihydroxyestra-1,3,5(10)-triene; 3,17-beta-Oestradiol; D-3,17beta-Estradiol; ESTRADIOL (USP-RS); ESTRADIOL [USP-RS]; 3,17.beta.-Dihydroxyestra-1,3,5(10)-triene; E(sub 2); Methyl 1-cyclopropyl-6,7-difluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate.; Benzogynestry; Estropause; Estasorb; (1S,10R,11S,14S,15S)-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-2(7),3,5-triene-5,14-diol; (8R,9S,13S,14S,17S)-13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; [2,4,6,7-3H]-E2; E 2; DTXCID80573; ESTRADIOL (USP MONOGRAPH); ESTRADIOL [USP MONOGRAPH]; Destradiol; ESTRADIOL IMPURITY A (IP); ESTRADIOL IMPURITY A [IP]; Yuvvexy; Zesteen; .alpha.-Estradiol; 17-beta-OH-oestradiol; D-3,17beta-Oestradiol; D-3,17-beta-Estradiol; Estrodiolum [INN-Latin]; Estra-1,3,5(10)-triene-3,17-diol (17.beta.)-; D-3,17-beta-Oestradiol; Activella (Salt/Mix); Combipatch (Salt/Mix); CCRIS 280; component of Menrium; Estradiol-17 alpha; Climara Pro (Salt/Mix); 3,17beta-Estradiol; 3,17-.beta.-Oestradiol; Estraderm TTS 100; HSDB 3589; 3,3,5(10)-triene; SR-01000075866; 17-.BETA.-Estradiol; EINECS 200-023-8; 1,3,5-Estratriene-3,17-beta-diol; oestrodiol; Estradiol [USP:INN:BAN]; 3,17beta-Dihydroxyestra-1,3,5-triene; 3,17beta-Dihydroxyoestra-1,3,5-triene; Yuvafem; delta-Estradiol; dihydro-Theelin; dl-estradiol; 3,17-beta-Dihydroxyoestra-1,3,5-triene; NSC20293; UNII-4TI98Z838E; beta -estradiol; delta-Oestradiol; Estradiol pellet; Estradiol,; TX-004HR; MFCD00003693; Vivelle Dot; Estra-1,3,5(10)-triene-3,17-beta-diol; Estradiol Vaginal; Estrogel HBF; Oestra-1,3,5(10)-triene-3,17-beta-diol; 1jgl; 1lhu; 1qkt; 1qku; 3,17-beta-Dihydroxyestra-1,3,5(10)-triene; [3H]estradiol; 1,3,5-Estratriene-3,17.beta.-diol; 3,17-beta-Dihydroxy-1,3,5(10)-oestratriene; CAS-50-28-2; 17-beta-Estra-1,3,5(10)-triene-3,17-diol; 17beta-Oestra-1,3,5(10)-triene-3,17-diol; .alpha.-Oestradiol; 17-beta-Oestra-1,3,5(10)-triene-3,17-diol; Estra-1,3,5(10)-triene-3,17-diol; Estradiol1557; Prestwick_207; 3,17b-Estradiol; Bio-E-Gel; Fem7; [3H]-Estrogen; 3,17.beta.-Dihydroxyestra-1,3,5-triene; 3,17.beta.-Dihydroxyoestra-1,3,5-triene; CMC_11154; Therapeutic Estradiol; DOTTI; LYLLANA; Estra-25; Estra-50; 1,3,5,(10)-Estratrien-3,17.beta.-diol; SL-1100; Beta-estradiol (E2); Estra-1,3,5(10)-triene-3,17.beta.-diol; Oestra-1,3,5(10)-triene-3,17.beta.-diol; Estradiol Gel 0.1%; Estradiol Vaginal Cream; 2j7x; 3,17.beta.-Dihydroxy-1,3,5(10)-estratriene; 3,17.beta.-Dihydroxy-1,3,5(10)-oestratriene; 3,3,5-triene; [3H]17beta-estradiol; ESTROGEN PHENOLIC; ESTRADIOL [INN]; ESTRADIOL [JAN]; 17.beta.-Estra-1,3,5(10)-triene-3,17-diol; ESTRADIOL [MI]; ESTRADIOL [HSDB]; 17.beta.-Oestra-1,3,5(10)-triene-3,17-diol; Opera_ID_1688; Prestwick0_000441; Prestwick1_000441; Prestwick2_000441; Prestwick3_000441; Spectrum5_002055; 17beta-estradiol (E2); ESTRADIOL [VANDF]; alpha-estradiol (obsolete); beta-Estradiol, >=98%; bmse000642; Epitope ID:136018; (+)-3,17b-Estradiol; E 8875; EC 200-023-8; ESTRADIOL [WHO-DD]; SCHEMBL8049; Estradiol Transdermal System; (+)-3,17beta-Estradiol; Estradiol (JAN/USP/INN); Tritiated estradiol-17-beta; BIDD:PXR0065; Lopac0_000503; S-21400; BSPBio_000482; BSPBio_001065; KBioGR_000405; KBioGR_002269; KBioSS_000405; KBioSS_002270; MLS000758312; MLS001076331; MLS001424022; BIDD:ER0125; SPBio_002421; ESTRADIOL [GREEN BOOK]; BPBio1_000532; GTPL1012; GTPL1013; ESTRADIOL [ORANGE BOOK]; ESTRADIOL VAGINAL INSERTS; NIOSH/KG7030000; BDBM17292; HY-B0141R; KBio2_000405; KBio2_002269; KBio2_002973; KBio2_004837; KBio2_005541; KBio2_007405; KBio3_000769; KBio3_000770; KBio3_002749; 1a52; 1g50; 2d06; cMAP_000005; Bio1_000403; Bio1_000892; Bio1_001381; Bio2_000363; Bio2_000843; HMS1362E07; HMS1569I04; HMS1792E07; HMS1990E07; HMS2051C17; HMS2090E18; HMS2096I04; HMS2236H04; HMS3261F07; HMS3403E07; HMS3713I04; HMS3884A08; beta-Estradiol, analytical standard; (8S,9S,13S,14S,17S)-13-Methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; 17916-67-5; BCP08579; ESTRADIOL 17-BETA [VANDF]; HY-B0141; ESTRADIOL COMPONENT OF BIJUVA; Tox21_111148; Tox21_202057; Tox21_300288; Tox21_500503; 1,5-Estratriene-3,17.beta.-diol; HB2494; LMST02010001; s1709; ESTRADIOL COMPONENT OF ANGELIQ; ESTRADIOL COMPONENT OF ORIAHNN; ESTRADIOL COMPONENT OF PREFEST; Estradiol-17-beta-6,7-(sup 3)H; [2,4,6,7-3H]-17beta-estradiol; AKOS015896570; CCG-100808; CS-1938; DB00783; ESTRADIOL COMPONENT OF ACTIVELLA; LP00503; NC00058; SDCCGSBI-0050487.P002; ESTRADIOL COMPONENT OF COMBIPATCH; IDI1_002118; SMP1_000121; NCGC00091544-00; NCGC00091544-01; NCGC00091544-02; NCGC00091544-05; NCGC00091544-06; NCGC00091544-07; NCGC00091544-09; NCGC00091544-10; NCGC00091544-11; NCGC00091544-12; NCGC00091544-13; NCGC00091544-14; NCGC00091544-15; NCGC00091544-16; NCGC00091544-18; NCGC00091544-27; NCGC00179321-01; NCGC00179321-02; NCGC00254177-01; NCGC00259606-01; NCGC00261188-01; 17-E; AC-22346; AS-13729; CPD000059126; ESTRADIOL COMPONENT OF CLIMARA PRO; Estra-1,3,5(10)-triene-3,17b-diol; Oestra-1,3,5(10)-triene-3,17b-diol; WLN: L E5 B666TTT&J E1 FQ OQ; 17 beta-Estradiol, 1mg/ml in Acetonitrile; DB-246618; Estra-1,5(10)-triene-3,17.beta.-diol; Estradiol, meets USP testing specifications; 3,17beta-dihydroxyestra-1,3,5(10)-trien; CS-0694760; Estra-1,3,5(10)-triene-3,17beta-diol-; EU-0100503; KG70300000; NS00008517; NS00115904; Oestra-1,5(10)-triene-3,17.beta.-diol; C00951; D00105; EN300-119518; (17b)-Estra-1,3,5(10)-triene-3,17-diol; 13b-Methyl-1,3,5(10)-gonatriene-3,17b-ol; 17.beta.-Estra-1,5(10)-triene-3,17-diol; 17.beta.-Oestra-1,5(10)-triene-3,17-diol; ETHINYLESTRADIOL IMPURITY D [EP IMPURITY]; 17-beta-Estradiol 100 microg/mL in Acetonitrile; Q422416; SR-01000721892; 13beta-Methyl-1,3,5(10)-gonatriene-3,17beta-ol; Estra-1,5(10)-triene-3,17-diol (17.beta.)-; ESTRADIOL BENZOATE IMPURITY A [EP IMPURITY]; ESTRADIOL VALERATE IMPURITY A [EP IMPURITY]; Q-201503; SR-01000075866-1; SR-01000075866-4; SR-01000721892-3; BRD-K18910433-001-04-4; BRD-K18910433-001-43-2; estra-1(10),2,4-triene-3,17-diol, (17beta)-; Estra-1,5(10)-triene-3,17-diol, (17.beta.)-; Z1521553843; B8B5AEF5-4957-49EB-A14F-444A8212C482; beta-Estradiol, BioReagent, powder, suitable for cell culture; Estradiol, United States Pharmacopeia (USP) Reference Standard; 13.BETA.-METHYL-1,3,5(10)-GONATRIENE-3,17.BETA.-OL; beta-Estradiol, powder, gamma-irradiated, suitable for cell culture; Estra-1,3,5(10)-triene-3,17-diol, (6,7-(sup 3)H,17-beta)-; (9beta,13alpha,14beta,17alpha)-estra-1,3,5(10)-triene-3,17-diol; Estradiol, Pharmaceutical Secondary Standard; Certified Reference Material; (13S,17S)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-beta-diol; (1S,10R,11S,14S,15S)-15-methyltetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadeca-2,4,6-triene-5,14-diol; (1S,10R,11S,14S,15S)-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-2,4,6-triene-5,14-diol"	TAR10055	Estrogen receptor (ESR)	P03372	5757	D08QMX	DB00783	CHEMBL135
DRG00077	Estrone	Estrone	.	"estrone; 53-16-7; folliculin; OESTRONE; Theelin; Thelykinin; Ketohydroxyestrin; Estrugenone; Estron; Tokokin; estrovarin; Disynformon; Folliculine; Follicunodis; Glandubolin; Hiestrone; Hormestrin; Oestroform; Oestronum; Oestroperos; Destrone; Femidyn; Folipex; Folisan; Kestrone; Menagen; Oestrin; Kolpon; Estrone-A; Ketohydroxyoestrin; Cristallovar; Endofolliculina; Aquacrine; Crinovaryl; Crystogen; Estrusol; Folikrin; Follestrine; Follestrol; Hormofollin; Hormovarine; Ketodestrin; Menformon; Mestronaq; Ovifollin; Perlatan; Solliculin; Thelestrin; Thynestron; Wynestron; 1,3,5(10)-Estratrien-3-ol-17-one; 3-Hydroxyestra-1,3,5(10)-trien-17-one; Unden; Femestrone injection; Estrogenic Substance; Ovex (tablets); estrol; Estrona [Spanish]; Folliculine benzoate; Fem-O-Gen; Estronum [INN-Latin]; Estrona [INN-Spanish]; Estronum; Estra-1,3,5(10)-trien-17-one, 3-hydroxy-; Ketohydroxy-Estratriene; E(sub 1); Folliculinum; 3-Hydroxy-oestra-1,3,5(10)-trien-17-one; Estrona; 3-Hydroxy-17-keto-estra-1,3,5-triene; 1,3,5(10)-Oestratrien-3-ol-17-one; delta-1,3,5-Estratrien-3beta-ol-17-one; delta-1,3,5-Oestratrien-3beta-ol-17-one; delta-1,3,5-estratrien-3-beta-ol-17-one; 3-Hydroxyestra-1,3,5(10)-triene-17-one; delta-1,3,5-oestratrien-3-beta-ol-17-one; (+)-Estrone; Estrone (E1); 3-Hydroxy-17-keto-oestra-1,3,5-triene; CCRIS 285; (+/-)-Oestrone; 3-Hydroxy-1,3,5(10)-estratrien-17-one; (+/-)-Estrone; Aquest; Estrone DL-form [MI]; HSDB 3324; Unden (pharmaceutical); Estrone, (+/-)-; NATURAL ESTROGENIC SUBSTANCE-ESTRONE; 1,3,5-Estratrien-3-ol-17-one; NSC 9699; 19973-76-3; EINECS 200-164-5; UNII-2DI9HA706A; Estrone (Standard); BRN 1915077; (8R,9S,13S,14S)-3-hydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-one; DTXSID4022367; Estradiol metabolite e1; 3-hydroxy-estra-1,3,5(10)-trien-17-one; NSC-9699; WAY 164397; Estrone [USP:INN:BAN]; CHEMBL1405; MLS000028475; 2DI9HA706A; DTXCID402367; X9XKA379T9; CHEBI:17263; EC 200-164-5; 3-08-00-01171 (Beilstein Handbook Reference); Estra-1,3,5(10)-trien-17-one, 3-hydroxy-, (+/-)-; Estronum (INN-Latin); SMR000058338; Estrona (INN-Spanish); 3-hydroxyl-1,3,5(10)-estratien-17-one; ESTRONE (MART.); ESTRONE [MART.]; ESTRONE (USP-RS); ESTRONE [USP-RS]; Estrone (USP:INN:BAN); (13S)-3-hydroxy-13-methyl-7,8,9,11,12,13,15,16-octahydro-6H-cyclopenta[a]phenanthren-17(14H)-one; [2,4,6,7-3H]-E1; ESTRONE (USP MONOGRAPH); ESTRONE [USP MONOGRAPH]; hydroxyestrones; Unden (pharmaceutical) (VAN); (9beta,13alpha)-3-Hydroxyestra-1,3,5(10)-Trien-17-One; Oestrone [Steroidal oestrogens]; Follidrin (tablets); MFCD00003620; (8R,9S,13S,14S)-3-HYDROXY-13-METHYL-6,7,8,9,11,12,13,14,15,16-DECAHYDRO-17H-CYCLOPENTA(A)PHENANTHREN-17-ONE; Estrone (TN); ETHINYLESTRADIOL IMPURITY C (EP IMPURITY); ETHINYLESTRADIOL IMPURITY C [EP IMPURITY]; Estrone (JAN/USP/INN); UNII-X9XKA379T9; 1,3,5-Oestratrien-3-ol-17-one; CAS-53-16-7; NCGC00015423-03; (8R,9S,13S,14S)-3-hydroxy-13-methyl-6,7,8,9,11,12,13,14,15,16-decahydro-17H-cyclopenta[a]phenanthren-17-one; J3Z; CMC_13458; Estrone1516; ESTRONE [VANDF]; Opera_ID_330; ESTRONE [HSDB]; Estrone, >=99%; ESTRONE [INN]; ESTRONE [JAN]; ESTRONE [MI]; Prestwick0_000914; Prestwick1_000914; Prestwick2_000914; Prestwick3_000914; Spectrum5_002047; E0026; ESTRONE [WHO-DD]; bmse000549; E 9750; FOLLICULINUM [HPUS]; Lopac0_000513; SCHEMBL21702; BSPBio_000788; MLS001077340; MLS002695951; MLS006011890; BIDD:ER0145; ESTRONE [ORANGE BOOK]; SPBio_002977; BPBio1_000868; GTPL2818; MEGxm0_000444; SGCUT00128; Estrone 1.0 mg/ml in Methanol; ACon0_000083; ACon1_000122; BDBM17289; HY-B0234R; [2,4,6,7-3H]-Estrone; G03CA07; G03CC04; HMS1570H10; HMS2090E22; HMS2097H10; HMS2232O15; HMS3261H07; HMS3714H10; BCP13336; HY-B0234; to_000049; Tox21_113567; Tox21_201375; Tox21_303651; Tox21_500513; BBL033470; BL-090; LMST02010004; s1665; STK801833; AKOS005622512; AKOS007930641; Tox21_113567_1; AC-1395; CCG-204604; DB00655; DS-6316; Estrone 100 microg/mL in Acetonitrile; LP00513; SDCCGSBI-0050497.P002; SMP1_000123; NCGC00023643-03; NCGC00023643-04; NCGC00023643-05; NCGC00023643-06; NCGC00023643-07; NCGC00023643-08; NCGC00023643-09; NCGC00023643-10; NCGC00023643-11; NCGC00023643-12; NCGC00023643-13; NCGC00023643-15; NCGC00023643-16; NCGC00023643-22; NCGC00179433-01; NCGC00179433-02; NCGC00179433-03; NCGC00257402-01; NCGC00258926-01; NCGC00261198-01; Estrone, meets USP testing specifications; D1,3,5(10)-Estratrien-3-ol-17-one; 3-Hydroxyoestra-1,3,5(10)-trien-17-one; AB00382990; CS-0694877; Estrone, VETRANAL(TM), analytical standard; EU-0100513; FT-0625717; NS00010299; 3-hydroxy-estra-1,3,5(10)-triene-17-one; C00468; D00067; EN300-120636; AB00382990-16; AB00382990-17; AB00382990_18; estra-1(10),2,4-trien-17-one, 3-hydroxy-; Q414986; SR-01000000085; SR-01000075867; Q-201073; SR-01000000085-3; SR-01000075867-1; BRD-K81839095-001-04-6; BRD-K81839095-001-30-1; ESTRADIOL HEMIHYDRATE IMPURITY A [EP IMPURITY]; 86C77018-146D-4603-ACEA-CA0D8C4F1E2C; Estrone, European Pharmacopoeia (EP) Reference Standard; Z1530425070; Estrone, United States Pharmacopeia (USP) Reference Standard; Estrone, Pharmaceutical Secondary Standard; Certified Reference Material; (1S,10R,11S,15S)-5-hydroxy-15-methyltetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadeca-2,4,6-trien-14-one; (1S,10R,11S,15S)-5-hydroxy-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-2,4,6-trien-14-one; (8R,13S)-3-Hydroxy-13-methyl-6,7,8,9,11,12,13,14,15,16-decahydro-cyclopenta[a]phenanthren-17-one"	TAR10055	Estrogen receptor (ESR)	P03372	5870	D00ZFP	DB00655	CHEMBL1405
DRG00078	Cholesterol	Cholesterol	.	"cholesterol; 57-88-5; Cholesterin; Cholest-5-en-3beta-ol; Cholesteryl alcohol; Dythol; Cholestrin; Cordulan; Dusoline; Dusoran; Cholesterine; Cholestrol; Hydrocerin; Lidinite; Kathro; Lanol; Super hartolan; Lidinit; Cholesterol base H; Provitamin D; Nimco cholesterol base H; (-)-Cholesterol; Cholesterinum; Tegolan; 5:6-Cholesten-3beta-ol; 3beta-Hydroxycholest-5-ene; (3beta)-cholest-5-en-3-ol; Tegolan (VAN); Cholest-5-en-3-beta-ol; 5-Cholesten-3beta-ol; CCRIS 2834; Cholest-5-en-3-ol (3beta)-; HSDB 7106; Cholest-5-en-3-ol; 3beta-Hydroxy-5-cholestene; NSC 8798; (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; 3-beta-Hydroxycholest-5-ene; 5-Cholesten-3B-ol; Cholest-5-en-3-ol (3.beta.)-; Dastar; CHEBI:16113; Provitamin-d; Cholest-5-en-3-ol, (3beta)-; AI3-03112; delta(sup 5)-Cholesten-3-beta-ol; Fancol CH; NSC-8798; 3h-cholesterol; EINECS 200-353-2; UNII-97C5T2UQ7J; 97C5T2UQ7J; DTXSID3022401; Nimco cholesterol base No. 712; NSC8798; 5-cholestene-3beta-ol; 5:6-Cholesten-3-ol; (3beta,14beta,17alpha)-cholest-5-en-3-ol; 5-Cholesten-3.beta.-ol; Cholest-5-en-3.beta.-ol; 5,6-Cholesten-3.beta.-ol; 3.beta.-Hydroxycholest-5-ene; DTXCID402401; EC 200-353-2; MFCD00003646; 129111-15-5; NCGC00159351-02; CHOLESTEROL (II); CHOLESTEROL [II]; CHOLESTEROL (IARC); CHOLESTEROL [IARC]; CHOLESTEROL (MART.); CHOLESTEROL [MART.]; CHOLESTEROL (USP-RS); CHOLESTEROL [USP-RS]; CHOLESTEROL (EP MONOGRAPH); CHOLESTEROL [EP MONOGRAPH]; Cholesterol-t; (3S,8S,9S,10R,13R,14S,17R)-17-[(1R)-1,5-dimethylhexyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; (3H)-Cholesterol; epicholesterin; Cholesterol [BAN:JAN:NF]; ?Cholesterol; .DELTA.5-Cholesten-3-.beta.-ol; 80356-14-5; 1zhy; Cholesterol,(S); Cholest-5-en-3-ol, (3.beta.)- #; Cholesterol1551; Cholesterol (TN); 20-epi-cholesterol; 20-iso-cholesterol; Cholesterol, 94%; Liquid crystal CN/9; (+)-ent-Cholesterol; cholest-5-en-3b-ol; 5-Cholesten-3ss--ol; Cholesterol (>99%); Cholesterol, 99.0%; CHOLESTEROL [MI]; ALF component cholesterol; CHOLESTEROL [JAN]; ALFQ component cholesterol; Cholesterol (JP17/NF); CHOLESTEROL [HSDB]; Phospholipon & Cholesterol; Delta5-Cholesten-3beta-ol; Epitope ID:150761; CHOLESTEROL [VANDF]; 3beta-cholest-5-en-3-ol; 3ss--Hydroxy-5-cholestene; CHOLESTERINUM [HPUS]; BIDD:PXR0095; (3b)-cholest-5-en-3-ol; CHOLESTEROL [WHO-DD]; 5:6-Cholesten-3.beta.-ol; 20bFH-cholest-5-en-3b-ol; BIDD:ER0548; Cholest-5-en-3-ol (3beta)-, labeled with tritium; CHEMBL112570; Cholest-5-en-3-ol (3beta); GTPL2718; BDBM20192; (20bFH)-cholest-5-en-3b-ol; CHEBI:140435; (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol; 10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; Cholesterol, Sigma Grade, >=99%; HY-N0322; Tox21_111595; Analytical Reagent,>95.0%(HPLC); CMC_13392; LMST01010001; s4154; AKOS005267135; Cholest-5-en-3-ol, (3-.beta.)-; CS-5106; DB04540; GS-6857; CAS-57-88-5; Cholesterol, NIST(R) SRM(R) 911c; SMP1_000069; NCGC00159351-03; 22243-67-0; BP-26125; Cholesterol 10 microg/mL in Acetonitrile; Cholesterol, tested according to Ph.Eur.; C3624; Cholesterol, from lanolin, >=95.0% (GC); Cholesterol, from lanolin, >=99.0% (GC); FT-0623719; NS00005787; Army Liposome Formulation component cholesterol; C00187; D00040; EN300-323186; F70214; Q43656; AB00443913_03; Cholesterol, >=95% (GC), powder, Ash, free; Cholesterol, Vetec(TM) reagent grade, >=92.5%; Soya phospholipon & Cholesterol (2:1 molar ratio); W-105431; 5BBA213B-ECF4-44AF-8AAF-8A0120F2F886; WLN: L E5 B666 LUTJ A1 E1 FY1&3Y1&1 OQ; Z2033589790; Cholesterol, European Pharmacopoeia (EP) Reference Standard; Cholesterol, powder, BioReagent, suitable for cell culture, >=99%; Cholesterol, United States Pharmacopeia (USP) Reference Standard; Cholesterol, Pharmaceutical Secondary Standard; Certified Reference Material; (1R,3aS,3bS,7S,9aR,9bS,11aR)-9a,11a-dimethyl-1-[(2R)-6-methylheptan-2-yl]-1H,2H,3H,3aH,3bH,4H,6H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-ol; (1S,2R,5S,10S,11S,14R,15R)-2,15-dimethyl-14-[(2R)-6-methylheptan-2-yl]tetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadec-7-en-5-ol"	TAR10051	Cholinephosphate cytidylyltransferase (PCYT1B)	Q9Y5K3	5997	D02DLW	DB04540	CHEMBL112570
DRG00079	Cephalothin	Cephalothin	.	"cephalothin; Cefalotin; 153-61-7; Cephalotin; Cefalothin; Cephalothinum; Cefalotina; Cefalotine; Cefalotinum; (6R,7R)-3-(Acetoxymethyl)-8-oxo-7-(2-(thiophen-2-yl)acetamido)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Cemastin; 7-(2-Thienylacetamido)cephalosporanic acid; Coaxin; Keflin; Cefalotine [INN-French]; Cefalotinum [INN-Latin]; Cefalotina [INN-Spanish]; Averon-1; 7-(Thiophene-2-acetamido)cephalosporin; Cephalotin acid; 3-Acetoxymethyl-7-(2-thienylacetamido)-3-cephem-4-carboxylic acid; (6R,7R)-3-(acetyloxymethyl)-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Cefalotin [INN]; (6R,7R)-3-[(acetyloxy)methyl]-8-oxo-7-[2-(thiophen-2-yl)acetamido]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; CHEBI:124991; MLS001048966; 7-(2'-thienylacetamido)cephalosporanic acid; DTXSID4022783; R72LW146E6; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-((acetyloxy)methyl)-8-oxo-7-((2-thienylacetyl)amino)-, (6R-trans)-; NCGC00159332-02; SMR000386987; DTXCID202783; C16H16N2O6S2; Cefalotin (BAN); 7-(Thiophene-2-acetamido)cephalosporanic acid; (6R,7R)-3-(acetoxymethyl)-8-oxo-7-(2-(thiophen-2-yl)acetamido)-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-(acetoxymethyl)-8-oxo-7-[[2-(2-thienyl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; CAS-153-61-7; 7-(2-(2-Thienyl)acetylamido)cephalosporanic acid; HSDB 3024; Cefalotina fabra (TN); EINECS 205-815-7; BRN 0945586; UNII-R72LW146E6; 6R-trans-3-((Acetyloxy)methyl)-8-oxo-7-((2-thienylacetyl)amino)-5-thia-1-azabicyclo(4.2.0)-oct-2-ene-2-carboxylic acid; 4kox; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-((acetyloxy)methyl)-8-oxo-7-((2-thienylacetyl)amino)-, (6R,7R)-; 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-, (6R,7R)-; (+-)-Cephalothin; 3-(Acetoxymethyl)-8-oxo-7-(2-(2-thienyl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; 3-(Hydroxymethyl)-8-oxo-7-(2-(2-thienyl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid acetate; Spectrum_000110; CEPHALOTHIN [MI]; Prestwick0_000719; Prestwick1_000719; Prestwick2_000719; Prestwick3_000719; Spectrum2_000121; Spectrum3_000332; Spectrum4_000269; Spectrum5_000669; CEPHALOTHIN [HSDB]; CHEMBL617; Epitope ID:116207; CEPHALOTHIN [VANDF]; CEFALOTIN [WHO-DD]; cid_6024; SCHEMBL2990; Lopac0_000283; BSPBio_000937; BSPBio_001963; KBioGR_000738; KBioSS_000550; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(hydroxymethyl)-8-oxo-7-(2-(2-thienyl)acetamido)-, acetate (ester); DivK1c_000097; SPBio_000162; SPBio_002858; BPBio1_001031; GTPL8798; CEPHALOTHIN [GREEN BOOK]; SCHEMBL20477170; BDBM82898; HY-B1275A; KBio1_000097; KBio2_000550; KBio2_003118; KBio2_005686; KBio3_001183; NINDS_000097; HMS2267P23; Tox21_111579; MFCD00242614; s5294; AKOS015920120; Tox21_111579_1; CCG-268605; CS-W008776; DB00456; GS-3577; SDCCGSBI-0050271.P005; 7beta-(thiophen-2-ylacetamido)-3-acetoxymethyl-3,4-didehydrocepham-4-carboxylic acid; IDI1_000097; NCGC00023699-09; (6R,7R)-3-(Acetoxymethyl)-8-oxo-7-(2-(thiophen-2-yl)acetamido)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylicacid; (6R,7R)-3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; SBI-0050271.P004; 7-(2-thienylacetamido) cephalosporanic acid; 7-(2-thienylacetamido)-cephalosporanic acid; C2769; NS00126621; C-2484; C07761; D07635; EN300-267043; A809447; Cephalothin, Antibiotic for Culture Media Use Only; SR-01000003118; Q2736126; SR-01000003118-3; BRD-K28210218-236-05-7; Z1741977144; CEPHALOTHIN 7-(2-THIENYLACETAMIDO)CEPHALOSPORANIC ACID; 3-acetoxymethyl-7beta-(2-thienylacetamido) ceph-3-em-4-carboxylic acid; 3-acetoxymethyl-7beta-(2-thienylacetamido)-3-cephem-4-carboxylic acid; 3-Acetoxymethyl-7beta-(2-thienylacetamido)ceph-3-em-4-carboxylic acid; (6R,7R)-3-(acetoxymethyl)-8-keto-7-[[2-(2-thienyl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-(acetyloxymethyl)-8-oxidanylidene-7-(2-thiophen-2-ylethanoylamino)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-(acetyloxymethyl)-8-oxo-7-[(1-oxo-2-thiophen-2-ylethyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(acetyloxy)methyl]-8-oxo-7-[(thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 51098-29-4"	TAR10041	Bacterial DD-carboxypeptidase (Bact vanYB)	Q47746	6024	D01PLN	DB00456	CHEMBL617
DRG00080	Kanamycin A	Kanamycin A	.	"kanamycin; KANAMYCIN A; 59-01-8; Kanamycin Base; Kanamicina; Kanamycine; Kanamycinum; KanamycinA; KM (the Antibiotic); CHEBI:17630; HSDB 3107; EINECS 200-411-7; UNII-EQK9Q303C5; 8063-07-8; BRN 0061647; EQK9Q303C5; 4,6-Diamino-2-hydroxy-1,3-cyclohexane 3,6'diamino-3,6'-dideoxydi-alpha-D-glucoside; Kanamycin A monosulfate; (2R,3S,4S,5R,6R)-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-3-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4,5-triol; KAN; DTXSID3023184; Glucopyranoside, 4,6-diamino-2-hydroxy-1,3-cyclohexylene 3,6'-diamino-3,6'-dideoxydi-, D-; D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1,4))-2-deoxy-; D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1-4))-2-deoxy-; Kanamycin A Deuterated; 4,6-diamino-2-hydroxy-1,3-cyclohexylene 3,6'-diamino-3,6'-dideoxydi-D-glucopyranoside; Kanamicina [Italian]; Kanamycin [INN:BAN]; Kanamycine [INN-French]; Kanamycinum [INN-Latin]; (1S,2R,3R,4S,6R)-4,6-diamino-3-(6-amino-6-deoxy-alpha-D-glucopyranosyloxy)-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside; (1S,2R,3R,4S,6R)-4,6-diamino-3-[(6-amino-6-deoxy-alpha-D-glucopyranosyl)oxy]-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside; (2R,3S,4S,5R,6R)-2-(aminomethyl)-6-{[(1R,2R,3S,4R,6S)-4,6-diamino-3-{[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-2-hydroxycyclohexyl]oxy}oxane-3,4,5-triol; 2-(aminomethyl)-6-[4,6-diamino-3-[4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4,5-triol; D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1->4))-2-deoxy-; O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1->4))-2-deoxy-D-streptamine; UNII-RUC37XUP2P; Kanamycins; Kanamycin Complex; Kanamycin,(S); Liposomal Kanamycin; (2R,3S,4S,5R,6R)-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-3-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-2-hydroxy-cyclohexoxy]tetrahydropyran-3,4,5-triol; 1174286-24-8; Kanamycinum (Latin); Prestwick3_000394; Kantrex (1:1 sulfate); Klebcil (1:1 sulfate); KANAMYCIN A [MI]; RUC37XUP2P; KANAMYCIN A [HSDB]; SCHEMBL2735; CHEMBL1384; BSPBio_000607; DivK1c_000024; KANAMYCIN A [WHO-IP]; BPBio1_000669; CHEBI:6104; DTXCID503184; DTXSID2041171; GTPL12132; KBio1_000024; A07AA08; J01GB04; S01AA24; NINDS_000024; EINECS 232-512-7; BDBM50031282; AKOS025293505; DB01172; IDI1_000024; SMP2_000007; NCGC00179506-01; NCGC00179506-05; AS-14003; D-Streptamine, O-3-amino-3-deoxy-.alpha.-D-glucopyranosyl-(1.fwdarw.6)-O-[6-amino-6-deoxy-.alpha.-D-glucopyranosyl-(1.fwdarw.4)]-2-deoxy-; HY-16566; AB00513827; CS-0006792; NS00098990; C01822; K-0250; EN300-19735925; BRD-K08327065-065-01-9; Q27094615; Kanamycin sulfate, Antibiotic for Culture Media Use Only; (2R,3S,4S,5R,6R)-2-(aminomethyl)-6-((1R,2R,3S,4R,6S)-4,6-diamino-3-((2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yloxy)-2-hydroxycyclohexyloxy)tetrahydro-2H-pyran-3,4,5-triol; ANTIBIOTIC COMPLEX FROM STREPTOMYCES KANAMYCETICUS CONTAINING KANAMYCIN A (MAJOR), KANAMYCIN B AND KANAMYCIN C; D-STREPTAMINE, O-3-AMINO-3-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->6)-O-(6-AMINO-6-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->4))-2-DEOXY-; D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1.fwdarw.6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1.fwdarw.4))-2-deoxy-; O-3-Amino-3-deoxy-.alpha.-D-glucopyranosyl-(1->6)-O-[6-amino-6-deoxy-.alpha.-D-glucopyranosyl-(1->4)]-2-deoxy-D-streptamine"	TAR10047	Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)	F4NA87	6032	D0YV1Q	DB01172	.
DRG00081	Cytarabine	Cytarabine	.	"cytarabine; 147-94-4; Ara-C; Cytosine arabinoside; Aracytidine; Arabinocytidine; Cytarabinoside; Spongocytidine; Aracytin; Cytosar-U; Depocyt; Udicil; Arabinofuranosylcytosine; Arabitin; Aracytine; Cytarabina; Tarabine; Arafcyt; Erpalfa; 1-beta-D-Arabinofuranosylcytosine; arabinocytosine; Cytarabinum; Cytosine beta-D-arabinofuranoside; DepoCyte; Arabinosylcytosine; Cytarabin; Cytosar; Cytosinearabinoside; Citarabina; Depocyt (liposomal); beta-D-Arabinosylcytosine; Cytosine arabinofuranoside; Alexan; Cytosine beta-D-arabinoside; Cytarabinum [INN-Latin]; Arabinoside C; 1beta-D-Arabinosylcytosine; 4-Amino-1-((2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; Citarabina [INN-Spanish]; Cytosine-1-beta-D-arabinofuranoside; AraC; Cytosine arabinose; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone; 1beta-Arabinofuranasylcytosine; Iretin; Cytosine 1-beta-D-arabinofuranoside; 1beta-D-Arabinofuranosylcytosine; 1-beta-D-Arabinofaranosylcytosine; beta-Arabinosylcytosine; Ara-Cytidine; U 19920A; Beta-cytosine arabinoside; Cytosine-beta-arabinoside; Cytosine-beta-D-arabinofuranoside; cytarabine liposome; 1-Arabinofuranosylcytosine; CHX 3311; CCRIS 913; U-19,920; 4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one; Arabinofuranosyl Cytidine; Cytosine, 1-beta-D-arabinosyl-; 1-beta-D-Arabinosylcytosine; HSDB 3049; 1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone; EINECS 205-705-9; 1-(arabinofuranosyl)cytosine; Cyclocide; Cytosine, 1-beta-D-arabinofuranosyl-; NSC 287459; UNII-04079A1RDZ; 1-beta-arabinofuranosylcytosine; U-19920; Cytosine ; A-D-Arabinofuranoside; DTXSID3022877; CHEBI:28680; AI3-52329; (beta-D-Arabinofuranosyl)cytosine; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin; 04079A1RDZ; 2(1H)-Pyrimidinone, 4-amino-1-beta-D-arabinofuranosyl-; MFCD00066487; CHEMBL803; NSC-287459; MK 8242; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon; 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydropyrimidin-2-one; C9H13N3O5; DTXCID702877; 2(1H)-Pyrimidinone, 4-amino-1-.beta.-D-arabinofuranosyl-; AR3; Cytonal; NCI-C04728; VYXEOS COMPONENT CYTARABINE; 1-beta-D-arabinofuranosyl-cytosine; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine; AC-1075; beta-Ara C; Cytarabine [USAN:USP:INN:BAN:JAN]; NCGC00093356-03; 2(1H)-Pyrimidinone, 4-amino-1-y-D-arabinofuranosyl- [CAS]; Cytarbel; (Arabinofuranosyl)cytosine; Cytarabinum (INN-Latin); Citarabina (INN-Spanish); CYTARABINE (MART.); CYTARABINE [MART.]; CYTARABINE (USP-RS); CYTARABINE [USP-RS]; Citozar; ara-Cytosine; Cytosine arabinoside (VAN); Tarabine PFS; CYTARABINE (EP MONOGRAPH); CYTARABINE (USP IMPURITY); CYTARABINE [EP MONOGRAPH]; CYTARABINE [USP IMPURITY]; Cytosine-1-beta-arabinofuranoside; CYTARABINE (USP MONOGRAPH); CYTARABINE [USP MONOGRAPH]; 69-74-9; Ara-cell; Cytarabine (USAN:USP:INN:BAN:JAN); cytarabine liposome injection; Arabinosyl Cytosine; Cytosine, beta-D-arabinoside; CAS-147-94-4; SMR000449317; Depocyt (TN); Arabinoside, Cytosine; 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; Cytartbine; Arabine; 1-.beta.-D-Arabinofuranosylcytosine; Cytarabine; 4-amino-1-beta-d-arabinofuranosylpyrimidin-2(1H)-one; SR-01000075773; NSC287459; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]; 1-(beta-d-arabinofuranosyl)cytosine; 1-.beta.-D-arabinofuranosyl-cytosine; 4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone; U-19920 A; cytarabine ocphosphate; 1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside; beta -arabinosylcytosine; Arabinofuranosylcytosine?; CYTARABINE [MI]; U 19920; CYTARABINE [INN]; CYTARABINE [JAN]; CYTARABINE [HSDB]; CYTARABINE [USAN]; beta -cytosine arabinoside; beta -D-arabinosylcytosine; Cytosine-beta -arabinoside; CYTARABINE [VANDF]; SCHEMBL3140; 1beta -D-Arabinosylcytosine; CYTARABINE [WHO-DD]; CYTARABINE [WHO-IP]; BIDD:PXR0139; Lopac0_000316; MLS000758310; MLS001066340; MLS001424023; 1-beta-D-Arabinosyl-Cytosine; BIDD:GT0371; CYTARABINE [EMA EPAR]; Cytosine, beta -D-arabinoside; 1beta -Arabinofuranasylcytosine; Cytarabine (JP17/USP/INN); GTPL4827; 1-ss-D-Arabinofuranosylcytosine; 2(1H)-Pyrimidinone, 4-amino-1beta-D-arabinofuranosyl-; CYTARABINE [ORANGE BOOK]; SCHEMBL22591193; SCHEMBL23152019; 1beta -D-Arabinofuranosylcytosine; BETA-CYTOSINE, ARABINOSIDE; L01BC01; Cytosine, 1-beta -D-arabinosyl-; 1-beta -d-arabinofuranosylcytosine; 1-beta-D-arabinofuranosyl cytosine; Cytosine-beta -D-arabinofuranoside; HMS2051K19; HMS2090A18; HMS2230M16; HMS3713N12; 1-beta -D-Arabinofaranosylcytosine; CYTARABINE LIPOSOME [VANDF]; CYTARABINUM [WHO-IP LATIN]; BCP02876; Tox21_111203; Tox21_301971; BDBM50087289; CCG-51297; s1648; AKOS007930145; AKOS015896896; AM84428; Cytosine, 1-beta -D-arabinofuranosyl-; DB00987; KS-5063; NC00070; SDCCGSBI-0050304.P002; NCGC00093356-04; NCGC00093356-05; NCGC00093356-06; NCGC00093356-19; NCGC00142483-02; NCGC00255381-01; 1(BETA-D-ARABINOFURANOSYL)CYTOSINE; BA164339; HY-13605; SRI-10828-19; SRI-10828-20; SRI-10828_24; WR-28453; SL-000002; U 19,920A; C2035; NS00005949; SW197450-5; C02961; D00168; EN300-118320; 1-BETA-D-ARABINOFURANOSYLCYTOSINE; ARA-C; A808710; Q180983; SR-01000721860; J-520199; J-700005; J-700166; SR-01000075773-3; SR-01000075773-5; SR-01000721860-6; U 19,920; 1-beta -D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone; 2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl; BRD-K33106058-001-07-7; BRD-K33106058-003-20-6; 1-BETA-D-ARABINOSYL-4-AMINO-2(1H)PYRIMIDINONE; 2(1H)-Pyrimidinone, 4-amino-1beta -D-arabinofuranosyl-; Cytosine -D-arabinofuranoside;Cytosine Arabinoside;Ara-C; Z1511499171; 2(1H)-Pyrimidinone, 4-amino-1-beta -D-arabinofuranosyl-; Cytarabine, European Pharmacopoeia (EP) Reference Standard; Cytarabine, United States Pharmacopeia (USP) Reference Standard; Cytosine beta-D-arabinofuranoside, crystalline, >=90% (HPLC); Cytosine beta-D-arabinofuranoside, Vetec(TM) reagent grade, 90%; Cytarabine, Pharmaceutical Secondary Standard; Certified Reference Material; 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; Cytosine -D-arabinofuranoside hydrochloride;Cytosine Arabinoside hydrochloride;Ara-C hydrochloride"	TAR10039	Herpes simplex virus DNA polymerase UL30 (HSV UL30)	P04293	6253	D07XSN	DB00987	CHEMBL803
DRG00082	P-Toluenesulfonamide	P-Toluenesulfonamide	.	"P-TOLUENESULFONAMIDE; 4-Methylbenzenesulfonamide; 70-55-3; 4-Toluenesulfonamide; Tosylamide; p-Tosylamide; Toluene-4-sulfonamide; Benzenesulfonamide, 4-methyl-; para-Toluenesulfonamide; p-Tolylsulfonamide; 4-methylbenzene-1-sulfonamide; p-Methylbenzenesulfonamide; p-Toluenesulfonylamide; Tolylsulfonamide; Toluene-4-sulphonamide; p-Toluenesulfamide; Toluene-p-sulphonamide; tosylamine; 4-tolylsulfonamide; TOLUENESULFONAMIDE, P-; p-toluene sulphonamide; NSC-9908; MFCD00011692; 4-methylbenzenesulphonamide; CHEMBL574; DTXSID8029105; CHEBI:34435; I8266RI90M; 4-Toluenesulfanamide; DTXCID109105; CAS-70-55-3; 4-Toluenesulfonic acid, amide; HSDB 5203; NSC 9908; EINECS 200-741-1; BRN 0472689; UNII-I8266RI90M; AI3-19503; p-toluensulfonamide; 4-tolylsulphonamide; 4J8; p-Toluenesulphonamide; 4-toluenesulphonamide; p-toluene sulfonamide; p-toluene-sulfonamide; PASAM; Toluene-p-sulfonamide; N-p-tolylsulfonylamine; Paratoulene sulfonamide; p-toluenesulfonic amide; para-toluen sulphonamide; para-toluene sulphonamide; 4-methylphenylsulphonamide; 4-methylphenyl sulfonamide; P-Toluenesulfonamide,(S); Analytical Reagent, 98%; 4-methyl benzenesulfonamide; 4-methyl-benzenesulfonamide; WLN: ZSWR D1; 4-methylphenylsulphonylamine; EC 200-741-1; p-methyl-benzene sulfonamide; SCHEMBL7370; 4-11-00-00376 (Beilstein Handbook Reference); MLS001065595; BIDD:ER0609; BDBM10859; benzene, 1-methyl-4-sulphamoyl-; NSC9908; HMS3039B12; P-TOLUENESULFONAMIDE [HSDB]; AMY37180; Tox21_201594; Tox21_303506; aromatic/heteroaromatic sulfonamide 4; STK416410; P-TOLUENESULFONAMIDE [USP-RS]; AKOS000149655; FS-3585; NCGC00091435-01; NCGC00091435-02; NCGC00091435-03; NCGC00257435-01; NCGC00259143-01; BP-12584; HY-79602; NCI60_042220; p-Toluenesulfonamide, reagent grade, 98%; SMR000568494; GLICLAZIDE IMPURITY A [EP IMPURITY]; CS-0012133; FT-0646496; NS00010636; T0281; TOLBUTAMIDE IMPURITY A [EP IMPURITY]; EN300-15721; p-Toluenesulfonamide, ReagentPlus(R), >=99%; AE-562/40173366; p-Toluenesulfonamide, Vetec(TM) reagent grade, 98%; W-104550; W-109664; Q23013959; Z45415564; F0722-8812; p-Toluenesulfonamide, United States Pharmacopeia (USP) Reference Standard; 12552-95-3"	TAR10030	Carbonic anhydrase IX (CA-IX)	Q16790	6269	D0ZC3W	DB17299	CHEMBL574
DRG00083	Mestranol	Mestranol	.	"mestranol; 72-33-3; Menophase; Norquen; Ovastol; Devocin; EE3ME; Ethynylestradiol 3-methyl ether; Mestranolum; 3-Methoxyethynylestradiol; EE(sub3)ME; Ethynylestradiol methyl ether; 3-Methylethynylestradiol; 3-O-Methylethynylestradiol; Compound 33355; Inostral; 3-Methylethynyloestradiol; 3-Methoxyethynyloestradiol; 3-Methoxy-17alpha-ethynylestradiol; SC 4725; EE3-ME; 17-Ethynyloestradiol 3-methyl ether; component of Norinyl; EEI3ME; component of Ortho-Novum; EE-3ME; Ethinylestradiol 3-methyl ether; Ethinyloestradiol 3-methyl ether; Ethynyloestradiol 3-methyl ether; MLS000028595; B2V233XGE7; CHEBI:6784; (8R,9S,13S,14S,17R)-17-Ethynyl-3-methoxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-17-ol; DTXSID0020814; 17-Ethynylestradiol 3-methyl ether; component of Ovulen; component of Norquen; delta-MVE; 17alpha-Ethynylestradiol 3-methyl ether; NSC-84032; Inostral (steroid); Mestranolo [DCIT]; NCGC00093347-02; Mestranolo; SMR000059128; (17beta)-17-ethynyl-3-(methyloxy)estra-1,3,5(10)-trien-17-ol; Mestranolum [INN-Latin]; (8R,9S,13S,14S,17R)-17-ethynyl-3-methoxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-ol; DTXCID20814; Caswell No. 547A; .delta.-MVE; 17alpha-Ethinyl estradiol 3-methyl ether; 17-Ethynyl-3-methoxyestra-1,3,5(10)-trien-17-ol; 3-Methoxy-17alpha-ethinylestradiol; 3-Methoxy-17alpha-ethinyloestradiol; 3-Methoxy-17alpha-ethynyloestradiol; 3-Methoxy-17-alpha-ethinylestradiol; 3-Methoxy-17-alpha-ethynylestradiol; 17alpha-Ethynylestradiol methyl ether; 3-Methoxy-17-alpha-ethinyloestradiol; 3-Methoxy-17-alpha-ethynyloestradiol; CCRIS 377; 17-alpha-Ethynyloestradiol methyl ether; 17alpha-Ethinylestradiol 3-methyl ether; 8027 C. B.; 17alpha-Ethynyloestradiol 3-methyl ether; 3-Methoxy-17-ethynyloestradiol-17-beta; Mestranol [Steroidal oestrogens]; 17alpha-Ethinyl oestradiol 3-methyl ether; HSDB 3588; 17-alpha-Ethinyl estradiol 3-methyl ether; 17-alpha-Ethinyl oestradiol 3-methyl ether; EINECS 200-777-8; NSC 84032; EPA Pesticide Chemical Code 115401; 17beta-Estradiol, 17-ethynyl-, 3-(methyl ether); BRN 2625905; UNII-B2V233XGE7; NSC84032; 17-Ethynyl-3-methoxy-1,3,5(10)-oestratien-17-beta-ol; AI3-51798; 3-Methoxy-17alpha-ethynyl-1,3,5(10)-estratrien-17beta-ol; 19-Norpregna-1,3,5(10)-trien-20-yn-17-ol, 3-methoxy-, (17.alpha.)-; 3-Methoxy-17alpha-ethynyl-1,3,5(10)-oestratrien-17beta-ol; 17-alpha-Ethynyl-3-methoxy-1,3,5(10)-estratrien-17-beta-ol; 3-Methoxy-17-alpha-ethynyl-1,3,5(10)-estratrien-17-beta-ol; 3-Methoxy-17-alpha-ethynyl-1,3,5(10)-oestratrien-17-beta-ol; CAS-72-33-3; 3-Methoxy-17-alpha-19-norpregna-1,3,5(10)-trien-20-yn-17-ol; 3-Methoxy-19-nor-17-alpha-pregna-1,3,5(10)-trien-20-yn-17-ol; 3-Methoxy-19-nor-17alpha-pregna-1,3,5(10)-trien-20-yn-17-ol; 19-Norpregna-1,3,5(10)-trien-20-yn-17-ol, 3-methoxy-, (17alpha)-; Prestwick_966; Mestranol, 99%; Mestranol [USAN:USP:INN:BAN:JAN]; Estra-1,3,5(10)-trien-17beta-ol, 17-ethynyl-3-methoxy-; MESTRANOL [INN]; MESTRANOL [JAN]; Opera_ID_872; MESTRANOL [MI]; MESTRANOL [HSDB]; MESTRANOL [USAN]; 17alpha-19-Norpregna-1,3,5(10)-trien-20-yn-17-ol, 3-methoxy-; Estra-1,3,5(10)-trien-17-beta-ol, 17-alpha-ethynyl-3-methoxy-; Prestwick0_000846; Prestwick1_000846; Prestwick2_000846; Prestwick3_000846; MESTRANOL [VANDF]; (+)-17-alpha-Ethynyl-17-beta-hydroxy-3-methoxy-1,3,5(10)-estratriene; (17-alpha)-3-Methoxy-19-norpregna-1,3,5(10)-trien-20-yn-17-ol; 17-ethynyl-3-methoxyestra-1(10),2,4-trien-17-ol; EE3 ME; MESTRANOL [MART.]; (+)-17-alpha-Ethynyl-17-beta-hydroxy-3-methoxy-1,3,5(10)-oestratriene; 17-alpha-Ethynyl-3-methoxy-17-beta-hydroxy-delta-1,3,5(10)-estratriene; 17-alpha-Ethynyl-3-methoxy-17-beta-hydroxy-delta-1,3,5(10)-oestratriene; 3,17-beta-Dihydroxy-17-alpha-ethynyl-1,3,5(10)-estratriene-3-methyl ether; MESTRANOL [USP-RS]; MESTRANOL [WHO-DD]; SCHEMBL41391; BSPBio_000831; MLS001077321; MLS001424224; BIDD:ER0199; SPBio_002752; Mestranol (JP17/USP/INN); BPBio1_000915; ethynylestradiol-3-methyl ether; GTPL7087; MESTRANOL [ORANGE BOOK]; 17-ethynyl-3-methoxyestra-1(10),2,4-trien-17beta-ol; CHEMBL1201151; MESTRANOL [EP MONOGRAPH]; ENOVID COMPONENT MESTRANOL; OVULEN COMPONENT MESTRANOL; 17-ethynyl-3-methoxyoestra-1(10),2,4-trien-17beta-ol; MESTRANOL [USP MONOGRAPH]; IMSSROKUHAOUJS-MJCUULBUSA-N; 3-Methoxy-19-norpregna-1,3,5(10)-trien-20-yn-17beta-ol; HMS1570J13; HMS2051J22; HMS2097J13; HMS2230L20; HMS3714J13; HY-B0390; Tox21_111200; Tox21_301837; 17-alpha-19-Norpregna-1,3,5(10)-trien-20-yn-17-ol, 3-methoxy-; 19-Nor-17alpha-pregna-1,3,5(10)-trien-20-yn-17-ol, 3-methoxy-; AKOS005267152; Tox21_111200_1; CCG-101067; DB01357; NC00317; NCGC00093347-03; NCGC00093347-05; NCGC00093347-07; NCGC00179410-01; NCGC00255342-01; AC-13293; AS-56063; NS00009656; S2125; Mestranol, VETRANAL(TM), analytical standard; C07618; C76306; D00575; Q904308; SR-01000695429; SR-01000695429-4; BRD-K31920458-001-03-8; BRD-K31920458-001-23-6; Z1557501642; Mestranol, European Pharmacopoeia (EP) Reference Standard; (17beta)-17-ethynyl-3-methoxyestra-1(10),2,4-trien-17-ol; Mestranol, United States Pharmacopeia (USP) Reference Standard; (17alpha)-3-Methoxy-19-norpregna-1,3,5(10)-trien-20-yn-17-ol; 17.Alpha.-19-Norpregna-1,3,5(10)-trien-20-yn-17-ol, 3-meth; (+)-17alpha-Ethynyl-17beta-hydroxy-3-methoxy-1,3,5(10)-estratriene; (+)-17alpha-Ethynyl-17beta-hydroxy-3-methoxy-1,3,5(10)-oestratriene; (+ )-17.alpha.-Ethynyl-17.beta.-hydroxy-3-methoxy-1,3, 5(10)-oestratriene; (+)-17.alpha.-Ethynyl-17.beta.-hydroxy-3-methoxy-1,3, 5(10)-estratriene; 3-METHOXY-19-NOR-17.ALPHA.-PREGNA-1,3,5(10)-TRIEN-20-YN-17-OL.; (1S,10R,11S,14R,15S)-14-ethynyl-5-methoxy-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-2(7),3,5-trien-14-ol; (8R,13S,17R)-17-Ethynyl-3-methoxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-17-ol"	TAR10055	Estrogen receptor (ESR)	P03372	6291	D0J1ML	DB01357	CHEMBL1201151
DRG00084	Cholestanol	Cholestanol	.	"Dihydrocholesterol; 80-97-7; beta-Cholestanol; 5alpha-Cholestan-3beta-ol; Zymostanol; 5alpha-Cholestanol; CHOLESTANOL; Dihydrocholesterin; Cholestan-3beta-ol; Cholestan-3-ol, (3beta,5alpha)-; 5-alpha-Cholestan-3-beta-ol; 3beta-Hydroxy-5alpha-cholestane; 5; A-Cholestan-3; A-ol; 5a-Cholestan-3b-ol; MFCD00066413; NSC 18188; (5alpha)-cholestan-3beta-ol; (3beta,5alpha)-cholestan-3-ol; CHEBI:86570; 3beta-Cholestanol; 8M308U816E; Epicholestanol; (3S,5S,8R,9S,10S,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol; Cholestan-3-ol, (3b,5a)-; 5?-cholestan-3?-ol; Cholestan-3-ol, (3.beta.,5.alpha.)-; Cholestanol (VAN); 3beta-Hydroxycholestane; (+)-Dihydrocholesterol; 29466-38-4; 5alpha-Dihydrocholesterol; Cholestan-3-ol, (3.beta.)- #; 5a-Cholestanol; NSC-18188; UNII-8M308U816E; Cholestan-3b-ol; EINECS 201-315-8; 3b-Hydroxycholestane; 5-Cholestan-3-ol; 5a-Dihydrocholesterol; CHOLESTANOL [MI]; 3b-Hydroxy-5a-cholestane; bmse000541; (3b,5a)-Cholestan-3-ol; CHOLESTANOL [USP-RS]; SCHEMBL133951; CHEMBL1289436; 5 alpha -Cholestan-3 beta -ol; DTXSID40883258; LMST01010077; s5123; 5alpha-Cholestan-3beta-ol, >=95%; Cholestane, 3beta-hydroxy-, 5alpha-; AKOS016036214; CCG-268506; AS-58118; 1ST001398; HY-107819; CS-0030696; Dihydrocholesterol;5-Cholestanol;NSC 18188; CHOLESTAN-3-OL,(3.BETA.,5.ALPHA.)-; D94638; Q27159255; 1814DD66-70FE-4610-86FB-FA8455101768; Cholestanol, United States Pharmacopeia (USP) Reference Standard; (3S,5S,8R,9S,10S,13R,14S,17R)-17-((R)-1,5-dimethylhexyl)-10,13-dimethylhexadecahydrocyclopenta[a]phenanthren-3-ol"	.	.	.	6665	.	.	.
DRG00085	"1,4-dihydroxyanthraquinone (quinizarin) derivative"	"1,4-dihydroxyanthraquinone (quinizarin) derivative"	.	"Quinizarin; 1,4-Dihydroxyanthraquinone; 81-64-1; 1,4-dihydroxyanthracene-9,10-dione; Quinizarine; Chinizarin; Solvent Orange 86; 1,4-Dihydroxyanthrachinon; Smoke Orange R; 1,4-Dihydroxy-9,10-anthraquinone; Macrolex Orange GG; 9,10-Anthracenedione, 1,4-dihydroxy-; Anthraquinone, 1,4-dihydroxy-; 1,4-Dioxyanthraquinone; 1,4-Dihydroxyanthra-9,10-quinone; 103220-12-8; 1,4-Doa; C.I. 58050; 1,4-DIHYDROXY-9,10-ANTHRACENEDIONE; NSC 15367; NSC 646569; CHEBI:37487; NSC-15367; NSC-646569; CHEMBL17594; 8S496ZV3CS; DTXSID8044464; DIHYDROXYANTHRAQUINONE, 1,4-; MFCD00001209; NSC646569; 9, 1,4-dihydroxy-; 1,4-dihydroxy-9,10-dihydroanthracene-9,10-dione; 1,4-Dihydroxy-anthraquinone; 1,4-Doa [Russian]; WLN: L C666 BV IVJ DQ GQ; CCRIS 3524; HSDB 5242; 1,4-Dioxyanthraquinone [Russian]; 1,4-Dihydroxyanthrachinon [Czech]; EINECS 201-368-7; UNII-8S496ZV3CS; CI 58050; AI3-17616; 1,4-Dihydroxy-9,10-anthraquinone; 1,4-Dihydroxyanthraquinone; Smoke Orange R; Quinizarine; 4,9-dihydroxy-1,10-anthraquinone; 9,10-Dihydroxy-1,4-anthraquinone; Quinizarin, 96%; Solvent Orange 86; QUINIZARIN [MI]; EC 201-368-7; 1,4 Dihydroxy-Anthraquinone; SCHEMBL160038; MEGxp0_001867; SCHEMBL2639287; DTXCID6024464; ACon1_000101; HY-D0226; NSC15367; NSC40899; Tox21_302041; BBL010354; BDBM50240382; CCG-48149; NSC-40899; NSC229036; STK264108; 1,4-dihydroxy-anthracene-9,10-dione; AKOS001595052; 1,4-Dihydroxy-9,10-anthracene-dione; 1,4-Dihydroxyanthra-9,10-quinone #; 9,10-Anthraquinone, 1,4-dihydroxy-; NSC-229036; Quinizarin; 1,4-Dihydroxyanthraquinone; CAS-81-64-1; NCGC00160196-01; NCGC00160196-02; NCGC00255951-01; AC-11267; AS-14244; NCI60_001089; CS-0010138; D0243; FT-0657575; NS00003772; F87345; EN300-6486266; A840176; AE-641/02529036; Q906609; SR-01000108129; 1,4-DIHYDROXY-9,10-ANTHRACENEDIONE [HSDB]; doi:10.14272/GUEIZVNYDFNHJU-UHFFFAOYSA-N.1; SR-01000108129-1; SR-01000637713-1; W-104202; F1565-0160; 1,4-Dihydroxyanthraquinone, purum, >=98.0% (HPLC), powder, red-brown; InChI=1/C14H8O4/c15-9-5-6-10(16)12-11(9)13(17)7-3-1-2-4-8(7)14(12)18/h1-6,15-16"	TAR10019	DNA topoisomerase 1 (TOP1); Human Deoxyribonucleic acid (hDNA)	P11387	6688	D0Y6OK	.	.
DRG00086	Pyromellitic acid	Pyromellitic acid	.	"PYROMELLITIC ACID; 89-05-4; 1,2,4,5-Benzenetetracarboxylic acid; Benzene-1,2,4,5-tetracarboxylic acid; USAF XR-20; 1,2,4,5-Tetracarboxybenzene; 1,2,4,5-Benzene-tetracarboxylic acid; D9UXG2U6ZU; DTXSID8044466; CHEBI:45165; NSC-6369; NSC 6369; EINECS 201-879-5; UNII-D9UXG2U6ZU; BRN 1887659; AI3-28523; MFCD00002471; bmse000771; EC 201-879-5; 1,4,5-Tetracarboxybenzene; SCHEMBL22443; 4-09-00-03804 (Beilstein Handbook Reference); WLN: QVR BVQ DVQ EVQ; PYROMELLITIC ACID [MI]; CHEMBL1235346; DTXCID6024466; 1,2,4,5-benzenetetracarboxylic; NSC6369; BDBM512625; 1,4,5-Benzenetetracarboxylic acid; 1,2,4,5-benzenetetracarboxylicacid; Tox21_302030; AKOS004114682; 1,2,4,5-benzene tetracarboxylic acid; DB02749; CAS-89-05-4; NCGC00255745-01; AC-10249; AS-14280; DB-078292; 1,2,4,5-Benzenetetracarboxylic acid, 96%; B0039; CS-0128778; FT-0657165; NS00007494; EN300-24939; A843055; AE-562/43282615; Q3453375; W-100384; Z203045292; InChI=1/C10H6O8/c11-7(12)3-1-4(8(13)14)6(10(17)18)2-5(3)9(15)16/h1-2H,(H,11,12)(H,13,14)(H,15,16)(H,17,18"	.	.	.	6961	.	DB02749	.
DRG00087	Methyl acrylate	Methyl acrylate	.	"METHYL ACRYLATE; 96-33-3; Methyl prop-2-enoate; Methylacrylate; Acrylic acid methyl ester; 2-Propenoic acid, methyl ester; Methyl propenoate; Methyl 2-propenoate; Methylacrylaat; Metilacrilato; Methyl-acrylat; Methoxycarbonylethylene; Acrylate de methyle; Acrylic acid, methyl ester; Curithane 103; Acrylsaeuremethylester; Methyl acrylate, monomer; Methyl propenate; Methylester kyseliny akrylove; NSC 24146; CCRIS 1839; HSDB 194; Methyl-acrylat [German]; EINECS 202-500-6; UNII-WC487PR91H; 2-propenoic acid methyl ester; BRN 0605396; WC487PR91H; DTXSID0024183; CHEBI:82482; AI3-15715; acrylic acid-methyl ester; CH2=CHCOOCH3; Methyl ester acrylic acid; NSC-24146; Methyl acrylate, inhibited; METHYL-2-PROPENOATE; Methyl Acrylate (Stabilized); DTXCID204183; Methyl ester of 2-propenoic acid; EC 202-500-6; 4-02-00-01457 (Beilstein Handbook Reference); MFCD00008627; Methyl-acrylat (german); METHYL ACRYLATE (IARC); METHYL ACRYLATE [IARC]; Methylacrylaat [Dutch]; Metilacrilato [Italian]; Acrylate de methyle [French]; Acrylsaeuremethylester [German]; UN1919; Methylester kyseliny akrylove [Czech]; methoxyacrolein; methyacrylate; methylacrilate; methyl acrilate; methyl-acrylate; Acrilato de metilo; methyl 2-propen-oate; CHEMBL9019; METHYL ACRYLATE [MI]; WLN: 1U1VO1; METHYL ACRYLATE [HSDB]; Methyl acrylate, inhibited [UN1919] [Flammable liquid]; NSC24146; Methyl acrylate, analytical standard; Tox21_201000; BBL011432; BDBM50245463; Methyl acrylate, monomer(SRI 773); STL146539; AKOS000120907; Methyl Acrylate, stabilized with MEHQ; UN 1919; CAS-96-33-3; Methyl Acrylate (stabilized with MEHQ); NCGC00091096-01; NCGC00091096-02; NCGC00258553-01; BP-13449; A0145; NS00007683; EN300-20010; Methyl acrylate, SAJ first grade, >=99.0%; C19443; Methyl acrylate stabilized with 10-20ppm MEHQ; Q343028; J-522585; F0001-2293; InChI=1/C4H6O2/c1-3-4(5)6-2/h3H,1H2,2H; Methyl acrylate, inhibited [UN1919] [Flammable liquid]; >99.0%(GC),contains inverted exclamation markU100 ppm MEHQ as stabilizer; Methyl acrylate (MA), 99.0%(GC), contains 10-20 ppm MEHQ as stabilizer; Methyl acrylate (MA), AR, 98.5%, contains 0.05% MEHQ as stabilizer; Methyl acrylate, 99%, contains <=100 ppm monomethyl ether hydroquinone as inhibitor"	.	.	.	7294	.	.	.
DRG00088	Sulfosalicylic acid	Sulfosalicylic acid	.	"2-Hydroxy-5-sulfobenzoic acid; 5-Sulfosalicylic acid; SULFOSALICYLIC ACID; 97-05-2; 5-Sulphosalicylic acid; Salicylsulfonic acid; Benzoic acid, 2-hydroxy-5-sulfo-; Salicylic acid, sulfo-; 2-Hydroxybenzoic-5-sulfonic acid; Benzoic acid, 2-hydroxysulfo-; Sulphosalicylic acid; Salicylic acid, 5-sulfo-; 3-Carboxy-4-hydroxybenzenesulfonic acid; NSC 190565; 5-Sulfosalicylate; 5-sulfo-Salicylic acid; L8XED79U3U; CHEMBL229241; CHEBI:68555; NSC-190565; 2-hydroxy-5-sulfo-benzoic acid; WLN: WSQR DQ CVQ; Kalcolor anodizing acid; Sulfosalicylic acid (VAN); Salicylsulfonic acid (VAN); Sulphosalicylic acid (VAN); EINECS 202-555-6; UNII-L8XED79U3U; BRN 0650741; CP 18121; AI3-18246; AI3-32582; sulfo salicylic acid; SULFOSALICYLIC; 5-sulfosalicyclic acid; 2-hydroxysulfo-Benzoate; 2-hydroxysulfo-Benzoic acid; SCHEMBL34766; 2-Hydroxy-5-sulfobenzoicacid; 4-11-00-00702 (Beilstein Handbook Reference); DTXSID7059145; SULFOSALICYLIC ACID [MI]; NSC4741; HY-B1785; NSC-4741; BBL008587; BDBM50219498; NSC190565; STK301570; SULFOSALICYLIC ACID [WHO-DD]; AKOS000120294; AC-11271; CS-0013816; FT-0620777; NS00014762; S0830; EN300-20563; G76479; A845677; Q238569; W-100120; Z104478882; InChI=1/C7H6O6S/c8-6-2-1-4(14(11,12)13)3-5(6)7(9)10/h1-3,8H,(H,9,10)(H,11,12,13"	.	.	.	7322	.	.	.
DRG00089	Tosyl chloride	Tosyl chloride	.	"P-TOLUENESULFONYL CHLORIDE; 98-59-9; Tosyl chloride; 4-Methylbenzenesulfonyl chloride; p-Tosyl chloride; 4-Toluenesulfonyl chloride; 4-methylbenzene-1-sulfonyl chloride; p-Toluenesulphonyl chloride; p-Tolylsulfonyl chloride; p-Toluenesulfochloride; tosylchloride; p-Toluenesulfonic acid chloride; p-Methylbenzenesulfonyl chloride; para-Toluenesulfonyl chloride; 4-Tosyl chloride; Benzenesulfonyl chloride, 4-methyl-; 4-methyl-benzenesulfonyl chloride; 4-toluene sulfonyl chloride; p-Toluene sulphonyl chloride; Toluenesulfonyl chloride; p-toluensulfonyl chloride; p-Methylphenylsulfonyl chloride; p-Toluenesulfonic chloride; p-toluene sulfonyl chloride; toluene-p-sulfonyl chloride; Toluene-4-sulfonyl chloride; NSC 175822; 4-methylphenylsulfonyl chloride; MFCD00007450; Para-toluene sulphonyl chloride; 027KYN78B4; NSC-175822; TsCl; para-Toluenesulfochloride; p-?Toluenesulfonyl Chloride; Toluenesulfonyl chloride (VAN); 4-Toluenesulfonic acid, chloride; HSDB 5317; p-toluenesulfonylchloride; EINECS 202-684-8; toluene-4-sulfonylchloride; tosyl-chloride; 4-methylbenzenesulfonylchloride; UNII-027KYN78B4; p-tosyl cloride; tosylic chloride; AI3-52254; TosCl; p-Toluenesulfonyl chloride(PTSC); 4-methylbenzene-1-sulfonylchloride; p-TsCl; Tos-Cl; Ts-Cl; p-toluensufonylchloride; p-toluenesulfonylchoride; p-Toluensulfonylchloride; p-toluensulphonylchloride; paratoluene sulfochloride; 4-toluenesulfonylchloride; 4toluenesulfonyl chloride; p-toluenesufonyl chloride; p-toluenesulfonyl chlorde; p-toluenesulfonyl chlorie; p-toluenesulphonylchloride; 4-toluensulfonyl chloride; 4-toluylsulfonyl chloride; p-tolyl-sulfonyl chloride; 4-toluenesulphonylchloride; p-toluen-sulphonylchloride; p-toluene sulfonylchloride; p-toluene-sulfonylchloride; p-toluenesulfonyl-chloride; p-toluensulphonyl chloride; paratoluensulfonyl chloride; p-toluene sulphonylchloride; p-toluene-sulphonylchloride; p-toluenesulfonoyl chloride; para-tolylsulfonyl chloride; toluene-p-sulphonylchloride; para-toluenesulfonylchloride; 4-toluene-sulphonylchloride; 4-toluenesulphonic chloride; 4-toluenesulphonyl chloride; p -toluenesulfonyl chloride; p- toluenesulfonyl chloride; p-toluen-sulphonyl chloride; p-toluene sulfonic chloride; p-toluene-sulfonyl chloride; toluene4-sulphonyl chloride; EC 202-684-8; para-Toluenesufonyl chloride; para-toluensulfonyl chloride; rho-toluenesulfonyl chloride; Toluene p-sulfonyl chloride; Toluene-4-sulphonylchloride; 4-toluene-sulfonyl chloride; p-toluene sulphonic chloride; p-toluene-sulphonyl chloride; para-toluenesulphonylchloride; paratoluenesulphonyl chloride; SCHEMBL1586; toluene p-sulphonyl chloride; toluene-p-sulphonyl chloride; para toluenesulfonyl chloride; para-toluene sulfonylchloride; paratoluene sulfonyl chloride; rho-toluenesulphonyl chloride; toluene-4-sulphonyl chloride; 4-Toluene-sulphonyl chloride; p-toluene- sulphonyl chloride; para-toluenesulphonyl chloride; para-toluene sulfonyl chloride; para-toluene-sulphonyl chloride; Para toluene sulphonyl chloride; 4-methylphenylsulphonyl chloride; 4-toluenesulfonic acid chloride; p-toluenesulphonic acid chloride; 4-methylbenzenesulphonyl chloride; 4-methylbenzenesulphonyl-chloride; DTXSID1052660; p-toluene sulfonic acid chloride; p-toluene-sulfonic acid chloride; p-toluene-sulfonic-acid-chloride; 4-methyl benzenesulfonyl chloride; 4-methylbenzene sulfonyl chloride; 4-methylphenyl-sulphonyl chloride; 4-TOLUOLSULFONYL CHLORIDE; toluene-4-sulfonic acid chloride; (4-methylphenyl)sulfonyl chloride; para-toluenesulfonic acid chloride; toluene-4-sulphonic acid chloride; 4-methyl-benzenesulphonyl chloride; (4-methylphenyl)sulphonyl chloride; 4-methyl benzene sulfonyl chloride; para-toluenesulphonic acid chloride; paratoluene sulphonic acid chloride; 4-methylbenzene-1-sufonyl chloride; 4-methyl-1-benzenesulfonyl chloride; 4-methylbenzene-l-sulfonyl chloride; BCP26003; CS-D1466; p-methylphenylsulfonic acid chloride; 4-methylbenzenesulfonic acid chloride; BR1703; NSC175822; STK298722; 4-methylbenzenesulphonic acid chloride; AKOS000120295; 4-methyl-benzenesulphonic acid chloride; 4-methylbenzene-sulphonic acid chloride; 4-methylbenzenesulphonic acid, chloride; P-TOLUENESULFONYL CHLORIDE [MI]; AM101769; AS-14041; BP-20587; NS00007323; T0272; EN300-20564; E78843; T-3900; p-Toluenesulfonyl chloride, reagent grade, >=98%; Q285621; p-Toluenesulfonyl chloride, ReagentPlus(R), >=99%; W-110674; p-Toluenesulfonyl chloride, ReagentPlus(R), >=99.0%; F2190-0563; P-Toluenesulfonyl chloride ; 4-Methylbenzenesulfonyl chloride; InChI=1/C7H7ClO2S/c1-6-2-4-7(5-3-6)11(8,9)10/h2-5H,1H; 4-Toluene sulphonyl chloride;4-methylbenzene-1-sulfonyl chloride;4-Toluene sulfochloride; methyl (2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-5-guanidino-pentanoate"	.	.	.	7397	.	.	.
DRG00090	L-Pyroglutamic acid	L-Pyroglutamic acid	.	"L-Pyroglutamic acid; 98-79-3; Pyroglutamic acid; Pidolic acid; 5-oxo-L-proline; H-Pyr-OH; (S)-5-Oxopyrrolidine-2-carboxylic Acid; (2S)-5-oxopyrrolidine-2-carboxylic acid; Pyroglutamate; 5-OXOPROLINE; pyroglu; GLUTIMIC ACID; L-Proline, 5-oxo-; (S)-(-)-2-Pyrrolidone-5-carboxylic acid; 5-L-Oxoproline; L-5-Oxoproline; Pyrrolidonecarboxylic acid; Pidolate; Pidolidone; Proline, 5-oxo-; (-)-2-Pyrrolidone-5-carboxylic acid; AJIDEW A-100; (S)-PYROGLUTAMIC ACID; 5-Carboxy-2-pyrrolidinone; 2-Pyrrolidinone-5-carboxylic acid; L-5-Carboxy-2-pyrrolidinone; L-GLUTIMINIC ACID; L-5-Oxo-2-pyrrolidinecarboxylic acid; (S)-5-Oxo-2-pyrrolidinecarboxylic acid; 5-Pyrrolidinone-2-carboxylic acid; Pyr-OH; 2-L-Pyrrolidone-5-carboxylic acid; Pyroglutamic acid, l-; 5-Pyrrolidone-2-carboxylic acid; L-Pyroglutamate; L-2-PYRROLIDONE-5-CARBOXYLIC ACID; L-5-Pyrrolidone-2-carboxylic acid; L-pca; l-pyrrolidone carboxylic acid; OXOPROLINE; NSC 143034; (5S)-2-Oxopyrrolidine-5-carboxylic acid; NSC-760414; SZB83O1W42; DTXSID6046260; CHEBI:18183; NSC9966; MFCD00005272; (S)-2-Pyrrolidone-5-carboxylic acid; NSC-143034; 5-OXO-2-PYRROLIDINECARBOXYLIC ACID; NCGC00160613-01; DTXCID4026260; GLUTIMINIC ACID; Pidolic acid [INN]; L-GLUTIMIC ACID; Acide pidolique; oxo-proline; Acido pidolico; Acidum pidolicum; CAS-98-79-3; 2-Pyrrolidone-5-carboxylate; L-Glutamic acid gamma-lactam; pGlu-OH; SMR000857158; Acide pidolique [INN-French]; Acido pidolico [INN-Spanish]; Acidum pidolicum [INN-Latin]; PYRROLIDINONECARBOXYLIC ACID; L-PYRROLIDONECARBOXYLIC ACID; 2-Oxopyrrolidine-5-carboxylic acid; NSC 9966; EINECS 202-700-3; L-PYRROLIDINONECARBOXYLIC ACID; PYRROLIDONE-5-CARBOXYLIC ACID; Proline, 5-oxo-, L-; Pidolic acid [INN:BAN]; 2-Benzothiazolesulfenic acid morpholide; UNII-SZB83O1W42; Glutiminate; Glutimate; pidolic-acid; pGlu; L-Glutiminate; L-Glutimate; (S)-Pyroglutamate; (-)-Pyroglutamate; L-pyro-glutamic acid; Pyrrolidinonecarboxylate; (L)-pyroglutamic acid; Ajidew A 100; L-Pyrrolidonecarboxylate; Oxopyrrolidinecarboxylate; (-)-Pyroglutamic acid; L-Glutamic Acid Lactam; L-Pyrrolidinonecarboxylate; Pyrrolidone-5-carboxylate; L-Glutamic acid g-lactam; Rec-PGA 273K; pyrrolidone car-boxylic acid; L-Pyroglutamic acid, 97%; Oxopyrrolidinecarboxylic acid; SCHEMBL15790; (S)-(-)-pyroglutamic acid; L-Pyroglutamic acid, BioXtra; MLS001332421; MLS001332422; 2-Pyrrolidinone-5-carboxylate; 5-Pyrrolidinone-2-carboxylate; 2-L-Pyrrolidone-5-carboxylate; L-2-Pyrrolidone-5-carboxylate; PIDOLIC ACID [WHO-DD]; CHEMBL397976; L-Glutamic acid .gamma.-lactam; PYROGLUTAMIC ACID, (L); L-PYROGLUTAMIC ACID [MI]; (S)-2-Pyrrolidone-5-carboxylate; L-5-Oxo-2-pyrrolidinecarboxylate; (-)-2-Pyrrolidone-5-carboxylate; HMS2231L11; HMS3264E20; Pharmakon1600-01506185; 2-Oxopyrrolidine-5(S)-carboxylate; PYROGLUTAMIC ACID [USP-RS]; CS-M0659; GLP; NSC-9966; NSC11742; STR02331; (S)-5-Oxo-2-pyrrolidinecarboxylate; Tox21_111936; CCG-36432; GEO-04256; NSC-11742; NSC760414; s5823; (5S)-2-Oxopyrrolidine-5-carboxylate; AKOS015855330; Tox21_111936_1; (2S)-5-pyrrolidone-2-carboxylic acid; (S)-(-)-g-Butyrolactam-g-carboxylate; (S)-5-oxopyrolidine-2-carboxylic acid; 2-Oxopyrrolidine-5(S)-carboxylic acid; AM83732; DB03088; (S)-(-)-2-Pyrrolidone-5-carboxylate; L-Pyroglutamic acid, >=99.0% (T); (5S)-2-xopyrrolidine-5-carboxylic acid; NCGC00160613-02; (S)-5-oxo-pyrrolidine-2-carboxylic acid; AC-15173; BP-12844; HY-76082; (S)-(-)-g-Butyrolactam-g-carboxylic acid; DB-002779; (s)-(-)-2-pyrrolidinone-5-carboxylic acid; NS00006581; P0573; (S)-(-)-gamma-Butyrolactam-gamma-carboxylate; EN300-72896; C01879; M03204; P-8490; P17107; AB00514366_07; (S)-(-)-gamma-Butyrolactam-gamma-carboxylic acid; A845910; Q60998677; F8889-8712; Z1154378309; Pidolic acid, European Pharmacopoeia (EP) Reference Standard; E478F48D-E369-43AE-8132-08D819242518; Pyroglutamic Acid, United States Pharmacopeia (USP) Reference Standard"	TAR10049	Orexin (HCRT)	O43612	7405	D0U7QA	DB03088	.
DRG00091	Terephthalic acid	Terephthalic acid	.	"TEREPHTHALIC ACID; 100-21-0; p-Phthalic acid; 1,4-Benzenedicarboxylic acid; benzene-1,4-dicarboxylic acid; p-Dicarboxybenzene; p-Benzenedicarboxylic acid; p-Carboxybenzoic acid; Acide terephtalique; Tephthol; 1,4-dicarboxybenzene; para-Phthalic acid; Kyselina tereftalova; 4-Carboxybenzoic Acid; TA-33MP; WR 16262; NSC 36973; HSDB 834; TA 12; CCRIS 2786; p-Phthalate; UNII-6S7NKZ40BQ; EINECS 202-830-0; Kyselina terftalova; 6S7NKZ40BQ; BRN 1909333; DTXSID6026080; CHEBI:15702; AI3-16108; NSC-36973; Benzene-p-dicarboxylic acid; para-benzenedicarboxylic acid; DTXCID006080; EC 202-830-0; 4-09-00-03301 (Beilstein Handbook Reference); MFCD00002558; terephthalicacid; Acide terephtalique [French]; Kyselina tereftalova [Czech]; CAS-100-21-0; terephtalic acid; P-Phthelate; P-Phthelic acid; UB7; p-Benzenedicarboxylate; terephthalsure; Benzene-p-dicarboxylate; p-Dicarboxybenzoic acid; P-PTHALIC ACID; benzene-1,4-dioic acid; WLN: QVR DVQ; Terephthalic acid, 97%; Terephthalic acid, 98%; Purified terephthalic acid; benzoic acid, 4-carboxy-; SCHEMBL1655; Benzene, p-dicarboxylic acid; BIDD:ER0245; 1,4-benzene dicarboxylic acid; TEREPHTHALIC ACID [MI]; CHEMBL1374420; TEREPHTHALIC ACID [HSDB]; Benzene, 1,4-Dicarboxylic acid; BCP06429; NSC36973; STR02759; Tox21_201659; Tox21_303229; s6251; STL281856; Terephthalic acid, analytical standard; AKOS000119464; CS-W010814; HY-W010098; NCGC00091618-01; NCGC00091618-02; NCGC00091618-03; NCGC00257014-01; NCGC00259208-01; AC-10250; BP-21157; FT-0674866; FT-0773240; NS00003928; T0166; EN300-18042; C06337; G73905; Terephthalic acid, SAJ special grade, >=98.0%; A852800; AE-562/40217759; Q408984; Terephthalic acid, Vetec(TM) reagent grade, 98%; Z57127536; 211863-90-0"	.	.	.	7489	.	.	.
DRG00092	2-Amino-5-nitrothiazole (NTZ-C2)	2-Amino-5-nitrothiazole (NTZ-C2)	.	"2-AMINO-5-NITROTHIAZOLE; 121-66-4; 5-Nitrothiazol-2-amine; Enheptin; 5-Nitro-1,3-thiazol-2-amine; Entramin; Nitramin IDO; Amnizol soluble; Enheptin-T; 5-Nitro-2-thiazolamine; 2-Thiazolamine, 5-nitro-; Enheptin premix; Aminonitrothiazole; 2-amino-5-nitro-1,3-thiazole; Enheptyne; Aminzol soluble; Thiazole, 2-amino-5-nitro-; 5-Nitro-2-thiazolylamine; Enheptin T; 5-Nitro-2-aminothiazole; USAF EK-6561; Nitromin ido; NCI-C03065; 5-nitro-thiazol-2-ylamine; CCRIS 37; NSC 4; U 7458; HSDB 4022; EINECS 204-490-9; NSC-4; UNII-1GR77A37Z5; BRN 0126797; DTXSID6020066; AI3-50030; AMINONITROTHIAZOL; 1GR77A37Z5; 2-amino-5-nitrothiazol; NSC4; MFCD00005326; DTXCID8066; CHEBI:82386; 4-27-00-04675 (Beilstein Handbook Reference); Enheptin (VAN); 5-Nitrothiazol-2-ylamine; Aminonitrothiazolum; 2-AMINO-5-NITROTHIAZOLE (IARC); 2-AMINO-5-NITROTHIAZOLE [IARC]; CAS-121-66-4; entramine; Hexamor; 2-amino-5-nitro-thiazol; 2-amino 5-nitro thiazole; Oprea1_237935; MLS002152868; SCHEMBL375929; WLN: T5N CSJ BZ DNW; CHEMBL408049; 2-AMINO-4-NITROTHIAZOLE; SCHEMBL19435597; 2-Amino-5-nitrothiazole, 97%; 5-Nitro-1,3-thiazol-2-amine #; ALBB-021308; STR02181; Tox21_202377; Tox21_303575; STK317992; AKOS000120496; 2-AMINO-5-NITROTHIAZOLE [MI]; AC-2989; PS-3292; SB31744; s12411; 2-AMINO-5-NITROTHIAZOLE [HSDB]; NCGC00091644-01; NCGC00091644-02; NCGC00257304-01; NCGC00259926-01; BP-10109; PD162659; SMR001224487; DB-000135; A0381; AM20080158; CS-0030564; FT-0611187; NS00002376; U7458; EN300-16819; C19324; A804773; W-108451; Q27155915; Z56786623; F0001-0347; InChI=1/C3H3N3O2S/c4-3-5-1-2(9-3)6(7)8/h1H,(H2,4,5"	.	.	.	8486	.	.	.
DRG00093	4-Carboxybenzenesulfonamide	4-Carboxybenzenesulfonamide	.	"4-Sulfamoylbenzoic acid; Carzenide; 138-41-0; 4-Carboxybenzenesulfonamide; 4-(Aminosulfonyl)benzoic acid; Benzoic acid, 4-(aminosulfonyl)-; p-Carboxybenzenesulfonamide; Carzenid; Dirnate; p-Sulfamoylbenzoic acid; p-Sulfamylbenzoic acid; Benzoic acid p-sulfamide; Carzenide [INN]; p-Sulfonamidobenzoic acid; 4-Aminosulfonylbenzoic acid; Benzoic acid 4-sulfamide; BENZOIC ACID, p-SULFAMOYL-; NSC22976; NSC 22976; NSC-22976; 4-sulfamolybenzoic acid; CHEMBL414; 30Z5HQB5A4; DTXSID1045089; Carzenide (INN); MFCD00007938; NSC683540; NCGC00013287-06; NCGC00013287-07; 4-Sulfamylbenzoic acid; DTXCID9025089; 4-Sulfamoylbenzoesaeure; Carzenidum; Carzenida; 4-Sulfamoyl-benzoic acid; Carzenidum [INN-Latin]; Carzenida [INN-Spanish]; CAS-138-41-0; 4-Sulfamidobenzoic acid; SR-01000000114; EINECS 205-327-4; BRN 1875393; UNII-30Z5HQB5A4; 4SO; 4-sulamoylbenzoic acid; CARZENIDE [MI]; Maybridge1_002385; 4-Carboxyphenylsulfonamide; 4-sulphamoyl-benzoic acid; Benzoic Acid deriv. 31; p-Aminosulfonylbenzoic acid; CARZENIDE [MART.]; 4-carboxy-benzenesulfonamide; Cambridge id 5121815; CARZENIDE [WHO-DD]; benzoic acid, 4-sulfamoyl-; NCIStruc1_000566; NCIStruc2_000413; p-Aminosulfonyl-benzoic Acid; Oprea1_448551; 4-carboxybenzenesulfonamide 1; Para-Carboxybenzenesulfonamide; JMC52646 Compound 23; MLS000069605; DivK1c_001137; SCHEMBL312419; 4-Carboxybenzenesulfonamide (4-Sulfamoylbenzoic acid); 4-Sulfamoylbenzoic acid, 97%; BDBM4703; JMC522226 Compound 22; JMC523116 Compound 22; P-SULFAMOYL-BENZOIC ACID; HMS548E09; UCAGLBKTLXCODC-UHFFFAOYSA-; 4-(Aminosulfonyl)benzoic acid #; CHEBI:177418; HMS2234G21; HMS3264O07; HMS3369M14; Pharmakon1600-01504505; HY-B0989; NCI22976; Tox21_110021; BBL011102; CCG-38010; NCGC00013287; NSC758886; s4556; STK802346; AKOS000144547; aromatic/heteroaromatic sulfonamide 23; Carzenide(4-Aminosulfonylbenzoic acid); Tox21_110021_1; CS-4482; NSC-683540; NSC-758886; SB78174; CDS1_000097; NCGC00013287-02; NCGC00013287-03; NCGC00013287-04; NCGC00013287-05; NCGC00021607-03; NCGC00021607-04; AS-14571; NCI60_001869; SMR000059013; SBI-0054135.P002; AM20060310; EU-0033692; FT-0619469; NS00024481; EN300-16248; D09322; AB00384334_11; SR-01000000114-2; SR-01000000114-3; SR-01000000114-4; W-108229; BRD-K09295674-001-08-0; Q27255987; Z53021532; F0347-1766; InChI=1/C7H7NO4S/c8-13(11,12)6-3-1-5(2-4-6)7(9)10/h1-4H,(H,9,10)(H2,8,11,12)"	TAR10038	Carbonic anhydrase I (CA-I)	P00915	8739	D09PWX	.	CHEMBL414
DRG00094	Propiolic acid	Propiolic acid	.	"PROPIOLIC ACID; 471-25-0; 2-Propynoic acid; prop-2-ynoic acid; Propynoic acid; Propargylic acid; Acetylenecarboxylic acid; Carboxyacetylene; Propiolic acidd; MFCD00004360; P2QW39G9LZ; Acetylenemonocarboxylate; CHEBI:33199; propiolate; NSC-16152; 26969-44-8; Acetylene carboxylic acid; EINECS 207-437-8; NSC 16152; UNII-P2QW39G9LZ; Propinsaeure; Propiolsaeure; propinic acid; HSDB 7857; HC.equiv.CCOOH; HC#CCOOH; Propiolic acid, 95%; HC.$.CCOOH; acetylenemonocarboxylic acid; PROPIOLIC ACID [MI]; CHEMBL1213530; DTXSID6060050; AMY7000; BCP18740; NSC16152; STR03210; 2-PROPYNE-1-CARBOXYLIC ACID; BBL011346; s6108; STL146436; AKOS000121542; Propiolic acid, technical, >=95% (T); DB-070776; NS00031666; P0497; EN300-21202; C00804; F10329; Q257590; F2191-0185; Z104493798"	.	.	.	10110	.	.	.
DRG00095	"1,3,5-Benzenetricarboxylic acid"	"1,3,5-Benzenetricarboxylic acid"	.	"Trimesic acid; 554-95-0; benzene-1,3,5-tricarboxylic acid; 1,3,5-BENZENETRICARBOXYLIC ACID; Trimesinic acid; Trimesitinic acid; 5-Carboxyisophthalic acid; 1,3,5-Tricarboxybenzene; MFCD00002517; OU36OO5MTN; CHEMBL77562; DTXSID8021488; CHEBI:46032; NSC-3998; 1,3,5-Benzene tricarboxylic acid; NSC 3998; EINECS 209-077-7; UNII-OU36OO5MTN; AI3-06468; H3BTCt; 1,5-Tricarboxybenzene; Trimesic acid, 95%; NCIOpen2_009462; SCHEMBL26189; DTXCID501488; benzene-1,3,5-tricarboxylicacid; NSC3998; STR04811; Tox21_200017; AC2199; BDBM50080275; AKOS007930167; DB08632; NCGC00248495-01; NCGC00257571-01; AC-10237; BP-31127; CAS-554-95-0; HY-78985; SY007111; DB-007934; B0043; CS-0010336; FT-0600423; NS00001398; EN300-175524; Trimesic acid, Vetec(TM) reagent grade, 94%; A830674; AC-907/25014230; Q981152; W-105561; Z1508914454; 1,3,5-Tricarboxybenzene; 5-Carboxyisophthalic Acid; NSC 3998;; InChI=1/C9H6O6/c10-7(11)4-1-5(8(12)13)3-6(2-4)9(14)15/h1-3H,(H,10,11)(H,12,13)(H,14,15"	TAR10048	Hemoglobin (HB)	P69905	11138	D0F2WQ	.	.
DRG00096	1-octyne	1-octyne	.	"1-OCTYNE; oct-1-yne; 629-05-0; Hexylacetylene; MFCD00009546; 7S3FMU8W67; 32073-03-3; Octyne-1; 1-Octine; Hexylacetylene; n-Hexylacetylene; EINECS 211-069-3; 1-Octyne, 97%; BRN 1734494; n-hexylacetylide; n-octyne; n-Hexylacetylene; EC 211-069-3; UNII-7S3FMU8W67; 4-01-00-01034 (Beilstein Handbook Reference); DTXSID9060863; AMY25742; AKOS015836216; AS-46789; DB-054325; NS00003304; O0050; F10502; A834081; Q161668; J-802040; InChI=1/C8H14/c1-3-5-7-8-6-4-2/h1H,4-8H2,2H"	.	.	.	12370	.	.	.
DRG00097	Vancomycin	Vancomycin	.	"VANCOMYCIN; Vancocin; 1404-90-6; Vancoled; Vancomicina; Vancomycine; Vancomycinum; VANCOR; vancomicin; HSDB 3262; Vancomycine [INN-French]; Vancomycinum [INN-Latin]; Vancomicina [INN-Spanish]; EINECS 215-772-6; UNII-6Q205EH1VU; 6Q205EH1VU; CHEBI:28001; Vancomycin [USP:INN:BAN]; CHEMBL262777; DTXSID0042664; Vancomycin ( >85%); Vancomycine (INN-French); Vancomycinum (INN-Latin); Vancomicina (INN-Spanish); VANCOMYCIN (MART.); VANCOMYCIN [MART.]; Vancomycin (USP:INN:BAN); VANCOMYCIN (USP IMPURITY); VANCOMYCIN [USP IMPURITY]; VANCOMYCIN (USP MONOGRAPH); VANCOMYCIN [USP MONOGRAPH]; Vancomycin (USP); vanomycin; Vancomycin hydrochloride from Streptomyces orientalis; Viomycin derivative; [(2S,3R,4S,5S,6R)-3-[(2S,4S,5S,6S)-4-amino-5-hydroxy-4,6-dimethyl-tetrahydropyran-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-(2-amino-2-oxo-ethyl)-dichloro-pentahydroxy-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-pentaoxo-[?]carboxylic acid; Vancomycinum (Latin); Glycopeptide Antibiotic; C06689; D00212; VANCOMYCIN [MI]; VANCOMYCIN [INN]; Prestwick0_000497; Prestwick1_000497; Prestwick2_000497; VANCOMYCIN [HSDB]; SCHEMBL3177; VANCOMYCIN [WHO-DD]; Chloroorienticin B derivative; Lopac0_001267; N-demethylvancomycin derivative; SPBio_002314; CHEMBL3735877; SCHEMBL25297175; VANCOMYCIN [ORANGE BOOK]; GTPL10932; A07AA09; J01XA01; S01AA28; DTXCID401031367; HY-B0671; BDBM50335519; s5784; AKOS030526092; CCG-205340; CS-3242; DB00512; SDCCGSBI-0051233.P002; NCGC00162383-04; NCGC00162383-11; FT-0700925; NS00001544; 4-Naphthalen-2-ylmethyl-4,5-dihydro-1H-imidazole; A929942; Q424027; SR-01000076194-5; BRD-K91065602-003-05-5; (2.2Sp,3.5Sa,2.6Sp)-O4.2,C3.4:C5.4,O4.6:C3.5,C2.7-tricyclo[N-methyl-D-leucyl-3-chloro-(R)-beta-hydroxy-D-tyrosyl-L-asparaginyl-D-2-(4-{[2-O-(3-amino-2,3,6-trideoxy-3-C-methyl-alpha-L-lyxo-hexopyranosyl)-beta-D-glucopyranosyl]oxy}phenyl)glycyl-D-2-(4-hydroxyphenyl)glycyl-3-chloro-(R)-beta-hydroxy-L-tyrosyl-L-2-(3,5-dihydroxyphenyl)glycine]; (S)-3,6-Diamino-hexanoic acid {(3S,9S,12S,15S)-3-((S)-6-hydroxy-2-imino-hexahydro-pyrimidin-4-yl)-9,12-bis-hydroxymethyl-2,5,8,11,14-pentaoxo-6-[1-ureido-meth-(Z)-ylidene]-1,4,7,10,13pentaaza-cyclohexadec-15-yl}-amide; 22H-8,11:18,21-Dietheno-23,36-(iminomethano)-13,16:31,35-dimetheno-1H,16H-[1,6,9]oxadiazacyclohexadecino[4,5-m][10,2,16]benzoxadiazacyclotetracosine,vancomycin deriv."	.	.	.	14969	D0B1IV	DB00512	CHEMBL262777
DRG00098	"2,2-Dithiobis[5-nitropyridine]"	"2,2-Dithiobis[5-nitropyridine]"	.	"2,2'-Dithiobis(5-nitropyridine); 2127-10-8; 1,2-Bis(5-nitropyridin-2-yl)disulfane; DTNP; Bis(5-nitro-2-pyridyl) disulfide; 5-nitro-2-[(5-nitropyridin-2-yl)disulfanyl]pyridine; 2,2'-Dithio-bis(5-nitropyridine); Pyridine, 2,2'-dithiobis[5-nitro-; 5,5'-Dinitro-2,2'-dipyridyl disulfide; NSC677436; NSC-677436; PYRIDINE, 2,2'-DITHIOBIS(5-NITRO-; 2,2'-Dithiobis[5-nitropyridine]; 5,5'-Dinitro-2,2'-dithiodipyridine; EINECS 218-344-7; NSC 149336; BRN 0305413; AI3-62509; 5,2'-dipyridyl disulfide; SCHEMBL25358; CHEMBL120580; Pyridine,2'-dithiobis[5-nitro-; DTXSID00175520; 2,2'-dithiobis(5-nitro-pyridine); MFCD00006453; NSC149336; Pyridine, 2,2'-dithiobis*5-nitro-; AKOS015833310; NSC-149336; 2,2'-disulfanediylbis(5-nitropyridine); 2,2'-Dithiobis(5-nitropyridine), 96%; AS-63460; BP-23824; DB-045526; D2222; FT-0634051; NS00045666; 2,2'-DITHIOBIS(5-NITROPYRIDINE); E78124; 5-21-02-00066 (Beilstein Handbook Reference); 5-Nitro-2-(5-nitropyridin-2-yl)disulfanyl-pyridine; 5-nitro-2-[(5-nitro-2-pyridyl)disulfanyl]pyridine; J-013966; 5-Nitro-2-[(5-nitro-2-pyridinyl)disulfanyl]pyridine #; 2,2 inverted exclamation marka-Dithiobis(5-nitropyridine); InChI=1/C10H6N4O4S2/c15-13(16)7-1-3-9(11-5-7)19-20-10-4-2-8(6-12-10)14(17)18/h1-6"	.	.	.	16474	.	.	.
DRG00099	()-Menthol	()-Menthol	.	"l-Menthol; (-)-menthol; 2216-51-5; Levomenthol; l-(-)-Menthol; Menthomenthol; (1R,2S,5R)-2-Isopropyl-5-methylcyclohexanol; Menthacamphor; Peppermint camphor; (1r,2s,5r)-(-)-menthol; U.S.P. Menthol; Levomentholum; Racementhol; Hexahydrothymol; (-)-Menthyl alcohol; Menthol racemic; (1R)-(-)-Menthol; d,l-Menthol; (-)-(1R,3R,4S)-Menthol; 89-78-1; (R)-(-)-Menthol; D-(-)-Menthol; Cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1R,2S,5R)-; p-Menthan-3-ol; (-)-trans-p-Menthan-cis-ol; rac-Menthol; 1-Menthol; (L)-MENTHOL; Menthol(-); (1R,2S,5R)-5-methyl-2-(propan-2-yl)cyclohexan-1-ol; Menthol natural; Menthol, (1R,3R,4S)-(-)-; (1R,3R,4S)-(-)-MENTHOL; Menthol, dl-; NCI-C50000; Cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1R,2S,5R)-rel-; 1R-Menthol; NSC 62788; Racemic menthol; Water-soluble menthol; (1R,2S,5R)-5-methyl-2-propan-2-ylcyclohexan-1-ol; (1R,2S,5R)-Menthol; 5-Methyl-2-(1-methylethyl)cyclohexanol; BZ1R15MTK7; (1R,2S,5R)-5-methyl-2-(1-methylethyl)cyclohexanol; (+/-)-Menthol; (1R-(1-alpha,2-beta,5-alpha))-5-Methyl-2-(1-methylethyl)cyclohexanol; CHEMBL470670; YS08XHA860; DTXSID1020805; DTXSID1022180; CHEBI:15409; NSC2603; (1R,2S,5R)-2-isopropyl-5-methyl-cyclohexanol; Headache crystals; NSC-2603; (1R,2S,5R)-2-isopropyl-5-methylcyclohexan-1-ol; FEMA No. 2665; MFCD00062979; NSC-62788; Menthol (VAN); Racementholum; Thymomenthol; Menthol, cis-1,3,trans-1,4-; Racementol; l-Menthol (natural); NSC 2603; (+-)-Menthol; I-menthol; Menthol racemique; Levomenthol; (-)-Menthol; Levomenthol [INN:BAN]; Racementhol [INN:BAN]; Cyclohexanol, 5-methyl-2-(1-methylethyl)-, [1R-(1.alpha.,2.beta.,5.alpha.)]-; Menthol natural, brazilian; Menthol, l-; Racementol [INN-Spanish]; rel-(1R,2S,5R)-2-Isopropyl-5-methylcyclohexanol; Levomentholum [INN-Latin]; Menthol racemique [French]; Racementholum [INN-Latin]; DTXCID802180; Tra-kill tracheal mite killer; (1alpha,2beta,5alpha)-5-methyl-2(1-methylethyl)cyclohexanol; DTXCID101305276; MEGGEZONE; CAS-89-78-1; CCRIS 375; CAS-2216-51-5; l-Menthol (TN); CCRIS 3728; CCRIS 4666; HSDB 5662; SR-05000001936; (-)-p-Menthan-3-ol; EINECS 201-939-0; EINECS 218-690-9; EINECS 239-388-3; UNII-BZ1R15MTK7; (1R,2S,5R)-rel-2-Isopropyl-5-methylcyclohexanol; BRN 1902288; BRN 3194263; levomentol; UNII-YS08XHA860; (+-)-(1R*,3R*,4S*)-Menthol; AI3-52408; Cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1.alpha.,2.beta.,5.alpha.)-; Cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1R-(1alpha,2beta,5alpha))-; CYCLOHEXANOL, 5-METHYL-2-(1-METHYLETHYL)-, (1R-(1.ALPHA.,2.BETA.,5.ALPHA.))-; L-Menthol natural; 1 -menthol; (1R,2S,5S)-2-Isopropyl-5-methyl-cyclohexanol; NCGC00159382-02; 98167-53-4; L-MENTHOLUM; l-Menthol (JP17); Spectrum_000305; LEVOMENTHOL [II]; MENTHOL [MI]; 5-Methyl-2-(1-methylethyl)cyclohexanol, (1alpha,2beta,5alpha)-; L-MENTHOL [JAN]; Menthol, (+/-)-; Spectrum2_000855; Spectrum3_001561; Spectrum5_001060; LEVOMENTHOL [INN]; RACEMENTHOL [INN]; M0545; DL-MENTHOL [JAN]; Menthol,3,trans-1,4-; LEVOMENTHOL [HSDB]; RACEMENTHOL [HSDB]; pound - pound(c)-Menthol; EC 201-939-0; EC 218-690-9; SCHEMBL4613; BSPBio_003062; KBioSS_000785; LEVOMENTHOL [WHO-DD]; 2-06-00-00052 (Beilstein Handbook Reference); 4-06-00-00151 (Beilstein Handbook Reference); MLS002207256; DivK1c_000820; MENTHOL RACEMATE [MI]; SPECTRUM1503134; Menthol,3R,4S)-(-)-; SPBio_000869; GTPL2430; NPO-11; (-)-Menthol, USP, 97%; HMS502I22; KBio1_000820; KBio2_000785; KBio2_003353; KBio2_005921; KBio3_002562; NOOLISFMXDJSKH-KXUCPTDWSA-; (-)-Menthol, analytical standard; NINDS_000820; Cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1R,3R,4S)-; HMS1922G13; HMS2092L14; HMS3885J18; LEVOMENTHOL [EP MONOGRAPH]; Pharmakon1600-01503134; 3623-52-7; NSC62788; L-Menthol, >=99%, FCC, FG; Tox21_111620; Tox21_201823; Tox21_201919; Tox21_202608; Tox21_302999; Tox21_303028; WLN: L6TJ AY1&1 BQ D1; BDBM50318482; CCG-40300; Cyclohexanol, 2-isopropyl-5-methyl-; Cyclohexanol, 5-methyl-2-(1-methylethyl)-, (1alpha,2beta,5alpha)-; NSC758395; s4714; AKOS016842647; (1R, 2S, 5R-)-(-)-Menthol; 1ST1669; BS-3863; DB00825; LMPR0102090001; NSC-758395; SDCCGMLS-0066659.P001; (-)-TRANS-P-METHAN-CIS-3-OL; IDI1_000820; WLN: L6TJ AY1&1 DQ D1 -L; NCGC00164247-01; NCGC00164247-02; NCGC00164247-03; NCGC00256525-01; NCGC00256561-01; NCGC00259372-01; NCGC00259468-01; NCGC00260156-01; FEMA NO. 2665, (-)-; SMR001306785; L-Menthol, natural, >=99%, FCC, FG; SBI-0051777.P002; FT-0600039; FT-0604399; FT-0604426; FT-0604430; FT-0620596; FT-0625488; FT-0695077; FT-0695078; FT-0695079; NS00068027; NS00102112; S5868; EN300-92163; FEMA NO. 2665, (+/-)-; Menthol (racemic) 100 microg/mL in Methanol; (+/-)-(1R*,3R*,4S*)-MENTHOL; (1R,2S,5R)-(-)-Menthol, synthetic pellets; C00400; Cyclohexanol, (1.alpha.,2.beta.,5.alpha.)-; D00064; D70313; (1R,2R,5S)-2-isopropyl-5-methyl-cyclohexanol; AB00052320_02; L-Menthol; Levomenthol; Menthomenthol; Menthacamphor; (1R,2S,5R)-(-)-Menthol, >=99%, sublimed; A843308; Q407418; Q-201316; SR-05000001936-1; SR-05000001936-2; (-)-Menthol, primary pharmaceutical reference standard; (1R,2S,5R)-(-)-Menthol, ReagentPlus(R), 99%; 2-Isopropyl-5-methylcyclohexanol-, (1R,2S,5R)- #; Cyclohexanol, [1R-(1.alpha.,2.beta.,5.alpha.)]-; (1R,2S,5R)-5-methyl-2-propan-2-yl-cyclohexan-1-ol; Z1255438640; (1R,2S,5R)-(-)-Menthol, Vetec(TM) reagent grade, 98%; 6C6A4A8C-A054-468C-A1F0-F29E39838CF2; (1R, 2S, 5R)-5-methyl-2-(1-methylethyl)cyclohexyl alcohol; Menthol, United States Pharmacopeia (USP) Reference Standard; (1R,2S,5R)-REL-5-METHYL-2-(1-METHYLETHYL)CYCLOHEXANOL; L-Menthol, Pharmaceutical Secondary Standard; Certified Reference Material; (-)-Menthol, puriss., meets analytical specification of Ph. Eur., BP, USP, 98.0-102.0%; (1R-(1-.alpha.,2-.beta.,5-.alpha.))-5-Methyl-2-(1-methylethyl)cyclohexanol; 114376-98-6; InChI=1/C10H20O/c1-7(2)9-5-4-8(3)6-10(9)11/h7-11H,4-6H2,1-3H3/t8-,9+,10-/m1/s1"	.	.	.	16666	.	.	CHEMBL470670
DRG00100	Fluorescein isothiocyanate	Fluorescein isothiocyanate	.	"3326-32-7; FITC; Fluorescein isothiocyanate isomer I; 5-FITC; FLUORESCEIN-5-ISOTHIOCYANATE; 5-isothiocyanatofluorescein; fluorescein 5-isothiocyanate; Fluorescein 5(6)-isothiocyanate; 3',6'-dihydroxy-5-isothiocyanato-3H-spiro[isobenzofuran-1,9'-xanthen]-3-one; FITC isomer 1; MFCD00005063; CHEBI:37918; F5ITC; Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 3',6'-dihydroxy-5-isothiocyanato-; Fluorescein-5-isothiocyanat; Fluoreszein-5-isothiocyanat; 2-(6-Hydroxy-3-oxo-(3H)-xanthen-9-yl)-5-isothiocyanatobenzoic acid; Fluorescein isothiocyanate isomer I, tech grade; I223NX31W9; fluorescein isothiocyanate isomer 1; 3',6'-dihydroxy-6-isothiocyanatospiro[2-benzofuran-3,9'-xanthene]-1-one; Fluorescein 5-Isothiocyanate, Isomer 1, 95%; Spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one, 3',6'-dihydroxy-5-isothiocyanato-; FITC ISOMER I; 3',6'-dihydroxy-5-isothiocyanatospiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one; FITC ISOMER; FITC-I; Fluorescein 5-Isothiocyanate, Isomer 1 (~90%); EINECS 222-042-0; Fluorescein isothiocyanate isomer I, >=97.5% (HPLC); UNII-I223NX31W9; FITC?; FLUORESCEIN ISOTHIOCYANATE, ISOMER 1; 5-Fluoresceinisothiocyanate; Epitope ID:115575; 5-isothiocyanato fluorescein; DSSTox_CID_29368; DSSTox_RID_83483; Fluorescein-4-Isothiocyanate; DSSTox_GSID_49408; SCHEMBL71426; Fluorescein 5-isothiocyanate;; CHEMBL516313; FITC, 5-; 5(6)-Fluorescein isothiocyanate; FITC, Fluorescein isothiocyanate; DTXSID80892440; Fluorescein-5-isothiocyanate tech.; GLXC-10848; AMY19560; BCP04195; EX-A1778; Tox21_202818; 5-FITC;5-Isothiocyanato fluorescein; Fluorescein-5-isothiocyanate (FITC); s6928; AKOS015897625; GS-6079; NCGC00260364-01; AC-37042; BP-23367; BP-30030; Fluorescein isothiocyanate isomer I, 90%; HY-66019; SY011095; CAS-27072-45-3; F0026; FT-0600599; FT-0626453; NS00028252; F-2999; F-3000; A818907; A821696; A853838; Fluorescein 5(6)-isothiocyanate, >=90% (HPLC); F04-0012; J-100155; Q59647575; 3',6'-dihydroxy-6-isothiocyanato-1-spiro[isobenzofuran-3,9'-xanthene]one; 3',6'-dihydroxy-6-isothiocyanato-spiro[isobenzofuran-3,9'-xanthene]-1-one; 3',6'-dihydroxy-5-isothiocyanato-3H-spiro[2-benzofuran-1,9'-xanthen]-3-one; 3',6'-Dihydroxy-5-isothiocyanato-spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one; 6-isothiocyanato-3',6'-bis(oxidanyl)spiro[2-benzofuran-3,9'-xanthene]-1-one; Fluorescein isothiocyanate isomer I, suitable for protein labeling, >=90% (HPLC), powder; Fluorescein isothiocyanate isomer I-Celite(R), suitable for fluorescent labeling techniques"	.	.	.	18730	.	.	.
DRG00101	Vidarabine	Vidarabine	.	"Vidarabine; 5536-17-4; Adenine arabinoside; Vira-A; Arabinosyladenine; Ara-A; Spongoadenosine; Araadenosine; 9-beta-D-Arabinofuranosyladenine; Arasena-A; Vidarabine anhydrous; Arabinosyl adenine; Arabinoside adenine; (2R,3S,4S,5R)-2-(6-Amino-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; Vidarabin; Vidarabine [INN]; 9beta-D-Arabinofuranosyladenine; NSC-404241; araA; 9-BETA-D-ARABINOFURANOSYL-ADENINE; Vira ATM; 9-beta-D-arabinofuranosyl-9H-purin-6-amine; 6-Amino-9-b-D-arabinofuranosylpurine; Vidarabine, anhydrous; Adenine 9-beta-D-arabinofuranoside; Vidarabine (Vira-A); Adenine 9-beta;-D-arabinofuranoside; Vidarabine (JAN); CI-673; 2-(6-Amino-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol; 3XQD2MEW34; CHEMBL1090; (2R,3S,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; Adenine-beta-D-arabinofuranoside; CHEBI:45327; 9-(beta-D-Arabinofuranosyl)adenine; 9H-Purin-6-amine, 9-.beta.-D-arabinofuranosyl-; NSC-247519; NSC-757383; Vidarabina [DCIT]; Vidarabinum; Vidarabina; CI 673; RAB; Vidarabine (monohydrate); 9-beta-Arabinoadenosine; beta-D-Arabinosyladenine; Vidarabinum [INN-Latin]; (+)-Cyclaradine; Vira A; SMR000471872; beta-D-Arabinofuranosyladenine; CCRIS 3383; Armes (TN); Adenine beta-D-arabinofuranoside; HSDB 6514; Adenine-9-beta-D-arabinofuranoside; Adenine, 9beta-D-arabinofuranosyl-; EINECS 226-893-9; 9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-; Adenine, 9-beta-D-arabinofuranosyl-; UNII-3XQD2MEW34; NSC 247519; BRN 0624881; 6-Amino-9-beta-D-arabinofuranosylpurine; AI3-52821; MFCD00065471; 9H-Purin-6-amine, 9beta-D-arabinofuranosyl-; 9-.beta.-D-Arabinofuranosyl-9H-purin-6-amine; Spectrum_001894; VIDARABINE [MI]; Spectrum2_001336; Spectrum3_000580; Spectrum4_000782; Spectrum5_001429; VIDARABINE [HSDB]; (2R,3S,4S,5R)-2-(6-Aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; VIDARABINE [WHO-DD]; BSPBio_002000; KBioGR_001224; KBioSS_002424; MLS001066352; MLS001333133; MLS001333134; DivK1c_000191; SCHEMBL110914; SPECTRUM1500609; SPBio_001491; 9-ss-D-Arabinofuranosyladenine; GTPL4806; 9-ss -D-Arabinofuranosyladenine; HMS500J13; KBio1_000191; KBio2_002418; KBio2_004986; KBio2_007554; KBio3_001500; Adenine 9-ss-D-arabinofuranoside; DTXSID80873976; 9-beta-D-arabinofuranosyl adenine; NINDS_000191; Adenine 9-ss -D-arabinofuranoside; HMS1921K05; HMS2090F06; HMS2092C16; HMS2230N24; HMS3259I08; HMS3714I18; Pharmakon1600-01500609; BCP27778; HY-B0277; BDBM50144936; CCG-39634; HG1001; NSC757383; PDSP1_001036; PDSP2_001020; s1784; AKOS015919711; DB00194; DS-1755; NC00547; IDI1_000191; SMP1_000312; 9-(beta-D-arabinofuranosyl)-9H-adenine; 9--D-arabinofuranosyl-9H-purin-6-amine; 9H-adenin-9-yl beta-D-arabinofuranoside; NCGC00023673-08; NCGC00178869-01; 6-amino-9-(beta-D-arabinofuranosyl)purine; SBI-0051555.P002; Adenine 9-beta-D-arabinofuranoside, >=99%; NS00124064; SW199234-2; V0098; V0175; D06298; 9-.beta.-D-Arabinofuranosyl-9H-purine-6-amine; AB00430250-08; AB00430250-09; AB00430250_11; AB00430250_12; EN300-6477965; Q415107; SR-01000765435; SR-05000001737; SR-01000765435-2; SR-05000001737-1; Vidarabine, United States Pharmacopeia (USP) Reference Standard; (2R,3S,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol"	TAR10044	Adenosine A2b receptor (ADORA2B)	P29275	21704	D0NI0C	DB00194	CHEMBL1090
DRG00102	&Beta;-N-Acetylglucosamine	b-N-Acetylglucosamine	.	"N-Acetyl-beta-D-glucosamine; acetylglucosamine; 2-acetamido-2-deoxy-beta-D-glucopyranose; betaGlcNAc; GlcNAc-beta; Beta-N-Acetylglucosamine; CHEBI:28009; 14131-68-1; 2-Acetamido-2-deoxy-beta-D-glucosamine; beta-N-Acetylglucosamin; N-[(2R,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide; 2-Acetamido-2-deoxy-beta-D-glucose; 72-87-7; 2-acetamido-2-deoxyhexopyranose; 8P59336F68; UNII-8P59336F68; N-Acetyl Glucosamine; 103094-10-6; Glucopyranose, 2-acetamido-2-deoxy-, beta-D-; 125304-10-1; 137630-09-2; 1398-61-4; NAcGlc; Cheon shim bo yun; n-acetyl-b-d-glucosamine; C8H15NO6; pharmaceutical aid; ssGlcNAc-R; Crab Shell Chitin; b-N-Acetylglucosamine; Spectrum_000999; Spectrum2_001353; Spectrum3_001400; Spectrum4_001179; b-N-Acetyl-D-glucosamine; bmse000231; Epitope ID:135813; beta-N-Acetyl-D-glucosamine; SCHEMBL19345; BSPBio_003020; KBioGR_001817; KBioSS_001479; DivK1c_000352; SPECTRUM1500715; n-acetyl-.beta.-d-glucosamine; SPBio_001565; CHEMBL447878; beta-N-Acetyl-delta-glucosamine; SCHEMBL21358982; CHEBI:17029; HMS501B14; KBio1_000352; KBio2_001479; KBio2_004047; KBio2_006615; KBio3_002240; .BETA.-N-ACETYLGLUCOSAMIN; [4)-beta-D-GlcpNAc(1->]n; 2-Acetamido-2-deoxy-b-D-glucose; NINDS_000352; DTXSID301045979; HMS1921E22; N-Acetyl-D-glucosamine, USP grade; BDBM50481442; CCG-39291; AKOS015960418; AT21015; 2-Acetamido-2-deoxy-beta-delta-glucose; IDI1_000352; N-[(2R,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-3-yl]acetamide; NCGC00178341-01; [1,4-(N-Acetyl-beta-D-glucosaminyl)]n; 2-deoxy-2-acetamido-beta-D-glucopyranose; AC-11093; (1->4)-2-acetamido-2-deoxy-beta-D-glucan; 2-(acetylamino)-2-deoxy-beta-D-glucopyranose; 2-ACETAMIDO-2-DEOXY-.BETA.-D-GLUCOSE; C03878; N-acetyl-D-glucosamine (complete stereochemistry); Q284367; 2-ACETAMIDO-2-DEOXY-.BETA.-D-GLUCOPYRANOSE; GLUCOPYRANOSE, 2-ACETAMIDO-2-DEOXY-, .BETA.-D-; Poly-(b1-4)-N-acetyl glucosamine/Poly-(a1-4)-N-acetyl glucosamine; WURCS=2.0/1,1,0/(a2122h-1b_1-5_2*NCC/3=O)/1/"	.	.	.	24139	.	.	.
DRG00103	ADP ribose	ADP ribose	.	"ADP Ribose; Ribose adenosinediphosphate; ADPR (nucleotide); ADPR; Adenosine diphosphoribose; XV3S4KV26E; Adenosine pyrophosphate-ribose; JNT; [32P]-ADP-ribose; UNII-XV3S4KV26E; GTPL2444; Adenosine 5'-diphosphate, D-ribose ester; Adenosine 5'-diphosphate, D-ribose ester (6CI); Q27074316; Adenosine 5'-(trihydrogen diphosphate), P'-->5-ester with D-ribose; Adenosine 5'-pyrophosphate, 5'-5-ester with D-ribofuranose (7CI); Adenosine 5'-(trihydrogen diphosphate), P'-5-ester with D-ribose (9CI); Adenosine 5'-(trihydrogen pyrophosphate), 5'-5-ester with D-ribofuranose; Ribofuranose, 5-5'-ester with adenosine 5'-(trihydrogen pyrophosphate), D-; Adenosine 5'-(trihydrogen pyrophosphate), 5'-5-ester with D-ribofuranose (8CI); Ribofuranose, 5-5'-ester with adenosine 5'-(trihydrogen pyrophosphate), D- (8CI); [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl [hydroxy-[(2R,3R,4R)-2,3,4-trihydroxy-5-oxopentoxy]phosphoryl] hydrogen phosphate"	TAR10035	Long transient receptor potential channel 2 (TRPM2)	O94759	30243	D0E9LJ	.	.
DRG00104	Tobramycin	Tobramycin	.	"tobramycin; 32986-56-4; Nebramycin VI; Nebramycin 6; Nebramycin factor 6; Tobi; Tobramicin; 3'-Deoxykanamycin B; Aktob; Tobrex; Tobi Podhaler; Nebcin; Deoxykanamycin B; vantobra; Tobralex; Tobramycin Base; 1-Epitobramycin; Tobramycetin; Tobramycinum; Gotabiotic; Tobradistin; Tobramicina; Tobramycine; Tobrased; Bethkis; Tobacin; Kitabis Pak; Tobramitsetin; Tenebrimycin; Tenemycin; Tobramaxin; TOBRAMYCIN SULFATE; NEBRAMYCIN; Distobram; Nebramycin factir 6; Kitabis; NSC 180514; HSDB 3259; UNII-VZ8RRZ51VK; VZ8RRZ51VK; Tobramycine [INN-French]; Tobramycinum [INN-Latin]; Tobramicina [INN-Spanish]; EINECS 251-322-5; Lilly 47663; Tobracin (TN); Tobrex (TN); BRN 1357507; Tobramycin Deuterated; DTXSID8023680; CHEBI:28864; NSC-180514; DTXCID903680; (2S,3R,4S,5S,6R)-4-amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol; Obramycin; ZYLET COMPONENT TOBRAMYCIN; TOBRADEX COMPONENT TOBRAMYCIN; TOBRASONE COMPONENT TOBRAMYCIN; TOBRADEX ST COMPONENT TOBRAMYCIN; Tobramycin [USAN:USP:INN:BAN:JAN]; Nebicin; Tobramycine (INN-French); Tobramycinum (INN-Latin); Tobramicina (INN-Spanish); TOBRAMYCIN (MART.); TOBRAMYCIN [MART.]; TOBRAMYCIN (USP-RS); TOBRAMYCIN [USP-RS]; (2S,3R,4S,5S,6R)-4-amino-2-(((1S,2S,3R,4S,6R)-4,6-diamino-3-(((2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxytetrahydro-2H-pyran-2-yl)oxy)-2-hydroxycyclohexyl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,5-diol; O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribo-hexopyranosyl-(1-6))-2-deoxy-L-streptamine; O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribohexopyranosyl-(1-4))-2-deoxy-D-streptamine; C18H37N5O9; TOBRAMYCIN (EP MONOGRAPH); TOBRAMYCIN [EP MONOGRAPH]; TOBRAMYCIN (USP MONOGRAPH); TOBRAMYCIN [USP MONOGRAPH]; Tobramycin (USAN:USP:INN:BAN:JAN); (1S,2S,3R,4S,6R)-4,6-diamino-3-[(2,6-diamino-2,3,6-trideoxy-alpha-D-ribo-hexopyranosyl)oxy]-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside; (2S,3R,4S,5S,6R)-4-amino-2-{[(1S,2S,3R,4S,6R)-4,6-diamino-3-{[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-6-(hydroxymethyl)oxane-3,5-diol; O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribohexopyranosyl-(1-4))-2-deoxy-D-streptamine; TOB; TOY; SR-05000001726; SPRC-AB01; torbamycin; Nebramycin Factor 6;Deoxykanamycin B; Tobramycin,(S); Nebcin (Sulfate); NCGC00016814-01; (2S,3R,4S,5S,6R)-4-amino-2-((1S,2S,3R,4S,6R)-4,6-diamino-3-((2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxytetrahydro-2H-pyran-2-yloxy)-2-hydroxycyclohexyloxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,5-diol; D-STREPTAMINE, O-3-AMINO-3-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->6)-O-(2,6-DIAMINO-2,3,6-TRIDEOXY-.ALPHA.-D-RIBO-HEXOPYRANOSYL-(1->4))-2-DEOXY-; D-Streptamine, O-3-amino-3-deoxy-.alpha.-D-glucopyranosyl-(1->6)-O-[2,6-diamino-2,3,6-trideoxy-.alpha.-D-ribo-hexopyranosyl-(1->4)]-2-deoxy-; O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-[2,6-diamino-2,3,6-trideoxy-alpha-D-ribohexopyranosyl-(1-4)]-2-deoxy-D-streptamine; Bethkis (TN); CAS-32986-56-4; MFCD00077885; Tobramycin Inhalation; Tobramycinum (Latin); AT02 - Tobramycin; D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribo-hexopyranosyl-(1-4))-2-deoxy-; Tobi (TN); Spectrum_001072; TOBRAMYCIN [MI]; TOBRAMYCIN [INN]; TOBRAMYCIN [JAN]; Prestwick3_000544; Spectrum2_000078; Spectrum3_000588; Spectrum4_000752; Spectrum5_001038; TOBRAMYCIN [HSDB]; TOBRAMYCIN [USAN]; TOBRAMYCIN [VANDF]; Tobramycin (JP17/USP); SCHEMBL2838; CHEMBL1747; TOBRAMYCIN [WHO-DD]; BSPBio_000587; BSPBio_002036; KBioGR_001104; KBioSS_001552; 4-(2,6-Diamino-2,3,6-trideoxy-alpha-D-glycopyranosyl)-6-(3-amino-3-deoxy-alpha-D-glycopyranosyl)-2-deoxystreptamine; MLS000069544; Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,6-tyrideoxy-alpha-D-ribohexopyranosyl-(1-6))-2-deoxy-, D-; BIDD:GT0503; SPECTRUM1500579; Tobramycin Inhalation Solution; Tobramycin Ophthalmic Solution; SPBio_000295; BPBio1_000647; TOBRAMYCIN [ORANGE BOOK]; GTPL10930; KBio2_001552; KBio2_004120; KBio2_006688; KBio3_001536; TobramycinInhalation Solution Pak; J01GB01; S01AA12; HMS2090B16; HMS2092M17; HMS2096N09; HMS3713N09; Pharmakon1600-01500579; HY-B0441; TOBRAMYCIN COMPONENT OF ZYLET; Tox21_110626; BDBM50366778; CCG-39936; HB4564; NSC757352; s2514; Tobradex (tobramycin + dexamethasone); AKOS016339662; DB00684; KS-1405; NSC-757352; TOBRAMYCIN COMPONENT OF TOBRADEX; TOBRAMYCIN COMPONENT OF TOBRASONE; NCGC00178852-01; NCGC00178852-02; (2S,3R,4S,5S,6R)-4-amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxy-tetrahydropyran-2-yl]oxy-2-hydroxy-cyclohexoxy]-6-(hydroxymethyl)tetrahydropyran-3,5-diol; SMR000058793; Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribohexopyranosyl-(1-6))-2-deoxy-, D-; SBI-0051915.P003; TOBRAMYCIN COMPONENT OF TOBRADEX ST; AB00513858; FT-0630567; NS00003131; T2503; C00397; D00063; AB00052438-12; AB00052438_13; AB00052438_14; EN300-7480857; SR-01000721898; Tobramycin, Antibiotic for Culture Media Use Only; Q-201837; Q1758380; SR-01000721898-2; SR-05000001726-1; SR-05000001726-2; BRD-K05619559-001-12-7; (1S,2S,3R,4S,6R)-4,6-diamino-3-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribo-hexopyranosyloxy)-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside; D-Streptamine, O-3-amino-3-deoxy-.alpha.-D-glucopyranosyl-(1->6)-O-[2,6-diamino-2,3,6-trideoxy-.alpha.-D-ribohexopyranosyl-(1->4)]-2-deoxy-; D-Streptamine, O-3-amino-3-deoxy-.alpha.-D-glucopyranosyl-(1?6)-O-[2,6-diamino-2,3,6-trideoxy-.alpha.-D-ribo-hexopyranosyl-(1?4)]-2-deoxy-; O-[3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-->6)]-O-[2,6-diamino-2,3,6-trideoxy-alpha-D-ribohexopyranosyl-(1-->4)]-2-deoxy-D-streptamine; O-[3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1->6)]-O-[2,6-diamino-2,3,6-trideoxy-alpha-D-ribo-hexopyranosyl-(1->4)]-2-deoxy-D-streptamine; O-3-AMINO-3-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->4)-O-(2,6-DIAMINO-2,3,6-TRIDEOXY-.ALPHA.-D-RIBO-HEXOPYRANOSYL-(1.ALPHA.6))-2-DEOXY-L-STREPTAMINE; O-3-Amino-3-deoxy-a-D-glucopyranosyl-(1-6)-O-[2,6-diamino-2,3,6-trideoxy-a -D-ribo-hexopyranosyl-(1-4)]-2-deoxy-D-streptamine; O-3-AMINO-3-DEOXY-alpha-D-GLUCOPYRANOSYL-(1->4)-O-(2,6-DIAMINO-2,3,6-TRIDEOXY-alpha-D-RIBO-HEXOPYRANOSYL-(1alpha6))-2-DEOXY-L-STREPTAMINE"	TAR10046	Bacterial 30S ribosomal RNA (Bact 30S rRNA)	.	36294	D07BCT	DB00684	.
DRG00105	Aminosteroid	Aminosteroid	.	"Aminosteroid; 51740-76-2; Auluton; Auluton hydrochloride; [(2S,3S,5S,8R,9S,10S,13S,14S)-2-hydroxy-10,13-dimethyl-17-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-yl]azanium;chloride; ORG 6001; 3-alpha-Amino-5-alpha-androstan-2-beta-ol-17-one hydrochloride; ANDROSTAN-17-ONE, 3-AMINO-2-HYDROXY-, HYDROCHLORIDE, (2-beta,3-alpha,5-alpha)-; NS00124742"	.	.	.	40111	.	.	.
DRG00106	Captopril	Captopril	.	"captopril; 62571-86-2; Capoten; L-Captopril; Captopryl; Lopirin; Cesplon; Garranil; Acepress; Captolane; Captoril; Tensoprel; Dilabar; Hypertil; Tenosbon; Alopresin; Captoprilum; Acepril; Apopril; Lopril; Acediur; Aceplus; Asisten; Farcopril; Hypopress; Isopresol; Tensiomin; Tensobon; Zapto; SQ-14225; (2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid; Captoprilum [INN-Latin]; D-2-Methyl-3-mercaptopropanoyl-L-proline; SQ 14225; D-3-Mercapto-2-methylpropanoyl-L-proline; Novocaptopril; Captomax; SQ 14,225; Mepha; Lopirin [Switzerland]; C9H15NO3S; SA 333; D-3-Mercapto-2-methylpropionylproline; 1-((2S)-3-Mercapto-2-methylpropionyl)-L-proline; (2S)-1-(3-Mercapto-2-methylpropionyl)-L-proline; 3-Mercapto-2-methylpropionyl-proline; CHEBI:3380; HSDB 6527; L-Proline, 1-[(2S)-3-mercapto-2-methyl-1-oxopropyl]-; UNII-9G64RSX1XD; EINECS 263-607-1; 9G64RSX1XD; Hipertil; NSC-757419; 1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline; DTXSID1037197; C09AA01; 1-[(2S)-3-Mercapto-2-methyl-1-oxopropyl]-L-proline; L-Proline, 1-(3-mercapto-2-methyl-1-oxopropyl)-, (S)-; SA-333; (S)-1-((S)-3-mercapto-2-methylpropanoyl)pyrrolidine-2-carboxylic acid; CHEMBL1560; MLS000069484; DTXCID9017197; (-)-Captopril; 1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline; Captopril [USAN:USP:INN:BAN:JAN]; NSC 757419; Lopirin (Switzerland); (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline; L-Proline, 1-((2S)-3-mercapto-2-methyl-1-oxopropyl)-; NCGC00023654-04; SMR000059061; SQ -14225; Captoprilum (INN-Latin); CAPTOPRIL (MART.); CAPTOPRIL [MART.]; CAPTOPRIL (USP-RS); CAPTOPRIL [USP-RS]; 1-Pyrrolidinecarboxylic acid, 1-(D-3-mercapto-2-methyl-1-propionyl)-, L-(S,S)-; CAPTOPRIL (EP MONOGRAPH); CAPTOPRIL (USP IMPURITY); CAPTOPRIL [EP MONOGRAPH]; CAPTOPRIL [USP IMPURITY]; CAPTOPRIL (USP MONOGRAPH); CAPTOPRIL [USP MONOGRAPH]; Captril; Captopril (Capoten); (2S)-1-((2S)-2-methyl-3-sulfanylpropanoyl)pyrrolidine-2-carboxylic acid; Captopril (USAN:USP:INN:BAN:JAN); Capozide (Salt/Mix); X8Z; Apopril (TN); Capoten (TN); 1-[(2s)-3-mercapto-2-methylpropionyl]-l-proline; SR-01000075603; component of Captea (Salt/Mix); component of Acezide (Salt/Mix); component of Ecazide (Salt/Mix); 1-(D-3-Mercapto-2-methyl-1-oxopropyl)-L-proline (S,S); MFCD00168073; Captopril,(S); Prestwick_103; Capoten;L-Captopril; CAPTORPIL; SQ14534; SCHEMBL4; Spectrum_000688; CAPTOPRIL [INN]; CAPTOPRIL [JAN]; CAPTOPRIL [MI]; CAPTOPRIL [HSDB]; CAPTOPRIL [USAN]; Opera_ID_1041; Prestwick3_000019; Spectrum2_001211; Spectrum3_001388; Spectrum4_000811; Spectrum5_001587; CAPTOPRIL [VANDF]; Lopac-C-4042; 1-((2S)-2-Methyl-3-sulfanylpropanoyl)-L-proline #; Epitope ID:114065; UPCMLD-DP003; C 4042; CAPTOPRIL [WHO-DD]; CAPTOPRIL [WHO-IP]; Lopac0_000302; N-[(S)-3-Mercapto-2-methylpropionyl]-L-proline; BSPBio_000057; BSPBio_002976; KBioGR_001321; KBioSS_001168; MLS001076488; DivK1c_000208; SPECTRUM1500682; SPBio_001022; Captopril (JP17/USP/INN); (S)-1-(3-Mercapto-2-methyl-1-oxo-propyl)-L-proline; BPBio1_000063; GTPL5158; CAPTOPRIL [ORANGE BOOK]; Captopril for system suitability; UPCMLD-DP003:001; BDBM21642; HMS500K10; KBio1_000208; KBio2_001168; KBio2_003736; KBio2_006304; KBio3_002196; 1j37; NINDS_000208; HMS1921C12; HMS2089P19; HMS2092I12; HMS2095C19; HMS2233I04; HMS3259G10; HMS3260N06; HMS3712C19; Pharmakon1600-01500682; CAPTOPRILUM [WHO-IP LATIN]; HY-B0368; Tox21_110890; Tox21_500302; BBL033600; CCG-39104; EI-213; HB3636; NSC719847; NSC757419; s2051; STK802012; AKOS005622581; Captopril, >=98% (HPLC), powder; Tox21_110890_1; BCP9000485; CS-2425; DB01197; KS-5025; LP00302; NC00554; SDCCGSBI-0050290.P006; IDI1_000208; SMP1_000056; NCGC00015235-01; NCGC00015235-02; NCGC00023654-03; NCGC00023654-05; NCGC00023654-06; NCGC00023654-07; NCGC00023654-08; NCGC00023654-09; NCGC00023654-10; NCGC00023654-11; NCGC00023654-13; NCGC00023654-25; NCGC00023654-26; NCGC00260987-01; 1ST10103; AC-12047; AC-32120; SBI-0050290.P004; Captopril, meets USP testing specifications; EU-0100302; FT-0602923; NS00008201; BIM-0050290.0001; C06867; D00251; EN300-118718; AB00052156-16; AB00052156_17; AB00052156_18; Q421119; SR-01000000039; SR-01000000039-2; SR-01000075603-1; SR-01000075603-3; 1-[(S)-3-mercapto-2-methyl-1-oxopropyl]-L-proline; BRD-K54529596-001-04-0; BRD-K54529596-001-15-6; Captopril, British Pharmacopoeia (BP) Reference Standard; Z1269124804; Captopril, European Pharmacopoeia (EP) Reference Standard; Captopril, United States Pharmacopeia (USP) Reference Standard; (S)-1-((S)-3-mercapto-2-methylpropanoyl)pyrrolidine-2-carboxylicacid; Captopril, Pharmaceutical Secondary Standard; Certified Reference Material; Captopril for system suitability, European Pharmacopoeia (EP) Reference Standard"	TAR10036	HUMAN angiotensin-converting enzyme (ACE)	P12821	44093	D06VSD	DB01197	.
DRG00107	Betulinic acid	Betulinic acid	.	"betulinic acid; 472-15-1; Mairin; Betulic acid; Lupatic Acid; als-357; 3-Hydroxylup-20(29)-en-28-oic acid; 3beta-Hydroxy-20(29)-lupaene-28-oic acid; CCRIS 6748; NSC 113090; EINECS 207-448-8; beta-betulinic acid; NSC 677578; NSC-677578; CHEBI:3087; UNII-4G6A18707N; .beta.-betulinic acid; Lupatic acid;Betulic acid; NSC677578; 4G6A18707N; NSC-113090; Lup-20(29)-en-28-oic acid, 3-hydroxy-, (3beta)-; CHEMBL269277; 3beta-Hydroxy-lup-20(29)-en-28-oic acid; Lup-20(29)-en-28-oic acid, 3beta-hydroxy-; (3beta)-3-hydroxylup-20(29)-en-28-oic acid; MFCD00009619; 3beta-hydroxylup-20(29)-en-28-oic acid; (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-hydroxy-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[a]chrysene-3a-carboxylic acid; Betulinicacid; NSC113090; C30H48O3; (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-hydroxy-1-isopropenyl-5a,5b,8,8,11a-pentamethyl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carboxylic acid; SMR000445624; betulinic-acid; Betulinic acid?; Prestwick_95; (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-hydroxy-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carboxylic acid; Betulinic Acid, 24; Prestwick0_000417; Prestwick1_000417; Prestwick2_000417; Prestwick3_000417; BETULINIC ACID [MI]; Lup-20(29)-en-28-oic acid, 3-hydroxy-, (3.beta.)-; SCHEMBL61767; BSPBio_000374; BSPBio_001587; cid_64971; MLS000728510; MLS006011257; SPBio_002313; BPBio1_000412; GTPL3945; BDBM23208; DTXSID80861974; HMS1569C16; HMS1791P09; HMS1989P09; HMS2096C16; HMS2232K03; HMS3402P09; Betulinic acid, analytical standard; Betulinic acid, >=98% (HPLC); HB3799; s3603; STL570261; AKOS015920276; Betulinic acid, technical grade, 90%; CCG-208159; CS-1216; DB12480; LMPR0106140004; RL9-080; SMP2_000205; NCGC00163409-02; NCGC00163409-03; NCGC00163409-09; BP-25391; DS-15257; HY-10529; NS00042781; C08619; Lup-20(29)-en-28-oic acid, 3beta -hydroxy-; (3beta)-3-Hydroxy-lup-20(29)-en-28-oic Acid; 3-Hydroxy-(3beta)-Lup-20(29)-en-28-oic acid; Q384111; SR-01000779609; Q-100500; SR-01000779609-3; BRD-K45401373-001-05-0; BRD-K45401373-001-22-5; (3.BETA.)-3-HYDROXYLUP-20(29)-EN-28-OIC ACID; (1R,2R,5S,8R,9R,10R,13R,14R,17S,19R)-17-hydroxy-1,2,14,18,18-pentamethyl-8-(prop-1-en-2-yl)pentacyclo[11.8.0.0^{2,10}.0^{5,9}.0^{14,19}]henicosane-5-carboxylic acid; (1R,3 aS,5aR,5bR,7aR,9S,11aR,11bR,13 aR,13bR)-9-hydroxy-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[a]chrysene-3a-carboxylic acid; (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-Hydroxy-1-isopropenyl-5a,5b,8,8,11a-pentamethyl-eicosahydro-cyclopenta[a]chrysene-3a-carboxylic acid; (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-hydroxy-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[a]chrysene-3a-carboxylicacid; (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-hydroxy-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carboxylicacid; 06L"	TAR10039	Herpes simplex virus DNA polymerase UL30 (HSV UL30)	P04293	64971	D0R9YR	DB12480	CHEMBL269277
DRG00108	2-Anthraquinonecarboxylic acid	2-Anthraquinonecarboxylic acid	.	"Anthraquinone-2-carboxylic acid; 117-78-2; 9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid; 2-Carboxyanthraquinone; 2-Anthraquinonecarboxylic acid; 9,10-Dioxoanthracene-2-carboxylic acid; 9,10-Anthraquinone 2-carboxylic acid; 9,10-Dihydro-9,10-dioxo-2-anthracenecarboxylic acid; 2-Carboxyl-9,10-anthraquinone; 2-Anthracenecarboxylic acid, 9,10-dihydro-9,10-dioxo-; Anthraquinone-2-carboxylate; NSC 5001; CHEMBL455581; 2-Anthroic acid, 9,10-dihydro-9,10-dioxo-; .beta.-Anthraquinonecarboxylic acid; NSC-5001; Anthraquinone-.beta.-carboxylic acid; beta-Anthraquinonecarboxylic acid; EINECS 204-207-9; SCHEMBL123492; 9,10-Dioxo-9,10-dihydroanthracene-2-carboxylicacid; 3WS64LL78M; AQCA-9,10; DTXSID70151659; NSC5001; ALBB-031338; AMY14558; STR02766; BDBM50312647; MFCD00001231; s9359; STK396684; 9,10-anthraquinone-2-carboxylic acid; AKOS001482342; Anthraquinone-2-carboxylic acid, 98%; CCG-266977; HY-W031757; AC-24478; DB-041384; A0504; CS-0075781; FT-0622422; NS00023795; D82129; EN300-234866; A803823; AE-641/00185012; SR-01000078364; J-003668; SR-01000078364-1; 9,10-Dioxo-9,10-dihydro-2-anthracenecarboxylic acid; Q59196332; 9,1 0-dihydro-9,10-dioxo-2-anthracenecarboxylic acid; F0074-0035"	.	.	.	67030	.	.	.
DRG00109	Artemisinin	Artemisinin	.	"artemisinin; Qinghaosu; 63968-64-9; Huanghuahaosu; Artemisinine; Artemisine; (+)-Artemisinin; Artemisinina; Artemisininum; Qinghosu; Quing Hau Sau; Qing Hau SU; Artemisinin [INN]; Qing Hau Sau; Artemisininum [Latin]; CHEBI:223316; UNII-9RMU91N5K2; NSC 369397; BRN 4194670; 9RMU91N5K2; DTXSID2040652; GNF-Pf-5341; Octahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10(3H)-one; DTXCID40819890; EC 700-290-5; (+)-Arteannuin; (3R,5aS,6R,8aS,9R,12S,12aR)-Octahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10(3H)-one; Artemisininum (Latin); quinghaosu; ARTEMISININ (MART.); ARTEMISININ [MART.]; ARTEMISININ (USP-RS); ARTEMISININ [USP-RS]; (1R,4S,5R,8S,9R,12S,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0^{4,13}.0^{8,13}]hexadecan-10-one; (1R,4S,5R,8S,9R,12S,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one; (3R,5aS,6R,8aS,9R,12S,12aR)-3,6,9-Trimethyloctahydro-3,12-epoxypyrano(4,3-j)(1,2)benzodioxepin-10(3H)-one; 3,12-Epoxy-12H-pyranol(4,3-j)-1,2-benzodioxepin-10(3H)-one, octahydro-3,6,9-trimethyl-, (3-alpha,5a-beta,6-beta,8a-beta,9-alpha,12-beta,12aR*)-(+)-; Qinghaosu [Chinese]; Artemisinine [French]; Artemisinina [Spanish]; Qing Hau Sau [Chinese]; qing hao su; NSC-369397; (3R,5aS,6R,8aS,9R,12S,12aR)-3,6,9-trimethyloctahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepin-10(3H)-one; (3R,5aS,6R,8aS,9R,12S,12aR)-Octahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10(3H)-one; 1,5,9-trimethyl-(1R,4S,5R,9R,12S,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one; SMR000578089; SR-01000802560; Artesin; MFCD00081057; NCGC00160207-01; 1,5,9-trimethyl-(1R,4S,5R,9R,12S,13R)-11,14,15,16-tetraoxatetracyclo(10.3.1.04,13.08,13)hexadecan-10-one; Artemisinin; (3R,5aS,6R,8aS,9R,12S,12aR)-Octahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10(3H)-one; CAS-63968-64-9; (+/-)-Artemisinin; Spectrum_001351; ARTEMISININ [MI]; Prestwick0_000498; Prestwick1_000498; Prestwick2_000498; Prestwick3_000498; Spectrum2_001512; Spectrum3_001549; Spectrum4_000721; Spectrum5_001098; SCHEMBL60304; ARTEMISININ [WHO-DD]; ARTEMISININ [WHO-IP]; BSPBio_000395; BSPBio_002998; KBioGR_000982; KBioSS_001831; MLS001097650; MLS001304036; MLS002153846; DivK1c_000656; SPBio_001583; SPBio_002316; BPBio1_000435; CHEMBL269671; GTPL9954; KBio1_000656; KBio2_001831; KBio2_004399; KBio2_006967; KBio3_002498; P01BE01; NINDS_000656; DTXSID501045125; HMS2090I17; HMS2096D17; HMS2267N09; HMS3269L13; HMS3413P13; HMS3677P13; HMS3713D17; Pharmakon1600-01503042; BCP02096; HY-B0094; Tox21_111750; ARTEMISININUM [WHO-IP LATIN]; BDBM50088447; HB1115; NSC758216; AKOS024457231; Tox21_111750_1; CCG-220498; CS-1794; DB13132; LMPR0103190003; NSC-758216; IDI1_000656; NCGC00161634-06; NCGC00161634-18; (3R,5aS,6R,8aS,9R,12S,12aR)-3,6,9-trimethyloctahydro-12H-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10(3H)-one; (3R,5AS,6R,8AS,9R,12S,12aR)-3,6,9-trimethyloctahydro-3,12-epoxypyrano(4,3-j)-1,2-benzodioxepin-10(3H)-one; AS-12692; NS00010623; S1282; EN300-7390753; Q426921; SR-01000802560-2; SR-01000802560-3; SR-01000802560-4; BRD-K13112821-001-08-3; BRD-K13112821-001-17-4; 2AB44F63-5D0F-424A-AA3F-24062F9C1CED; (3R,5AS,6R,8AS,9R,12S,12AR)-3,6,9-TRIMETHYLOCTAHYDRO-3,12-EPOXYPYRANO(4,3-J )-1,2-BENZODIOXEPIN-10(3H)-ONE; (3R,5aS,6R,8aS,9R,12S,12aR)-Octahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1, 2-benzodioxepin-10(3H)-one; 119241-68-8"	TAR10057	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase); Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A)	.	68827	D0S3WH	DB13132	.
DRG00110	N-acylbenzimidazolinone (Nbz)	N-acylbenzimidazolinone (Nbz)	.	"2-Acetylbenzimidazole; 939-70-8; 1-(1H-benzo[d]imidazol-2-yl)ethanone; 1-(1H-benzimidazol-2-yl)ethanone; 2-acetyl benzimidazole; Ethanone, 1-(1H-benzimidazol-2-yl)-; 1-(1H-1,3-Benzimidazol-2-yl)-1-ethanone; 1-(1H-1,3-Benzodiazol-2-Yl)Ethan-1-One; MFCD00159994; 2-acetylbenzoimidazole; 1-(1H-1,3-benzodiazol-2-yl)ethanone; M11 2-Acetylbenzimidazole; F2101-0111; SCHEMBL1132610; DTXSID90239867; 2-acetylbenzimidazole, AldrichCPR; UYFMRVDIXXOWLR-UHFFFAOYSA-N; ALBB-020352; STK803098; AKOS000275482; CS-W023047; AM807152; SY081619; DB-020321; DB-057456; EU-0063375; FT-0633161; FT-0656141; NS00067465; EN300-13259; I10097; 12P-660; AE-848/01427028; Q-101101; Z90124730; InChI=1/C9H8N2O/c1-6(12)9-10-7-4-2-3-5-8(7)11-9/h2-5H,1H3,(H,10,11"	.	.	.	70322	.	.	.
DRG00111	4-Nitrobenzyl chloroformate	4-Nitrobenzyl chloroformate	.	"4-Nitrobenzyl chloroformate; 4457-32-3; 4-Nitrobenzyl carbonochloridate; Carbonochloridic acid, (4-nitrophenyl)methyl ester; p-Nitrobenzyl chloroformate; 4-Nitrobenzyl Chlorocarbonate; 4-Nitrocarbobenzoxychloride; (4-nitrophenyl)methyl carbonochloridate; (4-nitrophenyl)methyl chloroformate; 4-Nitrobenzyloxycarbonyl chloride; DG2GS0JJV0; Chloroformic Acid 4-Nitrobenzyl Ester; p-Nitrobenzyloxycarbonyl chloride; Chloroformic acid p-nitrobenzyl ester; Formic acid, chloro-, p-nitrobenzyl ester; Chloroformic Acid p-Nitrobenzyl Ester; 4-Nitrobenzyl Chloroformate; 4-Nitrobenzyloxycarbonyl Chloride; p-Nitrobenzyl Chloroformate; p-Nitrobenzyloxycarbonyl Chloride; p-Nitrocarbobenzoxy Chloride; EINECS 224-708-6; 4nitrobenzyl chloroformate; UNII-DG2GS0JJV0; p-Nitrocarbobenzoxy chloride; p-nitrobenzyl chlorocarbonate; (4-nitrobenzyl)chloroformate; 4-Nitrobenzylcarbonochloridate; 4-(nitro)benzyl chloroformate; SCHEMBL158920; DTXSID6063482; MHSGOABISYIYKP-UHFFFAOYSA-; p-nitrobenzyloxy-carbonyl chloride; 4-Nitrobenzyl chloridocarbonate #; 4-Nitrobenzyl chloroformate, 97%; AMY28701; BCP28673; Chloroformic acid 4-nitrobenyl ester; MFCD00007375; AKOS015888117; AKOS024437890; CS-W014887; AS-11619; BP-24064; FT-0619220; NS00031439; EN300-66748; F15442; W-106188; InChI=1/C8H6ClNO4/c9-8(11)14-5-6-1-3-7(4-2-6)10(12)13/h1-4H,5H2"	.	.	.	78205	.	.	.
DRG00112	N-Hydroxysuccinimide	N-Hydroxysuccinimide	.	"N-Hydroxysuccinimide; 6066-82-6; 1-hydroxypyrrolidine-2,5-dione; HOSu; 1-Hydroxysuccinimide; 1-Hydroxy-2,5-pyrrolidinedione; Hydroxysuccinimide; 2,5-Pyrrolidinedione, 1-hydroxy-; Succinimide, N-hydroxy-; N-hydroxy succinimide; N-hydroxysuccinimide (HOSu); MFCD00005516; NHS; MJE3791M4T; NSC-74335; N-hydroxysuccinimid; CCRIS 2604; N-hydroxy-succinimide; EINECS 228-001-3; NSC 74335; UNII-MJE3791M4T; N-hydroxysucinimide; N-hyroxysuccinimide; N-Hydroxysuccinimde; N-Hydroxylsuccinimide; n-hydroxysuccin imide; 1-Hydroxy-2,5-pyrrolidinedione; NHS; HOSu.; N-hydroxyl succinimide; 2, 1-hydroxy-; N-hy dr oxy succinimide; n-hydroxysuccinimide (nhs); SCHEMBL1123; Sigma 130672; N-hydroxysuccinic acid imide; N-Hydroxysuccinimide, 98%; NCIOpen2_000470; HYDROXYSUCCINIMIDE, N-; hydroxy-pyrrolidine-2,5-dione; CHEMBL403753; n-hydroxypyrrolidine-2,5-dione; DTXSID7064102; 1-hydroxy-pyrrolidine-2,5-dione; N-HYDROXYSUCCINIMIDE [MI]; HY-Y0623; NSC74335; STR01867; STL183832; AKOS000121489; AB00437; AM83849; CS-W008598; N-HYDROXY-2,5-DIOXOPYRROLIDINE; PS-4557; AC-10509; AC-15786; BP-13159; SY001334; DB-298765; A8451; B0249; FT-0635964; H0623; NS00022482; EN300-17439; N-Hydroxysuccinimide, purum, >=97.0% (T); Q408833; Q-201468; Z56933833; F0001-1588; 1-hydroxypyrrolidine-2,5-dione;N-Hydroxysuccinimide (HOSu); InChI=1/C4H5NO3/c6-3-1-2-4(7)5(3)8/h8H,1-2H"	.	.	.	80170	.	.	.
DRG00113	Fluorene-9-methanol	Fluorene-9-methanol	.	"9-Fluorenemethanol; 24324-17-2; 9-Fluorenylmethanol; 9H-Fluorene-9-methanol; 9H-Fluoren-9-ylmethanol; (9h-fluoren-9-yl)methanol; 9-Fluorenyl Methanol; 9-Hydroxymethylfluorene; 9-(Hydroxymethyl)fluorene; MFCD00001139; Fluorene-9-methanol; 9-fluorenmethanol; hofm; (Fluoren-9-yl)methanol; 9-(hydroxymethyl)-fluoren; 9-fluoroenylmethanol; EINECS 246-167-5; 9-fluorene methanol; 9H-fluorene-9-ylmethanol; ChemDiv3_002715; 9-Fluorenemethanol, 99%; (9h-fluorene-9-yl)methanol; 9H-Fluoren-9-ylmethanol #; SCHEMBL261028; (9H-Fluoren-9-yl)-methanol; 9-(hydroxymethyl)-9h-fluorene; DTXSID7066980; XXSCONYSQQLHTH-UHFFFAOYSA-; HMS1480L09; STK013801; AKOS001646888; AC-4867; CCG-110312; CS-W010592; AS-10948; BP-21372; SY012649; DB-002627; AM20030438; EU-0076483; F0200; FT-0621658; FT-0621659; NS00027616; EN300-185373; F-2870; A817227; AN-512/13501009; SR-01000477721; SR-01000477721-1; (Fluoren-9-yl)methanol; 9-(Hydroxymethyl)fluorene; Fluorene-9-methanol; InChI=1/C14H12O/c15-9-14-12-7-3-1-5-10(12)11-6-2-4-8-13(11)14/h1-8,14-15H,9H2"	.	.	.	90466	.	.	.
DRG00114	4-Amino-7-chloroquinoline	4-Amino-7-chloroquinoline	.	"7-chloroquinolin-4-amine; 1198-40-9; 4-AMINO-7-CHLOROQUINOLINE; 7-Chloro-4-aminoquinoline; 4-Quinolinamine, 7-chloro-; 7-Chloro-quinolin-4-ylamine; CHEMBL44789; 2SJ6Y866TU; NSC-13; GNF-PF-5425; MFCD00828822; NSC-119495; 7-Chloro-4-quinolinamine; NSC13; NSC 13; QBC; Cambridge id 5511102; 4-amino-7-chloro-quinoline; UNII-2SJ6Y866TU; (7-chloro-4-quinolyl)amine; 7-Chloro-4-quinolinamine #; SCHEMBL596040; quinoline, 4-amino-7-chloro-; BDBM23300; (7-chloro-quinolin-4-yl)-amine; DTXSID00152593; CHEBI:166513; BCP33126; CS-D0096; BBL029042; STL162609; AKOS002669413; 4-Amino-7-chloroquinoline, AldrichCPR; AB07356; AC-18574; AS-35920; BM-07365; SY123068; DB-041504; FT-0633467; NS00023887; EN300-316308; A804373; 4-amino-7-chloroquinoline (ACQ)-based compound, 5; F9995-2431; 7-Chloro-4-quinolinamine pound>>4-Quinolinamine, 7-chloro-"	.	.	.	94711	.	.	CHEMBL44789
DRG00115	9-Acridinecarboxylic acid	9-Acridinecarboxylic acid	.	"9-Acridinecarboxylic acid; ACRIDINE-9-CARBOXYLIC ACID; 5336-90-3; 9-Carboxyacridine; 9-Acridinecarboxylicacid; NSC-386; MFCD00009734; acridine-9-carboxylicacid; Acridine-9-carboxylic Acid; 9-Acridinecarboxylic acid; NSC 386; NSC 386; 9-carboxy-acridine; acridine, 9-carboxy-; acridinium-9-carboxylate; Acridine-9 carboxylic acid; 9-Acridine Carboxylic Acid; Cambridge id 6662990; SCHEMBL641899; 8RKF684UT3; NSC386; CHEMBL2159007; DTXSID90201524; BCP07119; BBL001778; STK011178; AKOS000805666; AM10461; CCG-256327; DS-7461; AC-33261; SY029726; DB-052316; CS-0041991; FT-0621610; NS00008413; EN300-235645; AB00114872-01; A829546; J-200083; BRD-K47879117-001-01-5; F2130-0063"	.	.	.	94721	.	.	.
DRG00116	Methylenenorcamphor	Methylenenorcamphor	.	"3-Methylene-2-norbornanone; 5597-27-3; 3-methylidenebicyclo[2.2.1]heptan-2-one; 2-Norbornanone, 3-methylene-; Bicyclo[2.2.1]heptan-2-one, 3-methylene-; 3-Methylenebicyclo[2.2.1]heptan-2-one; 3-Methylenenorbornan-2-one; MFCD00151643; NSC91505; EINECS 227-009-4; SCHEMBL646654; CHEMBL364131; DTXSID50971372; NSC 91505; NSC-91505; AKOS025295471; BS-53372; SY054769; 3-methylene-bicyclo[2,2,1]heptan-2-one; 3-Methylenebicyclo[2.2.1]heptan-2-one #; CS-0186844; FT-0694652; M1656; NS00044323; InChI=1/C8H10O/c1-5-6-2-3-7(4-6)8(5)9/h6-7H,1-4H"	.	.	.	96875	.	.	.
DRG00117	"9-(2,3,5-Tri-O-acetyl-&beta;-D-arabinofuranosyl)-9H-purin-6-amine"	.	.	"Ara-ata; GCVZNVTXNUTBFB-YGSHXTJESA-N; Vidarabine 2',3',5'-triacetate; NSC 103560; Arabinofuranosyladenine-2',3',5'-triacetate; SCHEMBL11423681; AKOS015896845; 9-(2,3,5-tri-O-acetyl-beta-D-arabinofuranosyl)adenine; 9H-Purin-6-amine, 9-(2,3,5-tri-O-acetyl-beta-D-arabinofuranosyl)-"	.	.	.	97185	.	.	.
DRG00118	Diethyl squarate	Diethyl squarate	.	"3,4-Diethoxy-3-cyclobutene-1,2-dione; 5231-87-8; Diethyl squarate; 3,4-diethoxycyclobut-3-ene-1,2-dione; Squaric acid diethyl ester; 3-Cyclobutene-1,2-dione, 3,4-diethoxy-; diethoxycyclobut-3-ene-1,2-dione; 1,2-diethoxycyclobutenedione; MFCD00001333; Diethoxycyclobutenedione; 3,4-Diethoxy-cyclobut-3-ene-1,2-dione; SCHEMBL94221; DFSFLZCLKYZYRD-UHFFFAOYSA-; DTXSID30200334; 1,2-diethoxycyclobutene-3,4-dione; 3,4-diethoxy-3-cyclobuten-1,2-dion; AKOS015905438; 3,4-diethoxy-3-cyclobuten-1,2-dione; CS-W004755; PS-4470; 3,4-diethoxy-3 cyclobutene-1,2-dione; 3.4-diethoxy-3-cyclobutene-1,2-dione; 3,4-diethyoxy-3-cyclobutene-1,2-dione; 3,4,-diethoxy-3-cyclobutene-1,2-dione; AC-22926; BP-13098; SY013529; DB-006276; AM20100287; D3253; FT-0600794; 3,4-Diethoxy-3-cyclobutene-1,2-dione, 98%; EN300-215540; A829027; J-511148; 3 pound not4-Diethoxy-3-cyclobutene-1 pound not2-dione; 3,4-diethoxycyclobut-3-ene-1,2-dione;Diethyl squarate; InChI=1/C8H10O4/c1-3-11-7-5(9)6(10)8(7)12-4-2/h3-4H2,1-2H3; Diethyl squarate; 3,4-Diethoxycyclobut-3-ene-1,2-dione; 3:4-diethoxycyclobut-3-ene-1:2-dione"	.	.	.	123228	.	.	.
DRG00119	"2,2,1-Cryptand"	"2,2,1-Cryptand"	.	"31364-42-8; 4,7,13,16,21-Pentaoxa-1,10-diazabicyclo[8.8.5]tricosane; Kryptofix 221; Kryptofix(R) 221; Cryptating agent 221; MFCD00005108; 4,7,13,16,21-Pentaoxa-1,10-diazabicyclo(8.8.5)tricosane; 4,7,13,16,21-Pentaoxa-1,10-diazabicyclo[8.8.5.]tricosane; Kryptofix-221; EINECS 250-592-1; Cryptand 221; Cryptand-221; Kryptofix(R)221; NSC 321059; KRYPTOFIX221; SCHEMBL25928; DTXSID60185286; BCP14291; NSC321059; AKOS015916737; NSC-321059; AC-37052; AS-70036; SY061353; FT-0660588; NS00029069; A875929; J-200342; 4,7,16,21-Pentaoxa-1,10-diazabicyclo[8.8.5.]tricosane; 4,7,13,16,21-pentaoxa-1,10-diazabicyclo-[8.8.5]tricosane; (4,7,13,16,21-Pentaoxa-1,10-diazabicyclo[8.8.5]tricosane); 4,7,13,16,21-Pentaoxa-1,10-diazabicyclo[8.8.5]tricosane #; 4,7,13,16,21-Pentaoxa-1,10-diazabicyclo[8.8.5]tricosane, 98%"	.	.	.	123438	.	.	.
DRG00120	3-[(1-Nitroacridin-9-yl)amino]propanoic acid (nitroacrin) derivative	.	.	"beta-Alanine, N-(1-nitro-9-acridinyl)-; 81483-74-1; N-(1-Nitro-9-acridinyl)-beta-Alanine; CHEMBL1774127; DTXSID90231129"	.	.	.	149942	.	.	.
DRG00121	Naproxen	Naproxen	.	"NAPROXEN; 22204-53-1; (S)-Naproxen; Naprosyn; (+)-Naproxen; Naproxene; Equiproxen; (S)-2-(6-methoxynaphthalen-2-yl)propanoic acid; Aleve; (S)-(+)-Naproxen; d-Naproxen; Ec-Naprosyn; (S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid; (+)-(S)-Naproxen; Laraflex; Naprosyne; Naproxeno; Naproxenum; Nycopren; Calosen; Naixan; Reuxen; Bonyl; Axer; (2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid; Novonaprox; Acusprain; Anexopen; Apronax; Artagen; Arthrisil; Artrixen; Artroxen; Atiflan; Bipronyl; Clinosyn; Danaprox; Flexipen; Genoxen; Lefaine; Leniartil; Nafasol; Nalyxan; Napflam; Naposin; Naprius; Veradol; Congex; Daprox; Fuxen; Napmel; Napren; Naxen; Naxyn; Xenar; Dysmenalgit N; Apo-Naproxen; naproxen(+); Floginax; Napratec; Naprontag; Naxopren; Pronaxen; Rheumaflex; Saritilron; Sinartrin; Soproxen; Anaprox; Flexen; Headlon; Napxen; Narocin; Noflam; Patxen; Prafena; Priaxen; Rahsen; Sinton; Sutolin; Sutony; Tohexen; Traumox; Velsay; Vinsen; Narma; Naxid; Roxen; Anax; Flanax Forte; Naprosyn LLE; Napren E; Proxen LE; Naxen F; Proxen LLE; U-Ritis; RS-3540; (S)-2-(6-Methoxy-2-naphthyl)propionic acid; (+)-2-(6-Methoxy-2-naphthyl)propionic acid; Naprosyn LLE Forte; Naproxi 250; Naproxi 500; (+)-2-(Methoxy-2-naphthyl)-propionic acid; (S)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid; Naxyn 250; Naxyn 500; Xenar-CR; (S)-2-(6-Methoxy-2-naphthyl)propanoic acid; d-2-(6-Methoxy-2-naphthyl)propionic acid; (+)-2-(Methoxy-2-naphthyl)-propionsaeure; CCRIS 5265; CHEBI:7476; Diocodal; Naprolag; Naprosine; Naprosy; Prexan; CG 3117; Apo-Napro-NA; (+)-(S)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid; HSDB 3369; Naproxene [INN-French]; Naproxenum [INN-Latin]; Naproxeno [INN-Spanish]; EINECS 244-838-7; UNII-57Y76R9ATQ; (S)-(+)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid; Dysmenalgit; NSC-750183; NSC-757239; Proxen; RS 3540; 57Y76R9ATQ; DTXSID4040686; PN400 COMPONENT NAPROXEN; d-2-(6'-Methoxy-2'-naphthyl)-propionsaeure; CHEMBL154; (+)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid; Propionic acid, 2-(6-methoxy-2-naphthyl)-, (+)-; (alphas)-6-methoxy-alpha-methyl-2-naphthaleneacetic acid; 2-Naphthaleneacetic acid, 6-methoxy-alpha-methyl-, (+)-; 2-Naphthaleneacetic acid, 6-methoxy-alpha-methyl-, (S)-; Duk; VIMOVO COMPONENT NAPROXEN; DTXCID2020686; Methoxypropiocin; (2S)-2-(6-methoxy-2-naphthyl)propanoic acid; EC 244-838-7; Apranax; Naprium; Naprux; MFCD00010500; Naproxen [USAN:USP:INN:BAN:JAN]; NSC 750183; NSC 757239; 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, (S)-; Naproxene (INN-French); Naproxenum (INN-Latin); 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, (.alpha.S)-; CAS-22204-53-1; Naproxeno (INN-Spanish); NAPROXEN (MART.); NAPROXEN [MART.]; NAPROXEN (USP-RS); NAPROXEN [USP-RS]; (S)-2-(6-Methoxy-naphthalen-2-yl)-propionic acid; NAPROXEN (EP MONOGRAPH); NAPROXEN [EP MONOGRAPH]; (S)-6-Methoxy-.alpha.-methyl-2-naphthaleneacetic acid; NAPROXEN (USP MONOGRAPH); NAPROXEN [USP MONOGRAPH]; Equiproxen (Veterinary); Naproxen (USAN:USP:INN:BAN:JAN); S-NAPROXEN; Panoxen; Proxine; (S)-6-Methoxy-alpha-methyl-2-naphthaleneacetate; Mnpa; Naproxen oral; SR-01000075977; DL Naproxen; Equiproxen Granules; Naprosyn (TN); Naproxen,(S); NPS; Prestwick_349; (+)-2-(Methoxy-2-naphthyl)-propionsaeure [German]; d-2-(6'-Methoxy-2'-naphthyl)-propionsaeure [German]; Naproxendelayed release; EC-NAPROXEN; 6-methoxy-alpha-methyl-2-naphthaleneacetic acid; Spectrum_000977; (R)-6-Methoxy-a-methyl-2-naphthaleneacetic acid; 4or0; 4po0; NAPROXEN [HSDB]; NAPROXEN [USAN]; (S)-(+)-Naproxene; NAPROXEN [INN]; NAPROXEN [JAN]; Naproxen Delayed Release; Naproxen Oral Suspension; NAPROXEN [MI]; NAPROXEN [VANDF]; Prestwick0_000791; Prestwick1_000791; Prestwick2_000791; Spectrum2_001043; Spectrum3_000514; Spectrum4_000069; Spectrum5_001327; (+)NAPROXEN; Equiproxen 10% Solution; Naproxen2-(6-Methoxy-naphthalen-2-yl)-propionic acid; Epitope ID:139974; NAPROXEN [WHO-DD]; UPCMLD-DP001; 2-(6-Methoxy-naphthalen-2-yl)-propionic acid(Naproxen); SCHEMBL3046; Lopac0_000792; BSPBio_002067; KBioGR_000597; KBioSS_001457; BIDD:GT0062; DivK1c_000242; NAPROXEN [GREEN BOOK]; SPECTRUM1500425; Naproxen (JP17/USP/INN); Naproxen, 1mg/ml in Methanol; SPBio_000966; SPBio_002861; NAPROXEN [ORANGE BOOK]; GTPL5230; UPCMLD-DP001:001; CMWTZPSULFXXJA-VIFPVBQESA-; HMS500M04; KBio1_000242; KBio2_001457; KBio2_004025; KBio2_006593; KBio3_001567; G02CC02; M01AE02; M02AA12; Naproxen 1.0 mg/ml in Methanol; NINDS_000242; HMS1920P13; HMS2089N21; HMS2091H12; HMS3649M13; HMS3886C15; Pharmakon1600-01500425; NAPROXEN COMPONENT OF VIMOVO; Tox21_301953; BDBM50339185; CCG-40130; NSC750183; NSC757239; AKOS005267223; AC-1363; DB00788; ME-0100; SDCCGSBI-0050769.P005; IDI1_000242; Naproxen 100 microg/mL in Acetonitrile; NCGC00016759-01; NCGC00016759-02; NCGC00016759-03; NCGC00016759-29; NCGC00016759-38; NCGC00021127-01; NCGC00161591-01; NCGC00255562-01; HY-15030; (+)-2-(Methoxy-2-naphthyl)-propionsaure; Naproxen, meets USP testing specifications; SBI-0050769.P004; Sallus Pain Relief Collection With Naproxen; AM20060551; M1021; NS00098611; S5177; Naproxen, VETRANAL(TM), analytical standard; (2S)-2-(6-Methoxynaphth-2-yl)propanoic acid; (S)-2-(6-methoxy-2-naphthyl)-propionic acid; (S)-2-(6-methoxynaphthalen-2-yl)propanoicacid; C01517; d-2-(6'-methoxy-2'-naphthyl)-propionic acid; D00118; EN300-139795; O10203; (2S)-2-(6-methoxy(2-naphthyl))propanoic acid; AB00052049-04; AB00052049_05; ()-2-(METHOXY-2-NAPHTHYL)-PROPIONIC ACID; ()-2-(METHOXY-2-NAPHTHYL)-PROPIONSAEURE; (+)(S)2-(6-methoxy-2-naphthyl)-propionic acid; 2-(6-Methoxy-2-naphthyl)propanoic acid , (+)-; SR-01000003110; Q-201447; Q1215575; SR-01000003110-5; SR-01000075977-3; SR-01000075977-4; (+)-6-Methoxy-.alpha.-methyl-2-napthaleneacetic acid; BRD-K59197931-001-02-9; BRD-K59197931-001-03-7; BRD-K59197931-236-09-6; SR-01000075977-10; (+)-6-Methoxy-.alpha.-methyl-2-naphthaleneacetic acid; (S)-(+)-2-(6-methoxy-naphthalen-2-yl)-propionic acid; (S)-6-Methoxy-.alpha.-methyl-2-naphthalene acetic acid; 2-naphthaleneacetic acid, 6-methoxy-alpha-methyl, (S)-; 2-naphthleneacetic acid, 6-methoxy-alpha-methyl-, (+)-; Naproxen, British Pharmacopoeia (BP) Reference Standard; Naproxen, European Pharmacopoeia (EP) Reference Standard; PROPIONIC ACID, 2-(METHOXY-2-NAPHTHYL)-, ()-; Z1695772815; (S)-(+)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid, 98%; 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, (+)-; Naproxen, United States Pharmacopeia (USP) Reference Standard; (+)-(S)-6-METHOXY-.ALPHA.-METHYL-2-NAPHTHALENEACETIC ACID; Naproxen, Pharmaceutical Secondary Standard; Certified Reference Material; (S)-(+)-2-(6-Methoxy-2-naphthyl)propionic Acid;(S)-(+)-6-Methoxy-alpha-methyl-2-naphthaleneacetic Acid; 131991-52-1; InChI=1/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)/t9-/m0/s1"	TAR10032	Prostaglandin G/H synthase 1 (COX-1)	P23219	156391	D0DJ1B	DB00788	CHEMBL154
DRG00122	Vinblastine	Vinblastine	.	"vinblastine; 865-21-4; Vincaleukoblastine; CHEBI:27375; Vinblastine (INN); (+)-vinblastine; Vinblastina (TN); NCGC00181127-01; VLB; SCHEMBL6146; CHEMBL22969; Vinblastine (Vincaleucoblastine); SCHEMBL17813675; BDBM227643; HMS2090K05; 132142-72-4; AKOS015969678; NCGC00181127-02; NCGC00263548-07; NCGC00263548-26; NCI60_004200; NS00003095; C07201; D08675; EN300-130971; AB01273959-01; AB01273959-02; Q282629; Q-100868; 72401-36-6; methyl (1R,9R,10S,11R,12R,19R)-11-(acetyloxy)-12-ethyl-4-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-(methoxycarbonyl)-1,11-diazatetracyclo[13.3.1.0^{4,12}.0^{5,10}]nonadeca-4(12),5(10),6,8-tetraen-13-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.0^{1,9}.0^{2,7}.0^{16,19}]nonadeca-2,4,6,13-tetraene-10-carboxylate; methyl (1R,9R,10S,11R,12R,19R)-11-(acetyloxy)-12-ethyl-4-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-(methoxycarbonyl)-1,11-diazatetracyclo[13.3.1.0^{4,12}.0^{5,10}]nonadeca-4(12),5,7,9-tetraen-13-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.0^{1,9}.0^{2,7}.0^{16,19}]nonadeca-2(7),3,5,13-tetraene-10-carboxylate; methyl acetoxy-ethyl-(ethyl-hydroxy-methoxycarbonyl-[?]yl)-hydroxy-methoxy-methyl-[?]carboxylate"	.	.	.	241903	.	DB00570	CHEMBL22969
DRG00123	2-Nitro-1H-imidazole-1-acetic acid	2-Nitro-1H-imidazole-1-acetic acid	.	"2-(2-Nitro-1H-imidazol-1-yl)acetic acid; 22813-32-7; 2-(2-Nitroimidazol-1-yl)acetic acid; NSC302988; MLS003115771; MFCD12022607; NSC-302988; 1H-Imidazole-1-acetic acid, 2-nitro-; NCIStruc1_000016; NCIStruc2_000181; SCHEMBL3914305; CHEMBL1741825; DTXSID20316397; TYDGDUVFDYKZMY-UHFFFAOYSA-N; XAA81332; (2-nitro-imidazol-1-yl)acetic acid; CCG-38321; NCGC00014673; NCI302988; (2-nitro-imidazol-1-yl) acetic acid; AKOS006317718; NCGC00014673-02; NCGC00097776-01; AS-63970; NCI60_002558; SMR001831337; SY358306; (2-NITROIMIDAZOL-1-YL)ACETIC ACID; 2-(2-Nitro-1H-imidazol-1-yl)aceticacid; 2-(2-nitro-1H-imidazol-1-yl)-acetic acid; CS-0155608; C74175; A925486; (2-(hydroxy(oxido)amino)-1H-imidazol-1-yl)acetic acid"	.	.	.	327544	.	.	.
DRG00124	4-[[4-Oxo-3-(2-propen-1-yl)-2-thioxo-5-thiazolidinylidene]methyl]benzaldehyde	.	.	CBMicro_000021; YYKZHHPAGZSXRI-UHFFFAOYSA-N; 4-(3-allyl-4-oxo-2-thioxo-thiazolidin-5-ylidenemethyl)-benzaldehyde	.	.	.	349350	.	.	.
DRG00125	2-Amino-5-methylthiazole (MTZ-C2)	2-Amino-5-methylthiazole (MTZ-C2)	.	"2-Amino-5-methylthiazole; 7305-71-7; 5-methylthiazol-2-amine; 5-Methyl-1,3-thiazol-2-amine; 2-Thiazolamine, 5-methyl-; 2-Amino-5-methyl-thiazole; 5-Methyl-2-aminothiazole; 5-METHYL-2-THIAZOLAMINE; (5-Methylthiazol-2-yl)amine; Thiazole, 2-amino-5-methyl-; NSC-523150; MFCD00078317; 7RAB78AF2P; CHEMBL502447; 2-amino-5-methyl-1,3-thiazole; 25T; UNII-7RAB78AF2P; 2-amino-5-methyl thiazole; 5-methyl-1,3-thiazole-2-ylamine; Meloxicam Imp. B (EP); Meloxicam USP Related Compound B; Meloxicam USP RC B; 5-Methylthiazol-2-amine; Meloxicam Related Compound B; Meloxicam Impurity B; Meloxicam specified impurity B [EP]; amino-5-methylthiazole; 5-methylthiazole-2-amine; EC 423-800-5; MELOXICAM IMPURITY B; 5-methyl-thiazol-2-yl-amine; SCHEMBL160815; CS-WAA0093; HY-WAA0093; SCHEMBL8086534; DTXSID10223329; 2-Amino-5-methylthiazole, 98%; 2-AMINO-5 inverted exclamation mark feminineMETHYLTHIAZOLE; 5-METHYL-THIAZOL-2-YLAMINE; STR04839; 5-Methyl-1,3-thiazol-2-amine #; BDBM50271509; NSC523150; STK320523; 5-methyl-1,3-thiazol-2(3h)-imine; AKOS000120781; AKOS005144921; AB03001; CS-W013636; AC-10741; AC-31822; TS-01581; MELOXICAM IMPURITY B [EP IMPURITY]; DB-020479; A1250; AM20100697; FT-0611180; NS00006037; EN300-21492; A56079; J-507967; Q27268750; F2190-0540; Z104500072; Meloxicam impurity B, European Pharmacopoeia (EP) Reference Standard; InChI=1/C4H6N2S/c1-3-2-6-4(5)7-3/h2H,1H3,(H2,5,6"	.	.	.	351770	.	.	.
DRG00126	Purvalanol B (PVB)	Purvalanol B (PVB)	.	"Purvalanol B; 212844-54-7; PURVALANOL; (R)-2-chloro-4-((2-((1-hydroxy-3-methylbutan-2-yl)amino)-9-isopropyl-9H-purin-6-yl)amino)benzoic acid; NG 95; (2R)-2-[[6-[(3-CHLORO-4-CARBOXYPHENYL)AMINO]-9-(1-METHYLETHYL)-9H-PURIN-2-YL]AMINO]-3-METHYL-1-BUTANOL; CHEMBL23254; CHEBI:49840; NG-95; MFCD04118312; 2-chloro-4-[[2-[[(2R)-1-hydroxy-3-methylbutan-2-yl]amino]-9-propan-2-ylpurin-6-yl]amino]benzoic acid; 2-Chloro-4-[[2-[[(1R)-1-(hydroxymethyl)-2-methylpropyl]amino]-9-(1-methylethyl)-9H-purin-6-yl]amino]benzoic acid; PurvalanolB; Purvalanol B(NG 95); Purvalanol B(NG-95); purvalanol-B; 2-chloro-4-[(2-{[(1R)-1-(hydroxymethyl)-2-methylpropyl]amino}-9-isopropyl-9H-purin-6-yl)amino]benzoic acid; 2-chloro-4-[(2-{[(2R)-1-hydroxy-3-methylbutan-2-yl]amino}-9-(propan-2-yl)-9H-purin-6-yl)amino]benzoic acid; 2-chloro-4-{[2-{[(1R)-1-(hydroxymethyl)-2-methylpropyl]amino}-9-(1-methylethyl)-9H-purin-6-yl]amino}benzoic acid; 2-chloro-4-{[2-{[(1R)-1-(hydroxymethyl)-2-methylpropyl]amino}-9-isopropyl-9H-purin-6-yl]amino}benzoic acid; 2-chloro-4-{[2-{[(2R)-1-hydroxy-3-methylbutan-2-yl]amino}-9-(propan-2-yl)-9H-purin-6-yl]amino}benzoic acid; Tocris-1581; 1v0p; SCHEMBL27951; BDBM7478; GTPL7806; NG95; EX-A354; DTXSID201317921; HMS3268E21; HMS3412L09; HMS3676L09; BCP01952; NG 95;NG95;NG-95; AKOS024456681; AM84743; CS-1714; DB02733; NCGC00025220-01; NCGC00025220-02; NCGC00025220-03; NCGC00025220-04; Purvalanol B, >=97% (HPLC), solid; (R)-2-chloro-4-(2-(1-hydroxy-3-methylbutan-2-ylamino)-9-isopropyl-9H-purin-6-ylamino)benzoic acid; AC-35738; AS-16225; HY-18299; NS00068318; S0500; SR-01000597589; J-502183; SR-01000597589-1; BRD-K41564320-001-01-2; Q27088484"	TAR10042	Adrenergic receptor beta-3 (ADRB3)	P13945	448991	D0WS1V	.	.
DRG00127	5-Bromothiazole (BTZ-C2)	5-Bromothiazole (BTZ-C2)	.	"5-Bromothiazole; 3034-55-7; 5-Bromo-1,3-thiazole; Thiazole, 5-bromo-; 5-bromo-thiazole; MFCD07787394; 5-bromothiazol; 5-bromo thiazole; 2-bromo-1,4-thiazole; 5-Bromothiazole, 95%; 5-Bromo-1,3-thiazole #; SCHEMBL290048; CHEMBL4569890; DTXSID60338053; CS-D1067; CL2517; AKOS005146151; AB42975; PS-3839; AC-23144; SY005152; DB-016091; A5588; AM20090420; FT-0649886; EN300-93405; M04059; W-202252"	.	.	.	546059	.	.	.
DRG00128	3-Maleimidopropionic acid	3-Maleimidopropionic acid	.	"3-Maleimidopropionic acid; 7423-55-4; 3-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanoic acid; N-Maleoyl-beta-alanine; 3-(2,5-dioxopyrrol-1-yl)propanoic acid; 1h-pyrrole-1-propanoic acid, 2,5-dihydro-2,5-dioxo-; BMPA Protein Modifier; Maleimide-(CH2)2-COOH; MFCD00043030; N-Maleoyl-.beta.-alanine; 3-(2,5-Dioxo-2,5-dihydro-pyrrol-1-yl)-propionic acid; 2,5-DIHYDRO-2,5-DIOXO-1H-PYRROLE-1-PROPANOIC ACID; 3-Maleimidopropionicacid; N-carboxyethylmaleimide; 3-Maleimidopropanoic acid; Mal-(CH2)2-COOH; Q5C4V9T6GU; N-(2-Carboxyethyl)maleimide; SCHEMBL34464; N-Maleoyl-beta-alanine, 97%; DTXSID00341526; BCP13655; BBL027986; s1127; STK934575; .BETA.-MALEIMIDOPROPIONIC ACID; AKOS000143815; AC-5036; CS-W019611; GS-6614; BP-20452; HY-42145; PD134103; SY021699; DB-023107; AM20100720; FT-0604091; FT-0608194; M1962; N-Maleoyl-beta-alanine, >=98.0% (HPLC); EN300-227402; J-512738; F1265-0534; Z245319606; 3-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanoic acid #"	.	.	.	573621	.	.	.
DRG00129	6-Maleimidocaproic acid derivative linker	.	.	"6-Maleimidocaproic acid; 55750-53-3; 6-Maleimidohexanoic acid; 6-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoic acid; 1H-Pyrrole-1-hexanoic acid, 2,5-dihydro-2,5-dioxo-; 6-Maleimidocapronic acid; 6-(2,5-dioxopyrrol-1-yl)hexanoic acid; Maleimide-(CH2)5-COOH; N-(5-Carboxypentyl)maleimide; CHEMBL47391; N-Maleoyl-6-aminocaproic acid; MFCD00043140; 6-Maleimidocaproicacid; N-maleoyl-6-aminohexanoic acid; Mal-(CH2)5-COOH; (EMCA); SCHEMBL43969; DTXSID10876051; CHEBI:176414; BCP12780; CS-M1809; N-(6-oxo-6-hydroxyhexyl)maleimide; BDBM50471014; 6-Maleimidohexanoic acid, 90% (GC); AKOS000139285; GS-6853; AC-25055; BP-20415; HY-77959; PD127389; SY030571; 6-Maleimidohexanoic acid, >=98% (HPLC); DB-052788; A8047; AM20100367; FT-0604083; M2338; 6-Maleimidohexanoic acid, >=98.0% (HPLC); EN300-395442; J-518825; 6-[2,5-Dioxo-2,5-dihydro-pyrrol-1-yl]hexanoic acid; Z245319376; 6-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoic acid #; 6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoic acid;6-Maleimidohexanoic acid"	.	.	.	573683	.	.	.
DRG00130	"Coumarine, 7-Methoxy-2-oxo-2H-1-benzopyran-3-carboxylic acid"	.	.	"20300-59-8; 7-Methoxy-2-oxo-2H-chromene-3-carboxylic acid; 7-Methoxycoumarin-3-carboxylic acid; 7-methoxy-2-oxochromene-3-carboxylic acid; 2H-1-Benzopyran-3-carboxylic acid, 7-methoxy-2-oxo-; CHEMBL1830821; MFCD00452770; 7-METHOXYCOUMARIN-3-CARBOXYLICACID; CBDivE_003875; 7-methoxy-3-carboxycoumarin; Oprea1_241131; 7-methoxy-3-carboxy-coumarin; SCHEMBL203997; DTXSID30342708; 7-Methoxycoumarin-3-carbonic acid; 7-Methoxycoumarine-3-carboxylic acid; BDBM50442714; STK387486; AKOS002230557; AM84699; CCG-251868; Cumarin-3-carboxylic acid, 7-methoxy-; HY-W039519; SY050789; 1ST164146; DB-026433; CS-0097515; FT-0621448; M2233; EN300-7416483; 7-Methoxy-2-oxo-2H-chromene-3-carboxylic acid #; SR-01000308907; 10X-0804; J-100198; SR-01000308907-1; 7-Methoxycoumarin-3-carboxylic acid, suitable for fluorescence, >=97.0% (HPCE)"	.	.	.	583941	.	.	CHEMBL1830821
DRG00131	Nerol	Nerol	.	"nerol; 106-25-2; Neryl alcohol; cis-Geraniol; (Z)-3,7-dimethylocta-2,6-dien-1-ol; (Z)-Geraniol; (2Z)-3,7-dimethylocta-2,6-dien-1-ol; cis-3,7-Dimethyl-2,6-octadien-1-ol; 2,6-Octadien-1-ol, 3,7-dimethyl-, (2Z)-; (Z)-Nerol; Nerol (natural); Nerol 900; (Z)-3,7-dimethyl-2,6-octadien-1-ol; Z-Geraniol; 2-cis-3,7-Dimethyl-2,6-octadien-1-ol; FEMA No. 2770; CHEBI:29452; 2,6-Octadien-1-ol, 3,7-dimethyl-, (Z)-; MFCD00063204; NSC-46105; (2Z)-3,7-Dimethyl-2,6-octadien-1-ol; 3,7-Dimethyl-2,6-octadien-1-ol, cis-; DTXSID3026728; 3,7-dimethyl-2Z,6-octadien-1-ol; Nerol 1000 microg/mL in Isopropanol; 38G5P53250; DTXCID806728; CAS-106-25-2; Vernol; 3,7-dimethylocta-2,6-dien-1-ol; 3,7-Dimethyl-2,6-octadien-1-ol; UNII-38G5P53250; EINECS 203-378-7; cis-2,6-dimethyl-2,6-octadien-8-ol; AI3-28202; .BETA.-NEROL; NEROL [FHFI]; 3,7-Dimethyl-2,6-octadien-1-ol, (Z)-; NEROL [FCC]; NEROL [MI]; Nerol, analytical standard; EC 203-378-7; SCHEMBL19825; CHEMBL452683; HSDB 8262; (E)3,7-Dimethyl-Octadien-1-ol; HMS3886M07; HY-N7063; Tox21_202029; Tox21_300542; BDBM50036946; s4970; AKOS016008578; 3,7-dimethyl-octa-2cis,6-dien-1-ol; CCG-266252; CS-W018031; LMPR0102010010; (E)3,7-dimethyl-2,6-Octadien-1-ol; (Z)3,7-dimethyl-2,6-Octadien-1-ol; (2E)3,7-dimethyl-2,6-octadien-1-ol; (2Z)3,7-dimethyl-2,6-octadien-1-ol; (cis)3,7-dimethyl-2,6-Octadien-1-ol; NCGC00164117-01; NCGC00164117-02; NCGC00164117-03; NCGC00254346-01; NCGC00259578-01; AS-61707; (2Z)-3,7-dimethyl-1-octa-2,6-dienol; 3,7-Dimethyl-trans-2, 6-octadien-1-ol; (2Z)-3,7-dimethyl-octa-2,6-dien-1-ol; DB-336423; FT-0623941; N0077; NS00095794; (2Z)-3,7-Dimethyl-2,6-octadien-1-ol #; cis-3,7-Dimethyl-2,6-octadien-1-ol, 97%; C09871; D70365; EN300-817771; 3,7-Dimethyl-Octane-1-ol tetrahydro derivative; A801400; Q415359; W-108769; cis-3,7-Dimethyl-2,6-octadien-1-ol, >=97%, FCC, FG; NZZ"	.	.	.	643820	.	.	CHEMBL452683
DRG00132	4-(2-Benzothiazolylamino)-4-oxobutanoic acid (BenzoTZ-C2)	.	.	"N-Benzothiazol-2-yl-succinamic acid; 79888-43-0; 4-(benzo[d]thiazol-2-ylamino)-4-oxobutanoic acid; 4-(1,3-benzothiazol-2-ylamino)-4-oxobutanoic acid; MLS000523241; 3-[(1,3-benzothiazol-2-yl)carbamoyl]propanoic acid; Oprea1_280998; Oprea1_610028; CHEMBL1603481; HMS1676F03; HMS2423E24; KUC106867N; KSC-09-229B; CCG-15747; STK028230; STL115123; AKOS000595948; AKOS005380166; SMR000123219; CS-0345873; SR-01000407571; SR-01000407571-1; F0769-0063; Z223847326; 4-[(2E)-1,3-benzothiazol-2(3H)-ylideneamino]-4-oxobutanoic acid; 3-{[(2E)-3H-1,3-BENZOTHIAZOL-2-YLIDENE]CARBAMOYL}PROPANOIC ACID"	.	.	.	680766	.	.	.
DRG00133	B-carboline alkaloid	B-carboline alkaloid	.	CHEMBL1770949	.	.	.	745794	.	.	.
DRG00134	"3-(4-piperidyl)-6-fluoro-1,2-benzisoxazole"	.	.	"84163-77-9; 6-fluoro-3-(4-piperidinyl)-1,2-benzisoxazole; 4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidine; 6-fluoro-3-(piperidin-4-yl)benzo[d]isoxazole; 6-Fluoro-3-piperidin-4-yl-benzo[d]isoxazole; 1,2-benzisoxazole, 6-fluoro-3-(4-piperidinyl)-; 6-fluoro-3-piperidin-4-yl-1,2-benzoxazole; 6-FLUORO-3-(PIPERIDIN-4-YL)-1,2-BENZISOXAZOLE; 6-fluoro-3-(piperidin-4-yl)-1,2-benzoxazole; R-56109; 3-(4-Piperidinyl)-6-fluorobenzo(d)isoxazole; 4-(6-Fluorobenzo(d)isoxazol-3-yl)piperidine; 3911L280X6; 6-Fluoro-3-(4-piperidinyl)-12-benzisoxazole; 3-(4-PIPERIDINYL)-6-FLUOROBENZO[D]ISOXAZOLE; 4-(6-FLUOROBENZO[D]ISOXAZOL-3-YL)PIPERIDINE; Risperidone impurity M [EP]; UNII-3911L280X6; 4-(6-fluoro-1,2-benzisoxazol-3-yl)-piperidine; 3-(4-piperidinyl)-6-fluoro-1,2-benzisoxazole; 6-FLUORO-3-(4-PIPERIDINYL)BENZISOXAZOLE; SCHEMBL461287; CHEMBL1668844; DTXSID50233083; BBL010824; MFCD03236724; STK629028; AKOS000301982; AB13829; AC-3455; GF-0135; 3-(4-piperidinyl)-6-fluorobenzisoxazole; 6-fluoro-3-(4-piperidinyl)-benzisoxazol; 4-(6-fluorobenzisoxazol-3-yl)-piperidine; DB-007159; 4-(6-fluoro-1,2-benzisoxazolyl)-piperidine; 6-fluoro-(4-piperidinyl)-1,2 benzisoxazole; 6-fluoro-(4-piperidinyl)-1,2-benzisoxazole; 6-Fluoro-3-piperid-4-yl-1,2-benzisoxazole; CS-0119629; F0735; FT-0656102; NS00116252; RISPERIDONE IMPURITY M [EP IMPURITY]; 3-(4-piperidyl)-6-fluoro-1,2-benzisoxazole; 3-(4piperidinyl)-6-fluoro-1,2-benzisoxazole; 4-(6-fluoro-1,2-benzisoxaz-3-yl)piperidine; 4-(6-fluoro-1,2-benzisoxazol-3yl)piperidine; 4-(6fluoro-1,2-benzisoxazol-3-yl)piperidine; 6-fluoro-3(4-piperidinyl)-1,2 benzisoxazole; 6-fluoro-3(4-piperidinyl)-1,2-benzisoxazole; 6-fluoro-3-(4-piperidinyl)-1,2benzisoxazole; 6-fluoro-3-(4-piperidinyl)1,2 benzisoxazole; 6-fluoro-3-(4-piperidinyl)1,2-benzisoxazole; 6-fluoro-3-(4-piperidyl)-1,2-benzisoxazole; 6-fluoro-3-(4piperidinyl)-1,2-benzisoxazole; 6-fluoro-3-piperidine-4-yl-benzo[d]isoxazole; 6-fluoro3-(4-piperidinyl)-1,2-benzisoxazole; 6fluoro-3-(4-piperidinyl)-1,2-benzisoxazole; 6-fluor-3-(4-piperidinyl)-1,2-benzisoxazole; 6-fluoro-3-(4-piperdinyl)-1,2-benzisoxazole; 6-fluoro-3-(4-piperidinyl)-1, 2benzisoxazole; 6-fluoro-3-(4-piperidinyl)-1,2 benzisoxazole; 6-fluoro-3-(4-piperidinyl)-1,2-benzisoxazol; 6-Fluoro-3-(4-piperidinyl)benzisoxazole, 95%; 6-fluoro-3-piperidine-4-yl-1,2-benzisoxazole; EN300-208580; 4-(6- fluoro-1,2-benzisoxazol-3-yl)piperidine; 4-(6-fluoro-1,2- benzisoxazol-3-yl)piperidine; 4-(6-fluoro-1,2-benzisoxazol-3-yl) piperidine; 4-(6-fluoro-1.2-benzisoxazol-3-yl) piperidine; 4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidine; 6 -fluoro-3-(4-piperidinyl)-1,2-benzisoxazole; 6-fluoro-3-(-4-piperidinyl)-1,2-benzisoxazole; 6-fluoro-3-(4-piperidinyl) -1,2-benzisoxazole; 6-fluoro-3-(4-piperidinyl)- 1,2-benzisoxazole; 6-fluoro-3-(4-piperidinyl)-1,2 -benzisoxazole; 6-fluoro-3-(4-piperidinyl)-1,2- benzisoxazole; 6-fluoro-3-(4-piperidinyl)-1,2-benzoisoxazole; J-518714; 6-Fluoro-3-(4-piperidinyl)benzisoxazole, AldrichCPR; 6-fluoro-3-(tetrahydropyridine-4-yl)benzo[b]isoxazole; Q27256839; 4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidine 84163-13-3"	.	.	.	849421	.	.	.
DRG00135	"1-(2,3-Dichlorophenyl)piperazine"	"1-(2,3-Dichlorophenyl)piperazine"	.	"1-(2,3-dichlorophenyl)piperazine; 41202-77-1; DCPP; 2,3-Dichlorophenylpiperazine; Piperazine, 1-(2,3-dichlorophenyl)-; 1-(2,3-Dichlorophenyl)-piperazine; N-(2,3-Dichlorophenyl)piperazine; 4-(2,3-dichlorophenyl)piperazine; (2,3-Dichlorophenyl)piperazine; CHEMBL1424807; 891W3EV0B1; MFCD01075181; UNII-891W3EV0B1; MLS000550163; 1-(2,3-dichlorophenyl) piperazine; EC 609-896-3; SCHEMBL8511; 2,3 dichlorophenyl piperazine; 2,3-Dichlorophenyl piperazine; DTXSID90961499; UDQMXYJSNNCRAS-UHFFFAOYSA-N; HMS2415O17; AC-328; BDBM50394930; 1-(2,3-dichloro-phenyl)-piperazine; 1-(2,3-Dichloro Phenyl)-Piperazine; AKOS009158229; GF-0124; PD047502; SMR000115758; SY005285; 1-(2 pound not3-Dichlorophenyl)piperazine; DB-025250; A6839; AM20090770; ARIPIPRAZOLE IMPURITY B [EP IMPURITY]; FT-0605474; NS00002643; EN300-1966560; AQ-360/42118436; Q4596761"	.	.	.	851833	.	.	CHEMBL1424807
DRG00136	4-[(3-Methyl-4-oxo-2-thioxo-5-thiazolidinylidene)methyl]benzaldehyde	.	.	DLDRJVRRHBGGBZ-UHFFFAOYSA-N; 4-(3-methyl-4-oxo-2-thioxothiazolidin-5-ylidenmethyl)benzaldehyde; 4-(3-methyl-4-oxo-2-thioxo-thiazolidin-5-ylidenemethyl)-benzaldehyde	.	.	.	1200985	.	.	.
DRG00137	"Benzaldehyde, 4-[[4-oxo-3-(phenylmethyl)-2-thioxo-5-thiazolidinylidene]methyl]"	.	.	CBMicro_009457	.	.	.	1201093	.	.	.
DRG00138	"(5Z)-5-[(3,4-Dimethoxyphenyl)methylene]-2-thioxo-4-thiazolidinone"	.	.	"948016-52-2; (5Z)-5-[(3,4-DIMETHOXYPHENYL)METHYLIDENE]-2-SULFANYLIDENE-1,3-THIAZOLIDIN-4-ONE; (5Z)-5-(3,4-dimethoxybenzylidene)-2-sulfanyl-1,3-thiazol-4(5H)-one; 5-((3,4-DIMETHOXYPHENYL)METHYLENE)-2-THIOXO-1,3-THIAZOLIDIN-4-ONE; CHEMBL255130; 6326-74-5; (Z)-5-(3,4-Dimethoxybenzylidene)-2-thioxothiazolidin-4-one; (5Z)-5-(3,4-dimethoxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one; NSC31101; SCHEMBL8171882; 5-(3,4-dimethoxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one; BBL015198; BDBM50372898; MFCD00088016; NSC-31101; STK031674; STK224851; AKOS001112965; AKOS003313100; UPCMLD0ENAT5387301:001; MS-10957; CS-0335945; FT-0679487; AG-690/32526046; SR-01000106919; SR-01000106919-1; (5Z)-5-(3,4-dimethoxybenzylidene)-2-mercapto-1,3-thiazol-4(5H)-one; 5-[(Z)-1-(3,4-dimethoxyphenyl)methylidene]-2-thioxo-1,3-thiazolan-4-one"	.	.	.	1204288	.	.	.
DRG00139	4-[(Z)-[4-Oxo-3-(phenylmethyl)-2-thioxo-5-thiazolidinylidene]methyl]benzoic acid	.	.	.	.	.	.	1214179	.	.	.
DRG00140	"Benzaldehyde, 4-[(4-oxo-3-phenyl-2-thioxo-5-thiazolidinylidene)methyl]"	.	.	.	.	.	.	1224736	.	.	.
DRG00141	Beta-carboline derivative	Beta-carboline derivative	.	"66863-43-2; Boc-L-1,2,3,4-Tetrahydronorharman-3-carboxylic acid; Boc-L-Tpi-OH; (S)-2-(tert-butoxycarbonyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid; (S)-2-Boc-1,2,3,4-tetrahydronorharmane-3-carboxylic acid; Boc-L-1,2,3,4-tetrahydro-norharman-3-carboxylic acid; (3S)-2-[(2-methylpropan-2-yl)oxycarbonyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole-3-carboxylic acid; MFCD00800580; FHEPEWKHTOVVAT-AWEZNQCLSA-N; SCHEMBL5880416; CHEMBL2032051; AKOS015948717; N-alpha-tert-Butyloxycarbonyl-1,2,3,4-tetrahydronorharman-L-3-carboxylic acid; AC-5891; CS-W012030; (3S)-2-(tert-butoxycarbonyl)-1H,3H,4H,9H-pyrido[3,4-b]indole-3-carboxylic acid; PS-12017; FT-0659177; A50152; EN300-1071066; N-; A-Boc-L-1,2,3,4-tetrahydronorharmane-3-carboxylic acid; Boc-L-1,2,3,4-tetrahydronorharman-3-carboxylic acid, AldrichCPR; (3S)-2-[(tert-butoxy)carbonyl]-1H,2H,3H,4H,9H-pyrido[3,4-b]indole-3-carboxylic acid; (S)-2-(tert-butoxycarbonyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylicacid; Boc-Tpi-OH;Boc-L-1,2,3,4-Tetrahydro--carboline-3-carboxylic acid;Boc-L-tryptoline-3-carboxylic acid;Boc-L-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole-3-carboxylic acid"	.	.	.	1268155	.	.	.
DRG00142	3-[(Z)-(4-Oxo-2-thioxo-5-thiazolidinylidene)methyl]benzoic acid	.	.	.	.	.	.	1311443	.	.	.
DRG00143	"Benzoic acid, 4-[(Z)-[4-oxo-3-(2-propen-1-yl)-2-thioxo-5-thiazolidinylidene]methyl]"	.	.	NSC409001; 29947-13-5; DTXSID00364316; AKOS000287984; NSC-409001	.	.	.	1549798	.	.	.
DRG00144	"Benzaldehyde, 4-[(Z)-(3-ethyl-4-oxo-2-thioxo-5-thiazolidinylidene)methyl]"	.	.	"4-{[(5Z)-3-ETHYL-4-OXO-2-SULFANYLIDENE-1,3-THIAZOLIDIN-5-YLIDENE]METHYL}BENZALDEHYDE; NSC80709; NSC-80709; AKOS001613043; SR-01000079280; SR-01000079280-1"	.	.	.	1550295	.	.	.
DRG00145	Vitamin E (alpha-tocopherol)	Vitamin E (alpha-tocopherol)	.	"(-)-alpha-tocopherol; 77171-97-2; (2S)-2,5,7,8-tetramethyl-2-[(4S,8S)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-ol; 1411583-24-8; (2S)-2,5,7,8-tetramethyl-2-[(4S,8S)-4,8,12-trimethyltridecyl]-3,4-dihydro-2H-chromen-6-ol; (s)-2,5,7,8-tetramethyl-2-((4s,8s)-4,8,12-trimethyltridecyl)chroman-6-ol; (2S,4'S,8'S)-alpha-Tocopherol; Prestwick0_000404; Prestwick1_000404; Prestwick2_000404; SPBio_002267; 2,5,7,8-Tetramethyl-2-(4,8,12-trimethyltridecyl)-6-chromanol; SCHEMBL13055549; CHEBI:46430; DTXSID60873171; HMS1569A10; '(2S, 4'S, 8'S)-alpha-Tocopherol'; Q27120650; (2S, 4 inverted exclamation mark S, 8 inverted exclamation mark S)-; A-Tocopherol; (2S)-3,4-Dihydro-2,5,7,8-tetramethyl-2-[(4S,8S)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-ol; L-a-Tocopherol"	.	.	.	1742129	.	.	.
DRG00146	"Benzoic acid, 4-[(Z)-[4-oxo-3-(phenylmethyl)-2-thioxo-5-thiazolidinylidene]methyl]"	.	.	"4-[(3-benzyl-4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene)methyl]benzoic acid; AM-900/12563007; AKOS000287954; 4-[(Z)-(3-benzyl-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]benzoic acid"	.	.	.	1778934	.	.	.
DRG00147	"4-[(Z)-(3-Ethyl-2,4-dioxo-5-thiazolidinylidene)methyl]benzoic acid"	.	.	AKOS002202866	.	.	.	2189310	.	.	.
DRG00148	"Benzoic acid, 4-[(Z)-[3-(4-methylphenyl)-4-oxo-2-thioxo-5-thiazolidinylidene]methyl]"	.	.	SCHEMBL12637129	.	.	.	2296893	.	.	.
DRG00149	Quinine	Quinine	.	"Quinine; 130-95-0; Chinin; Chinine; (-)-Quinine; 6'-Methoxycinchonidine; (8S,9R)-Quinine; Quinine anhydrous; (R)-(-)-quinine; chininum; quinina; Qualaquin; Quinine, Anhydrous; 6-Methoxycinchonine; Rezquin; Chininum purum; quinine bisulphate; Cinchonan-9-ol, 6'-methoxy-, (8alpha,9R)-; (8S,9R)-6'-Methoxycinchonan-9-ol; quinine sulfate; CHEBI:15854; (8-alpha,9R)-6'-Methoxycinchonan-9-ol; UNII-A7V27PHC7A; A7V27PHC7A; Aflukin; NSC 192949; CCRIS 5755; Coco-Quinine; (R)-(-)-Quinine, 6-methoxycinchonidine; DTXSID0044280; HSDB 2501; Quinoline alkaloid; EINECS 205-003-2; MFCD00198096; NSC-192949; Quinine sulphate; (R)-(6-methoxyquinolin-4-yl)((2S,4S,8R)-8-vinylquinuclidin-2-yl)methanol; WR297608; (9R)-6'-methoxy-8alpha-cinchonan-9-ol; (R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl](6-methoxyquinolin-4-yl)methanol; Cinchonan-9-ol, 6'-methoxy-; 6'-Methoxycinchonan-9-ol; DTXCID60819897; EC 205-003-2; GNF-Pf-506; NSC192949; (R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol; 2-Quinuclidinemethanol, alpha-(6-methoxy-4-quinolyl)-5-vinyl-; NSC 5362; QUININE (MART.); QUININE [MART.]; Quinine, tannate; (R)-(6-Methoxyquinolin-4-yl)((1S,2S,4S,5R)-5-vinylquinuclidin-2-yl)methanol; Chinin [German]; Cinchonan-9-ol, 6'-methoxy-, (8-alpha,9R)-; 72402-53-0; Quinineanhydrous; Kinder Quinina; (R)-[(2S,4S,5R)-1-Aza-5-vinylbicyclo[2.2.2]-oct-2-yl](6-methoxyquinolin-4-yl)methanol; CAS-130-95-0; 6'-Methoxycinchonine; NSC667852; Quinine [BAN:NF]; CHEMBL170; Quinine tannate [USP]; Cinchonan-9-ol, 6'-methoxy-, (8.alpha.,9R)-; UNII-26MX5YAL2R; Quinsan; Cinchonan-9-ol, 6'-methoxy-, (8a,9R)-; (-)quinine; NCGC00166281-01; QI9; EINECS 215-805-4; NSC5362; Dentojel (*Bisulfate heptathydrate*); Biquinate (*Bisulfate heptathydrate*); Quinine, 90%; Quine (*2:1 Sulfate salt*, dihydrate); QUININE [VANDF]; QUININE [HSDB]; (8.alpha.,9R)-6'-Methoxycinchonan-9-ol; Quinamm (*2:1 Sulfate salt*), dihydrate; Quinsan (*2:1 Sulfate salt*), dihydrate; QUININE [MI]; QUININE [WHO-DD]; Epitope ID:131786; SCHEMBL27031; CHININUM PURUM [HPUS]; GTPL2510; alpha-(6-Methoxy-4-quinoyl)-5-vinyl-2-quinclidinemethanol; Cinchonan-9-ol, 6'-methoxy-, (8.alpha.,9R)-, sulfate; HMS2089E05; STR03990; Tox21_112389; BDBM50367247; s4495; AKOS017343662; Tox21_112389_1; DB00468; NCGC00166281-06; NCGC00274071-01; FT-0656845; NS00002397; (3alpha,8alpha,9R)-6'-methoxycinchonan-9-ol; EN300-258513; O12066; AB00375052-11; AB00375052-12; AB00375052_13; Q189522; Quinine, certified reference material, TraceCERT(R); BRD-K07940445-003-01-2; Q27166273; Z2235811384; (R)-(6-methoxy-4-quinolyl)-[(2S,4S,5R)-5-vinylquinuclidin-2-yl]methanol; (R)-(6-methoxyquinolin-4-yl)((2S,4S,5R)-5-vinylquinuclidin-2-yl)methanol; (1R)-(6-methoxyquinolin-4-yl)((2S,4S,5R)-5-vinylquinuclidin-2-yl)methanol; (5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl)-(6-methoxy-4-quinolinyl)methanol; (R)-[(2S,4S,5R)-1-Aza-5-vinylbicyclo[2.2.2]oct-2-yl](6-methoxyquinolin-4-yl)methanol; Quinine, suitable for fluorescence, anhydrous, >=98.0% (dried material, NT); (R)-[(1S,2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl](6-methoxyquinolin-4-yl)methanol; (R)-[(4S,5R,7S)-5-ethenyl-1-azabicyclo[2.2.2]octan-7-yl]-(6-methoxyquinolin-4-yl)methanol"	.	.	.	3034034	D03DDR	DB00468	CHEMBL170
DRG00150	"Pplatinum-(SP-4-2)-(1,2-Ethanediamine-&kappa;N1,&kappa;N2)[propanedioato(2-)-&kappa;O1,&kappa;O3]"	.	.	"Malpen; JM-40; Ethylenediamine platinum(II) malonate; Ethylenediammineplatinum(II) malonate; 9BT36E343A; Platinum, (1,2-ethanediamine-N,N')(propanedioato(2-)-O,O')-, (SP-4-2)-; (Ethane-1,2-diamine-N,N')[malonato(2-)-O,O']platinum; (Ethane-1,2-diamine-N,N')(malonato(2-)-O,O')platinum; EINECS 255-484-8; NSC 146068; Malopen; Platinum (II), (ethylenediammine)malonato-; Platinum, (1,2-ethanediamine-kappaN,kappaN')(propanedioato(2-)-kappaO1,kappaO3)-, (SP-4-2)-; UNII-9BT36E343A; JM 40; MALONATOETHYLENEDIAMINEPLATINUM(II); ethane-1,2-diamine;platinum(2+);propanedioate; Q27895836; (SP-4-2)-(1,2-ETHANEDIAMINE-.KAPPA.N1,.KAPPA.N2)(PROPANEDIOATO(2-)-.KAPPA.O1,.KAPPA.O3)PLATINUM; PLATINUM, (1,2-ETHANEDIAMINE-.KAPPA.N,.KAPPA.N')(PROPANEDIOATO(2-)-.KAPPA.O1,.KAPPA.O3)-, (SP-4-2)-; PLATINUM, (1,2-ETHANEDIAMINE-.KAPPA.N1,.KAPPA.N2)(PROPANEDIOATO(2-)-.KAPPA.O1,.KAPPA.O3)-, (SP-4-2)-"	.	.	.	3035205	.	.	.
DRG00151	N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxy-Benzenesulfonamide	.	.	"ABT-751; 141430-65-1; ABT751; ABT 751; E-7010; ABT-751 (E7010); E 7010; E7010; 857447-92-8; WDT5V5OB9F; NSC-742134; N-[2-(4-hydroxyanilino)pyridin-3-yl]-4-methoxybenzenesulfonamide; n-(2-((4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide; N-{2-[(4-hydroxyphenyl)amino]pyridin-3-yl}-4-methoxybenzenesulfonamide; CHEMBL20684; N-[2-[(4-HYDROXYPHENYL)AMINO]-3-PYRIDYL]-4-METHOXYBENZENESULFONAMIDE; N-(2-(4-hydroxyphenylamino)pyridin-3-yl)-4-methoxybenzenesulfonamide; N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide; N-(2-((4-Hydroxyphenyl)amino)-3-pyridinyl)-4-methoxybenzenesulfonamide; Benzenesulfonamide, N-(2-((4-hydroxyphenyl)amino)-3-pyridinyl)-4-methoxy-; UNII-WDT5V5OB9F; N-[2-[(4-Hydroxyphenyl)amino]pyridin-3-yl]-4-methoxybenzenesulfonamide; MLS006011263; SCHEMBL111645; CHEBI:95043; DTXSID60869913; EX-A517; URCVCIZFVQDVPM-UHFFFAOYSA-N; BCPP000447; E 7010 [WHO-DD]; GLXC-04546; HMS3654C14; HMS3672M11; BCP02079; BDBM50101086; MFCD00910291; NSC742134; s1165; AKOS024457996; BCP9000219; CCG-264843; CS-0495; DB12254; E7010(ABT-751); NSC 742134; SB19450; ABT-751(E 7010); NCGC00346494-01; NCGC00346494-03; NCGC00346494-06; AC-32852; AS-55908; HY-13270; SMR004703014; DB-063374; FT-0700194; NS00068344; SW219685-1; J-007498; J-523312; BRD-K91623615-001-01-9; Q27166810; N-[2-(4-Hydroxy-phenylamino)-pyridin-3-yl]-4-methoxy-benzenesulfonamide; Benzenesulfonamide, N-?[2-?[(4-?hydroxyphenyl)?amino]?-?3-?pyridinyl]?-?4-?methoxy-; E70"	TAR10054	Tubulin beta (TUBB)	.	3035714	D09EHO	.	.
DRG00152	Coumarine derivative	Coumarine derivative	.	"67268-42-2; 7-(prop-2-yn-1-yloxy)-2H-chromen-2-one; 2H-1-Benzopyran-2-one, 7-(2-propynyloxy)-; 7-(Propargyloxy)coumarin; 7-Propargyloxy-cumarin; 7-Propargyloxy-cumarin [German]; 7-(2-Propynyloxy)-2H-1-benzopyran-2-one; 7-propargyloxycoumarin; 7-Propargyloxy-coumarin; CHEMBL308819; SCHEMBL8512573; DTXSID70217603; IEHFVZKMAOKFTR-UHFFFAOYSA-N; 7-(Prop-2-ynyloxy)-2H-chromen-2-one; 7-(prop-2-in-1-yloxy)-1-benzopyran-2-one"	.	.	.	3051101	.	.	CHEMBL308819
DRG00153	Acridone-4-carboxylic acid (4-carboxyacridone) derivative	.	.	"24782-64-7; 4-Carboxy-9-acridanone; 9-oxo-9,10-dihydroacridine-4-carboxylic acid; 9-oxo-10H-acridine-4-carboxylic Acid; acridone-4-carboxylic acid; 4-Acridinecarboxylic acid, 9,10-dihydro-9-oxo-; CHEMBL541514; MFCD00957937; 9,10-dihydro-9-oxoacridine-4-carboxylic acid; 4-Carboxy-9-acridanone (Technical Grade); 4-carboxyacridone; 4-carboxyacridanone; 9,10-Dihydro-9-oxo-4-acridinecarboxylic Acid; 4-Carboxyacridone; 9(10H)-Acridone-4-carboxylic Acid; Acridone-4-carboxylic Acid; 9-oxo-4-acridancarboxylic Acid;; 9-Oxo-9,10-Dihydro-4-Acridinecarboxylic Acid; SCHEMBL4943278; SCHEMBL21119051; DTXSID00393641; BATAOFZEDHPRTM-UHFFFAOYSA-N; BDBM50591347; 4-CARBOXY-9-ACRIDANONE 96; AKOS002664589; AS-67219; HY-34887; DB-229750; CS-0029726; NS00007336; 9-oxo-9,10-dihydroacridine-4-carboxylicacid; 9,10-dihydro-9-oxo-4-acridinecarboxylic acid; EN300-183303; A924853; J-015672; Z1873903872; 4-Carboxyacridone; 9(10H)-Acridone-4-carboxylic acid; Acridone-4-carboxylic acid"	.	.	.	3560758	.	.	.
DRG00154	6-Heptynoic acid	6-Heptynoic acid	.	"6-Heptynoic acid; 30964-00-2; hept-6-ynoic acid; MFCD00239430; 6-HeptynoicAcid; 6-heptynoic acid; 6-Heptynoic acid, 90%; SCHEMBL9407; LCWG004; OFCPMJGTZUVUSM-UHFFFAOYSA-; DTXSID40402600; CHEBI:184202; GEO-02852; LMFA01030490; AKOS006221475; GS-3709; BP-29683; SY021705; CS-0020150; FT-0602090; EN300-125161; A820669; J-018204; InChI=1/C7H10O2/c1-2-3-4-5-6-7(8)9/h1H,3-6H2,(H,8,9)"	.	.	.	4377950	.	.	.
DRG00155	"Benzaldehyde, 4-[(3-cyclopentyl-4-oxo-2-thioxo-5-thiazolidinylidene)methyl]"	.	.	.	.	.	.	4763205	.	.	.
DRG00156	"Benzaldehyde, 4-[(3-cyclohexyl-4-oxo-2-thioxo-5-thiazolidinylidene)methyl]"	.	.	.	.	.	.	4763206	.	.	.
DRG00157	"Benzaldehyde, 4-[[3-(4-chlorophenyl)-4-oxo-2-thioxo-5-thiazolidinylidene]methyl]"	.	.	.	.	.	.	4763255	.	.	.
DRG00158	"Coumarone derivative TB5, antitubercular drug"	.	.	Q27187200; 6-hydroxy-7-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]-2-[3-(2-methoxyphenyl)prop-2-enylidene]-3-benzofuranone	.	.	.	4894166	.	.	.
DRG00159	"4-[(Z)-(2,4-Dioxo-5-thiazolidinylidene)methyl]benzoic acid"	.	.	"4-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]benzoic Acid; 5-(4-carboxybenzylidene)thiazolidine-2,4-dione; 4-{[(5E)-2,4-DIOXO-1,3-THIAZOLIDIN-5-YLIDENE]METHYL}BENZOIC ACID; LXRKDEAFRQCTBN-UHFFFAOYSA-N; AKOS030744658; PD121308; 4-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-benzoic acid"	.	.	.	5003267	.	.	.
DRG00160	Vitamin D3 (calcitriol)	Vitamin D3 (calcitriol)	.	"Vitamin D3; cholecalciferol; 67-97-0; Colecalciferol; Calciol; Ricketon; Oleovitamin D3; Deparal; Arachitol; Delsterol; Trivitan; Ebivit; Vigantol; Vigorsan; vitamin d-3; Colecalcipherol; Colecalciferolum; Cholecalciferolum; D3-Vicotrat; D3-Vigantol; Vi-de-3-hydrosol; NEO Dohyfral D3; Provitina; Quintox; Rampage; 1406-16-2; Vitinc Dan-Dee-3; (+)-Vitamin D3; Cholecalciferol, D3; Colecalciferolo; Vi-De3; Duphafral D3 1000; Delta-D; Colecalciferol D3; Irradiated 7-dehydrocholesterol; CCRIS 6286; HSDB 820; Videkhol; 7-Dehydrocholesterol, irradiated; FeraCol; CHEBI:28940; Granuvit D3; CC; EINECS 200-673-2; Colecalciferolum [INN-Latin]; EPA Pesticide Chemical Code 202901; NSC 375571; NSC-375571; UNII-1C6V77QF41; VIGANTOLETTEN; Colecalciferol [INN]; 1C6V77QF41; (3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol; MFCD00078131; (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol; Vitamin d (cholecalciferol); 9,10-Secocholesta-5,7,10(19)-trien-3-beta-ol; AK R215 COMPONENT COLECALCIFEROL; AK-R215 COMPONENT COLECALCIFEROL; 9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3-ol; Micro-dee; DTXSID6026294; Vitamin d3 (as cholecalciferol); (5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-trien-3-ol; 9,10-Secocholesta-5,7,10(19)-trien-3-ol, (3beta,5Z,7E)-; Vitamin d assay system suitability; VidDe-3-hydrosol; Cholecalciferol [USP:BAN:JAN:ISO]; NSC375571; Colecalciferol (INN); (3S,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol; Vitamin D3 10 microg/mL in Acetonitrile; (5Z,7E)-(3S)-9,10-seco-5,7,10(19)-cholestatrien-3-ol; 9,10-Secocholestra-5,7,10(19)-trien-3-ol, (3beta,5Z,7E)-; 9,10-Secocholesta-5,7,10(19)-trien-3-ol; Colecalciferolum (INN-Latin); COLECALCIFEROL (MART.); COLECALCIFEROL [MART.]; CHOLECALCIFEROL (USP-RS); CHOLECALCIFEROL [USP-RS]; 9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3beta-ol; Colecalciferolo [DCIT]; 9,10-Secocholesta-5(Z),7(E),10(19)-trien-3(.beta.)-ol; 9,10-Secocholesta-5,7,10(19)-trien-3-ol, (3b,5Z,7E)-; 9,10-Secocholesta-5,7,10(19)-trien-3-ol, (3.beta.,5Z,7E)-; CHOLECALCIFEROL (EP MONOGRAPH); Cholecalciferol (USP:BAN:JAN:ISO); CHOLECALCIFEROL [EP MONOGRAPH]; CHOLECALCIFEROL (USP MONOGRAPH); CHOLECALCIFEROL [USP MONOGRAPH]; (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(1R)-1,5-dimethylhexyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylene-cyclohexanol; (S,Z)-3-(2-((1R,3aS,7aR,E)-7a-methyl-1-((R)-6-methylheptan-2-yl)octahydro-4H-inden-4-ylidene)ethylidene)-4-methylenecyclohexan-1-ol; Cyclohexanol, 3-[(2E)-2-[(1R,3aS,7aR)-1-[(1R)-1,5-dimethylhexyl]octahydro-7a-methyl-4H-inden-4-ylidene]ethylidene]-4-methylene-, (1S,3Z)-; Vitamin D 3; CCRIS 5813; Vitamin D3 emulsifiable; EINECS 215-797-2; DTXCID306294; UNII-9VU1KI44GP; Vitamin D3; Cholecalciferol; Devaron; Vitamin D3 (Cholecalciferol); (3.beta.,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol; vitaminum d3; DP-R206; Osteo-Vit3; Prestwick_63; Cholecalciferol D3; NCGC00159331-02; Cyclohexanol, 3-((2E)-2-((1R,3aS,7aR)-1-((1R)-1,5-dimethylhexyl)octahydro-7a-methyl-4H-inden-4-ylidene)ethylidene)-4-methylene-, (1S,3Z)-; 9,10-secocholesta-5,7,10-trien-3-ol; Novel-D3; DECALCITROL; ()-Vitamin D3; Cholecalciferol (D3); Delta-D (TN); VITA-DESIC; CHOLECALCIFEROL IMPURITY A (EP IMPURITY); Prestwick3_000429; bmse000507; UPCMLD-DP152; VITAMIN D3 [MI]; VITAMIN D3 [FCC]; SCHEMBL3126; 9VU1KI44GP; CHEMBL1042; BSPBio_000418; CHOLECALCIFEROL [ISO]; CHOLECALCIFEROL [JAN]; 9,10-Secocholesta-5,7,10(19)-trien-3beta-ol; Cholecalciferol; 67-97-0; Cholecalciferol (JP17/USP); CHOLECALCIFEROL [HSDB]; CHOLECALCIFEROL [VANDF]; BPBio1_000460; MEGxm0_000458; COLECALCIFEROL [WHO-DD]; COLECALCIFEROL [WHO-IP]; UPCMLD-DP152:001; ACon1_001997; A11CC05; COLECALCIFEROL [EMA EPAR]; HMS2096E20; Cholecalciferol, >=98% (HPLC); (1S,3Z)-3-((2E)-2-((1R,3AR,7AS)-7A-METHYL-1-((2R)-6-METHYLHEPTAN-2-YL)-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE)ETHYLIDENE)-4-METHYLIDENE-CYCLOHEXAN-1-OL; (1S,3Z)-3-[(2E)-2-[(1R,3AR,7AS)-7A-METHYL-1-[(2R)-6-METHYLHEPTAN-2-YL]-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLIDENE-CYCLOHEXAN-1-OL; Cholecalciferol, analytical standard; GROWTH SUPPORTPATCH, HAUTUKI; BDBM50030475; CHOLECALCIFEROL [ORANGE BOOK]; LMST03020001; s4063; Cholecalciferol for system suitability; 5,7-CHOLESTADIEN-3-BETAL-OL; AKOS015950641; AC-8884; CCG-268466; COLECALCIFEROLUM [WHO-IP LATIN]; CS-1179; DB00169; DP-R206 COMPONENT VITAMIN D3; SMP1_000068; USEPA/OPP Pesticide Code: 202901; NCGC00091072-01; NCGC00159331-04; BS-42465; HY-15398; Cholecalciferol (D3), analytical standard; FT-0623718; NS00008889; C05443; D00188; FOSAMAX PLUS D COMPONENT CHOLECALCIFEROL; Cholecalciferol, meets USP testing specifications; Q139347; (5E,7E)-9,10-Secocholesta-5,7,10-trien-3-ol; Q-201931; VITAMIN D ASSAY SYSTEM SUITABILITY [USP-RS]; 3-beta,Z,7E-9,10-Secocholestr-5,7,10(19)-trien-3-ol; (3beta,Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol; Cholecalciferol, European Pharmacopoeia (EP) Reference Standard; Colecalciferol, British Pharmacopoeia (BP) Reference Standard; (5E,7E)-9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3beta-OL; Cholecalciferol, United States Pharmacopeia (USP) Reference Standard; Cholecalciferol for system suitability, European Pharmacopoeia (EP) Reference Standard; (1S,3Z)-3-[(2E)-2-[7a-Methyl-1-(6-methylheptan-2-yl)-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol; Cholecalciferol (Vitamin D3), Pharmaceutical Secondary Standard; Certified Reference Material"	TAR10040	Vitamin D3 receptor (VDR)	P11473	5280795	D0F8JR	DB00136	CHEMBL1042
DRG00161	Geranylgeraniol	Geranylgeraniol	.	"Geranylgeraniol; 24034-73-9; Tetraprenol; Geranyl geraniol; (2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-ol; (E,E,E)-Geranylgeraniol; trans-Geranylgeraniol; 7614-21-3; (E,E,E)-Geranylgeranyl alcohol; Geranylgeranyl alcohol; All-trans-Geranylgeraniol; Geranylgeraniol (Natural); AIA02AJA3A; Geranylgeraniol (Synthetic); 2,6,10,14-Hexadecatetraen-1-ol, 3,7,11,15-tetramethyl-; CHEBI:46762; trans,trans,trans-Geranylgeraniol; MFCD00129083; all trans-3,7,11-15-Tetramethyl-2,6,10,14-hexadecatetraen-1-ol; Geranylgeraniol (Natural) ~85%; 3,7,11,15-tetramethylhexadeca-2E,6E,10E,14-tetraen-1-ol; (2~{E},6~{E},10~{E})-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-ol; UNII-AIA02AJA3A; Gernaylgeraniol; 2,6,10,14-Hexadecatetraen-1-ol, 3,7,11,15-tetramethyl-, (2E,6E,10E)-; Spectrum5_002040; SCHEMBL127330; SPECTRUM1505009; CHEMBL478589; CHEBI:24229; Geranylgeraniol, >=85% (GC); DTXSID001345665; BCP25724; 2,6,10,14-Hexadecatetraen-1-ol, 3,7,11,15-tetramethyl-, (E,E,E)-; AKOS028109426; CS-W012190; HY-W011474; LMPR0104010009; NCGC00096069-01; NCGC00096069-02; CS-17354; FT-0626663; C09094; P16964; A900978; J-015322; Q3123708; BRD-K95402279-001-02-9; (E,E,E)-3,7,11,15 tetramethyl-2,6,10,14-hexadecatetraen-1-ol; (2e,6e,10e)-3,7,11,15-tetramethyl hexadeca-2,6,10,14-tetraen-1-ol; 2,6,10,14-Hexadecatetraen-1-ol, 3,7,11,15-tetramethyl-, (2E,6E,10E)- (9CI); 2,6,10,14-Hexadecatetraen-1-ol, 3,7,11,15-tetramethyl-, (E,E,E)- (8CI); 3,7,11,15-TETRAMETHYL-2E,6E,10E,14E-2,6,10,14-HEXADECATETRAEN-1-OL; ELX"	.	.	.	5281365	.	.	.
DRG00162	Curcumin	Curcumin	.	"(1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one; BSPBio_003590; MLS002473126; SCHEMBL242412; SCHEMBL23884897; (1z,4z,6e)-5-Hydroxy-1,7-Bis(4-Hydroxy-3-Methoxyphenyl)hepta-1,4,6-Trien-3-One; REGID_for_CID_5281767; ZIUSSTSXXLLKKK-KOBPDPAPSA-N; BDBM191758; HMS3884M12; US9187397, 1 (curcumin); 147556-16-9; AC3841; CCG-38787; s1848; STL453143; AKOS016350684; SDCCGMLS-0066836.P001; US9187397, 3a; NCGC00095321-01; NCGC00095321-02; NCGC00095321-03; CI-75300; SMR001397223; AB00052986_07; (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; (1E,6E)-1,7-Bis(3-methoxy-4-hydroxyphenyl)-5-hydroxy-1,4,6-heptatriene-3-one; CC9; InChI=1/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-13,22,24-25H,1-2H3/b7-3+,8-4+,16-13"	TAR10029	Tissue transglutaminase (TG2)	P21980	5281767	D0IQ8I	DB11672	CHEMBL116438
DRG00163	Natamycin	Natamycin	.	"NATAMYCIN; pimaricin; Tennecetin; Delvocid; Mycophyt; Synogil; Myprozine; 7681-93-8; Pimafucin; Pimaracin; Natacyn; Antibiotic A-5283; Natamycinum; Delvolan; Natamicina; Natamycine; CL 12,625; 8O0C852CPO; INS NO.235; DTXSID6021163; INS-235; NSC-759167; Pimaricine; CL 12625; CL-12625; Delvopos; Natafucin; DTXCID301163; E-235; Natamycin(Pimaricin); MFCD00135085; Antibiotic A 5283; E 235; NATAMYCIN (MART.); NATAMYCIN [MART.]; NATAMYCIN (USP-RS); NATAMYCIN [USP-RS]; 16-(3-Amino-3,6-didesoxy-beta-D-mannopyranosyloxy)-5,6-epoxy-8,12,14-trihydroxy-26-methyl-2,10-dioxo-1-oxacyclohexacosa-3,17,19,21,23-pentaen-13-carbonsaeure; myuprozine; NATAMYCIN (USP MONOGRAPH); NATAMYCIN [USP MONOGRAPH]; Pimarizin; 6,11,28-Trioxatricyclo[22.3.1.05,7]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid, 22-[(3-amino-3,6-dideoxy-.beta.-D-mannopyranosyl)oxy]-1,3,26-trihydroxy-12-methyl-10-oxo-, (1R,3S,5R,7R,8E,12R,14E,16E,18E,20E,22R,24S,25R,26S)-; Pimarizin [German]; Natamycine [INN-French]; Natamycinum [INN-Latin]; CHEBI:7488; Natamicina [INN-Spanish]; UNII-8O0C852CPO; Natamatrix; Natajen; Natamax; Natamycin [USAN:USP:INN:BAN]; NCGC00016686-01; (1R,3S,5R,7R,8E,12R,14E,16E,18E,20E,22R,24S,25R,26S)-22-[(3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy]-1,3,26-trihydroxy-12-methyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.0~5,7~]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid; 6,11,28-TRIOXATRICYCLO(22.3.1.05,7)OCTACOSA-8,14,16,18,20-PENTAENE-25-CARBOXYLIC ACID, 22-((3-AMINO-3,6-DIDEOXY-.BETA.-D-MANNOPYRANOSYL)OXY)-1,3,26-TRIHYDROXY-12-METHYL-10-OXO-, (1R,3S,5R,7R,8E,12R,14E,16E,18E,20E,22R,24S,25R,26S)-; CAS-7681-93-8; EINECS 231-683-5; Pimaricin; Natamycin; NATAMYCIN [FCC]; NATAMYCIN [INN]; PIMARICIN [JAN]; NATAMYCIN [MI]; NATAMYCIN [USAN]; NATAMYCIN [VANDF]; NATAMYCIN [WHO-DD]; SCHEMBL18140; NATAMYCIN [ORANGE BOOK]; CHEMBL1200656; NCXMLFZGDNKEPB-FFPOYIOWSA-N; DTXCID501473823; EX-A1989; HY-B0133; PMR; Tox21_110561; BDBM50370755; AKOS030485970; 73 - Natamycin (pimaricin) in cheese; CS-1909; DB00826; NSC 759167; NICOTINAMIDE_ADENINE_DINUCLEOTIDE; Stereoisomer of 22-((3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy)-1,3,26-trihydroxy-12-methyl-10-oxo-6,11,28-trioxatricyclo(22.3.1.0(sup 5,7))octacosa-8,14,16,18,20-pentaene-25-carboxylic acid; NS00003340; Natamycin, VETRANAL(TM), analytical standard; NCGC00373238-02_C33H47NO13_Delvocid; EN300-22411493; Pimaricin preparation, ~2.5%, aqueous suspension; Q248466; Natamycin, United States Pharmacopeia (USP) Reference Standard; Pimaricin, from Streptomyces chattanoogensis, >=95% (HPLC); Natamycin, Pharmaceutical Secondary Standard; Certified Reference Material; (1R*,3S*,5R*,7R*,8E,12R*,14E,16E,18E,20E,22R*,24S*,25R*,26S*)-22-(3-Amino-3,6-dideoxy-beta-D-mannopyranosyloxy)-1,3,26-trihydroxy-12-methyl-10-oxo-6,11,28-trioxatricyclo(22.3.1.05,7)octacosa- 8,14,16,18,20-pentaene-25-carboxylic acid; (1R,3S,5R,7R,8E,12R,14E,16E,18E,20E,22R,24S,25R,26S)-22-((3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy)-1,3,26-trihydroxy-12-methyl-10-oxo-6,11,28-trioxatricyclo(22.3.1.0(5,7))octacosa-8,14,16,18,20-pentaene-25-carboxylic acid; (1R,3S,5R,7R,8E,12R,14E,16E,18E,20E,22R,24S,25R,26S)-22-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-1,3,26-trihydroxy-12-methyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.05,7]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid; (1R,3S,5R,7R,8E,12R,14E,16E,18E,20E,22R,24S,25R,26S)-22-{[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy}-1,3,26-trihydroxy-12-methyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.0,5,7]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid; (5R,7R,24S)-22R-[(3S-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy]-1R,3S,26S-trihydroxy-12R-methyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.05,7]octacosa-8E,14E,16E,18E,20E-pentaene-25R-carboxylic acid"	TAR10033	Fungal Cell membrane (Fung CM)	.	5284447	D02FEM	DB00826	.
DRG00164	Combretastatin A4	Combretastatin A4	.	"Combretastatin A4; 117048-59-6; Combretastatin A-4; Combrestatin A4; (Z)-2-METHOXY-5-(3,4,5-TRIMETHOXYSTYRYL)PHENOL; Combretastatin 4; Combretastatin-A4; CA-4; 2'-deoxycombretastatin A1; NSC-613729; 2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenol; Crc 87-09; CHEMBL67; MFCD03453309; 3,4,5-Trimethoxy-3'-hydroxy-4'-methoxystilbene; NSC-817373; 16U6OP69RQ; Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-; CA4; 2-Methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenol; 2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]phenol; 2-Methoxy-5-[(Z)-2-(3,4,5-trimethoxy-phenyl)-vinyl]-phenol; Phenol, 2-methoxy-5-(2-(3,4,5-trimethoxyphenyl)ethenyl)-, (Z)-; NSC 817373; Crc-98-09; UNII-16U6OP69RQ; combretastin A4; Combrestatin A-4; Combretastin A-4; combretastatin-A-4; Combretastastin A-4; NSC 609397; NSC 613729; 2-methoxy-5-(3,4,5-trimethoxystyryl)phenol; Z-Combretastatin A-4; 2-Methoxy-5-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-phenol; SCHEMBL18945; combretastatin A-4, (CSA4); CA 4; GTPL8854; COMBRETASTATIN A-4 [MI]; CHEBI:181391; DTXSID101025983; GLXC-02861; HMS3650G11; AMY24892; COMBRETASTATIN A4 [WHO-DD]; EX-A4207; HY-N2146; BDBM50005480; s7783; AKOS015950727; AC-5280; CCG-265026; CS-6023; DB14680; DS-5860; Phenol,4,5-trimethoxyphenyl)ethenyl]-; ST-1986; C2520; Combretastatin A4, >=98% (HPLC), powder; FT-0656602; NS00116331; 5-(3,4,5-trimethoxystyryl)-2-methoxyphenol; C20268; 3'-Hydroxy-3,4,4',5-tetramethoxy-cis-stilbene; EN300-1587417; (Z)-5-(3,4,5-trimethoxystyryl)-2-methoxyphenol; SR-01000946784; (Z)-3''-hydroxy-3,4,4'',5-tetramethoxystilbene; Q5150955; SR-01000946784-1; Z2312943638; [3,4,5-trimethoxy-3'-hydroxy-4'-methoxy-(z)-stilbene]; 2-Methoxy-5-[(Z)-2-(3,4,5-trimethox y-phenyl)-vinyl]-phenol; (combretastin A-4)2-Methoxy-5-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-phenol; 5-[(S)-2-Hydroxy-2-(3,4,5-trimethoxy-phenyl)-ethyl]-2-methoxy-phenol; (combretastatin A-4)2-Methoxy-5-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-phenol; 1-(3,4,5-Trimethoxyphenyl)-2-(3'-hydroxy-4'-methoxyphenyl) ethane 3,4,5-trimethoxy-3'-hydroxy-4'-methoxystilbene"	.	.	.	5351344	.	.	CHEMBL67
DRG00165	"Benzaldehyde, 4-[(Z)-(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]"	.	.	"NSC80710; 29947-17-9; 4-[(Z)-(4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]benzaldehyde; SCHEMBL12961168; DTXSID90422055; NSC-80710; AKOS001376590"	.	.	.	6139848	.	.	.
DRG00166	"Benzoic acid, 4-[(Z)-(3-cyclohexyl-4-oxo-2-thioxo-5-thiazolidinylidene)methyl]"	.	.	AKOS000287986	.	.	.	6210572	.	.	.
DRG00167	"Benzoic acid, 4-[(Z)-(3-cyclopentyl-4-oxo-2-thioxo-5-thiazolidinylidene)methyl]"	.	.	.	.	.	.	6229428	.	.	.
DRG00168	Diacetone-D-glucose	Diacetone-D-glucose	.	"582-52-5; Diacetone-D-glucose; Diacetoneglucose; 1,2:5,6-Di-O-isopropylidene-alpha-D-glucofuranose; D-Glucose diacetonide; (3aR,5S,6S,6aR)-5-((R)-2,2-Dimethyl-1,3-dioxolan-4-yl)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-6-ol; Diacetone glucose; Glucose diacetonide; Glucose Bisacetonide; 1,2:5,6-Di-O-isopropylidene-a-D-glucofuranose; R3P8TN410C; 1:2,5:6-Di-O-isopropylidene-alpha-D-glucofuranose; MFCD00005544; (3aR,5S,6S,6aR)-5-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-6-ol; 14686-89-6; (3aR,5S,6S,6aR)-5-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]-2,2-dimethyl-tetrahydro-2H-furo[2,3-d][1,3]dioxol-6-ol; UNII-R3P8TN410C; Diacetonglucose; NSC-1223; MFCD00069693; 1,2,5,6-diisopropylidene-D-glucose; NSC 1223; EINECS 209-486-0; 1,2:5,6-Diisopropylidene-D-glucose; 1,2:5,6-Bis-O-(1-methylethylidene)-a-D-Glucofuranose; 1,2:5,6-di-o-isopropylidene-d-glucofuranose; 1,2:5,6-Di-O-isopropylidene-a-D-gulofuranose; AI3-61543; 1,2-5,6-Di-O-isopropylidene-D-glucofuranose; 1,2:5,6-Diisopropylidene-alpha-D-glucofuranose; DIACETONEGLUCOSE [MI]; 1:2,5:6-Di-O-isopropyliden-alpha-D-glucofuranose; alpha-D-Glucofuranose, 1,2:5,6-bis-O-(1-methylethylidene)-; SCHEMBL350022; 1:2,5:6-Di-O-isopropyliden-alpha-D-glucofuranose [German]; 5-(2,2-DIMETHYL-(1,3)DIOXOLAN-4-YL)-2,2-DIMETHYL-4H-FURO(2,3-D)(1,3)DIOXOL-6-OL; AKOS016843090; AM83975; AT13182; 1,2:5,6-Di-O-isopropylidene-D-glucose; AS-12662; 1,2-5,6-Di-O-Isopropylidene-a-D-gulose; CS-0019953; D1949; FT-0602088; FT-0606273; FT-0606274; FT-0606276; FT-0624589; F10946; EN300-1725795; 1,2:5,6-Di-O-isopropylidene-; A-D-glucofuranose; 1,2:5,6-Diisopropylidene-.alpha.-D-glucofuranose; 1,2,5,6-Di-O-isopropylidene-alpha-D-glucofuranose; 1,2:5,6-Di-0-Isopropylidene-alpha-D-Glucofuranose; 1.2:5.6-Di-0-isopropylidene-alpha-D-glucofuranose; W-200121; 1,2: 5,6-di-O-isopropylidene-alpha-D-glucofuranose; 1,2:5,6,-di-O-isopropylidene-alpha-D-glucofuranose; 1,2:5,6-Di-O-isopropylidene-.alpha.-D-glucofuranose; Q27287751; 1,2:5,6-DI-O-ISOPROPYLIDENE-.ALPHA.-D-GLUCOSE; Glucofuranose, 1:2,5:6-di-O-isopropylidene-, alpha-D-; 1,2:5,6-Di-O-isopropylidene-alpha-D-glucofuranose, 98%; a-D-Glucofuranose,1,2:5,6-bis-O-(1-methylethylidene)-; alpha-D-Glucofuranose, 1,2:5,6-di-O-(1-methylethylidene)-; (-)-1,2:5,6-DI-O-ISOPROPYLIDENE-.ALPHA.-D-GLUCOFURANOSE; 1,2:5,6-Di-O-isopropylidene-alpha-D-glucofuranose, purum, >=98.0% (TLC); GLUCOFURANOSE, 1,2:5,6-DI-O-ISOPROPYLIDENE-, .ALPHA.-D- ."	.	.	.	7067560	.	.	.
DRG00169	Maleimide derivative of daunorubicin	Maleimide derivative of daunorubicin	.	"DTXSID001098331; 188530-64-5; (8S,10S)-7,8,9,10-Tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[3-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)benzoyl]amino]-I+/--L-lyxo-hexopyranosyl]oxy]-5,12-naphthacenedione"	.	.	.	10771312	.	.	.
DRG00170	Porphyrin derivative	Porphyrin derivative	.	CHEMBL138602	.	.	.	11104797	.	.	.
DRG00171	"L-Ornithine, N5-[[[(2,3-dihydro-2,2,4,6,7-pentamethyl-5-benzofuranyl)sulfonyl]amino]iminomethyl]-N2-[(9H-fluoren-9-ylmethoxy)carbonyl]"	.	.	"Fmoc-Arg(Pbf)-OH; 154445-77-9; Fmoc-L-arg(pbf)-OH; (S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-5-(3-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)guanidino)pentanoic acid; (2S)-5-[[amino-[(2,2,4,6,7-pentamethyl-3H-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]-2-(9H-fluoren-9-ylmethoxycarbonylamino)pentanoic acid; Nalpha-Fmoc-Nomega-Pbf-L-arginine; MFCD00235804; N5-[[[(2,3-Dihydro-2,2,4,6,7-pentamethyl-5-benzofuranyl)sulfonyl]amino]iminomethyl]-N2-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-ornithine; fmoc-arg(pbf); (2S)-2-([[(9H-Fluoren-9-yl)methoxy]carbonyl]amino)-5-[N'-[(2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5-yl)sulfonyl]carbamimidamido]pentanoic acid; (2S)-2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)-5-{N'-[(2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5-yl)sulfonyl]carbamimidamido}pentanoic acid; Fmoc-L-Arg(Pbf); Fmoc-Arg(Pbf) )-OH; Fmoc-D-Arg(Pbf) )-OH; Na-Fmoc-Nw-Pbf-L-arginine; G9NZE45G3H; SCHEMBL3431396; SCHEMBL8302353; DTXSID10463228; AMY31277; HY-Y1636; AKOS015888151; AKOS015924226; AKOS032949739; CS-W019715; N-alpha-Fmoc-N-g-(2,2,4,6,7-pentamethyl-dihydrobenzofuran-5-sulfonyl)-L-arginine; Nalpha-Fmoc-Nomega-(2,2,4,6,7-pentamethyldihydro-benzofuran-5-sulfonyl)-L-arginine; DS-13757; F0729; Fmoc-Arg(Pbf)-OH, >=98.0% (HPLC); FT-0602017; FT-0602041; EN300-67540; M03398; A809534; J-300031; Na-Fmoc-Nw-(2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl)-L-arginine; N-alpha-Fmoc-N'-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine; Nalpha-Fmoc-Nomega-(2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl)-L-arginine; (2S)-2-{[(9H-FLUOREN-9-YLMETHOXY)CARBONYL]AMINO}-5-[N'-(2,2,4,6,7-PENTAMETHYL-3H-1-BENZOFURAN-5-YLSULFONYL)CARBAMIMIDAMIDO]PENTANOIC ACID; (2S)-5-[[amino-[(2,2,4,6,7-pentamethyl-3H-benzofuran-5-yl)sulfonylamino]methylene]amino]-2-(9H-fluoren-9-ylmethoxycarbonylamino)pentanoic acid; (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-5-(3-(2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-ylsulfonyl)guanidino)pentanoic acid; L-Ornithine, N5-[[[(2,3-dihydro-2,2,4,6,7-pentamethyl-5-benzofuranyl)sulfonyl]amino]iminomethyl]-N2-[(9H-fluoren-9-ylmethoxy)carbonyl]-; N2-(((9H-fluoren-9-yl)methoxy)carbonyl)-Nw-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)-L-arginine; Nalpha-[(9H-Fluoren-9-ylmethoxy)carbonyl]-Nomega-(2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl)-L-arginine; Nalpha-Fmoc-Nomega-(2,2,4,6,7-pentamethyl-2,3-dihydrobenzo[b]furan-5-ylsulfonyl)-L-arginine"	.	.	.	11354259	.	.	.
DRG00172	N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-1-(triphenylmethyl)-L-histidine	.	.	"Fmoc-His(Trt)-OH; 109425-51-6; N-Fmoc-N'-trityl-L-histidine; (2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-(1-tritylimidazol-4-yl)propanoic acid; Nalpha-Fmoc-Nim-trityl-L-histidine; MFCD00043332; Nalpha-Fmoc-N(im)-trityl-L-histidine; (S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-(1-trityl-1H-imidazol-4-yl)propanoic acid; Na-Fmoc-Nim-trityl-L-histidine; FmocHis(Trt)OH; Fmoc-His(Trt) )-OH; Histidine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-1-(triphenylmethyl)-; N-Fmoc-1-trityl-L-histidine; SCHEMBL1737899; DTXSID80465310; N-; A-Fmoc-N-im-trityl-L-histidine; Nalpha-Fmoc-tele-trityl-L-histidine; N-Fmoc-N'-trityl-D-histidine; AKOS015924157; AC-8594; AM81823; CS-W011428; FD21664; HY-W010712; AS-12883; DB-030187; F0653; FT-0601834; FT-0658754; NS00005970; EN300-96350; M03415; J-300146; Fmoc-His(Trt)-OH, >=98.0% (sum of enantiomers, HPLC); N-alpha-(9-Fluorenylmethyloxycarbonyl)-N-im-trityl-L-histidine; Na-(((9H-fluoren-9-yl)methoxy)carbonyl)-Nt-trityl-L-histidine; Nalpha-[(9H-Fluoren-9-ylmethoxy)carbonyl]-tau-(triphenylmethyl)-L-histidine; Nalpha-[(9H-Fluoren-9-ylmethoxy)carbonyl]-tele-(triphenylmethyl)-L-histidine; (2S)-2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)-3-[1-(triphenylmethyl)-1H-imidazol-4-yl]propanoic acid; (2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-[1-[tri(phenyl)methyl]imidazol-4-yl]propanoic acid; (2S)-2-{[(9H-FLUOREN-9-YLMETHOXY)CARBONYL]AMINO}-3-[1-(TRIPHENYLMETHYL)IMIDAZOL-4-YL]PROPANOIC ACID; (S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-(1-trityl-1H-imidazol-4-yl)propanoicacid; (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-(1-trityl-1H-imidazol-4-yl)propanoic acid"	.	.	.	11422193	.	.	.
DRG00173	N-Methyl-N-phenylethenesulfonamide	.	.	SCHEMBL7157659; Z1336450047	.	.	.	11435546	.	.	.
DRG00174	"2,3-dihydro-2,2,4,6,7-pentamethyl-5-benzofuransulfonamide"	.	.	"378230-81-0; 2,2,4,6,7-Pentamethyl-2,3-dihydrobenzofuran-5-sulfonamide; 2,2,4,6,7-PENTAMETHYLDIHYDROBENZOFURAN-5-SULFONAMIDE; 2,2,4,6,7-PENTAMETHYL-3H-1-BENZOFURAN-5-SULFONAMIDE; Pbf-NH2; C13H19NO3S; SCHEMBL2477502; MFCD02093572; ZB1388; AKOS022182834; DS-16713; CS-0100890; F12164; A874002"	.	.	.	11437140	.	.	.
DRG00175	DOTA tri(tert-butyl) ester	DOTA tri(tert-butyl) ester	.	"137076-54-1; Tri-tert-butyl 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate; 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid; DOTA-tri(t-butyl ester); 2-[4,7,10-tris[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]-1,4,7,10-tetrazacyclododec-1-yl]acetic acid; TRI-TERT-BUTYL 1 4 7 10-TETRAAZACYCLODOD; DOTA(OtBu) hydrobromide salt; 2-(4,7,10-TRIS(2-TERT-BUTOXY-2-OXOETHYL)-1,4,7,10-TETRAAZACYCLODODECAN-1-YL)ACETIC ACID; MFCD02259697; 2-{4,7,10-tris[2-(tert-butoxy)-2-oxoethyl]-1,4,7,10-tetraazacyclododecan-1-yl}acetic acid; DOTA-tris (t-Bu ester) (~90%); DOTA-tri-t-Bu-ester; RVUXZXMKYMSWOM-UHFFFAOYSA-N; {4,7,10-TRIS[2-(TERT-BUTOXY)-2-OXOETHYL]-1,4,7,10-TETRAAZACYCLODODECAN-1-YL}ACETIC ACID; Tri-tert-Bu-DOTA; DOTA(OtBu)3; DOTA-tris(t-Bu)ester; DOTA(OBu-t)3; CVY7P26TWY; 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic Acid Tri-tert-butyl Ester; SCHEMBL1041478; DTXSID90469329; C28H52N4O8; BCP08918; 1,4,7,10-tetraazacyclododecane-1,4,7-tris-tert-butyl acetate-10-acetic acid; AKOS015893988; HY-W034551; 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, tris(1,1-dimethylethyl) ester; 4,7,10-Tri-(t-butyloxycarbonylmethyl)-1,4,7,10-tetraazacyclododecan-1-yl-acetic acid; BP-23988; DS-11439; SY053512; CS-0085511; FT-0728089; T2642; J-006958; [4,7,10-Tris(2-tert-butoxy-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl]acetic acid; 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)aceticacid; 2-(4,7,10-tris(2-t-butoxy-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid; Tri-tert-butyl 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate, >=95.0% (CHN)"	.	.	.	11606627	.	.	.
DRG00176	C-5-modified neomycin B analog	C-5-modified neomycin B analog	.	.	.	.	.	11715099	.	.	.
DRG00177	NSC 125620	NSC 125620	.	"4711-00-6; 6-AZIDO-6-DEOXY-1,2; (1S,2R,6R,8R,9S)-8-(azidomethyl)-4,4,11,11-tetramethyl-3,5,7,10,12-pentaoxatricyclo[7.3.0.0?,?]dodecane; 6-AZIDO-6-DEOXY-1,2:3,4-DI-O-ISOPROPYLIDENE-D-GALACTOPYRANOSIDE; 1,2:3,4-Di-O-isopropylidene-6-deoxy-6-azido-a-D-galactopyranose; 6-Azido-6-deoxy-1,2:3,4-di-O-isopropylidene-a-D-galactopyranose; SCHEMBL17223134; W-202826; 1,2:3,4-Di-O-isopropylidene-6-deoxy-6-azido-?-D-galactopyranose; 1,2:3,4-Di-O-isopropylidene-6-deoxy-6-azido-alpha-D-galactopyranose; 6-Azido-6-deoxy-1,2:3,4-di-O-isopropylidene-alpha-D-galactopyranose, >=96% (HPLC)"	.	.	.	11781095	.	.	.
DRG00178	Glycyrrhetinic acid dye	Glycyrrhetinic acid dye	.	CHEMBL2151602; AKOS016036251	.	.	.	12039226	.	.	.
DRG00179	Alpha-trifluoromethyl-alpha-hydroxy acid	Alpha-trifluoromethyl-alpha-hydroxy acid	.	2-Hydroxy-2-trifluoromethyl-pent-4-ynoic acid methyl ester; 537034-30-3; SCHEMBL24802924; AKOS017343539; methyl 2-hydroxy-2-trifluoromethyl-pent-4-inoate	.	.	.	12121555	.	.	.
DRG00180	"4-amino-1-[3,5-bis-O-[(1,1-dimethylethyl)dimethylsilyl]-&beta;-D-arabinofuranosyl]-2(1H)-Pyrimidinone"	.	.	"82845-96-3; CHEMBL567324; DTXSID10517018; 4-Amino-1-{3,5-bis-O-[tert-butyl(dimethyl)silyl]-beta-D-arabinofuranosyl}pyrimidin-2(1H)-one"	.	.	.	13064713	.	.	.
DRG00181	(R)-5-oxo-2-pyrrolidinecarboxamide	(R)-5-oxo-2-pyrrolidinecarboxamide	.	D-Pyroglutamic acid amide; SCHEMBL992630; MFCD28153223; AKOS026737763; 118929-65-0	.	.	.	13477716	.	.	.
DRG00182	"4-(Chlorocarbonyl)-1,2-benzenedicarboxylic acid"	.	.	SCHEMBL4613753	.	.	.	15105982	.	.	.
DRG00183	Fmoc-protected doxorubicine	Fmoc-protected doxorubicine	.	"(9H-Fluoren-9-yl)methyl ((2S,3S,4S,6R)-3-hydroxy-2-methyl-6-(((1S,3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl)oxy)tetrahydro-2H-pyran-4-yl)carbamate; SCHEMBL17404468"	.	.	.	15144731	.	.	.
DRG00184	Deacetylvinblastine	Deacetylvinblastine	.	"Deacetylvinblastine; Desacetylvinblastine; 3352-69-0; 2Q5SB43WZ2; O4-Deacetylvincaleukoblastine; 4-O-DEACETYLVINBLASTINE; DEACETYLVINCALEUKOBLASTINE; SCHEMBL13529362; DTXSID60955143; Vincaleukoblastine, O4-deacetyl-; 4-DESACETYLVINCALEUKOBLASTINE; VINCRISTINE SULFATE IMPURITY E [EP IMPURITY]; METHYL (3AR,4R,5S,5AR,10BR,13AR)-3A-ETHYL-9-((5S,7R,9S)-5-ETHYL-5-HYDROXY-9-(METHOXYCARBONYL)-1,4,5,6,7,8,9,10-OCTAHYDRO-2H-3,7-METHANOAZACYCLOUNDECINO(5,4-B)INDOL-9-YL)-4,5-DIHYDROXY-8-METHOXY-6-METHYL-3A,4,5,5A,6,11,12,13A-OCTAHYDRO-1H-INDOLIZINO(8,1-CD)CARBAZOLE-5-CARBOXYLATE"	.	.	.	15575614	.	.	.
DRG00185	"1,7-Dioxa-2-thiaspiro[4.4]nonane, 2(1H)-pyrimidinone deriv."	.	.	CHEMBL3142761	.	.	.	15928779	.	.	.
DRG00186	2-[2-(2-Azidoethoxy)ethoxy]acetic acid	.	.	"Azido-PEG2-CH2CO2H; 882518-90-3; Azido-PEG2-CH2COOH; N3-PEG2-CH2COOH; Acetic acid, [2-(2-azidoethoxy)ethoxy]-; 2-[2-(2-Azidoethoxy)ethoxy]acetic acid; 2-(2-(2-azidoethoxy)ethoxy)acetic acid; 3,6-Dioxa-8-azidooctanoic acid; N-(2-(2-(2-azidoethoxy)ethoxy))acetic acid; (2-(2-Azidoethoxy)ethoxy)acetic acid; [2-(2-azidoethoxy)ethoxy]acetic acid; Azide-PEG2-CH2COOH; SCHEMBL13671077; MFCD24395877; AKOS030213569; BP-22280; BS-32989; HY-108368; CS-0028491; D84642; A1-33028; R14-0275"	.	.	.	16723347	.	.	.
DRG00187	"3-amino-(3&beta;,5&beta;)-Cholan-24-oic aci methyl ester"	.	.	"SCHEMBL1251516; CHEMBL2159716; WQMNXHOWINIDRC-ARCWCCGYSA-N; 3Beta-Amino-Lithocholic Acid Methyl Ester; (3beta,5beta)-3-aminocholan-24-oic acid methyl ester"	.	.	.	20683740	.	.	.
DRG00188	2-chloro-1-(N-methylcarbamate)-benzenemethanol	.	.	SCHEMBL14031246	.	.	.	23548515	.	.	.
DRG00189	N-(4-Acetylphenyl)-5-bromo-2-hydroxybenzamide	.	.	CHEMBL5278943	.	.	.	24285161	.	.	.
DRG00190	Fluorescent xanthylium dye	Fluorescent xanthylium dye	.	.	.	.	.	24951286	.	.	.
DRG00191	"Benzoic acid, 4-[(Z)-[3-(2-hydroxyethyl)-4-oxo-2-thioxo-5-thiazolidinylidene]methyl]"	.	.	AKOS002679972	.	.	.	27409359	.	.	.
DRG00192	5-Bromo-2-thiazolecarboxylic acid (BTZCA)	.	.	"5-Bromothiazole-2-carboxylic acid; 957346-62-2; 5-bromo-1,3-thiazole-2-carboxylic acid; 5-BROMO-THIAZOLE-2-CARBOXYLIC ACID; 2-Thiazolecarboxylicacid, 5-bromo-; MFCD11521568; 5-BROMOTHIAZOLE-2-CARBOXYLICACID; 5-Bromo-2-thiazolecarboxylic acid; SCHEMBL1674175; DTXSID50670353; BQRYPTVDLJGHAU-UHFFFAOYSA-N; AMY33909; FD9045; AKOS007929926; CS-W022341; PB31583; AS-49320; SY006142; DB-080341; FT-0740503; EN300-95204; A858045; J-517212; Z1269166428"	.	.	.	45480406	.	.	.
DRG00193	"3-(2-propyn-1-yloxy)-, S-[(2,4,6-trimethoxyphenyl)methyl] benzenecarbothioic acid ester"	.	.	.	.	.	.	46237554	.	.	.
DRG00194	"3,5-bis(2-propyn-1-yloxy)-, S-[(2,4,6-trimethoxyphenyl)methyl] benzenecarbothioic acid ester"	.	.	.	.	.	.	46237670	.	.	.
DRG00195	"DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) derivative"	.	.	.	.	.	.	46237802	.	.	.
DRG00196	"4-[(Z)-[2,4-Dioxo-3-(phenylmethyl)-5-thiazolidinylidene]methyl]benzoic acid"	.	.	"CHEMBL2440330; STL379174; AKOS002393631; 4-[(Z)-(3-benzyl-2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]benzoic acid"	.	.	.	49887211	.	.	.
DRG00197	Alkyne-functionalized cysteine protease inhibitor L1	.	.	.	.	.	.	50901300	.	.	.
DRG00198	N-methyl-4-(2-propyn-1-yloxy)-benzenamine	.	.	N-methyl-4-(prop-2-yn-1-yloxy)aniline; 1178112-51-0; N-methyl-4-prop-2-ynoxyaniline; AKOS008142598; CS-0258980; EN300-71959; F97252; Z730521686	.	.	.	50989046	.	.	.
DRG00199	"9-[3,5-Bis-O-[(1,1-dimethylethyl)dimethylsilyl]-&beta;-D-arabinofuranosyl]-9H-purin-6-amine"	.	.	.	.	.	.	54514449	.	.	.
DRG00200	L-Ascorbic acid	L-Ascorbic acid	.	"DL-Ascorbic acid; 62624-30-0; 89924-69-6; D-erythro-Hex-2-enonic acid, gamma-lactone; 5-(1,2-dihydroxyethyl)-3,4-dihydroxyfuran-2(5H)-one; NSC8117; 2-(1,2-dihydroxyethyl)-4,5-dihydroxy-3-furanone; 2-(1,2-dihydroxyethyl)-3,4-dihydroxy-2H-furan-5-one; 5-(1,2-dihydroxyethyl)-3,4-dihydroxy-2,5-dihydrofuran-2-one; L-Ascorbic Acid-6-13C; Erycorbin; 1129294-89-8; Neo-cebicure; Ascorbyl radical; NSC33832; component of Cortalex; component of Ferancee; 5-(1,2-dihydroxyethyl)-3,4-dihydroxyfuran-2(5H)-one (non-preferred name); L-Erythroascorbic acid; Xyloascorbic acid, L-; Ferrous ascorbate; L-Ascorbic Acid-13C6; D-ASCORBIC ACID, ISO; SR-01000389660; 2-(1,2-Dihydroxyethyl)-4,5-dihydroxyfuran-3-one; ascorbyl; NSC-8117; MFCD00005378; DL-Ascorbinsaure; iso-Ascorbic acid; 149153-08-2; Prestwick_683; EINECS 263-644-3; Mercate '5'; starbld0035980; Araboascorbic acid, D-; SCHEMBL786; Oprea1_099167; MLS006011447; SCHEMBL332736; CHEMBL1161421; 5-(1,2-dihydroxyethyl)-3,4-dihydroxy-5-hydrofuran-2-one; L-Ascorbic acid, iron(2+) salt; TYQCGQRIZGCHNB-UHFFFAOYSA-N; HMS3370P18; HMS3372D17; HMS3651P22; 178101-88-7; L-Threoascorbic acid,Antiscorbutic factor,Vitamin C;(R)-5-((S)-1,2-Dihydroxyethyl)-3,4-dihydroxyfuran-2(5H)-one; WLN: T5OV EHJ CQ DQ EYQ1Q; BBL008110; HSCI1_000271; NSC218455; STK023644; AKOS000487668; AKOS015915124; AKOS016352178; SB44719; SB60900; SMP2_000183; Technetium-99 labeled ferrous ascorbate; NCGC00094971-01; NCGC00094971-02; NCGC00248925-01; NCI60_002981; SMR003217638; SY010444; VS-01830; DB-057152; FT-0624450; FT-0627701; FT-0652639; L-threo-Hex-2-enonic acid, .gamma.-lactone; NS00132719; (2R)-2-[(1S)-1,5-dihydroxyfuran-3-one; EN300-18134; A833894; SR-01000389660-1; SR-01000389660-3; Z57201291; 2-[1,2-bis(oxidanyl)ethyl]-4,5-bis(oxidanyl)furan-3-one; 3,4-dihydroxy-5-(1',2'-dihydroxyethyl)-2(5H)-furanone; 3,4-Dihydroxy-5-[(S)-1,2-dihydroxyethyl]furan-2(5H)-one; 5-(1,2-dihydroxyethyl)-3,4-dihydroxyfuran-2(5H)-one, AldrichCPR; 2252244-20-3"	.	.	.	54676860	.	DB00126	.
DRG00201	"2,3-Dihydro-2,2,4,6,7-pentamethyl-5-benzofuransulfonic acid"	.	.	"2,2,4,6,7-Pentamethyl-2,3-dihydrobenzofuran-5-sulfonic acid; 1430820-46-4; SCHEMBL4047614; BS-52609; 2,2,4,6,7-pentamethyl-3H-1-benzofuran-5-sulfonic acid; 2,2,4,6,7-Pentamethyl-2,3-dihydrobenzofuran-5-sulfonicacid"	.	.	.	57517466	.	.	.
DRG00202	2-[2-oxo-2-[[4-[3-oxo-3-(2-oxo-1-azetidinyl)propyl]phenyl]amino]ethoxy] acetic acid	.	.	1024602-85-4; ((4-[3-Oxo-3-(2-oxo-azetidin-1-yl)-propyl]-phenylcarbamoyl)-methoxy)-acetic acid; ({4-[3-Oxo-3-(2-oxo-azetidin-1-yl)-propyl]-phenylcarbamoyl}-methoxy)-acetic acid; SCHEMBL4400681; BP-22053; DB-181841; G62710; ((4-[3-Oxo-3-(2-oxo-azetidin-1-yl)-propyl]-phenylcarbamoyl)-methoxy)-aceticacid; 2-[2-Oxo-2-[[4-[3-oxo-3-(2-oxo-1-azetidinyl)propyl]phenyl]amino]ethoxy]acetic acid; 2-[2-oxo-2-[4-[3-oxo-3-(2-oxoazetidin-1-yl)propyl]anilino]ethoxy]acetic acid; 2-(2-OXO-2-((4-(3-OXO-3-(2-OXOAZETIDIN-1-YL)PROPYL)PHENYL)AMINO)ETHOXY)ACETIC ACID	.	.	.	57638734	.	.	.
DRG00203	"S,S-propargyloxyproline"	"S,S-propargyloxyproline"	.	SCHEMBL13164392; (4S)-1-Boc-4-(2-propyn-1-yloxy)-L-proline; 949924-32-7	.	.	.	57806896	.	.	.
DRG00204	Coumarintriazole derivative 6	Coumarintriazole derivative 6	.	3-azido-7-(diethylamino)-2H-chromen-2-one; 817638-71-4; 7-diethylamino-3-azidocoumarin; LCZC2154; CHEMBL3427719; SCHEMBL14417275; YXHRHSDKMLARBD-UHFFFAOYSA-N; 3-Azido-7-diethylaminochromen-2-one; DB-094172	.	.	.	58971806	.	.	.
DRG00205	"1,4,7-Triazacyclononane-1-glutaric acid-4,7-acetic acid"	.	.	"SCHEMBL1642509; 2-(4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl)pentanedioic acid"	.	.	.	67105129	.	.	.
DRG00206	"6,6-Bis-bromomethyl-[3,3]bipyridine"	.	.	"SCHEMBL9937888; 6,6'-bis-bromomethyl-[3,3']-bipyridine; EN300-11972083; 2-(bromomethyl)-5-[6-(bromomethyl)pyridin-3-yl]pyridine"	.	.	.	67974100	.	.	.
DRG00207	4-[(Z)-(5-Oxo-1-phenyl-2-thioxo-4-imidazolidinylidene)methyl]benzoic acid	.	.	CHEMBL2170159; BDBM50397330	.	.	.	71449815	.	.	.
DRG00208	"2-(carboxymethoxy)-5-(2,5-dimethyl-1H-pyrrol-1-yl)-benzoic acid"	.	.	"2-(carboxymethyloxy)-5-(2,5-dimethylpyrrol-1-yl)benzoic acid"	.	.	.	71601227	.	.	.
DRG00209	Neomycin B derivative	Neomycin B derivative	.	SCHEMBL19861023	.	.	.	72469338	.	.	.
DRG00210	3-[(4-Methoxyphenyl)methyl]-4-oxo-2-thioxo-5-thiazolidineacetic acid	.	.	.	.	.	.	72712458	.	.	.
DRG00211	6-Deoxy-6-thio-&alpha;-GalCer	.	.	"alpha-Gal6SCer(C26); SCHEMBL17748146; CHEBI:134025; Gal6Salpha-Cer(t18:0/26:0); 6''-deoxy-6''-thio-alpha-GalCer; 1-O-(6-thio-alpha-D-galactopyranosyl)-N-hexacosanylphytosphingosine; N-{(2S,3S,4R)-3,4-dihydroxy-1-[(6-deoxy-6-thio-alpha-D-galactosyl)oxy]octadecan-2-yl}hexacosanamide; N-{(2S,3S,4R)-3,4-dihydroxy-1-[(6-thio-alpha-D-galactopyranosyl)oxy]octadecan-2-yl}hexacosanamide; N-{(2S,3S,4R)-3,4-dihydroxy-1-[(6-thio-alpha-D-galactosyl)oxy]octadecan-2-yl}hexacosanamide"	.	.	.	86580860	.	.	.
DRG00212	Indole compound 6j	Indole compound 6j	.	CHEMBL3290361; 3-[[6-[1-[(3-carboxyphenyl)methyl]indol-6-yl]indol-1-yl]methyl]benzoic acid	.	.	.	90682141	.	.	.
DRG00213	Protein kinase C inhibitor 	Protein kinase C inhibitor 	.	.	.	.	.	101513770	.	.	.
DRG00214	Porphyrin-derivative	Porphyrin-derivative	.	.	.	.	.	101761510	.	.	.
DRG00215	Telithromycin (TEL) derivative	Telithromycin (TEL) derivative	.	.	.	.	.	102214304	.	.	.
DRG00216	"1,5,9-Triazacyclododecane-1-acetic acid"	"1,5,9-Triazacyclododecane-1-acetic acid"	.	"2-(1,5,9-Triazacyclododecan-1-yl)acetic acid; 1334610-50-2"	.	.	.	117064226	.	.	.
DRG00217	"Benzoic acid, 4-[(Z)-[4-oxo-3-(2-phenylethyl)-2-thioxo-5-thiazolidinylidene]methyl]"	.	.	AKOS027475773	.	.	.	119054003	.	.	.
DRG00218	Oleanolic acid dye	Oleanolic acid dye	.	CHEMBL3623384	.	.	.	122192472	.	.	.
DRG00219	"Benzoic acid, 4-[(Z)-(3-methyl-2,4-dioxo-5-thiazolidinylidene)methyl]"	.	.	.	.	.	.	125822161	.	.	.
DRG00220	7-Amino-4-(azidomethyl)-2H-1-benzopyran-2-one	.	.	.	.	.	.	129984736	.	.	.
DRG00221	Acyclovir	Acyclovir (ACV)	.	"acyclovir; Aciclovir; 59277-89-3; Acycloguanosine; Zovirax; Virorax; Vipral; Wellcome-248U; Aciclovirum; Zovir; 9-[(2-Hydroxyethoxy)methyl]guanine; Sitavig; 2-Amino-9-((2-hydroxyethoxy)methyl)-1H-purin-6(9H)-one; Gerpevir; Hascovir; Acyclovir-side chain-2-3H; Aciclovirum [Latin]; Acicloftal; Cargosil; Novirus; 9-(2-Hydroxyethoxy)methylguanine; 9-HYROXYETHOXYMETHYLGUANINE; W-248-U; 9-((2-Hydroxyethoxy)methyl)guanine; Aciclovirum [INN-Latin]; BW-248U; DRG-0008; CCRIS 1953; CHEBI:2453; NSC 645011; 141294-79-3; HSDB 6511; UNII-X4HES1O11F; 2-Amino-1,9-dihydro-9-((2-hydroxyethoxy)methyl)-6H-purin-6-one; EINECS 261-685-1; X4HES1O11F; Aciclovir [INN]; MFCD00057880; NSC-645011; NSC-758477; AVACLYR; 2-amino-9-(2-hydroxyethoxymethyl)-3H-purin-6-one; DTXSID1022556; Acyclovir (Aciclovir); 2-Amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6H-purin-6-one; 2-Amino-9-[(2-hydroxyethoxy)methyl]-1,9-dihydro-6H-purin-6-one; 6H-Purin-6-one, 2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-; ACYCLOVIR-SIDECHAIN-2-3H; Acyclovir [USAN:USP]; Zovirax (TN); NSC645011; 9-[(2-Hydroxyethoxy)-methyl]guanine; 2-amino-9-(2-hydroxyethoxymethyl)-1H-purin-6-one; MLS000069633; DTXCID102556; Activir; 9-(2-Hydroxyethoxymethyl)guanine; 6H-Purin-6-one, 2-amino-1,9-dihydro-9-((2-hydroxyethoxy)methyl)-; Aciclovirum (Latin); AC2; Acyclovir [USAN]; 2-amino-9-((2-hydroxyethoxy)methyl)-3H-purin-6(9H)-one; NCGC00015061-02; Aciclovier; SMR000058225; Genvir; Maynar; Zyclir; Acyclovir (USAN:USP); ACICLOVIR (IARC); ACICLOVIR [IARC]; 2-amino-9-[(2-hydroxyethoxy)methyl]-6,9-dihydro-3H-purin-6-one; CAS-59277-89-3; Aciclovirum (INN-Latin); 6H-Purin-6-one, 1,9-dihydro-2-amino-9-((2-hydroxyethoxy)methyl)-; 2-amino-9-(2-hydroxyethoxymethyl)purin-6-ol; ACICLOVIR (MART.); ACICLOVIR [MART.]; ACYCLOVIR (USP-RS); ACYCLOVIR [USP-RS]; ACICLOVIR (EP MONOGRAPH); ACICLOVIR [EP MONOGRAPH]; ACYCLOVIR (USP MONOGRAPH); ACYCLOVIR [USP MONOGRAPH]; Viropump; AcycloFoam; 2-amino-9-((2-hydroxyethoxy)methyl)-1,9-dihydro-6H-purin-6-one; 2-amino-9-[(2-hydroxyethoxy)methyl]-3,9-dihydro-6H-purin-6-one; 2-amino-9-[(2-hydroxyethoxy)methyl]-6,9-dihydro-1H-purin-6-one; Acic; C8H11N5O3; 2-amino-9-{[(2-hydroxyethyl)oxy]methyl}-1,9-dihydro-6H-purin-6-one; Acyclo-V; Acyclovir Lauriad; Acyclovir (USP); 88713-38-6; SR-01000075540; 69657-51-8; ACV & Pluronic F-68; VALACICLOVIR HYDROCHLORIDE IMPURITY B (EP IMPURITY); VALACICLOVIR HYDROCHLORIDE IMPURITY B [EP IMPURITY]; Aclovir; Acyclovir & Pluronic F-68; Cyclovir; Poviral; Sitavir; VALACICLOVIR HYDROCHLORIDE HYDRATE IMPURITY B (EP IMPURITY); VALACICLOVIR HYDROCHLORIDE HYDRATE IMPURITY B [EP IMPURITY]; Prestwick_6; 1pwy; BW-248-U; Sitavig (TN); Spectrum_001739; ACICLOVIR [JAN]; ACYCLOVIR [MI]; ACYCLOVIR [HSDB]; Opera_ID_1674; Prestwick0_000086; Prestwick1_000086; Prestwick2_000086; Prestwick3_000086; Spectrum2_001563; Spectrum3_001874; Spectrum4_000225; Spectrum5_001093; ACYCLOVIR [VANDF]; Lopac-A-4669; Aciclovir (JP17/INN); CHEMBL184; A 4669; ACICLOVIR [WHO-DD]; ACICLOVIR [WHO-IP]; SCHEMBL3175; Lopac0_000037; ACICLOVIRUM [WHO-IP]; BSPBio_000012; BSPBio_003348; KBioGR_000889; KBioSS_002219; BIDD:GT0646; DivK1c_000185; SPECTRUM1503603; SPBio_001466; SPBio_001951; 2-amino-9-[(2-hydroxyethoxy)methyl]hydropurin-6-one; BPBio1_000014; GTPL4829; SCHEMBL9828560; 9(2-hydroxyethoxymethyl)guanine; ACYCLOVIR [ORANGE BOOK]; HMS500J07; KBio1_000185; KBio2_002219; KBio2_004787; KBio2_007355; KBio3_002850; D06BB03; J05AB01; S01AD03; NINDS_000185; GLXC-04946; HMS1568A14; HMS1922E08; HMS2090G09; HMS2095A14; HMS2234K21; HMS3259N10; HMS3260G15; HMS3269M15; HMS3372K02; HMS3413D21; HMS3655C14; HMS3677D21; HMS3712A14; Pharmakon1600-01503603; BCP11036; 9-(2-hydroxyethoxy methyl) guanine; Tox21_110075; Tox21_500037; 69657-51-8 (Na salt); BBL009642; BDBM50021776; BDBM50103518; CCG-39909; NSC335752; NSC758477; NSC780378; s1807; STK796771; STL257059; STL301862; AKOS000656213; AKOS015995680; AKOS022135433; Tox21_110075_1; AC-8068; CS-1353; DB00787; KS-1027; LP00037; NC00717; NSC-780378; SDCCGSBI-0050026.P003; IDI1_000185; SMP1_000007; NCGC00015061-01; NCGC00015061-03; NCGC00015061-04; NCGC00015061-05; NCGC00015061-06; NCGC00015061-07; NCGC00015061-08; NCGC00015061-09; NCGC00015061-10; NCGC00015061-12; NCGC00015061-13; NCGC00015061-28; NCGC00015061-29; NCGC00022426-03; NCGC00093555-01; NCGC00093555-02; NCGC00093555-03; NCGC00093555-04; NCGC00167756-01; NCGC00167756-02; NCGC00260722-01; NCGC00381719-03; HY-17422; SY051130; Acycloguanosine, >=99% (HPLC), powder; Aciclovir 1.0 mg/ml in Dimethyl Sulfoxide; AM20100442; EU-0100037; FT-0621607; FT-0657847; NS00009000; SW196324-3; C06810; D00222; EN300-123010; A832236; A935190; Q147101; Q-200591; SR-01000075540-1; SR-01000075540-3; SR-01000075540-5; 2-amino-9-[(2-hydroxyethoxy)methyl]-9H-purin-6-ol; 2-azanyl-9-(2-hydroxyethyloxymethyl)-3H-purin-6-one; BRD-K32318651-001-17-9; Aciclovir, British Pharmacopoeia (BP) Reference Standard; F2173-0946; Z1546610471; Aciclovir, European Pharmacopoeia (EP) Reference Standard; 2-Amino-9-(2-hydroxy-ethoxymethyl)-5,9-dihydro-purin-6-one; Acyclovir, United States Pharmacopeia (USP) Reference Standard; 2-Amino-9-(2-hydroxy-ethoxymethyl)-5,9-dihydro-purin-6-one (ACV); 2-Amino-9-[(2-hydroxyethoxy)methyl]-1,9-dihydro-6H-purin-6-one #; ACV; Acycloguanosine; Acyclovir; NSC 645011; NSC-645011; NSC645011; Acyclovir, Pharmaceutical Secondary Standard; Certified Reference Material; Aciclovir for peak identification 1, European Pharmacopoeia (EP) Reference Standard; Aciclovir for peak identification 2, European Pharmacopoeia (EP) Reference Standard; Aciclovir for system suitability, European Pharmacopoeia (EP) Reference Standard; InChI=1/C8H11N5O3/c9-8-11-6-5(7(15)12-8)10-3-13(6)4-16-2-1-14/h3,14H,1-2,4H2,(H3,9,11,12,15"	TAR10037	Varicella-zoster virus DNA polymerase (VZV ORF28)	P09252	135398513	D0B5MP	DB00787	CHEMBL184
DRG00222	Pteroic acid	Pteroic acid	.	"Pteroic acid; 119-24-4; 4-(((2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl)amino)benzoic acid; 4-{[(2-amino-4-hydroxypteridin-6-yl)methyl]amino}benzoic acid; NSC 14972; p-((2-Amino-4-hydroxy-6-pteridylmethyl)amino)benzoic acid; 4-((2-Amino-4-hydroxy-6-pteridylmethyl)amino)benzoic acid; 4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoic acid; CHEMBL341824; CHEBI:27623; 8258W48TBZ; MFCD00075823; NSC-14972; 4-{[(2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoic acid; Pteroic Acid (>85%); 4-[(2-amino-4-oxo-3H-pteridin-6-yl)methylamino]benzoic acid; Pyrofolic acid; Benzoic acid, 4-(((2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)-; 4-[[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino]benzoic Acid (Pteroic Acid); Folic acid impurity D; C14H12N6O3; UNII-8258W48TBZ; Pterotic Acid; Peroic Acid; 4-[[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino]benzoic acid; 4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoic acid; 4-[[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino]benzoic Acid; Folic Acid Imp. D (EP); Pteroic Acid; Folic Acid Hydrate Impurity D; Folic Acid Impurity D; 78H; Pteridine deriv. 12; PTEROIC?ACID; 1br6; 4-BENZOIC ACID; Pteroic acid, >=93%; PTEROIC ACID [MI]; SCHEMBL245980; Pteroic Acid (>85per cent); BDBM6645; CHEBI:37055; CHEBI:37066; DTXSID40152279; BCP04836; CS-M2878; EX-A2652; NSC14972; AKOS015995562; AKOS016009238; DB04196; DS-3903; DA-16638; SY058064; AM20120647; FT-0674151; NS00023848; C07582; EN300-109015; SR-01000883746; FOLIC ACID HYDRATE IMPURITY D [EP IMPURITY]; J-004089; SR-01000883746-1; Q27095023; Benzoic acid,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]-; 4-((2-amino-4-hydroxypteridin-6-yl)methylamino)benzoic acid; 4-([(2-Amino-4-oxo-3,4-dihydro-6-pteridinyl)methyl]amino)benzoic acid #; 4-[(2-Amino-4-oxo-3,4-dihydropteridin-6-ylmethyl)-amino]-benzoic acid; 4-[[(2-amino-4-oxo-1,4 dihydropteridin-6-yl)methyl]amino]benzoic acid; 4-{[(2-amino-3,4-dihydro-4-oxopteridin-6-yl)methyl]amino}benzoic acid; Benzoic acid, p-[[(2-amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]-; Folic acid impurity D, European Pharmacopoeia (EP) Reference Standard; 4-(((2-AMINO-3,4-DIHYDRO-4-OXO-6-PTERIDINYL)METHYL)AMINO)BENZOIC ACID; BENZOIC ACID, 4-(((2-AMINO-3,4-DIHYDRO-4-OXO-6-PTERIDINYL)METHYL)AMINO)-; Folic Acid Impurity D, Pharmaceutical Secondary Standard; Certified Reference Material; 22d"	TAR10031	Bacterial Dihydropteroate synthetase (Bact folP)	P0AC13	135398749	D03GJB	DB04196	.
DRG00223	"3,4-Dihydro-4-oxo-2-quinazolinebutanoic acid"	"3,4-Dihydro-4-oxo-2-quinazolinebutanoic acid"	.	"4-(4-oxo-3,4-dihydroquinazolin-2-yl)butanoic acid; 95494-51-2; 4-(4-oxo-3H-quinazolin-2-yl)butanoic acid; MFCD05273570; 4-(4-Oxo-3,4-dihydro-quinazolin-2-yl)-butyric acid; CHEMBL3397958; 4-(4-oxo-1,4-dihydroquinazolin-2-yl)butanoic acid; NSC99368; 2-Quinazolinebutanoic acid, 1,4-dihydro-4-oxo-; SCHEMBL15575028; DTXSID40295034; IWUFDMAFCDCNMQ-UHFFFAOYSA-N; ALBB-000352; BBL030359; BDBM50285381; NSC-99368; STK502242; STK693864; STL521284; AKOS000303290; AKOS005605738; AKOS022667064; VS-09761; 4-(4-hydroxyquinazolin-2-yl)butanoic acid; CS-0221602; EN300-09566; F72192; A859035; SR-01000353583; 4-(4-oxo-3,4-dihydroquinazolin-2-yl)butanoicacid; J-513565; SR-01000353583-1; Z56983044; 4-(4-oxo-3,4-dihydroquinazolin-2-yl)butanoic acid, AldrichCPR"	.	.	.	135406772	.	.	.
DRG00224	Pemetrexed	Pemetrexed	.	"Pemetrexed; 137281-23-3; Pemetrexed disodium; Alimta; LY231514; CHEBI:63616; UNII-04Q9AIZ7NO; (S)-2-(4-(2-(2-Amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzamido)pentanedioic acid; 04Q9AIZ7NO; NSC-698037; PEMFEXY; HSDB 7316; LY-231514; N-[4-[2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid; DTXSID2048329; Pemetrexed (INN); N-(4-(2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-d)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid; LY-2315; N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid; PEMETREXED [INN]; Alimta (TN); (S)-2-(4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzamido)pentanedioic acid; 2-{4-[2-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)-ETHYL]-BENZOYLAMINO}-PENTANEDIOIC ACID; L-Glutamic acid, N-(4-(2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)-; L-Glutamic acid, N-[4-[2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-; Premetrexed (Common mis-spelling); Premetrexed [Common mis-spelling]; (2S)-2-[[4-[2-(2-amino-4-oxo-3,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; (2S)-2-{[4-(2-{2-amino-4-oxo-3H,4H,7H-pyrrolo[2,3-d]pyrimidin-5-yl}ethyl)phenyl]formamido}pentanedioic acid; (S)-2-(4-(2-(2-Amino-4-oxo-4,7-dihydro-1H-pyrrolo-[2,3-d]pyrimidin-5-yl)ethyl)benzamido)pentanedioic acid; L-GLUTAMIC ACID, N-(4-(2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO(2,3-D)PYRIMIDIN-5-YL)ETHYL)BENZOYL)-; LYA; N-(4-(2-(2-AMINO-4,7-DIHYDRO-4-OXO-1H-PYRROLO(2,3-D)PYRIMIDIN-5-YL)ETHYL)BENZOYL)-L-GLUTAMIC ACID; N-(P-(2-(2-AMINO-4,7-DIHYDRO-4-OXO-1H-PYRROLO(2,3-D)PYRIMIDIN-5-YL)ETHYL)BENZOYL)-L-GLUTAMATE; N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid; Pemetrexed [INN:BAN]; pemetrexedum; 1juj; Pemetrexed (TN); N-(4-(2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)-L-glutamic acid; N-(4-[2-(2-amino-4,7-Dihydro-4-Oxo-1H-Pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl)-L-Glutamic Acid; Pemetrexed- Bio-X; Multitargeted Antifolate; PEMETREXED [MI]; Alimta (TN) (Lilly); PEMETREXED [HSDB]; PEMETREXED [VANDF]; SCHEMBL7968; PEMETREXED [WHO-DD]; US9422297, Pemetrexed; PEMETREXED [EMA EPAR]; PEMETREXED FOR INJECTION; CHEMBL225072; DTXCID7028304; PEMETREXED [ORANGE BOOK]; WBXPDJSOTKVWSJ-ZDUSSCGKSA-N; BDBM50027656; NSC698037; s5971; AKOS015896253; AKOS016842348; AC-1701; CS-1297; DB00642; NCGC00166414-11; NCGC00167517-01; NCGC00242485-01; (2S)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; AS-30680; BP164240; HY-10820; N-[4-[2(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid; DB-024764; P2288; D07472; AB01273937-01; EN300-7396246; A807228; Q415220; J-502393; L-Glutamic acid,3-d]pyrimidin-5-yl]ethyl]benzoyl]-; 1006872-74-7; L-Glutamic Acid, N-(4-(2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl); N-({4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]phenyl}carbonyl)-L-glutamic acid; N-[4-[2(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo [2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid; N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7h-pyrrolo[2,3-d]pyrimi-din-5-yl)ethyl]benzoyl]l-glutamic acid; N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid disodium salt;Pemetrexed; N-[4-[2-[2-Amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl]ethyl]benzoyl]glutamic acid"	TAR10050	Candida Thymidylate synthase (Candi TMP1)	P12461	135410875	D0Y4GO	DB00642	CHEMBL225072
DRG00225	Rifampicin	Rifampicin	.	rifampin; Rifampicin; CHEMBL1523493; PD087064	.	.	.	136601293	.	DB01045	.
DRG00226	"5-[[2-[2-(dimethylamino)ethyl]-2,3-dihydro-1,3-dioxo-1H-benz[de]isoquinolin-5-yl]amino]-5-oxo-Pentanoic acid"	.	.	SCHEMBL21572660	.	.	.	140904172	.	.	.
DRG00227	N-(4-Hydroxyphenyl)-N-methylethenesulfonamide	.	.	.	.	.	.	141730051	.	.	.
DRG00228	Fallypride derivative	Fallypride derivative	.	.	.	.	.	143926521	.	.	.
DRG00229	"R,S-propargyloxyproline"	"R,S-propargyloxyproline"	.	(4R)-1-Boc-4-(2-propyn-1-yloxy)-L-proline; 1267640-69-6	.	.	.	156026587	.	.	.
DRG00230	"Benzoic acid, 4-[(Z)-(3-cyclopropyl-4-oxo-2-thioxo-5-thiazolidinylidene)methyl]"	.	.	"DTXSID601134359; Benzoic acid, 4-[(Z)-(3-cyclopropyl-4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-; 1474053-21-8"	.	.	.	165342428	.	.	.
DRG00231	"Benzoic acid, 3-[(Z)-(3-cyclopentyl-2,4-dioxo-5-thiazolidinylidene)methyl]"	.	.	.	.	.	.	.	.	.	.
DRG00232	"3-Thiazolidineacetic acid, &alpha;-butyl-5-[(4-carboxyphenyl)methylene]-4-oxo-2-thioxo-, 3-methyl ester, (5Z)"	.	.	.	.	.	.	.	.	.	.
DRG00233	"Benzoic acid, 4-[(Z)-[4-oxo-3-[(tetrahydro-2-furanyl)methyl]-2-thioxo-5-thiazolidinylidene]methyl]"	.	.	.	.	.	.	.	.	.	.
DRG00234	Betulonic acid derivative	Betulonic acid derivative	.	.	.	.	.	.	.	.	.
DRG00235	4-aminocyclophosphamide prodrug	4-aminocyclophosphamide prodrug	.	.	.	.	.	.	.	.	.
DRG00236	&Beta;-D-Galactopyranoside derivative	b-D-Galactopyranoside derivative	.	.	.	.	.	.	.	.	.
DRG00237	Ureidopyrimidinone (UPy)	Ureidopyrimidinone (UPy)	.	.	.	.	.	.	.	.	.
DRG00238	Functionalized oligo p-phenylenevinylene (OPV)	Functionalized oligo p-phenylenevinylene (OPV)	.	.	.	.	.	.	.	.	.
DRG00239	Kanamycin A derivative	Kanamycin A derivative	.	.	.	.	.	.	.	.	.
DRG00240	"5-O-[(1,1-Dimethylethyl)diphenylsilyl]-&beta;-D-ribofuranosyl azide"	.	.	.	.	.	.	.	.	.	.
DRG00241	"1-Fluoro-2-cyclooctyne-1-carboxylic acid + DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) derivative)"	.	.	.	.	.	.	.	.	.	.
DRG00242	Porphine derivative	Porphine derivative	.	.	.	.	.	.	.	.	.
DRG00243	"1,3-Diazido-2,4,5-trifluoro-6-nitrobenzene"	.	.	.	.	.	.	.	.	.	.
DRG00244	4-[(Ethenylsulfonyl)methylamino]-N-2-propyn-1-ylbenzamide	.	.	.	.	.	.	.	.	.	.
DRG00245	"(2S,2S)-1,1-bis(pyrid-2-ylmethyl)-2,2-bipyrrolidine ((S,S)-BPBP)"	.	.	.	.	.	.	.	.	.	.
DRG00246	"1,4-dimethyl-7-(2-pyridylmethyl)-1,4,7-triazacyclononane (Me2PyTACN)"	.	.	.	.	.	.	.	.	.	.
DRG00247	N-carboxyphenylpyrrole compound Gls-22	.	.	.	.	.	.	.	.	.	.
DRG00248	"5-(4-carboxyphenyl)-10,15,20-triphenylporphyrin"	.	.	.	.	.	.	.	.	.	.
DRG00249	H-glutaminyl-4-aminobenzyl phosphoramide mustard	H-glutaminyl-4-aminobenzyl phosphoramide mustard	.	.	.	.	.	.	.	.	.
DRG00250	Pyrrole-imidazole polyamide	Pyrrole-imidazole polyamide	.	.	.	.	.	.	.	.	.
DRG00251	Bisarylethyne	Bisarylethyne	.	.	.	.	.	.	.	.	.
DRG00252	Ureidopyrimidinone	Ureidopyrimidinone	.	.	.	.	.	.	.	.	.
DRG00253	"1H-Thieno[3,4-d]imidazole-4-hexanamide, N-[2-[2-(azidomethoxy)ethoxy]ethyl]hexahydro-2-oxo-, (3aS,4S,6aR)"	.	.	.	.	.	.	.	.	.	.
DRG00254	N-[4-(Azidomethyl)-2-oxo-2H-1-benzopyran-7-yl]acetamide	.	.	.	.	.	.	.	.	.	.
DRG00255	Azido-functionalised rhodamine fluorophore	.	.	.	.	.	.	.	.	.	.
DRG00256	Oxaliplatin	Oxaliplatin	.	.	.	.	.	.	.	.	.
DRG00257	"3-(2H-[5,6]Fullereno-C60-Ih-[1,9-c]pyrrol-1(5H)-yl)pentanedioic acid"	.	.	.	.	.	.	.	.	.	.
DRG00258	linker-only uridine diphosphate (UDP) analogue	.	.	.	.	.	.	.	.	.	.
DRG00259	"Benzoic acid, 4-[(Z)-[3-[(4-chlorophenyl)methyl]-4-oxo-2-thioxo-5-thiazolidinylidene]methyl]"	.	.	.	.	.	.	.	.	.	.
DRG00260	"Benzoic acid, 4-[(Z)-[3-[(4-fluorophenyl)methyl]-4-oxo-2-thioxo-5-thiazolidinylidene]methyl]"	.	.	.	.	.	.	.	.	.	.
DRG00261	"Benzoic acid, 4-[(Z)-[3-[(4-methoxyphenyl)methyl]-4-oxo-2-thioxo-5-thiazolidinylidene]methyl]"	.	.	.	.	.	.	.	.	.	.
DRG00262	"Benzoic acid, 4-[(Z)-[3-[(4-methylphenyl)methyl]-4-oxo-2-thioxo-5-thiazolidinylidene]methyl]"	.	.	.	.	.	.	.	.	.	.
DRG00263	"Benzoic acid, 4-[(Z)-[3-[2-(acetyloxy)ethyl]-4-oxo-2-thioxo-5-thiazolidinylidene]methyl]"	.	.	.	.	.	.	.	.	.	.
DRG00264	"Benzoic acid, 4-[(Z)-[3-(2-hydroxyethyl)-2,4-dioxo-5-thiazolidinylidene]methyl]"	.	.	.	.	.	.	.	.	.	.
DRG00265	"Benzoic acid, 4-[(Z)-(3-dodecyl-2,4-dioxo-5-thiazolidinylidene)methyl]"	.	.	.	.	.	.	.	.	.	.
DRG00266	"Benzoic acid, 4-[(Z)-(3-butyl-4-oxo-2-thioxo-5-thiazolidinylidene)methyl]"	.	.	.	.	.	.	.	.	.	.
DRG00267	"Benzoic acid, 4-[(Z)-[3-(1-methylethyl)-4-oxo-2-thioxo-5-thiazolidinylidene]methyl]"	.	.	.	.	.	.	.	.	.	.
DRG00268	"Benzoic acid, 4-[(Z)-(4-oxo-3-propyl-2-thioxo-5-thiazolidinylidene)methyl]"	.	.	.	.	.	.	.	.	.	.
DRG00269	2'-O-(tert-Butyldimethylsilyl)taxol	2'-O-(tert-Butyldimethylsilyl)taxol	.	"2'-O-(tert-Butyldimethylsilyl)taxol; 114655-02-6; [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-[tert-butyl(dimethyl)silyl]oxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate; 2'-O-(tert-Butyldimethylsilyl)paclitaxel; SCHEMBL12583607; FT-0664104; 2'-O-(tert-Butyldimethylsilyl) Paclitaxel"	.	.	.	10557870	.	.	.
DRG00270	Biotin	Biotin	.	"biotin; d-biotin; 58-85-5; Vitamin B7; Bioepiderm; coenzyme R; vitamin H; Bios II; Factor S; D(+)-Biotin; Biodermatin; D-(+)-Biotin; (+)-Biotin; Biotine; Biotinum; Injacom H; Biotina; Meribin; Factor S (vitamin); Lutavit H2; Ritatin; CCRIS 3932; HSDB 346; 3H-Biotin; MFCD00005541; NSC 63865; Biotine [INN-French]; Biotinum [INN-Latin]; Biotina [INN-Spanish]; cis-Hexahydro-2-oxo-1H-thieno(3,4)imidazole-4-valeric acid; cis-Tetrahydro-2-oxothieno(3,4-d)imidazoline-4-valeric acid; AI3-51198; 1swk; 1swn; 1swr; EINECS 200-399-3; Rovimix H 2; D-Biotin Factor S; UNII-6SO6U10H04; 5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanoic acid; 5-[(3aS,4S,6aR)-2-oxo-hexahydro-1H-thieno[3,4-d]imidazolidin-4-yl]pentanoic acid; 5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid; CHEBI:15956; 6SO6U10H04; 1H-thieno[3,4-d]imidazole-4-pentanoic acid, hexahydro-2-oxo-, (3aS,4S,6aR)-; 5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanoic acid; Medebiotin; NSC-63865; Biotin [USP:INN:JAN]; cis-(+)-Tetrahydro-2-oxothieno[3,4]imidazoline-4-valeric acid; (+)-cis-Hexahydro-2-oxo-1H-thieno[3,4]imidazole-4-valeric acid; MD-1003; 1H-Thieno(3,4-d)imidazole-4-pentanoic acid, hexahydro-2-oxo-, (3aS-(3aalpha,4beta,6aalpha))-; DTXCID102679; DTXSID7022679; 2'-Keto-3,4-imidazolido-2-tetrahydrothiophene-N-valeric acid; (3aS,4S,6aR)-Hexahydro-2-oxo-1H-thieno(3,4-d)imidazole-4-valeric acid; (3aS,4S,6aR)-Hexahydro-2-oxo-1H-thieno[3,4-d]imidazole-4-valeric acid; Hexahydro-2-oxo-1H-thieno(3,4-d)imidazole-4-pentanoic acid, (3aS-(3aalpha,4beta,6aalpha))-; D-Biotin 10 microg/mL in Acetonitrile; Biotine (INN-French); Biotinum (INN-Latin); Biotina (INN-Spanish); beta-Biotin; BIOTIN (USP-RS); BIOTIN [USP-RS]; BIOTIN (MART.); BIOTIN [MART.]; Vitamin Bw; Biotin (USP:INN:JAN); (3aS-(3aalpha,4b,6aalpha))-Hexahydro-2-oxo-1H-thieno(3,4-d)imidaz- ole-4-pentanoic acid; BIOTIN (EP IMPURITY); BIOTIN [EP IMPURITY]; BIOTIN (EP MONOGRAPH); BIOTIN [EP MONOGRAPH]; BIOTIN (USP MONOGRAPH); BIOTIN [USP MONOGRAPH]; Hexahydro-2-oxo-1H-thieno(3,4-d)imidazole-4-pentanoic acid; 1H-Thieno(3,4-d)imidazole-4-pentanoic acid, hexahydro-2-oxo-, (3aS,4S,6aR)-; 5-((3AS,4S,6aR)-rel-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanoic acid; Bios H; SMR000112255; D(+)Biotin; 22377-59-9; Biotitum; hexahydro-2-oxo-1H-thieno[3,4-d]imidazole-4-pentanoic acid; NSC63865; delta-Biotin; Amerix Biotin; Biotin Drops; Hairq-plus; Vitamin-h; Tk-nax; 1avd; 1ndj; 1stp; 1swg; 1swp; 2avi; 4bcs; 4ggz; 4jnj; Bioepiderm (TN); CAS-58-85-5; NCGC00094984-04; 1H-Thieno[3,4-d]imidazole-4-pentanoic acid, hexahydro-2-oxo-, [3as-(3aalpha,4beta,6aalpha)]-; Biotin111In; delta-(+)-Biotin; SUBIR; Biotin Drops2081; Biotin (8CI); delta-biotin factor s; TWINKLE ESSENCE; 1df8; 1n9m; 2gh7; 3t2w; 4bj8; BIOTIN [VANDF]; BIOTIN [HSDB]; SPAI-SONSPROCAPELL; BIOTIN [FCC]; BIOTIN [INN]; BIOTIN [JAN]; BIOTIN [WHO-DD]; Prestwick0_000418; Prestwick1_000418; Prestwick2_000418; Prestwick3_000418; BIOTIN [MI]; cid_253; D-BIOTIN [VANDF]; SPAI-SONSPROLAC-VIT; BDBM12; bmse000227; CHEMBL857; ExoSCRT Scalp Care HRLV; Probes2_000006; SCHEMBL8763; BIOTIN [ORANGE BOOK]; Biotin for system suitability; BSPBio_000376; Biotin (JP17/USP/INN); MLS001066402; MLS001074888; MLS001331736; MLS001333089; D-Biotin, analytical standard; SPBio_002315; BPBio1_000414; cid_171548; GTPL4787; HAIRJOY EYEBROW SIGNATURE; HAIRJOY EYELASH SIGNATURE; A11HA05; AMF0005; 1n43; 2f01; Biotin, >=99.0% (T); CIS-TETRAHYDRO-2-OXOTHIENO; HMS1569C18; HMS2096C18; HMS2271O06; HMS3713C18; Bonogen Activatorhair loss treatment; HY-B0511; Tox21_113050; Tox21_302161; AC8089; BBL028095; Biotin, tested according to Ph.Eur.; s3130; STK801941; AKOS001287669; Tox21_113050_1; 1ST1521; CCG-220418; CIS-HEXAHYDRO-2-OXO-1H-THIENO; DB00121; 1H-Thieno(3,4-d)imidazole-4-pentanoic acid, hexahydro-2-oxo-, (3aS-(3aalpha,4b,6aalpha))-; Biotin, meets USP testing specifications; Biotin, SAJ special grade, >=98.0%; NCGC00179580-01; NCGC00179580-02; NCGC00179580-04; NCGC00179580-08; NCGC00255377-01; 20 - Potency of multivitamin supplements; 56846-45-8; AC-19998; BP-20441; Biotin, >=99% (TLC), lyophilized powder; Biotin, Vetec(TM) reagent grade, >=99%; AB00374191; B0463; NS00126825; EN300-54173; BIONA-VITCONTROLS AND PREVENTS HAIR LOSS; C00120; D00029; M02926; AB00374191-08; AB00374191_11; A929752; Biotin, plant cell culture tested, >=99% (TLC); Q181354; SR-01000765521; Biotin, certified reference material, TraceCERT(R); Q-200929; SR-01000765521-2; BRD-K89210380-001-03-8; BRD-K89210380-001-13-7; 6AE43AA3-BC3D-4C49-9DB9-5913A2401EB6; Biotin, European Pharmacopoeia (EP) Reference Standard; F2173-0855; Hexahydro-2-oxo-1H-thieno(3,4-d)imidazole-4-pentanoate; Z210803762; Biotin, United States Pharmacopeia (USP) Reference Standard; cis-(+)-Tetrahydro-2-oxothieno[3,4]imidazoline-4-valerate; (+)-cis-Hexahydro-2-oxo-1H-thieno[3,4]imidazole-4-valerate; 5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanoate; Daunorubicin hydrochloride, Antibiotic for Culture Media Use Only; (3aS,4S,6aR)-Hexahydro-2-oxo-1H-thieno[3,4-d]imidazole-4-valerate; Biotin, Pharmaceutical Secondary Standard; Certified Reference Material; 1H-Thieno[3,4-d]imidazole-4-pentanoic acid, hexahydro-2-oxo-, (3aS,4S,6aR)- (9CI); 5-((3aR,6S,6aS)-2-Oxo-hexahydro-thieno[3,4-d]imidazol-6-yl)-pentanoic acid; 5-[(3aR,6S,6aS)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-6-yl]pentanoic acid; Biotin for system suitability, European Pharmacopoeia (EP) Reference Standard; hexahydro-2-oxo-[3aS-(3aa,4b,6aa)]-1H-Thieno[3,4-d]imidazole-4-pentanoate; hexahydro-2-oxo-[3aS-(3aa,4b,6aa)]-1H-Thieno[3,4-d]imidazole-4-pentanoic acid; hexahydro-2-oxo-[3as-(3alpha,4beta,6alpha)]-1H-Thieno[3,4-d]imidazole-4-pentanoate; hexahydro-2-oxo-[3as-(3alpha,4beta,6alpha)]-1H-Thieno[3,4-d]imidazole-4-pentanoic acid; Biotin, powder, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, >=99%"	.	.	.	171548	D0P8TJ	DB00121	.
DRG00271	Doxorubicin	Doxorubicin	.	"doxorubicin; Adriamycin; 23214-92-8; Adriablastin; Doxil; Doxorubicine; Adriblastina; Doxorubicinum; 14-Hydroxydaunomycin; Doxorubicina; 14-Hydroxydaunorubicine; Adriamycin semiquinone; Doxorubicine [INN-French]; Doxorubicinum [INN-Latin]; Doxorubicina [INN-Spanish]; Hydroxydaunorubicin; CCRIS 739; HSDB 3070; NCI-C01514; NDC 38242-874; EINECS 245-495-6; FI 106; NSC 123127; CHEBI:28748; UNII-80168379AG; NSC-759155; CHEMBL53463; Caelyx (liposomal doxorubicin); (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-; 80168379AG; DTXSID8021480; (1S,3S)-3-Glycoloyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl-(3-amino-2,3,6-tridesoxy-alpha-L-lyxo-hexopyranosid); (1S,3S)-3-glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (8S,10S)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; 1,2,3,4,6,11-Hexahydro-4beta,5,12-trihydroxy-4-(hydroxyacetyl)-10-methoxy-6,11-dioxonaphthacen-1beta-yl-3-amino-2,3,6-trideoxy-alpha-L-lyxohexopyranoside; ADR; ADM; Doxorubicine (INN-French); Doxorubicinum (INN-Latin); NSC-123127; Doxorubicina (INN-Spanish); DOXORUBICIN (MART.); DOXORUBICIN [MART.]; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (8S,10S)-10-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione; (8S,10S)-10-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione; (8S-cis)-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione; Doxorubicin [USAN:INN:BAN]; ThermoDox; hydroxydaunomycin; MLS000028393; DM2; Doxorubicin-hLL1; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-; 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)-; Adriblastina (TN); Doxorubicin-P4/D10; Doxorubicin (USAN/INN); VALRUBICIN IMPURITY, DOXORUBICIN (USP IMPURITY); VALRUBICIN IMPURITY, DOXORUBICIN [USP IMPURITY]; Doxorubicin-hLL1 conjugate; doxorrubicina; Doxorubicin-P4/D10 conjugate; Hydroxyldaunorubicin; Hydroxyl Daunorubicin; NSC123127; DOXORUBICIN [MI]; (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride; Prestwick0_000438; Prestwick1_000438; Prestwick2_000438; Prestwick3_000438; DOXORUBICIN [INN]; DOXORUBICIN [HSDB]; DOXORUBICIN [USAN]; Probes1_000151; Probes2_000129; DOXORUBICIN [VANDF]; SCHEMBL3243; BSPBio_000456; BSPBio_001031; DOXORUBICIN [WHO-DD]; 10-((3-Amino-2,3,6-trideoxy-D-lyxohexopyranosyl)oxy)-8-glycolcyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; SPBio_002395; (8S-cis)-10-; BPBio1_000502; cid_443939; DTXCID301480; GTPL7069; Valrubicin impurity, doxorubicin; BDBM22984; BDBM32022; L01DB01; HMS2089H06; (8S,10S)-10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-8-GLYCOLOYL-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-1-METHOXY-5,12-NAPHTHACENEDIONE; 5,12-NAPHTHACENEDIONE, 10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-8-(HYDROXYACETYL)-1-METHOXY-, (8S-CIS)-; GR-319; HY-15142A; LMPK13050001; AKOS015951330; Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74; Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120; DB00997; SMP1_000106; NCGC00024415-35; NCGC00024415-37; NCGC00024415-38; NCGC00024415-40; NCGC00024415-41; NCGC00024415-42; NCGC00024415-61; BP-23114; NS00002473; (8S,10S)-10; (8S,10S)-10-; C01661; D03899; EN300-120698; Epirubicin hydrochloride impurity, doxorubicin-; H11954; Q18936; A816625; BRD-K92093830-003-04-3; BRD-K92093830-003-25-8; EPIRUBICIN HYDROCHLORIDE IMPURITY C [EP IMPURITY]; DAUNORUBICIN HYDROCHLORIDE IMPURITY D [EP IMPURITY]; EPIRUBICIN HYDROCHLORIDE IMPURITY, DOXORUBICIN- [USP IMPURITY]; (7S,9R)-7-[(2S,4S,5S,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-9-glycoloyl-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-quinone;hydrochloride; (7S,9S)-7-[(2R,4S,5S,6S)-4-azanyl-6-methyl-5-oxidanyl-oxan-2-yl]oxy-4-methoxy-6,9,11-tris(oxidanyl)-9-(2-oxidanylethanoyl)-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride; (7S,9S)-7-[(4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-7-[[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-2-oxanyl]oxy]-6,9,11-trihydroxy-9-(2-hydroxy-1-oxoethyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride; (8S,10S)-10-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione;(7S,9S)-7-[(4S,5S,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S,10S)-10-((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione; (8S-cis)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione; (8S-cis)-10-[(3-Amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione; 1,2,3,4,6,11-hexahydro-4beta,5,12-trihydroxy-4-(hydroxyacetyl)-10-methoxy-6, 11-Dioxonaphthacen-1beta-yl-3-amino-2,3,6-trideoxy-alpha-l-lyxohexopyranoside; 1392315-46-6; 5,12-naphthacenedione, 10-((3-Amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro- 6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione"	.	.	.	31703	D07VLY	DB00997	CHEMBL53463
DRG00272	9-Fluorenylmethyl chloroformate	9-Fluorenylmethyl chloroformate	.	"28920-43-6; 9-Fluorenylmethyl chloroformate; Fmoc-Cl; Fmoc chloride; (9h-fluoren-9-yl)methyl carbonochloridate; Fmoc-chloride; Carbonochloridic acid, 9H-fluoren-9-ylmethyl ester; 9-Fluorenylmethoxycarbonyl chloride; 9H-Fluoren-9-ylmethyl chloroformate; 1-(9-Fluorenyl)methyl chloroformate; 9H-fluoren-9-ylmethyl carbonochloridate; 9-fluorenylmethylchloroformate; (9H-Fluoren-9-ylmethoxy)carbonyl Chloride; Fluoren-9-ylmethyl chloroformate; (9H-fluoren-9-yl)methyl chloroformate; Chloroformic Acid 9-Fluorenylmethyl Ester; FORMIC ACID, CHLORO-, FLUOREN-9-YLMETHYL ESTER; 9-fluorenylmethyloxycarbonyl chloride; MFCD00001138; 9PLB0BTT90; (9H-fluoren-9-yl)methylcarbonochloridate; 9-fluorenylmethyl chlorocarbonate; CCRIS 2608; EINECS 249-313-6; UNII-9PLB0BTT90; BRN 2279177; FmocCl; Fmoc chloride, 97%; Fmoc-Cl (9-Fluorenylmethyl chloroformate); Carbonochloridic acid 9H-fluoren-9-ylmethyl ester; SCHEMBL27547; 9-fluorenemethyl chloroformate; 9-fluorenylmethyl chlorformate; 9-flourenylmethyl chloroformate; 9-fluorenylmethyl-chloroformate; 9-fluoreneylmethyl chloroformate; DTXSID10183116; 9-fluorenylmethoxycarbonyl-chloride; 9-Fluorenylmethyoxycarbonyl chloride; STR02408; 9-Fluorenyl-methyloxycarbonyl chloride; 9H-fluoren-9-ylmethylcarbonochloridate; AKOS009157869; AC-24425; BP-21051; 9H-Fluoren-9-ylmethyl chloridocarbonate #; DB-004014; Fmoc chloride, purum, >=98.0% (HPLC); 9-FLUORENYLMETHYL CHLOROFORMATE [MI]; AM20040102; F0197; FT-0621660; NS00028578; EN300-37269; C93459; Fmoc chloride, BioReagent, >=99.0% (HPLC); FMOC-CL ChloroforMic acid 9-fluorenylMethyl ester; Q827647; Q-101295; F0001-0905; Fmoc chloride, for HPLC derivatization, >=99.0% (HPLC); Fmoc-Cl;9-Fluorenylmethoxycarbonyl-chloride; Fmoc-chloride; 9-Fluorenylmethyl chloroformate; Chloroformic acid 9-fluorenylmethyl ester"	.	.	.	34367	.	.	.
DRG00273	Dansylglycine	Dansylglycine	.	"Dansylglycine; 1091-85-6; DANSYL-GLYCINE; 2-(5-(Dimethylamino)naphthalene-1-sulfonamido)acetic acid; 2-[[5-(dimethylamino)naphthalen-1-yl]sulfonylamino]acetic acid; 5-DIMETHYLAMINONAPHTHALENE-1-SULFONYL-GLYCINE; Dns-Gly-OH; NSC626927; NSC-626927; N-[5-(Dimethylamino)naphthalene-1-sulfonyl]glycine; ((5-(dimethylamino)naphthalen-1-yl)sulfonyl)glycine; Glycine, N-[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]-; 2-[5-(dimethylamino)naphthalene-1-sulfonamido]acetic acid; N-dansylglycine; Dansyl glycine; Dansyl-Gly; DNS-glycine; EINECS 214-129-7; NSC 626927; 2QF9N67QFL; SCHEMBL386439; CHEMBL343297; DTXSID00148815; Dansylglycine, fluorescent amino acid; MFCD00037734; AKOS016674318; HY-W141889; AS-70382; Dansylglycine [for Albumin binding assay]; DB-040858; CS-0201683; D1501; D5406; FT-0624421; NS00023516; T70073; [1-(Dimethylamino)naphthalene-5-sulfonyl]glycine; A801976; N-((5-(Dimethylamino)-1-naphthyl)sulphonyl)glycine; N-[[5-(Dimethylamino)-1-naphthalenyl]sulfonyl]glycine; (5-Dimethylaminonaphthalene-1-sulfonylamino)ethanoic acid; (((5-(Dimethylamino)-1-naphthyl)sulfonyl)amino)acetic acid; 2-[[5-(dimethylamino)-1-naphthyl]sulfonylamino]acetic acid; (([5-(Dimethylamino)-1-naphthyl]sulfonyl)amino)acetic acid #; [5-(DIMETHYLAMINO)NAPHTHALENE-1-SULFONAMIDO]ACETIC ACID"	.	.	.	70666	.	.	.
DRG00274	1H-Benzotriazole	1H-Benzotriazole	.	"1H-Benzotriazole; Benzotriazole; 95-14-7; 1,2,3-BENZOTRIAZOLE; 1H-Benzo[d][1,2,3]triazole; 2H-Benzotriazole; Azimidobenzene; 1H-1,2,3-Benzotriazole; Aziminobenzene; Benztriazole; Benzisotriazole; Benzene azimide; Cobratec #99; 2,3-Diazaindole; 1,2-Aminoazophenylene; 1,2,3-Triazaindene; 2H-benzo[d][1,2,3]triazole; Cobratec 99; 273-02-9; 1,2,-Aminozophenylene; 1,2,3-Triaza-1H-indene; Cobratec 35G; NSC-3058; 1,2,3-1h-benzotriazole; Verzone Crystal; NCI-C03521; Kemitec TT; Rusmin R; Seetec BT; 27556-51-0; CCRIS 78; DTXSID6020147; U-6233; CHEBI:75331; HSDB 4143; EINECS 202-394-1; UNII-86110UXM5Y; BRN 0112133; AI3-15984; 86110UXM5Y; MFCD00005699; DTXCID00147; EC 202-394-1; 4-26-00-00093 (Beilstein Handbook Reference); 1H-Benzotriazol; Benzotriazole (VAN); Entek; BtaH; CAS-95-14-7; Pseudoazimidobenzene; Irgastab I 489; 1,2,3-Benzotriazole,1H-benzo[d][1,2,3]triazole; azaindazole; benzotriazol; ISK 3; aza-indazole; 3uzj; 1 h-benzotriazole; 1,3-Triazaindene; 0CT; 1,3-Benzotriazole; Cobratec No. 99; 1,2-Aminozophenylene; 1,2,3-Benztriazole; 1H-1,3-Benzotriazole; 1,3-Triaza-1H-indene; 1H-Benzotriazole (VAN8C; WLN: T56 BMNNJ; SCHEMBL8956; 1H-BT; MLS002302971; CHEMBL84963; 1H-benzo-[1,2,3]triazole; D 32-108; 1H-BENZOTRIAZOLE [MI]; BDBM36293; NSC3058; Benzotriazole, analytical standard; HMS3091M10; AMY37120; Benzotriazole, reagent grade, 97%; CS-D1407; HY-Y0688; STR01561; Tox21_201501; Tox21_302934; BDBM50234613; STL281967; Benzotriazole, ReagentPlus(R), 99%; 1,2,3-BENZOTRIAZOLE [HSDB]; 1H-Benzotriazole, >=98.0% (N); AKOS000119181; AKOS025396849; PS-3644; NCGC00091322-01; NCGC00091322-02; NCGC00091322-03; NCGC00256574-01; NCGC00259052-01; BP-21454; SMR001252218; 1ST159039; DB-022595; B0094; FT-0606217; FT-0698151; NS00010261; Benzotriazole, Vetec(TM) reagent grade, 98%; EN300-17964; Benzotriazole Solution in Toluene, 1000mug/mL; D77352; AB00374479-06; 1ST159039-1000; AC-907/34124039; Q220672; W-100172; Z57127352; F2190-0645; InChI=1/C6H5N3/c1-2-4-6-5(3-1)7-9-8-6/h1-4H,(H,7,8,9; BTR"	.	.	.	7220	.	.	.
DRG00275	(-)-Cinchonidine	(-)-Cinchonidine	.	"CINCHONIDINE; (-)-Cinchonidine; 485-71-2; (8S,9R)-Cinchonidine; Cinchovatine; alpha-Quinidine; Cinchovatine-; MFCD00006783; L-Cinchonidine; TCMDC-123934; cinchonine; (8S,9R)-cinchonan-9-ol; (8alpha,9R)-Cinchonan-9-ol; 1U622LRA8Z; CHEBI:3703; 485-71-2 (free base); (R)-quinolin-4-yl((1S,2S,4S,5R)-5-vinylquinuclidin-2-yl)methanol; .alpha.-Quinidine; NSC 5364; NSC-5364; Cinchonan-9-ol, (8.alpha.,9R)-; (R)-4-quinolyl-[(2S,4S,5R)-5-vinylquinuclidin-2-yl]methanol; (R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl](quinolin-4-yl)methanol; (R)-[(4S,5S,7S)-5-ethenyl-1-azabicyclo[2.2.2]octan-7-yl]-quinolin-4-ylmethanol; Cinchonan-9-ol, (8a,9R)-; (8-alpha,9R)-Cinchonan-9-ol; SR-05000001575; UNII-1U622LRA8Z; (8alpha,9R)Cinchonan-9-ol; -Quinidine; (-)cinchonidine; ; A-Quinidine; (-) cinchonidine; Cinchonidine,(S); Prestwick_66; EINECS 207-622-3; Cinchonidine, 96%; Spectrum_001165; AI3-15317; Prestwick3_000606; Spectrum2_000719; Spectrum3_001745; Spectrum4_001173; Spectrum5_002073; CINCHONIDINE [MI]; BSPBio_000512; BSPBio_003450; KBioGR_001805; KBioSS_001645; MLS002153905; CINCHONIDINE [WHO-DD]; CINCHONIDINE [WHO-IP]; DivK1c_000501; SCHEMBL159532; SPECTRUM1500839; SPBio_000937; BPBio1_000564; CHEMBL533841; HMS501J03; KBio1_000501; KBio2_001645; KBio2_004213; KBio2_006781; KBio3_002670; DTXSID60883396; NINDS_000501; Cinchonan-9-ol, (8alpha,9R)-; HMS1921K14; HMS2092M14; HMS2096J14; HMS2235F22; Pharmakon1600-01500839; 118-10-5; Cinchonan-9-ol, (8-alpha,9R)-; HY-N0173; STR04708; Cinchonan-9-ol, (8a alpha,9R)-; CCG-36455; CCG-37735; NSC757800; (-)-Cinchonidine, analytical standard; AKOS016008633; NSC-757800; SDCCGMLS-0066969.P001; (R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-quinolin-4-ylmethanol; IDI1_000501; NCGC00178057-01; NCGC00178057-02; NCGC00262526-04; NCGC00262526-10; SMR001233254; SBI-0051617.P002; QUININE SULFATE IMPURITY B [WHO-IP]; CS-0007887; FT-0627743; NS00100765; QUININE BISULFATE IMPURITY B [WHO-IP]; EN300-708682; F15420; AB00052182_03; QUININE SULFATE IMPURITY B [EP IMPURITY]; Q412713; SR-05000001575-1; SR-05000001575-6; SR-05000001575-7; SR-05000001575-8; BRD-K17661460-001-03-2; BRD-K17661460-001-04-0; BRD-K39079086-001-05-0; BRD-K39079086-001-07-6; Cinchonidine, purum, >=98.0% (dried material, NT); QUININE HYDROCHLORIDE IMPURITY B [EP IMPURITY]; Z1954806302; QUININE BISULFATE HEPTAHYDRATE IMPURITY B [WHO-IP]; (-)-Cinchonidine, 99% (total base), may cont. up to 5% quinine; (1R)-quinolin-4-yl((2S,4S,5R)-5-vinylquinuclidin-2-yl)methanol; (R)-quinolin-4-yl((2S,4S,5R)-5-vinylquinuclidin-2-yl)methanol; (R)-[(1R,2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl](quinolin-4-yl)methanol; (S)-[(2R,4R,5S)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-quinolin-4-ylmethanol; (R)-((2S,4S,5R)-5-ETHENYL-1-AZABICYCLO(2.2.2)OCT-2-YL)(QUINOLIN-4-YL)METHANOL [WHO-IP]"	.	.	.	101744	.	.	.
DRG00276	N-[2-[2-(4-nitrophenyl)ethynyl]-5-(2-phenylethynyl)phenyl]acetamide	N-[2-[2-(4-nitrophenyl)ethynyl]-5-(2-phenylethynyl)phenyl]acetamide	.	.	.	.	.	102409332	.	.	.
DRG00277	Dansyl chloride	Dansyl chloride	.	"Dansyl chloride; 605-65-2; 5-(Dimethylamino)naphthalene-1-sulfonyl chloride; DNS chloride; Dansyl; 5-(Dimethylamino)-1-naphthalenesulfonyl chloride; Dansylchloride; 1-NAPHTHALENESULFONYL CHLORIDE, 5-(DIMETHYLAMINO)-; DNSCl; 1-Dimethylaminonaphthalene-5-sulfonyl chloride; 1-Chlorosulfonyl-5-dimethylaminonaphthalene; 5-Dimethylaminonaphthalene-1-sulfonyl chloride; 5-Dimethylaminonaphthalene-1-sulphonyl chloride; 5-DIMETHYLAMINO-1-NAPHTHALENESULFONYL CHLORIDE; NSC 83616; MFCD00003985; QMU9166TJ4; 1-Chlorosulfonyl-5-(dimethylamino)naphthalene; 1-(Dimethylamino)-5-naphthalenesulfonyl chloride; NSC-83616; EINECS 210-092-6; Dimethylaminonaphthalenesulfonyl chloride; BRN 2217205; UNII-QMU9166TJ4; 5-Dimethylaminonaphthyl-5-sulfonyl chloride; AI3-52455; 1-Dimethylamino-naphthalene-5-sulfonyl chloride; NCIOpen2_004548; SCHEMBL21283; DANSYL CHLORIDE [MI]; 4-14-00-02801 (Beilstein Handbook Reference); DTXSID2060543; CHEBI:51907; HY-D0017; NSC83616; BBL100159; STL477538; TD8135; AKOS003789318; Dansyl Chloride - CAS 605-65-2; AM10162; CS-5026; 5-dimethylaminonaphthalenesulfonyl chloride; BP-30250; DS-18465; SY012882; (Dimethylamino)naphthalenesulfonyl chloride; DB-053653; D0005; D0656; FT-0624412; NS00034391; 5-(Dimethylamino)naphthyl-5-sulfonyl chloride; 5-Dimethylamino-l-naphthalenesulfonyl chloride; 5-dimethylamino-1-naphthalenesulphonyl chloride; 5-Dimethylamino-naphthalene-1-sulfonyl chloride; D-0250; EN300-189105; A832783; Q409512; Dansyl chloride, for HPLC derivatization, >=99.0% (HPLC); Dansyl chloride, BioReagent, suitable for fluorescence, >=99.0% (HPLC); Dansyl chloride, BioReagent, suitable for amino acid labeling, powder and chunks, >=99% (HPLC)"	.	.	.	11801	.	.	.
DRG00278	2-Pyrrolino-dox	2-Pyrrolino-dox	.	"2-Pyrrolino-dox; 175795-76-3; 2-Pyrrolinodoxorubicin; AN 201; AN 204; AN-201; AN-204; 3'-Deamino-3'-(2''-pyrroline-1''-yl)doxorubicin trifluoroacetate; DTXSID50938708; (7S,9S)-7-[(2R,4S,5S,6S)-4-(2,3-dihydropyrrol-1-yl)-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-((2,3,6-trideoxy-3-(2,3-dihydro-1H-pyrrol-1-yl)-alpha-L-lyxo-hexopyranosyl)oxy)-, (8S-cis)-; 3,5,12-Trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 2,3,6-trideoxy-3-(2,3-dihydro-1H-pyrrol-1-yl)hexopyranoside"	.	.	.	119196	.	.	.
DRG00279	Tetraxetan	Tetraxetan	.	"DOTA; Tetraxetan; 60239-18-1; 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid; Dota acid; 1,4,7,10-Dota; 1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid; 2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid; CHEBI:61028; DOT-A; 2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid; MFCD00068657; NSC-681107; 1HTE449DGZ; MLS001333612; 2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl]acetic acid; Tetraxetan (USAN); NSC681107; 2,2',2',2'''-(1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetryl)tetraacetic acid; SMR000857276; TETRAXETAN [USAN]; Gadobutrol impurity 1; UNII-1HTE449DGZ; tetraxetanum; gadoterate-meglumine; 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid hydrate; NSC 681107; TETRAXETAN [INN]; Tetraxetan [USAN:INN]; DOTA [MI]; Epitope ID:146095; TETRAXETAN [USP-RS]; SCHEMBL18018; cid_121841; GTPL5538; CHEMBL1721515; BDBM88700; AMY5853; DTXSID60208984; GLXC-02843; HMS2236N04; HMS3373H02; TETRAXETAN [USP MONOGRAPH]; BCP13075; AKOS015854210; NCGC00246979-01; AC-31772; AS-19566; NCI60_028933; SY057414; CS-0046228; FT-0606756; NS00006315; T1875; D06092; F16414; EN300-6503719; A851290; Q161515; J-650232; Z2681893158; 1,4,7,10-tetraazacylododeane-1,4,7,10-tetraacetic acid; 1,4,7,10-tetraazacyclododecane N,N',N',N''-tetraacetic acid; 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid; 1,4,7,10-Tetraazacyclododecane- 1,4,7,10-tetraacetic-acid; 1,4,7,10-TETRAAZACYCLODODECANE-N,N'N'',N'''-TETRAACETIC ACID; 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, >=97.0% (CHN); 1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid, min. 98% DOTA; 2,2',2'',2'''-(1,4,7,10-TETRAAZACYCLODODECANE-1,4,7,10-TETRYL)TETRAACETIC ACID; 2-[4,7,10-tris(2-hydroxy-2-oxoethyl)-1,4,7,10-tetrazacyclododec-1-yl]ethanoic acid"	.	.	.	121841	D09VOI	.	CHEMBL1721515
DRG00280	Erythromycin	Erythromycin	.	"erythromycin; 114-07-8; Erythromycin A; E-Mycin; Abomacetin; Erythromycinum; Emgel; Erymax; Ilotycin; Robimycin; Torlamicina; Eryderm; Erythro-Statin; Erythrocin; Erythromycin base; E-Glades; Ery-Tab; Erythromycine; Eritromicina; Erycette; Pantomicina; Erygel; Sansac; E-Base; Erythra-Derm; ERYC; Dumotrycin; Mephamycin; Ermycin; Eryacne; Stiemycin; Aknin; Erycen; Wemid; R-P Mycin; Eryc Sprinkles; Theramycin Z; Akne-Mycin; E-Solve 2; Ak-Mycin; Erythromast 36; T-Stat; Erytrociclin; Acneryne; Endoeritrin; Eritomicina; Eryacnen; Erydermer; Eryhexal; Erythroderm; Iloticina; Latotryd; Lederpax; Oftamolets; Pantoderm; Pantodrin; Pharyngocin; Primacine; Proterytrin; Stiemicyn; Tiprocin; Acnesol; Derimer; Deripil; Emuvin; Emycin; Erecin; Erisone; Erymed; Erysafe; Erytab; Erytop; Inderm; Mercina; Romycin; AustriaS; Eros; C-Solve-2; Ery-maxin; Erythro-Teva; Sans-acne; Erimycin-T; Ery-Diolan; Inderm Gel; Del-Mycin; Udima Ery Gel; Aknederm Ery Gel; Abboticin; Emu-Ve; Akne Cordes Losung; Eryc 125; Ilotycin T.S.; Skid Gel E; E-Mycin (base); Emu-V; Ery-B; Ery-Tab (base); E-Base (base); ERYC (base); erythromycin-A; A/T/S; Erythrogran; Erythroguent; Erythromid; Propiocine; Dotycin; Erycinum; Ilocaps; PCE Dispertab (base); Erycin; Kesso-Mycin; Eryc-125; Eryc-250; Taimoxin-F; ERYTHROMYCIN STEARATE; erythro; Oftalmolosa Cusi Eritromicina; Eritrocina; Staticin; Retcin; erthromycin; Sentry AQ mardel maracyn; Eritromicina [INN-Spanish]; Erythromycine [INN-French]; Erythromycinum [INN-Latin]; Benzamycin; MFCD00084654; CCRIS 9078; DTXSID4022991; UNII-63937KV33D; CHEBI:42355; HSDB 3074; EM-A; EINECS 204-040-1; NSC 55929; NSC-55929; PCE (ERYTHROMYCIN); CHEMBL532; 63937KV33D; AI3-50138; DTXCID102991; J01FA01; EC 204-040-1; Erythromycin [USP:INN:BAN:JAN]; NSC55929; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-14-ethyl-7,12,13-trihydroxy-4-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione; ERY; BENZAMYCIN COMPONENT ERYTHROMYCIN; Erythromycin C-13; Aknemycin; Eritromicina (INN-Spanish); Erythromycine (INN-French); Erythromycinum (INN-Latin); 8HPH7ND0LN; ERYTHROMYCIN (MART.); ERYTHROMYCIN [MART.]; (3R*,4S*,5S*,6R*,7R*,9R*,11R*,12R*,13S*,14R*)-4-((2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)oxacyclotetradecane-2,10-dione; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione; Ilosone (estolate); ERYTHROMYCIN (USP-RS); ERYTHROMYCIN [USP-RS]; N-Methylerythromycin A; ERYTHROMYCIN (EP MONOGRAPH); Erythromycin (USP:INN:BAN:JAN); ERYTHROMYCIN [EP MONOGRAPH]; ERYTHROMYCIN (USP MONOGRAPH); ERYTHROMYCIN [USP MONOGRAPH]; 643-22-1; Erythromycin, labeled with carbon-13; Staticin (TN); [3R-(3R*,4S*,5S*,6R*,7R*,9R*,11R*,12R*,13S*,14R*)]-4-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione; Akne-mycin (TN); Erygel (TN); Eryc (TN); T-stat (TN); Pce (TN); SR-05000001618; 7704-67-8; Spotex; ErythromycinBase; 82343-12-2; Gallimycin-36; NCGC00094670-01; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione; CAS-114-07-8; Prestwick_205; 215031-94-0; Spectrum_000115; Spectrum_000659; ErythromycinBase Filmtab; Erythro-100 Injection; API E.M. Erythromycin; Erythromycin Base Filmtab; Prestwick3_000151; Spectrum2_000759; Spectrum2_001263; Spectrum4_000538; Spectrum5_001596; UNII-8HPH7ND0LN; ERYTHROMYCIN [MI]; E0751; Erythromycin A, B + C; Erythro-36, Erythro-Dry; ERYTHROMYCIN [INN]; ERYTHROMYCIN [JAN]; ERYTHROMYCIN [HSDB]; SCHEMBL2601; API E.M ERYTHROMYCIN; ERYTHROMYCIN [VANDF]; BSPBio_000282; BSPBio_002480; KBioGR_001175; KBioSS_000555; KBioSS_001139; MLS001066618; BIDD:GT0017; DivK1c_000294; DivK1c_000397; DivK1c_000702; ERYTHROMYCIN [WHO-DD]; ERYTHROMYCIN [WHO-IP]; SPECTRUM1500280; SPBio_000778; SPBio_001226; BPBio1_000312; GTPL1456; CHEBI:48923; Erythromycin (JP17/USP/INN); HMS500O16; KBio1_000294; KBio1_000397; KBio1_000702; KBio2_000555; KBio2_001139; KBio2_003123; KBio2_003707; KBio2_005691; KBio2_006275; ERYTHROMYCIN [GREEN BOOK]; NINDS_000294; NINDS_000397; NINDS_000702; ERYTHROMYCIN [ORANGE BOOK]; HMS1920M04; HMS2091D05; HMS2095O04; HMS3712O04; Pharmakon1600-01500280; HY-B0220; RKL10096; Tox21_111311; Tox21_111869; Tox21_300515; BDBM50344942; CCG-38992; LMPK04000006; NSC756759; ERYTHROMYCINUM [WHO-IP LATIN]; Gallimycin Injection, Gallimycin-100; AKOS015895249; 1ST7801; DB00199; NSC-756759; IDI1_000294; IDI1_000397; IDI1_000702; SMP1_000119; NCGC00179619-01; NCGC00179619-02; NCGC00179619-03; NCGC00254234-01; AC-12744; AC-12901; SMR000544946; ERYTHROMYCIN COMPONENT OF BENZAMYCIN; Erythromycin, potency: >=850 mug per mg; Erythromycin, tested according to Ph.Eur.; SBI-0051368.P003; Erythromycin, N-demethyl-N-(methyl-11C)-; Erythromycin 1000 microg/mL in Acetonitrile; NS00000203; Erythromycin, meets USP testing specifications; C01912; D00140; E-3250; Erythromycin, plant cell culture tested, ~98%; AB00051981_09; AB00051981_10; Erythromycin, Biotechnology Performance Certified; Erythromycin estolate impurity, free erythromycin-; Q213511; SR-01000799155; Erythromycin, Antibiotic for Culture Media Use Only; Erythromycin, BioReagent, suitable for cell culture; SR-01000799155-2; SR-05000001618-1; SR-05000001618-2; BRD-K63550407-001-13-5; BRD-K63550407-028-03-9; Z2587996953; Erythromycin A, British Pharmacopoeia (BP) Reference Standard; Erythromycin A, European Pharmacopoeia (EP) Reference Standard; Erythromycin, United States Pharmacopeia (USP) Reference Standard; ERYTHROMYCIN ESTOLATE IMPURITY, FREE ERYTHROMYCIN [EP IMPURITY]; ERYTHROMYCIN ESTOLATE IMPURITY, FREE ERYTHROMYCIN- [USP IMPURITY]; Erythromycin, for microbiological assay, European Pharmacopoeia (EP) Reference Standard; Erythromycin, Pharmaceutical Secondary Standard; Certified Reference Material; (3R*,4S*,5S*,6R*,7R*,9R*,11R*,12R*,13S*,14R*)-4-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribo-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-4-(2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyloxy)-14-ethyl-7,12,13-trihydroxy-6-[3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyloxy]-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydropyran-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione (non-preferred name); 7540-22-9"	.	.	.	12560	D02YIZ	DB00199	CHEMBL532
DRG00281	"5-(4-Aminophenyl)-10,15,20-triphenyl porphine"	"5-(4-Aminophenyl)-10,15,20-triphenyl porphine"	.	"67605-64-5; 5-(4-aminophenyl)-10,15,20-triphenyl porphine; 4-(10,15,20-Triphenylporphyrin-5-yl)phenylamine; 5-(4-aminophenyl)-10,15,20-(triphenyl)porphyrin; 5-(4-Aminophenyl)-10,15,20-tris(phenyl)porphyrin; 5-(4-aminophenyl)-10,15,20-triphenylporphyrin; 4-(10,15,20-triphenyl-21,23-dihydroporphyrin-5-yl)aniline; 4-(10,15,20-Triphenyl-21H,23H-porphin-5-yl)benzenamine; YSWG152; SCHEMBL3999312; CHEMBL3408510; BS-47662; DB-315634; CS-0086506; E85151; 4-(10,15,20-triphenylporphyrin-5-yl)aniline; 5-(4-aminophenyl)-10,15,20-triphenylporphine"	.	.	.	135423398	.	.	.
DRG00282	[2.1.1]Cryptand siliconhexafluoride	[2.1.1]Cryptand siliconhexafluoride	.	"[2.1.1]cryptand siliconhexafluoride; 4,7,13,18-Tetraoxa-1,10-diazoniabicyclo[8.5.5]icosane hexafluoridosilicate"	.	.	.	139081637	.	.	.
DRG00283	"1-(2,4-dichloro-5-methoxyphenyl)-5-methyl-1H-1,2,4-triazole-3-carboxylic acid"	"1-(2,4-dichloro-5-methoxyphenyl)-5-methyl-1H-1,2,4-triazole-3-carboxylic acid"	.	"1-(2,4-dichloro-5-methoxyphenyl)-5-methyl-1H-1,2,4-triazole-3-carboxylic acid; 103058-64-6; 1-(2,4-dichloro-5-methoxyphenyl)-5-methyl-1,2,4-triazole-3-carboxylic acid; AKOS005098461; 7L-352S; 1-(2,4-dichloro-5-methoxyphenyl)-5-methyl-1H-1,2,4-triazole-3-carboxylicacid"	.	.	.	1484187	.	.	.
DRG00284	"1-(4-chlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxylic acid"	"1-(4-chlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxylic acid"	.	"1-(4-chlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxylic acid; 103058-60-2; 1-(4-chlorophenyl)-5-methyl-1,2,4-triazole-3-carboxylic Acid; HMS1784O15; MFCD00173066; AKOS001187833; 12G-370S; DS-020201; CS-0234989; EN300-15149; AB00744767-01; AP-501/43386247; Z118308194"	.	.	.	1487023	.	.	.
DRG00285	Fluorescein	Fluorescein	.	"fluorescein; 2321-07-5; Solvent Yellow 94; Resorcinolphthalein; Fluoresceine; 3',6'-Dihydroxy-3H-spiro[isobenzofuran-1,9'-xanthen]-3-one; Yellow fluorescein; 3,6-Fluorandiol; Japan Yellow 201; D and C Yellow No. 7; C.I. Solvent Yellow 94; D&C Yellow No. 7; 3',6'-Dihydroxyfluoran; Fluoreszein; Fluorescein acid; Soap Yellow F; Hidacid fluorescein; Fluorescein Red; D+C Yellow No. 7; 11712 Yellow; CHEBI:31624; Japan Yellow No. 201; Zlut kysela 73; D & C Yellow no. 7; 9-(o-Carboxyphenyl)-6-hydroxy-3-isoxanthenone; 9-(o-Carboxyphenyl)-6-hydroxy-3H-xanthen-3-one; Fluoran, 3',6'-dihydroxy-; Fluorescein (free acid); Dihydroxyfluorane; 3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one; TPY09G7XIR; Resorcinol phthalein; Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 3',6'-dihydroxy-; Diresorcinolphthalein; C.I. 45350:1; NSC 667256; CCRIS 7076; DTXSID0038887; 3',6'-Fluorandiol; HSDB 2128; CI 45350:1; EINECS 219-031-8; UNII-TPY09G7XIR; MFCD00005050; NSC-667256; NSC-759114; 3H-Xanthen-3-one, 9-(o-carboxyphenyl)-6-hydroxy-; BRN 0094324; CHEMBL1057; Ki201; DTXCID8018887; 3,6-Dihydroxyspiro(xanthene-9,3'-phthalide); 3',6'-Dihydroxyspiro(isobenzofuran-1(3H),9'(9H)-xanthen)-3-one; NSC667256; Benzoic acid, o-(6-hydroxy-3-oxo-3H-xanthen-9-yl)-; Benzoic acid, 2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)-; NCGC00161643-03; D & C YELLOW NO. 7 K7133; 3',6'-dihydroxy-3H-spiro[2-benzofuran-1,9'-xanthen]-3-one; FLUORESCEIN (II); FLUORESCEIN [II]; 3',6'-Dihydroxyspiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one; Spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one, 3',6'-dihydroxy-; EC 219-031-8; FLUORESCEIN (MART.); FLUORESCEIN [MART.]; FLUORESCEIN (USP-RS); FLUORESCEIN [USP-RS]; 5-19-06-00456 (Beilstein Handbook Reference); Fluorescein (USP:BAN:JAN); Fluorescein [USP:BAN:JAN]; FLUORESCEIN (EP MONOGRAPH); FLUORESCEIN [EP MONOGRAPH]; FLUORESCEIN (USP MONOGRAPH); FLUORESCEIN [USP MONOGRAPH]; CAS-2321-07-5; 3,6-Dihydroxyspiro[xanthene-9,3'-phthalide]; C20H12O5; Zlut kysela 73 [Czech]; Fluoresceina; Diofluor; 3',6'-dihydroxy-3H-spiro(2-benzofuran-1,9'-xanthen)-3-one; Fluorescein; 3',6'-Dihydroxy-3H-spiro[isobenzofuran-1,9'-xanthen]-3-one; fluorescein lactone; Fluorescite (TN); D&C yellow No 7; Fluorescite (Salt/Mix); 3',6' dihydroxyfluoran; Fluorescein (JAN/USP); FLUORESCEIN [MI]; 3',4'-Dehydroxyfluoran; FLUORESCEIN [JAN]; 3',6'-Dihydroxyfluorane; fluorescein (lactone form); FLUORESCEIN [HSDB]; Epitope ID:137337; UPCMLD-DP087; FLUORESCEIN [VANDF]; SCHEMBL16533; FLUORESCEIN [WHO-DD]; 2-(6-Hydroxy-3-oxo-(3H)-xanthen-9-yl)benzoic acid; UPCMLD-DP087:001; GNBHRKFJIUUOQI-UHFFFAOYSA-; C.I. 45350 (free acid); Fluorescein (Solvent Yellow 94); C.I. 45350 (Salt/Mix); HMS2093F21; HMS3744C17; MOLI001003; Pharmakon1600-01505396; AMY22388; HY-D0251; Tox21_113500; Tox21_303508; BDBM50237588; C.I. Acid Yellow 73 (Salt/Mix); NSC759114; s5488; Spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one,3'6'-dihydroxy-; AKOS015903296; CCG-213417; CS-7537; DB00693; C.I. 45350A; Fluorescein, for fluorescence, free acid; NCGC00161643-01; NCGC00161643-02; NCGC00257491-01; BP-31220; SY012645; SBI-0206827.P001; F0095; Fluorescein (free acid), Dye content 95 %; FT-0668579; NS00004148; D01261; D70685; EN300-702817; AB00643381_02; Q410922; SR-05000001696; SR-05000001696-1; W-107417; BRD-K21913543-001-01-6; Benzoic acid, 2-(6-Hydroxy-3-oxo-3H-xanthen-9-yl)-,; Benzoic acid, o-(6-hydroxy-3-oxo-3H-xanthen-9-yl)-,; 3',6'-dihydroxyspiro[isobenzofuran-3,9'-xanthene]-1-one; E89FA0B4-4844-46A2-AF9B-29ECA50E5599; Fluorescein, European Pharmacopoeia (EP) Reference Standard; O-(6-HYDROXY-3-OXO-3H-XANTHEN-9-YL)BENZOIC ACID; 3',6'-Dihydroxyspiro(isobenzofuran-1(3H), 9'(9H)-xanthen)-3-one; Fluorescein, United States Pharmacopeia (USP) Reference Standard; 11712 YELLOW9-(O-CARBOXYPHENYL)-6-HYDROXY-3H-XANTHEN-3-ONE; spiro(isobenzofuran-1(3H),9'-(9H)xanthen-3-one, 3',6'-Dihydroxy-; Fluorescein Low Range DNA standard, fluorescein-labeled marker for DNA electrophoresis; Spiro[isobenzofuran-1(3H),9'-[9H]xanthene]-ar-carboxylicacid, 3',6'-dihydroxy-3-oxo-; InChI=1/C20H12O5/c21-11-5-7-15-17(9-11)24-18-10-12(22)6-8-16(18)20(15)14-4-2-1-3-13(14)19(23)25-20/h1-10,21-22H"	.	.	.	16850	D06TJJ	DB00693	.
DRG00286	Phenytoin	Phenytoin	.	"phenytoin; 5,5-DIPHENYLHYDANTOIN; 57-41-0; Diphenylhydantoin; Dilantin; 5,5-diphenylimidazolidine-2,4-dione; Phenytoine; Zentropil; Epamin; Lepitoin; Dihydantoin; Aleviatin; Dilabid; Diphantoin; Diphenylan; Diphedan; Fenylepsin; Phentytoin; Sodanton; Difenin; Dihycon; Lehydan; Diphenylhydatanoin; Dantoinal; Di-Hydan; Dilantine; Dillantin; Diphenine; Diphentyn; Ditoinate; Elepsindon; Epilantin; Fenitoina; Fenytoine; Hidantilo; Hidantina; Hidantomin; Hydantoinal; Kessodanten; Phanantin; Phanatine; Phenatoine; Sodantoin; Sylantoic; Thilophenyl; Zentronal; Auranile; Dantinal; Dantoine; Difetoin; Difhydan; Dintoin; Dintoina; Diphedal; Diphenin; Enkelfel; Epifenyl; Epihydan; Fentoin; Hidantal; Hydantal; Idantoil; Idantoin; Labopal; Phentoin; Ritmenal; Saceril; Sanepil; Silantin; Solantin; Danten; Denyl; Epelin; Epinat; Epised; Eptal; Hidan; Lepsin; Oxylan; Ekko; Ictalis simple; Toin unicelles; Dilantin acid; Dantoinal klinos; Om-Hydantoine; Di-Phetine; Epdantoine simple; Hidantina vitoria; Gerot-epilan-D; Epilan-D; Neosidantoina; Comitoina; Hidantina senosian; Hydantol; Minetoin; Novantoina; Causoin; Convul; Di-Lan; Ekko capsules; Neos-Hidantoina; 2,4-Imidazolidinedione, 5,5-diphenyl-; Om hidantoina simple; TOIN; Phenhydanin; Phenytex; Phenytoinum; Sinergina; Sodanthon; Iphenylhydantoin; Phenytoin-Gerot; Difenilhidantoina; Fenytoin Dak; Didan TDC 250; Dilantin-125; Epdantoin Simple; Phenytoin AWD; Epilan D; 5,5-Diphenyl-2,4-imidazolidinedione; Diphenat; Hindatal; Hydantin; Epanutin; Fenitoina [INN-Spanish]; Phenytoine [INN-French]; Phenytoinum [INN-Latin]; Difenilhidantoina [Spanish]; Diphenylhydantoine [French]; 5,5-Dwufenylohydantoina; Antisacer; Fenantoin Mn Pharma; Diphenylhydantoine; Di-Lan (VAN); PHENYTOIN SODIUM; Diphenylhydantoin (VAN); Diphentoin; DILANTIN-30; Solantoin; Solantyl; Eptoin; DPH (VAN); 5,5-diphenyl hydantoin; 5,5-Diphenylimidazolidin-2,4-dione; 5,5-Diphenyl-imidazolidine-2,4-dione; 5,5-Diphenylhydantoin (IUPAC); 5,5-Dwufenylohydantoina [Polish]; Hydantoin, 5,5-diphenyl-; CCRIS 515; CHEBI:8107; NCI-C55765; 5,5-Diphenylhydantoin (phenytoin); AI3-52498; NSC-8722; Dilantin (TN); Novophenytoin; MFCD00005264; MLS000069789; Citrulliamon; DTXSID8020541; Phenitoin; 5,5-diphenyltetrahydro-1H-2,4-imidazoledione; Fenidantoin s; NSC8722; SM-88 COMPONENT PHENYTOIN; 6158TKW0C5; Epasmir 5; NCGC00021139-03; SMR000059026; Fenidantoin 's'; 5,5-DIPHENYLHYDANTOIN-D5 98 ATOM % D; DTXCID60541; Epasmir '5'; Didan-tdc-250; CAS-57-41-0; phenytoin (PHN); component of Mebroin; fenidantoin ''s''; epasmir ''5''; NSC 8722; EINECS 200-328-6; UNII-6158TKW0C5; SR-01000075211; IFLab1_000214; Fenidantoin 's'; HSDB 3160; Episar (Salt/Mix); Epasmir '5'; Aladdin (Salt/Mix); Alepsin (Salt/Mix); Epsolin (Salt/Mix); Phenytoin (Lepitoin); Tacosal (Salt/Mix); Phenytoin [USAN:USP:INN:BAN:JAN]; Antisacer (Salt/Mix); Epdantoin (Salt/Mix); Epileptin (Salt/Mix); Hydantoin,5-diphenyl-; Spectrum_001105; Fenigramon (Salt/Mix); Citrullamon (Salt/Mix); Opera_ID_394; PHENYTOIN [INN]; PHENYTOIN [JAN]; 2, 5,5-diphenyl-; PHENYTOIN [MI]; CHEMBL16; PHENYTOIN [HSDB]; PHENYTOIN [IARC]; PHENYTOIN [USAN]; Spectrum2_001281; Spectrum3_000890; Spectrum4_000984; Spectrum5_001369; Lopac-D-4007; PHENYTOIN [VANDF]; Epitope ID:117723; PHENYTOIN [MART.]; D 4007; PHENYTOIN [USP-RS]; PHENYTOIN [WHO-DD]; PHENYTOIN [WHO-IP]; SCHEMBL3440; BIDD:PXR0090; Lopac0_000329; Lopac0_000378; Oprea1_373280; BSPBio_001437; KBioGR_001387; KBioSS_001585; MLS001074087; MLS002454401; BIDD:GT0625; DivK1c_000507; Soluble phenytoin (Salt/Mix); SPBio_001281; Phenytoin (JP17/USP/INN); Phenytoin, 1mg/ml in Methanol; GTPL2624; PHENYTOIN [ORANGE BOOK]; 2-hydroxy-5,5-diphenyl-3,5-dihydro-4H-imidazol-4-one; PHENYTOIN [EP MONOGRAPH]; PHENYTOIN [USP IMPURITY]; KBio1_000507; KBio2_001585; KBio2_004153; KBio2_006721; KBio3_001780; PHENYTOIN [USP MONOGRAPH]; WLN: T5MVMV EHJ ER& ER; 5,5-Diphenylhydantoin, >=99%; NINDS_000507; Phenytoin 1.0 mg/ml in Methanol; HMS1412J16; HMS1694O05; HMS1791H19; HMS1989H19; HMS2089E11; HMS2236J06; HMS3261K17; HMS3402H19; HMS3657O03; PHENYTOINUM [WHO-IP LATIN]; BCP05960; HY-B0448; Hydantoin, 5,5-diphenyl- (8CI); Tox21_110861; Tox21_202299; Tox21_300281; Tox21_500378; AC-376; BDBM50003655; BDBM50101816; s2525; STK058029; STK182871; STL454130; AKOS000416887; AKOS003245432; Tox21_110861_1; CCG-104011; CCG-221682; DB00252; LP00378; Phenytoin 1000 microg/mL in Methanol; 5,5-di(phenyl)imidazolidine-2,4-dione; IDI1_000507; IDI1_008433; NCGC00015342-01; NCGC00015342-02; NCGC00015342-03; NCGC00015342-04; NCGC00015342-05; NCGC00015342-06; NCGC00015342-07; NCGC00015342-08; NCGC00015342-09; NCGC00015342-10; NCGC00015342-11; NCGC00015342-12; NCGC00021139-01; NCGC00021139-02; NCGC00021139-04; NCGC00021139-05; NCGC00021139-06; NCGC00021139-07; NCGC00021139-08; NCGC00021139-09; NCGC00021139-10; NCGC00021139-11; NCGC00091492-01; NCGC00091492-02; NCGC00091492-03; NCGC00091492-04; NCGC00091492-05; NCGC00093810-01; NCGC00093810-02; NCGC00254135-01; NCGC00259848-01; NCGC00261063-01; 5,5-?Diphenyl-?2,4-?imidazolidinedione; imidazolidine-2,4-dione, 5,5-diphenyl-; 5,5-Diphenyl-1H-imidazolidine-2,4-dione; D0894; EU-0100378; FT-0667653; FT-0699999; NS00010290; SW203757-2; EN300-16818; 5,5-diphenylimidazolidine-2,4-dione;Phenytoin; C07443; D00512; E76094; 2,4-Imidazolidinedione, 5,5-diphenyl- (9CI); AB00374253-10; AB00374253-11; AB00374253_13; A831435; Q410400; SR-01000003141; SR-01000003141-8; SR-01000075211-2; W-105468; BRD-K55930204-001-02-7; BRD-K55930204-236-11-0; Z56786458; 4-hydroxy-5,5-diphenyl-1,5-dihydro-2H-imidazol-2-one; F0020-1370; Phenytoin, European Pharmacopoeia (EP) Reference Standard; Phenytoin, United States Pharmacopeia (USP) Reference Standard; Phenytoin, Pharmaceutical Secondary Standard; Certified Reference Material; Phenytoin for system suitability, European Pharmacopoeia (EP) Reference Standard; InChI=1/C15H12N2O2/c18-13-15(17-14(19)16-13,11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10H,(H2,16,17,18,19"	.	.	.	1775	D0E4DW	DB00252	CHEMBL16
DRG00287	Vitamin e succinate	Vitamin e succinate	.	"vitamin e succinate; 4345-03-3; alpha-Tocopheryl succinate; D-alpha-Tocopherol succinate; tocopherol succinate; alpha-tocopherol succinate; D-; A-Tocopherol succinate; D-ALPHA-TOCOPHERYL SUCCINATE; Vitamin E hemisuccinate; Alpha-tocopherol succinate, d-; d-alpha-Tocopherol acid succinate; alpha tocopheryl acid succinate; alpha-Tocopheryl acid succinate; (+)-alpha-Tocopheryl succinate; alpha-Vitamin E succinate; D-?-Tocopherol succinate; Vitamine E succinate; LU4B53JYVE; .alpha.-Tocopherol succinate; DTXSID2026151; MFCD00072055; 4-Oxo-4-(((R)-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trimethyltridecyl)chroman-6-yl)oxy)butanoic acid; 4-oxo-4-[[(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl]oxy]butanoic acid; a-Tocopheryl Succinate; D-alpha tocopheryl acid succinate; NCGC00167561-01; NSC 173849; Butanedioic acid,mono[(2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl] ester; DTXCID706151; d-alpha-Tocopheryl acid succinate; ; A-Tocopheryl Succinate; 4-oxo-4-{[(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydro-2H-1-benzopyran-6-yl]oxy}butanoic acid; Butanedioic acid, 1-((2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl) ester; Butanedioic acid, mono((2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl) ester; CAS-4345-03-3; Covitol 1210; D-.alpha.-Tocopherol succinate; D-.alpha.-Tocopheryl succinate; alpha-Tocopherol, succinate; alpha-Tocopherol hemisuccinate; CCRIS 4734; alpha-Tocopheryl succinate, D-; NSC173849; NSC-173849; Tocopherol acid succinate, alpha-; 6-Chromanol, 2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-, hydrogen succinate, (+)-; alpha-Tocopheryl hydrogen succinate; Vitamin-E Dragees; 4-oxo-4-((R)-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trimethyltridecyl)chroman-6-yloxy)butanoic acid; Butanedioic acid, mono(3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl) ester, (2R-(2R*(4R*,8R*)))-; Butanedioic acid, mono[(2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl] ester; RRR-alpha-Tocopheryl hydrogen succinate; (2R)-2,5,7,8-Tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydro-2H-1-benzopyran-6-yl hydrogen succinate; d-alpha-tocopherol succinate; Vitamin E succinate; (+)-alpha-tocopheryl acid succinate; D-alpha-Tocopheryl hydrogen succinate; Succinic acid, mono(2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-6-chromanyl) ester, (+)-; Tocopheryl succinate; alpha-Tocopherol acid succinate, D-; Dal-E; EINECS 224-403-8; EINECS 241-433-7; (+)-alpha-Tocopherol acid succinate; CV 104; TOCOPHERYL ACID SUCCINATE,D-ALPHA; .ALPHA.-TOCOPHEROL SUCCINATE, D-; d-a-tocopherol succinate; UNII-LU4B53JYVE; D-alpha-tocopheryl-succinate; .alpha.-tocopheryl succinate; semisynthetic, 1210?IU/g; White-e [veterinary] (TN); CHEMBL81421; SCHEMBL134422; D- alpha -Tocopheryl Succinate; alpha-Tocopherol, succinate, D-; .alpha.-tocopheryl succinate, d-; CHEBI:135821; Tocopheryl Acid Succinate, d-Alpha; Tox21_112556; Tox21_200568; BDBM50458511; D-alpha-Tocopheryl hydrogen succinate; AKOS015902063; Dal-Vita brand of vitamin E succinate; Wiedemann brand of vitamin E succinate; (+)-.alpha.-Tocopherol acid succinate; AC-1132; CCG-207945; DB14001; 2,5,7,8-Tetramethyl-2-(4,8,12-trimethyltridecyl)-6-chromanyl hydrogen succinate, (+)-; Mono(2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-6-chromanyl) succinate, (+)-; RRR-alpha-Tocopheryl Hydrogen Succinate; NCGC00167561-02; NCGC00167561-03; NCGC00258122-01; TOCOPHERYL ACID SUCCINATE [VANDF]; 3-{[(2R)-2-((4R,8R)-4,8,12-trimethyltridecyl)-2,5,7,8-tetramethylchroman-6-yl] oxycarbonyl}propanoic acid; 4-oxo-4-[(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]chroman-6-yl]oxy-butanoic acid; 55134-51-5; AS-75106; J24.824J; Mono(3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl) butanedioate, (2R-(2R*(4R*,8R*)))-; .ALPHA.-TOCOPHEROL SUCCINATE [MI]; RRR-ALPHA-TOCOPHERYL ACID SUCCINATE; TOCOPHERYL ACID SUCCINATE [WHO-DD]; HY-131553; CS-0136520; NS00045903; T2628; VITAMIN E (ALPHA-TOCOPHERYL SUCCINATE); C90299; D08612; D-ALPHA TOCOFERIL ACID SUCCINATE [MART.]; D-alpha-Tocopherol succinate, analytical standard; RRR-.ALPHA.-TOCOPHERYL HYDROGEN SUCCINATE; C033716; EN300-23011947; RRR-ALPHA-TOCOPHERYL ACID SUCCINATE [FCC]; SR-01000883728; TOCOPHERYL ACID SUCCINATE,D-ALPHA [VANDF]; SR-01000883728-1; Q27283185; D-alpha-Tocopherol succinate, semisynthetic, 1210 IU/g; Z2216889767; D-alpha-Tocopherol succinate, BioXtra, >=98.0% (HPLC); RRR-.ALPHA.-TOCOPHERYL HYDROGEN SUCCINATE [EP IMPURITY]; Alpha tocopheryl acid succinate, United States Pharmacopeia (USP) Reference Standard; RRR-alpha-Tocopheryl hydrogen succinate, European Pharmacopoeia (EP) Reference Standard; (3,4-Dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl) hydrogen succinate; 4-Oxo-4-(((R)-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trimethyltridecyl)chroman-6-yl)oxy)butanoicacid; mono((2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl) butanedioate; Tocopheryl Acid Succinate, a, Pharmaceutical Secondary Standard; Certified Reference Material"	.	.	.	20353	.	DB14001	.
DRG00288	"3-nitro-4-(1H-1,2,4-triazol-1-yl)benzoic acid"	"3-nitro-4-(1H-1,2,4-triazol-1-yl)benzoic acid"	.	"3-nitro-4-(1H-1,2,4-triazol-1-yl)benzoic acid; 162848-24-0; 3-nitro-4-(1H-1,2,4-triazol-1-yl)benzenecarboxylic acid; 3-nitro-4-(1,2,4-triazol-1-yl)benzoic Acid; Oprea1_690291; MLS000774262; SCHEMBL299335; Benzoic acid, 3-nitro-4-(1H-1,2,4-triazol-1-yl)-; CHEMBL1444714; ZVCHVNGMLDMGIN-UHFFFAOYSA-N; DTXSID301252700; HMS2756P24; MFCD00141985; AKOS000118240; 2G-304S; SMR000365330; CS-0225386; EN300-12365; AB00653286-02; 3-nitro-4-(1H-1,2,4-triazol-1-yl)benzoicacid; Z85932111; 3-nitro-4-(1H-1,2,4-triazol-1-yl)benzenecarboxylic acid, AldrichCPR"	.	.	.	2060096	.	.	CHEMBL1444714
DRG00289	4-Pentynoic acid	4-Pentynoic acid	.	"4-PENTYNOIC ACID; Pent-4-ynoic acid; 6089-09-4; Propargylacetic acid; 4-pentynoicacid; Pent-4-yn-1-oic acid; Propargylacetic Acid;; MFCD00004407; pent4-ynoic acid; EINECS 228-028-0; BRN 1742047; Pent-4-yn-1-oicacid; 4-Pentynoic acid, 95%; LCWG002; MLBYLEUJXUBIJJ-UHFFFAOYSA-; DTXSID20209730; BCP33459; HY-Y1230; BBL103677; STL557487; AKOS000188069; CS-W008784; GS-6696; BP-31168; 4-Pentynoic acid, purum, >=97% (GC); Pent-4-yn-1-oic acid;Propargylacetic acid; DB-053734; DB-367931; FT-0619364; NS00034491; P2341; EN300-115626; 4-02-00-01693 (Beilstein Handbook Reference); Q27455468; Z295890062; InChI=1/C5H6O2/c1-2-3-4-5(6)7/h1H,3-4H2,(H,6,7)"	.	.	.	22464	.	.	.
DRG00290	Paclitaxel Succinate	Paclitaxel Succinate	.	"Paclitaxel Succinate; 117527-50-1; Paclitaxel-Succinic acid; 2'-Succinyltaxol; 4-(((1S,2R)-1-benzamido-3-(((2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-diacetoxy-12-(benzoyloxy)-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxet-9-yl)oxy)-3-oxo-1-phenylpropan-2-yl)oxy)-4-oxobutanoic acid; Taxol-2'-hemisuccinate; 2'-O-Succinoylpaclitaxel; 2' Succinyltaxol; 2'-succinyl-taxol; 2'-Succinyl Taxol; CHEMBL231831; SCHEMBL13640304; RBNOJYDPFALIQZ-LAVNIZMLSA-N; DTXSID801315159; AKOS040753416; 4-[(1S,2R)-1-benzamido-3-[[(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-2-benzoyloxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-15-yl]oxy]-3-oxo-1-phenylpropan-2-yl]oxy-4-oxobutanoic acid"	.	.	.	25024567	.	.	.
DRG00291	"2-(1H-pyrrol-1-yl)-1,3-benzothiazole-6-carboxylic acid"	"2-(1H-pyrrol-1-yl)-1,3-benzothiazole-6-carboxylic acid"	.	"2-(1H-pyrrol-1-yl)-1,3-benzothiazole-6-carboxylic acid; 251457-88-2; 2-pyrrol-1-yl-1,3-benzothiazole-6-carboxylic acid; MFCD01764668; 2-(1H-Pyrrol-1-yl)benzo[d]thiazole-6-carboxylic acid; SCHEMBL261142; ALBB-015908; BKA45788; BBL010439; STK801604; AKOS001476272; VS-02500; DB-133128; EN300-186519; 2-(1H-pyrrol-1-yl)-6-benzothiazolecarboxylic acid; 2-(1H-Pyrrol-1-yl)benzo[d]thiazole-6-carboxylicacid; 6-Benzothiazolecarboxylic acid, 2-(1H-pyrrol-1-yl)-; 2-(1H-Pyrrol-1-yl)-1,3-benzothiazole-6-carboxylic acid, AldrichCPR"	.	.	.	2728386	.	.	.
DRG00292	"4-Azido-2,3,5,6-tetrafluorobenzoic acid"	"4-Azido-2,3,5,6-tetrafluorobenzoic acid"	.	"4-azido-2,3,5,6-tetrafluorobenzoic acid; 122590-77-6; Benzoic acid, 4-azido-2,3,5,6-tetrafluoro-; 4-azido-2,3,5,6-tetrafluoro-benzoic Acid; Benzoic acid,4-azido-2,3,5,6-tetrafluoro-; MFCD00467436; 4-azidotetrafluorobenzoic acid; YSZC4012; SCHEMBL13475524; DTXSID80376316; IOJFHZXQSLNAQJ-UHFFFAOYSA-N; ALBB-005224; STK503298; AKOS005171570; BS-43785; SY051242; DB-081108; HY-151662; CS-0617886; FT-0617626; T70158; J-004832; 4-Azido-2,3,5,6-tetrafluorobenzoic acid, AldrichCPR"	.	.	.	2762578	.	.	.
DRG00293	"5-methyl-1-(4-nitrophenyl)-1H-1,2,4-triazole-3-carboxylic acid"	"5-methyl-1-(4-nitrophenyl)-1H-1,2,4-triazole-3-carboxylic acid"	.	"1025-88-3; 5-methyl-1-(4-nitrophenyl)-1H-1,2,4-triazole-3-carboxylic acid; 5-methyl-1-(4-nitrophenyl)-1,2,4-triazole-3-carboxylic Acid; AGPQLGNAAHYBPG-UHFFFAOYSA-N; HMS2598H08; MLS000755431; SCHEMBL1820467; CHEMBL1466251; DTXSID80377666; 5-Methyl-1-(4-nitrophenyl)-1H-1,2,4-triazole-3-carboxylicacid; BAA02588; MFCD00173063; AKOS005069617; 12G-348S; DA-38885; SMR000337811; FT-0680062; J-517720; 1H-1,2,4-Triazole-3-carboxylic acid, 5-methyl-1-(4-nitrophenyl)-; 5-methyl-1(4-nitrophenyl)-1h-1,2-4-triazole-3-carboxylic acid"	.	.	.	2768762	.	.	.
DRG00294	Carbamic acid	Carbamic acid	.	"CARBAMIC ACID; 463-77-4; Aminoformic acid; imidocarbonic acid; aminocarboxylic acid; O0UC6XOS4H; CHEBI:28616; Aminoameisensaeure; Aminomethanoic Acid; UNII-O0UC6XOS4H; Aminoformate; Carbamidsaeure; ammoniocarboxylate; Carbonimidic acid; ISOCARBAMIC ACID; azanium carbamate hydrate; IMINOCARBONIC ACID; FORMIC ACID, AMINO-; CHEMBL125278; DTXSID5048009; BDBM50369454; AKOS006223007; DB04261; NCGC00166327-01; NS00003466; C01563; EN300-379173; Q412078; VQO"	.	.	.	277	D0H9UT	DB04261	.
DRG00295	"1-(2,4-dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxylic acid"	"1-(2,4-dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxylic acid"	.	"1-(2,4-dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxylic acid; 103058-79-3; 1-(2,4-dichlorophenyl)-5-methyl-1,2,4-triazole-3-carboxylic Acid; SCHEMBL10729168; MFCD00172421; AKOS005085011; 2H-334S; DB-210966; G54570; EN300-26375021; 1-(2,4-dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxylicacid"	.	.	.	3471374	.	.	.
DRG00296	Zidovudine	Zidovudine	.	"zidovudine; Azidothymidine; 30516-87-1; 3'-Azido-3'-deoxythymidine; Retrovir; AZT; Thymidine, 3'-azido-3'-deoxy-; Zidovudinum; Compound S; Zidovudina; ZIDOVUDINE [AZT]; zidovudin; Trizivir; BW A509U; Zidovudinum [Latin]; 3'-Deoxy-3'-azidothymidine; BWA509U; BW-A509U; ZDV; BW-A-509U; DRG-0004; Azidothymidine (AZT); Aztec; CCRIS 105; 3'-azt; HSDB 6515; 3'-Azidothymidine; UNII-4B9XT59T7S; NSC 602670; 4B9XT59T7S; DTXSID8020127; CHEBI:10110; 1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione; BW-A 509U; MFCD00006536; 1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione; CHEMBL129; NSC-602670; Azitidin; 1-(3-Azido-2,3-dideoxy-beta-D-ribofuranosyl)thymine; DTXCID60127; MLS000028548; 1-((2R,4S,5S)-4-AZIDO-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL)-5-METHYLPYRIMIDINE-2,4(1H,3H)-DIONE; AZT Antiviral; COMBIVIR COMPONENT ZIDOVUDINE; TRIZIVIR COMPONENT ZIDOVUDINE; AZT, Antiviral; Zidovudinum (Latin); 1-(3-Azido-2,3-dideoxy-beta-D-ribofuranosyl)-5-methylpyrimidine-2,4-(1H,3H)-dione; AZT (Antiviral); Zidovudine [USAN:USP:INN:BAN:JAN]; NCGC00023945-05; SMR000058351; Zidovudina [Spanish]; ZIDOVUDINE (IARC); ZIDOVUDINE [IARC]; Antiviral AZT; ZIDOVUDINE (MART.); ZIDOVUDINE [MART.]; ZIDOVUDINE (USP-RS); ZIDOVUDINE [USP-RS]; Timazid; 399024-19-2; ZIDOVUDINE (EP IMPURITY); ZIDOVUDINE [EP IMPURITY]; ZIDOVUDINE (EP MONOGRAPH); ZIDOVUDINE [EP MONOGRAPH]; ZIDOVUDINE (USP MONOGRAPH); ZIDOVUDINE [USP MONOGRAPH]; Propolis+AZT; 3'-Azido-2',3'-Dideoxythymidine; Zidovudine (USAN:USP:INN:BAN:JAN); Retrovir(TM); AZT & Li & EPO; Retrovir (TN); 3' Azido 3' deoxythymidine; Cpd S; Intron A & AZT; Racemic Liposomal AZT; Liposomal AZT-SN-1; Liposomal AZT-SN-3; Zidovudine+PRO 140; PC-SOD+AZT; 3' Azido 2',3' Dideoxythymidine; AZT & srCD4; AZT & rIFN.alpha.2; AZT & rsT4; rIFN-beta seron & AZT; 3'-Azido-3'-deoxythymidine (AIDS); AZT & EPO; AZT & GM-CSF; AZT & HPA; AZT & sCD4; AZT & SST; zudovidine; Aziodothymidine; AZT & Li & GM-CSF; AZT+PRO 140; Met-SDF-1.beta. & AZT; AZT & Li & IL-1; AZT & Li & IL-6; AZT & IL-1; AZT & IL-2; AZT & IL-6; AZT & Interferon-.alpha.-2; AZT & Concanavalin A (ConA); AZT & Lymphoblastoid Interferon; AZT & PM-19; Met-SDF-1.beta. & Zidovudine; 4lhm; 1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione (AZT); 1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione [AZT]; AZT & rsCD4 & rIFN.alpha.A; 3'-azido-3'-deoxythymidine, AZT; DS-4152 & AZT; 1-((2R,4R,5S)-4-azido-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione; 1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-methyl-pyrimidine-2,4-dione; 5-methyl-1-[rac-(2R,4S,5S)-4-azido-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidine-2,4-dione; AZT & Colony-stimulating factor 2; AZT & NP (from PHCA or HSA); Zidovudine; 1-(3-Azido-2,3-dideoxy-ss-d-erythro-pentofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione; Zidovudine (GR 63367X); BP Zidovudine and Lamivudine Impurity Standard; 3''-azido-thymidine; K7 [P Ti2 W10 O40]; Zidovudine & IFNL1; Zidovudine & IFNL2; Zidovudine & IFNL3; Zidovudine (Retrovir); COMPOUND-S; Spectrum_001348; AZT & CD4(178)-PE 40; AZT & IFN.alpha.; Zidovudine & IL-29; ZIDOVUDINE [MI]; Zidovudine & IL-28A; Zidovudine & IL-28B; ZIDOVUDINE [INN]; ZIDOVUDINE [JAN]; AZT & Interleukin 29; Opera_ID_1602; Prestwick3_000333; Spectrum2_000927; Spectrum3_001507; Spectrum4_000332; Spectrum5_001101; 3'azido-3'deoxythymidine; ZIDOVUDINE [HSDB]; ZIDOVUDINE [USAN]; 3'-Azido-3'-deoxythymidine & Erythropoietin; 3'-Azido-3'-deoxythymidine & Sho-Saiko-To; Azidothymidine; Zidovudine; Interferon AD + 3'-azido-3'-deoxythymidine; AZT & Interleukin 28A; AZT & Interleukin 28B; 3'-Azido-3'-deoxythymidine & Concanavalin A; 3'-Azido-3'-deoxythymidine & Interleukin-1; 3'-Azido-3'-deoxythymidine & Interleukin-2; 3'-Azido-3'-deoxythymidine & Interleukin-6; ZIDOVUDINE [VANDF]; 3'-azido-3-deoxythimydine; 3'-azido3'-deoxythymidine; AZT & IFNL1; AZT & IFNL2; AZT & IFNL3; AZT & Interferon lambda-1; AZT & Interferon lambda-2; AZT & Interferon lambda-3; AZT (PHARMACEUTICAL); ZIDOVUDINE [WHO-DD]; ZIDOVUDINE [WHO-IP]; 3''-Deoxy-3-azidothymidine; BSPBio_000365; BSPBio_003153; KBioGR_000703; KBioSS_001828; MLS001055351; MLS001076358; MLS002153202; MLS002222249; Zidovudine & Interleukin 29; DivK1c_000524; SPECTRUM1502109; ZIDOVUDINE [EMA EPAR]; 3'-deoxy-3'-azido-thymidine; SPBio_000834; Zidovudine & Interleukin 28A; Zidovudine & Interleukin 28B; AZT & IL-28A; AZT & IL-28B; BPBio1_000403; GTPL4825; Zidovudine (JP17/USP/INN); 3'-Azido-3'-deoxythymidine & Lithium & Erythropoietin; 3'-Azido-3'-deoxythymidine & Lithium & Interleukin-1; 3'-Azido-3'-deoxythymidine & Lithium & Interleukin-6; 3'-Azido-3'-deoxythymidine & Lymphoblastoid Interferon; SCHEMBL14615088; SN-1-dipalmitoylglycerophospho-AZT (in a lipid vesicle); SN-3-dipalmitoylglycerophospho-AZT (in a lipid vesicle); ZIDOVUDINE [ORANGE BOOK]; AZT & IL-29; HMS501K06; KBio1_000524; KBio2_001828; KBio2_004396; KBio2_006964; KBio3_002653; J05AF01; racemic-dipalmitoylglycerophospho-AZT (in a lipid vesicle); 3''-Azido-3''-deoxy-thymidine; NINDS_000524; Zidovudine & Interferon lambda-1; Zidovudine & Interferon lambda-2; Zidovudine & Interferon lambda-3; HMS1921J20; HMS2090G11; HMS2092D06; HMS2096C07; HMS2234K17; HMS3259H17; HMS3713C07; Pharmakon1600-01502109; ZIDOVUDINUM [WHO-IP LATIN]; 3''azido-2''3''-dideoxythymidine; Tox21_110062; Tox21_110894; Tox21_202203; Tox21_300578; BBL033764; BDBM50002692; CCG-39924; NSC758185; STK801891; AKOS005622576; AKOS015842610; Tox21_110062_1; 3''-azido-2'',3''-dideoxythymidine; DB00495; NC00666; NSC-758185; ZIDOVUDINE COMPONENT OF COMBIVIR; ZIDOVUDINE COMPONENT OF TRIZIVIR; IDI1_000524; NCGC00014918-01; NCGC00023945-03; NCGC00023945-04; NCGC00023945-06; NCGC00023945-07; NCGC00023945-08; NCGC00023945-09; NCGC00023945-10; NCGC00023945-12; NCGC00023945-13; NCGC00023945-24; NCGC00023945-25; NCGC00178237-01; NCGC00178237-02; NCGC00254276-01; NCGC00259752-01; 1-((2R,4S,5S)-4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione; AS-13019; SBI-0051731.P002; DB-225998; FT-0601543; NS00000600; Propolis & Thymidine, 3'-azido-3'-deoxy-; S2579; SW198799-2; EN300-52518; 3'-Azido-3'-deoxythymidine, >=98% (HPLC); C07210; D00413; D88500; 3'-Azido-3'deoxythymidine & Interferon .alpha.; 3'-Azido-3'-deoxythymidine, >=99.0% (HPLC); A820413; Q198504; SR-01000000098; SR-05000001587; J-700147; SR-01000000098-3; SR-05000001587-1; BRD-K72903603-001-04-6; BRD-K72903603-001-14-5; LAMIVUDINE/ZIDOVUDINE TEVA COMPONENT ZIDOVUDINE; Z754931264; Zidovudine, European Pharmacopoeia (EP) Reference Standard; 3'-Azido-3'-deoxythymidine & Recombinant Interferon-.alpha.-2; Zidovudine, United States Pharmacopeia (USP) Reference Standard; 3'-Azido-3'-deoxythymidine & CD4-Pseudomonas exotoxin A hybrid; Beta interferon(rIFN-beta seron) & 3'-Azido-3'-deoxythymidine(AZT); Lecithinized superoxide dismutase & Thymidine, 3'-azido-3'-deoxy-; 3'-Azido-2',3'-dideoxythymidine & sCD4(soluble recombinant protein); Thymidine, 3'-azido-3'-deoxy- & PRO 140 (Anti-CCR5 monoclonal antibody); Zidovudine, Pharmaceutical Secondary Standard; Certified Reference Material; (AZT) 1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione; (AZT)1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione; 1-(3-Azido-2,3-dideoxy-beta-D-ribofuranosy)-5-methylpyridimine-2,4-(1H,3H)-dione; 1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione; 1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione(AZT); 3'-Azido-3'-deoxythymidine & Granulocyte-macrophage colony-stimulating factor; 3'-Azido-3'-deoxythymidine & Lithium & Granulocyte-macrophage colony-stimulating factor; 3'-Azido-3'deoxythymidine & Recombinant Soluble CD4 & Recombinant Interferon.alpha.A; 4-(4-Azido-5-hydroxy-tetrahydro-furan-2-yl)-5-methyl-3H-pyrazine-2,6-dione; Met-Stromal Cell-derived Factor-1.beta. (Human) & 3'-Azido-3'-deoxythymidine; 1-((2R,4S,5S)-4-(diazoamino)-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione; 1-((2R,4S,5S)-4-azido-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione; 1-((2R,5S)-4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione; 1-((2S,4R,5R)-4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione; 1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione (AzddThd, AZT); 1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione (N3ddThd); 1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione(3''-azido-2'',3''-dideoxythymidine); 1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione(azidothymidine, AZT); 1-(4-Azido-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-methyl-1H-pyrimidine-2,4-dione(Zidovudine, AZT); 3-((2S,3S,5R)-2-(hydroxymethyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl)triaz-1-en-2-ium-1-ide"	.	.	.	35370	D01XYJ	DB00495	CHEMBL129
DRG00297	"1-(4-fluorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxylic acid"	"1-(4-fluorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxylic acid"	.	"1-(4-fluorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxylic acid; 103058-62-4; 1-(4-fluorophenyl)-5-methyl-1,2,4-triazole-3-carboxylic Acid; SCHEMBL3356061; DTXSID50393858; IOKWGFCAXYAKKM-UHFFFAOYSA-N; MFCD00172410; STL133429; AKOS001183682; BS-3574; DB-290743; CS-0309014; EN300-15150; G37719; AB00744773-01; J-000865; Z118308196; 1-(4-fluorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxylicacid; 1-(4-fluoro-phenyl)-5-methyl-1H-[1,2,4]triazole-3-carboxylic acid; 1H-1,2,4-Triazole-3-carboxylic acid, 1-(4-fluorophenyl)-5-methyl-; 1-(4-Fluorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxylic acid, AldrichCPR"	.	.	.	3581337	.	.	.
DRG00298	7-Methoxy-4-methylcoumarin	7-Methoxy-4-methylcoumarin	.	"7-Methoxy-4-methylcoumarin; 2555-28-4; 7-Methoxy-4-methyl-2H-chromen-2-one; 4-Methylherniarin; HYMECROMONE METHYL ETHER; 2H-1-Benzopyran-2-one, 7-methoxy-4-methyl-; 7-methoxy-4-methylchromen-2-one; 7-Methoxy-4-methyl-chromen-2-one; 4-Methyl-7-methoxycoumarin; 39JDG776HP; 7-Methoxy-4-methyl-2H-1-benzopyran-2-one; MFCD00009773; NSC688805; NSC 688805; UNII-39JDG776HP; NSC-688805; 7-methoxy-4-methyl-1-benzopyran-2-one; Herniarin, 4-methyl-; coumarin,4-methyl-7-methoxy; Coumarin, 7-methoxy-4-methyl-; Spectrum_000788; ST060441; SpecPlus_000316; Spectrum2_001769; Spectrum3_001256; Spectrum4_001475; Spectrum5_000149; 2(1H)-Benzopyran-2-one, 7-methoxy-4-methyl; 7-Methoxy-4-Methylcoumarine; BSPBio_002792; KBioGR_002049; KBioSS_001268; SPECTRUM300540; 7-Methoxy-4-Methyl coumarin; MLS002207059; CHEMBL12636; DivK1c_006412; SCHEMBL314248; SPBio_001637; KBio1_001356; KBio2_001268; KBio2_003836; KBio2_006404; KBio3_002292; DTXSID70180242; Methyl 4-methylumbelliferyl ether; CHEBI:107662; ALBB-023165; HY-D0128; CCG-38419; GEO-02734; s4780; STK392110; AKOS001086638; AM84842; SDCCGMLS-0066546.P001; NCGC00095600-01; NCGC00095600-02; NCGC00178467-01; 7-Methoxy-4-methyl-2H-chromen-2-one #; AS-17835; SMR001306707; SY048371; 1ST164145; DB-029378; CS-0010038; FT-0602217; M1393; NS00027916; F16417; EN300-6734931; A817898; SR-05000002424; J-100205; SR-05000002424-1; BRD-K55766625-001-02-6; BRD-K55766625-001-04-2; Q27185984; Z53836589"	.	.	.	390807	.	.	CHEMBL12636
DRG00299	Trolox	Trolox	.	"trolox; 53188-07-1; 6-Hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid; TROLOX C; 3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-carboxylic acid; 6-Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid; 2H-1-Benzopyran-2-carboxylic acid, 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-; MFCD00006846; 6-hydroxy-2,5,7,8-tetramethyl-chromane-2-carboxylic acid; CHEBI:82625; 6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromene-2-carboxylic acid; S18UL9710X; 6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromene-2-carboxylic acid; (+/-)-6-Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid; (+/-)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid; 56305-04-5; 6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-1-benzopyran-2-carboxylic acid; EINECS 258-422-8; BRN 5052542; UNII-S18UL9710X; Trolox(TM); Prestwick_855; (S)-Trolox?; Prestwick0_000530; Prestwick1_000530; Prestwick2_000530; Prestwick3_000530; TROLOX [MI]; CHEMBL153; SCHEMBL3226; 2H-1-Benzopyran-2-carboxylic acid, 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-, (+-)-; Oprea1_727377; BSPBio_000519; MLS002153860; SPBio_002440; (+/-)-TROLOX; BPBio1_000571; 6-Hydroxy-2,5,7,8-tetramethyl-chroman-2-carboxylic acid; DTXSID60866306; HMS1569J21; HMS2096J21; HMS2230A15; HMS3369E20; HMS3713J21; HMS3885K19; (R,S)-6-hydroxy-2,5,7,8-tetramethyl-2-chromanecarboxylic acid; BCP16474; BBL103047; BDBM50359629; GEO-03688; s3665; STL556856; AKOS015856256; CCG-207912; CS-8035; ( inverted exclamation markA)-6-Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid; 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2h-1-benzopyran-2- carboxylic acid; NCGC00179534-01; AS-30121; SMR001233218; DB-052268; DB-071631; HY-101445; FT-0621156; FT-0770514; H0726; NS00015501; EN300-370592; Q245489; SR-01000841227; SR-01000841227-2; BRD-A17846016-001-03-0; BRD-A17846016-001-07-1; 6-hydroxy-2,5,7,8-tetramethychroman-2-carboxylic acid; 6-Hydroxy-2,5,7,8-tetramethyl-2-chromancarboxylic acid; Z3013814504; 6-Hydroxy-2,5,7,8-tetramethyl-2-chromanecarboxylic acid #; (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)carboxylic acid; (+/-)- 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid; (+/-)-6-Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid, 97%; 6-HYDROXY-2,5,7,8-TETRAMETHYLCHROMAN-2-CARBOXYLIC ACID, (+/-)-; 3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-carboxylic Acid;; 6-hydroxy-3,4-dihydro-2,5,7,8-tetramethyl-2H-1-benzopyran-2-carboxylic acid; Trolox is also know as 6-Hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid.; 2H-1-BENZOPYRAN-2-CARBOXYLIC ACID, 3,4-DIHYDRO-6-HYDROXY-2,5,7,8-TETRAMETHYL-, (+/-)-"	.	.	.	40634	.	.	CHEMBL153
DRG00300	Nalidixic Acid	Nalidixic Acid	.	"nalidixic acid; 389-08-2; Nalidixate; Nalidixin; NegGram; Nevigramon; Uronidix; Innoxalon; Nalidixan; Nalitucsan; Sicmylon; Unaserus; Nalidic acid; Nalidixinic acid; Wintomylon; Dixiben; Dixinal; Jicsron; Nalurin; Naxuril; Cybis; Nalix; Nogram; Urisal; Uroman; 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; Betaxina; Kusnarin; Nalidicron; Nicelate; Specifen; Specifin; Urodixin; Narigix; Negram; Poleon; Uralgin; Uriben; Uriclar; Uroneg; Uropan; Naldixic acid; Acide nalidixique; Acide nalidixico; Acido nalidixico; WIN 18,320; Acidum nalidixicum; NSC-82174; Eucistin; 1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; Acido nalidissico; Nalidixane; NCI-C56199; 1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; 3-Carboxy-1-ethyl-7-methyl-1,8-naphthyridin-4-one; 1,4-Dihydro-1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid; 1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-1,4-dihydro-7-methyl-4-oxo-; 3-Carboxy-1-ethyl-7-methyl-1,8-naphthidin-4-one; MFCD00006884; CCRIS 2365; Acide nalidixique [INN-French]; Acido nalidixico [INN-Spanish]; Acidum nalidixicum [INN-Latin]; HSDB 3241; 1-Ethyl-7-methyl-1,4-dihydro-1,8-naphthyridin-4-one-3-carboxylic acid; EINECS 206-864-7; UNII-3B91HWA56M; WIN-18320; 1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure; BRN 0750515; 3B91HWA56M; DTXSID3020912; CHEBI:100147; NSC82174; Acide 1-etil-7-metil-1,8-naftiridin-4-one-3-carbossilico; Nalidixic acid (NegGram); DTXCID70912; MLS000028504; Win 18320; 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 5-25-07-00384 (Beilstein Handbook Reference); NCGC00018181-08; SMR000058264; Wintron; Nalidixic acid [USAN:USP:INN:BAN:JAN]; 1,4-Dihydro-1-ethyl-7-methyl-1,8-naphthyridin-4-one-3-carboxylic acid; Acid, Nalidixic; Nalidixic acid 100 microg/mL in Acetonitrile; Acido nalidissico [DCIT]; Acide nalidixico [Italian]; Acide nalidixique [French]; NALIDIXIC ACID (MART.); NALIDIXIC ACID [MART.]; Acide nalidixique (INN-French); Acido nalidixico (INN-Spanish); Acidum nalidixicum (INN-Latin); 1-Ethyl-7-methyl-1,8-naphthyridin-4-one-3-carboxylic acid; Nalidixic; NALIDIXIC ACID (EP IMPURITY); NALIDIXIC ACID [EP IMPURITY]; NALIDIXIC ACID (USP IMPURITY); NALIDIXIC ACID [USP IMPURITY]; 1,8-Naphthyridine-3-carboxylic acid,1-ethyl-1,4-dihydro-7-methyl-4-oxo-; CAS-389-08-2; Nalidixic acid (USAN:USP:INN:BAN:JAN); NegGram (TN); wil 18,320; Innoxalomn; Nalidixinsaure; Eucisten; nalidixic-acid; SR-01000003086; 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-(1,8)naphthyridine-3-carboxylic acid; 1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure [German]; Acide 1-etil-7-metil-1,8-naftiridin-4-one-3-carbossilico [Italian]; NALIDIXICACID; WIN 183203; CHEMBL5; Spectrum_000918; Maybridge1_007101; Opera_ID_1064; Prestwick0_000187; Prestwick1_000187; Prestwick2_000187; Prestwick3_000187; Spectrum2_001360; Spectrum3_000075; Spectrum4_000817; Spectrum5_001540; Nalidixic acid, >=98%; UPCMLD-DP129; N-1200; NALIDIXIC ACID [MI]; NCIOpen2_004342; Lopac0_000837; Oprea1_010545; SCHEMBL21736; BSPBio_000113; BSPBio_001889; KBioGR_001333; KBioSS_001398; NALIDIXIC ACID [INN]; NALIDIXIC ACID [JAN]; MLS001148578; MLS002303041; MLS004820190; MLS006011875; 1-ethyl-7-methyl-4-oxo-1; BIDD:GT0529; DivK1c_000058; NALIDIXIC ACID [HSDB]; NALIDIXIC ACID [USAN]; SPECTRUM1500756; SPBio_001579; SPBio_002034; NALIDIXIC ACID [VANDF]; BPBio1_000125; NALIDIXIC ACID [WHO-DD]; UPCMLD-DP129:001; BDBM21691; GTPL12773; HMS500C20; HMS561K17; KBio1_000058; KBio2_001398; KBio2_003966; KBio2_006534; KBio3_001109; J01MB02; NINDS_000058; HMS1921G10; HMS2092K04; HMS2232H24; HMS3259O13; HMS3374G11; HMS3656K05; Pharmakon1600-01500756; Nalidixic acid (JP17/USP/INN); Nalidixic acid, analytical standard; ALBB-021275; HY-B0398; Tox21_110835; Tox21_201477; Tox21_302754; BBL012279; CCG-39298; NALIDIXIC ACID [ORANGE BOOK]; NSC757432; STK735579; 1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxilic acid; AKOS000120074; Tox21_110835_1; DB00779; NC00494; NSC-757432; SDCCGSBI-0050814.P004; IDI1_000058; NCGC00018181-01; NCGC00018181-02; NCGC00018181-03; NCGC00018181-04; NCGC00018181-05; NCGC00018181-06; NCGC00018181-07; NCGC00018181-09; NCGC00018181-10; NCGC00018181-12; NCGC00018181-13; NCGC00021730-03; NCGC00021730-04; NCGC00021730-05; NCGC00021730-06; NCGC00021730-07; NCGC00256581-01; NCGC00259028-01; AS-13289; NCI60_041807; SMR004703506; SY049448; WLN: T66 BN EV JNJ B2 DVQ I1; Nalidixic acid 100 microg/mL in Methanol; SBI-0050814.P003; DB-049349; Nalidixic acid 1000 microg/mL in Methanol; 1, 1-ethyl-1,4-dihydro-7-methyl-4-oxo-; FT-0603390; N0490; NS00009829; S2328; SW219624-1; 1-Ethyl-1,8-naphthyridine-3-carboxilic acid; 1-Ethyl-1,8-naphthyridine-3-carboxylic acid; EN300-20573; VU0239598-6; C05079; D00183; D91720; Nalidixic acid, meets USP testing specifications; Q281082; SR-01000003086-4; SR-01000003086-6; BRD-K47886988-323-03-0; Nalidixic acid, Antibiotic for Culture Media Use Only; SR-01000003086-10; F0850-6751; Z104478940; 3-CARBOXY-1-ETHYL-7-METHYL-1,8-NAPTHIDIN-4-ONE; 1-ethyl-7-methyl-4-oxo-[1,8]naphthyridine-3-carboxylic acid; Nalidixic acid, European Pharmacopoeia (EP) Reference Standard; Nalidixic acid, United States Pharmacopeia (USP) Reference Standard; 1-ETHYL-7-METHYL-1,4-DIHYDRO-1,8-NAPTHYRIDIN-4-ONE-CARBOXYLIC ACID; 1-Ethyl-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1-ETHYL-1,4-DIHYDRO-7-METHYL-4-OXO-1,8-NAPTHYRIDINE-3-CARBOXYLIC ACID; 1-ETHYL-7-METHYL-4-OXO-1,4-DIHYDRO[1,8]NAPHTHYRIDINE-3-CARBOXYLIC ACID; InChI=1/C12H12N2O3/c1-3-14-6-9(12(16)17)10(15)8-5-4-7(2)13-11(8)14/h4-6H,3H2,1-2H3,(H,16,17"	.	.	.	4421	D07JGT	DB00779	CHEMBL5
DRG00301	"5-Chloro-2-phenylimidazo[1,2-a]pyridine-3-carboxylic acid"	"5-Chloro-2-phenylimidazo[1,2-a]pyridine-3-carboxylic acid"	.	.	.	.	.	44717145	.	.	.
DRG00302	3'-O-Acetylthymidine	3'-O-Acetylthymidine	.	"3'-O-Acetylthymidine; 21090-30-2; Thymidine, 3'-acetate; CHEMBL266234; (2R,3S,5R)-2-(Hydroxymethyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl acetate; C12H16N2O6; SCHEMBL265600; 3'-O-Ac-T; 3'-ACETYLTHYMIDINE; IRFKBRPHBYCMQU-IVZWLZJFSA-N; BDBM50375420; MFCD00056059; [(2R,3S,5R)-2-(hydroxymethyl)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl] acetate; AC-32259; FT-0638092; (2R,3S,5R)-2-(HYDROXYMETHYL)-5-(5-METHYL-2,4-DIOXO-3H-PYRIMIDIN-1-YL)OXOLAN-3-YL ACETATE; [(2R,3S,5R)-2-(hydroxymethyl)-5-(5-methyl-2,4-dioxo-pyrimidin-1-yl)tetrahydrofuran-3-yl] acetate"	.	.	.	464365	.	.	.
DRG00303	Prednisolone	Prednisolone	.	"prednisolone; 50-24-8; Metacortandralone; Hydroretrocortine; Delta-Cortef; Deltacortril; Deltahydrocortisone; Codelcortone; Cortalone; Meticortelone; Predonine; Prenolone; Hydroretrocortin; Meti-Derm; Deltacortenol; Hydrodeltalone; Hydrodeltisone; Precortancyl; Predniliderm; Cotogesic; Decaprednil; Delcortol; Deltisilone; Dicortol; Donisolone; Dydeltrone; Erbacort; Erbasona; Estilsona; Fernisolone; Hydeltra; Hydeltrone; Lentosone; Paracortol; Paracotol; PRDL; Precortilon; Precortisyl; Prednelan; Prednicen; Predonin; Rolisone; Scherisolon; Sterolone; Cordrol; Prednis; Prelone; Steran; Sterane; Ulacort; Delta-stab; Fernisolone P; Hostacortin H; Ultracorten H; Ultracortene-H; Predne-Dome; Decortin H; CO-Hydeltra; Eazolin D; Di-adreson F; Delta F; Derpo PD; Solone; 1-Dehydrohydrocortisone; Fernisolone-P; delta(1)-Hydrocortisone; delta(1)-Dehydrocortisol; Delta-Ef-Cortelan; Predniretard; Dexa-Cortidelt hostacortin H; Panafcortelone; Prednisolona; Prednisolonum; Cotolone; 1,2-Dehydrohydrocortisone; delta(1)-Cortisol; Deltasolone; Supercortisol; Klismacort; Prednisolonum [INN-Latin]; Prednisolona [INN-Spanish]; Bubbli-Pred; delta(sup 1)-Cortisol; Delta(1)-dehydrohydrocortisone; 1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione; Ultracortene-hydrogen; delta(sup 1)-Hydrocortisone; delta(sup 1)-Dehydrocortisol; CCRIS 980; (11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione; 1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol; 11beta,17,21-Trihydroxypregna-1,4-diene-3,20-dione; K 1557; HSDB 3385; UNII-9PHQ9Y1OLM; 3,20-Dioxo-11beta,17alpha,21-trihydroxy-1,4-pregnadiene; 9PHQ9Y1OLM; delta(sup 1)-Dehydrohydrocortisone; NSC 9120; NSC-9120; NSC-9900; EINECS 200-021-7; delta-hydrocortisone; delta-dehydrocortisol; DELTA.1-Cortisol; APREDNISLON; BRN 1354103; EQUISOLON; VETSOLONE; CHEBI:8378; DTXSID9021184; .DELTA.1-Cortisol; Prednisolone (Standard); 11beta,17alpha,21-Trihydroxypregna-1,4-diene-3,20-dione; delta-dehydrohydrocortisone; MFCD00003649; (+)-PREDNISOLONE; .DELTA.1-Hydrocortisone; (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one; .DELTA.1-Dehydrocortisol; CHEMBL131; PREDNISOLONE ANHYDROUS; DTXCID301184; .DELTA.1-Dehydrohydrocortisone; .delta.-Cortef; 1-Dehydrocortisol; Neo-Delta-Cortef; NSC9120; EC 200-021-7; .delta.-Stab; 4-08-00-03467 (Beilstein Handbook Reference); component of Ataraxoid; PREDNISOLONE (EMA EPAR: VETERINARY); Prednisolonum (INN-Latin); component of K-Predne-Dome; Prednisolona (INN-Spanish); PREDNISOLONE (MART.); PREDNISOLONE [MART.]; CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE; PREDNISOLONE (USP-RS); PREDNISOLONE [USP-RS]; PREDNISOLONE (EP MONOGRAPH); PREDNISOLONE [EP MONOGRAPH]; PREDNISOLONE (USP MONOGRAPH); PREDNISOLONE [USP MONOGRAPH]; Prednisolone (1.0 mg/mL in Methanol); (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one; SMR000718761; Prednisolone [INN:BAN:JAN]; PREDNICARBATE IMPURITY A (EP IMPURITY); PREDNICARBATE IMPURITY A [EP IMPURITY]; HYDROCORTISONE IMPURITY A (EP IMPURITY); HYDROCORTISONE IMPURITY A [EP IMPURITY]; METHYLPREDNISOLONE IMPURITY K (EP IMPURITY); METHYLPREDNISOLONE IMPURITY K [EP IMPURITY]; MLS002638110; Pregna-1,20-dione, 11.beta.,17,21-trihydroxy-; Predisolone Sodium Phosphate; prednisolon; Adnisolone; Deltidrosol; Kuhlprednon; Lenisolone; Longiprednil; Predeltilone; Prednicortelone; Capsoid; Dhasolone; Fisopred; Frisolona; Gupisone; Opredsone; Preflam; Prenilone; Pregna-1,20-dione, 11,17,21-trihydroxy-, (11.beta.)-; PrednisTab; Delta-Phoricol; Lepi-Cortinolo; Dontisolon D; Predni-Coelin; Dacortin H; Delta-Diona; Pred-Clysma; Predni-Helvacort; Prednisolone oral; Meti Derm; Delta-F; CAS-50-24-8; Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-; Linola-H-Fett N; NCGC00094764-01; Prednisolone Powder; Linola-H N; TUA; Prestwick_404; delta1-Hydrocortisone; Delta-Cortef (TN); 11-beta,17,21-Trihydroxypregna-1,4-diene-3,20-dione; T-Pred (Salt/Mix); 1,4-Pregnadien-11-beta,17-alpha,21-triol-3,20-dione; 1,4-Pregnadiene-11-beta,17-alpha,21-triol-3,20-dione; 1,4-Pregnadiene-3,20-dione-11-beta,17-alpha,21-triol; Delta(1)Hydrocortisone; Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-; Prednisolone, >=99%; Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11b)-; Prestwick0_000274; Prestwick1_000274; Prestwick2_000274; Prestwick3_000274; PREDNISOLONE [EP]; PREDNISOLONE [MI]; PREDNISOLONE [INN]; PREDNISOLONE [JAN]; PREDNISOLONE [HSDB]; SCHEMBL3233; K-Predne-Dome (Salt/Mix); PREDNISOLONE [VANDF]; PREDNISONE IMPURITY B; .DELTA.(sup 1)-Cortisol; BSPBio_000148; Delta1-dehydro-hydrocortisone; MLS001304083; MLS002154250; MLS002207037; MLS002548883; PREDNISOLONE [WHO-DD]; PREDNISOLONE [WHO-IP]; SPBio_002367; BPBio1_000164; GTPL2866; Prednisolone anhydrous Micronized; .DELTA.(sup 1)-Hydrocortisone; BDBM19190; Prednisolone (JP17/USP/INN); NSC9900; PREDNISOLONE [GREEN BOOK]; .DELTA.(sup 1)-Dehydrocortisol; HMS1568H10; HMS2090J05; HMS2095H10; HMS2230P10; HMS3259E09; HMS3712H10; PREDNISOLONE [ORANGE BOOK]; PREDNISONE IMPURITY B [EP]; BCP09053; Tox21_111327; Tox21_201673; Tox21_302987; HY-17463R; LMST02030179; PREDNISOLONUM [WHO-IP LATIN]; Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11.beta.)-; s1737; .DELTA.(sup 1)-Dehydrohydrocortisone; AKOS015894935; Tox21_111327_1; AC-1773; CCG-220274; DB00860; NC00473; NCGC00179649-01; NCGC00179649-02; NCGC00179649-03; NCGC00179649-04; NCGC00179649-06; NCGC00256577-01; NCGC00259222-01; AS-13665; HY-17463; CS-0695025; NS00000394; P0637; EN300-53017; C07369; D00472; D91990; Prednisolone, VETRANAL(TM), analytical standard; A929791; SR-01000837502; Q-201616; SR-01000837502-2; BRD-K98039984-001-03-0; BRD-K98039984-001-06-3; PREDNISOLONE ACETATE IMPURITY B [EP IMPURITY]; PREDNISOLONE COMPONENT OF CHLOROPTIC-P S.O.P.; Q11426176; 11beta,17,21-trihydroxy-1,4-pregnadiene-3,20-dione; Prednisolone, British Pharmacopoeia (BP) Assay Standard; Z778141968; 11-.beta.,17,21-Trihydroxypregna-1,4-diene-3,20-dione; 11beta,17alpha,21-Trihydroxy-1,4-pregnadiene-3,20-dione; 1,4-Pregnadien-11-.beta.,17-.alpha.,21-triol-3,20-dione; 1,4-Pregnadiene-11-.beta.,17-.alpha.,21-triol-3,20-dione; 1,4-Pregnadiene-3,20-dione-11-.beta.,17-.alpha.,21-triol; Prednisolone, European Pharmacopoeia (EP) Reference Standard; Pregna-1,4-diene-3,20-dione, 11.beta.,17,21-trihydroxy-; 11,17,21-Trihydroxypregna-1,4-diene-3,20-dione, (11.beta.)-; 11-.beta.,17-.alpha.,21-Trihydroxy-1,4-pregnadiene-3,20-dione; 11-.beta.,17-.alpha.,21-Trihydroxypregna-1,4-diene-3,20-dione; 11.BETA.,17,21-TRIHYDROXYPREGNA-1,4-DIENE-3,20-DIONE.; 11.beta.,17.alpha.,21-Trihydroxypregna-1,4-diene-3,20-dione; Prednisolone, United States Pharmacopeia (USP) Reference Standard; Prednisolone for peak identification, European Pharmacopoeia (EP) Reference Standard; Prednisolone for system suitability, European Pharmacopoeia (EP) Reference Standard; Prednisolone, Pharmaceutical Secondary Standard; Certified Reference Material; PREGNA-1,4-DIENE-3,20-DIONE, 11,17,21-TRIHYDROXY-, (11.BETA)-; (1R,3aS,3bS,9aR,9bS,10S,11aS)-1,10-dihydroxy-1-(2-hydroxyacetyl)-9a,11a-dimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-one; (1S,2R,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadeca-3,6-dien-5-one; (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-8,10,13-trimethyl-3-oxo-6,7,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carboxylic acid;Prednisolone; 8056-11-9"	.	.	.	5755	D0D1SG	DB00860	CHEMBL131
DRG00304	D-Galactose	D-Galactose	.	"D-Gal; D-Galactopyranose; D-Galactopyranoside; D-Galactose; Gal; Galactopyranose; Galactopyranoside; Galactose; 10257-28-0; Galactose, pure; (3R,4S,5R,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol; CHEBI:4139; brain sugar; (+)-Galactose; EINECS 233-595-2; cerebrose; AI3-18440; D-galacto-hexose; DTXSID001015860; NSC 8102; CHEBI:12936; NSC-8102; D Galactose; D-Glucose-2-13C; SMR000857326; UNII-7IOF6H4H77; Galaktose; galacto-hexose; D-aGalactopyranose; Galactose; D-Galactopyranose; D(+)-Galactose; GSK 620104E; Allopurinol related; 40825-89-6; D-Galactose (9CI); Galactose, D- (8CI); Epitope ID:141794; D-Galactose 1000 microg/mL in Methanol:Water; SCHEMBL38935; MLS001335983; MLS001335984; CHEMBL195923; DTXCID903088; CHEBI:28260; BDBM228805; DTXCID601437050; HMS2230N07; MFCD00006969; s3849; AKOS030573864; CCG-266426; NCGC00166082-01; AS-46931; CS-0204480; G0008; NS00087175; C00124; EN300-135967; F10950; G-1701; O_FULL_10000000000000_GS_94; Q27106307; Z1665647488; (3R,4S,5R,6R)-6-methyloltetrahydropyran-2,3,4,5-tetrol; WURCS=2.0/1,1,0/(a2112h-1x_1-5)/1/"	.	.	.	6036	D0A7GX	DB11735	CHEMBL195923
DRG00305	Adenosine Phosphate	Adenosine Phosphate	.	"5'-adenylic acid; adenosine 5'-monophosphate; Adenosine monophosphate; adenosine phosphate; 61-19-8; adenylic acid; adenosine 5'-phosphate; 5'-AMP; adenylate; Phosphentaside; Adenovite; Cardiomone; Phosaden; Phosphaden; Lycedan; AMP; Adenosine-5'-monophosphate; Vitamin B8; My-B-Den; Myoston; Monophosphadenine; 5'-adenosine monophosphate; Muskeladenylsaeure; AMP (nucleotide); Ergadenylic acid; Muscle adenylic acid; a-5mp; Adenosini phosphas; Adenosine 5'-(dihydrogen phosphate); Adenyl; Fosfato de adenosina; Adenosine-5'-monophosphoric acid; Adenosine 5'-phosphoric acid; Phosphate d'adenosine; PAdo; adenosine-monophosphate; adenosine-5'P; Adenosine-5-monophosphoric acid; Muskeladenosin-phosphorsaeure; Adenylic acid (VAN); Ado5'P; Adenosine 5'-monophosphoric acid; adenosine-phosphate; 5'-O-phosphonoadenosine; A5MP; AMP (VAN); NSC-20264; Adenosini phosphas [INN-Latin]; Adenosine, mono(dihydrogen phosphate) (ester); HSDB 3281; A 5MP; Fosfato de adenosina [INN-Spanish]; Phosphate d'adenosine [INN-French]; CHEBI:16027; BRN 0054612; EINECS 200-500-0; NSC 20264; UNII-415SHH325A; [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate; DTXSID5022560; 415SHH325A; ((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl dihydrogen phosphate; Adenosine phosphate [USAN:BAN:INN]; Adenosine 5' monophosphate; CHEMBL752; {[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}phosphonic acid; DTXCID002560; Adenosine 5-Monophosphate; 4-26-00-03615 (Beilstein Handbook Reference); NCGC00163319-01; NCGC00163319-03; ADENOSINE 5'-(DIHYDROGEN PHOSPHATE).; 136920-07-5; 122768-03-0; Adenosini phosphas (INN-Latin); Adenosine-5-phosphate; ADENOSINE PHOSPHATE (MART.); ADENOSINE PHOSPHATE [MART.]; NSC20264; 5'-ADENYLIC ACID (USP-RS); 5'-ADENYLIC ACID [USP-RS]; Fosfato de adenosina (INN-Spanish); Phosphate d'adenosine (INN-French); Adenosine-5'-Monophosphate, Free acid; 7gpb; 8gpb; CAS-61-19-8; Adenosine phosphate [USAN:INN:BAN]; adenosin-5'-monophosphat; Adenyl (TN); MFCD00005750; MFCD00149360; Adenosine 5' Phosphate; Adenosine5'-monophosphate; 5'-Phosphate, Adenosine; Adenosine Monophosphate (Amp); Muscle adenylate; adenosina fosfato; 5'adenylic acid; Adenosine phosphate (USAN/INN); 1pyg; 2gsu; 5'-adenylate; My-beta-Den; T-ADENYLIC; 1ua4; 1z6s; Adenosine 5monophosphate; adenosine 5'-phosphates; Adenosine 5'-phosphorate; Prestwick0_000356; Prestwick1_000356; Prestwick2_000356; Prestwick3_000356; Adenosine 5 -monophosphate; bmse000005; bmse000873; bmse000992; Epitope ID:137353; Adenosine-5-monophosphorate; SCHEMBL5588; 5-AMP; Adenosine-5'-monophosphorate; BSPBio_000451; SPBio_002372; BPBio1_000497; GTPL2455; [3h]adenosine 5'-monophosphate; Adenosine phosphate(Vitamin B8); SCHEMBL18287224; 5'-ADENYLIC ACID [MI]; BDBM18137; CHEBI:22256; CHEBI:37096; 5'-ADENYLIC ACID [FCC]; ADENOSINE PHOSPHATE [INN]; C01EB10; [(2R,3S,4R)-5-(6-aminopurin-9-yl)-3,4-dihydroxy-2-oxolanyl]methyl dihydrogen phosphate; ADENOSINE PHOSPHATE [HSDB]; ADENOSINE PHOSPHATE [USAN]; ADENOSINE PHOSPHATE [VANDF]; 7A8E6D15-9136-44C1-88C9-E1A224638E56; AMY30021; HY-A0181; Tox21_112046; ADENOSINE PHOSPHATE [WHO-DD]; s9366; AKOS015833068; AKOS015888563; Tox21_112046_1; CCG-267996; DB00131; NCGC00163319-02; [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl dihydrogen phosphate; AS-11783; BP-58695; DB-022416; A0158; CS-0017523; C00020; D02769; F20323; EN300-1700412; Adenosine-3(+2')-monophosphoric acid monohydrate*; Q318369; J-700145; W-105182; Adenosine 5'-monophosphate-Agarose, lyophilized powder; Adenosine 5'-monophosphate-Agarose, saline suspension; Z2216887941; 9H-Purin-6-amine, 9-(5-O-phosphono-.beta.-D-ribofuranosyl)-; 9H-purin-6-amine, 9-(5-O-phosphono-beta-D-ribofuranosyl)-; [(2R,3S,4R,5R)-5-adenin-9-yl-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl dihydrogen phosphate;hydrate; 53624-78-5; Adenosine 5'-monophosphate-Agarose, lyophilized powder, Contains lactose stabilizers that must be removed prior to use."	.	.	.	6083	D06ACW	DB00131	CHEMBL752
DRG00306	p-Toluenesulfonic acid	p-Toluenesulfonic acid	.	"P-TOLUENESULFONIC ACID; 4-Methylbenzenesulfonic acid; 104-15-4; 4-Toluenesulfonic acid; p-Toluenesulphonic acid; Toluene-4-sulfonic acid; Tosic acid; p-Tolylsulfonic acid; Tosylic acid; Toluenesulfonic acid; Benzenesulfonic acid, 4-methyl-; p-Methylbenzenesulfonic acid; p-Methylphenylsulfonic acid; Eltesol; p-Toluenesulfonate; Toluene sulfonic acid; Methylbenzenesulfonic acid; Cyclophil P T S A; PARA-TOLUENE SULFONATE; ar-Toluenesulfonic acid; p-Toluolenesulfonic acid; PTSA; Toluene-4-sulphonic acid; P-Toluene Sulfonic acid; Cyzac 4040; Kyselina p-toluenesulfonova; Nacure 1040; Manro PTSA 65 E; Manro PTSA 65 H; TSA-HP; TSA-MH; Benzenesulfonic acid, methyl-; Manro PTSA 65 LS; p-Toluene sulfonate; Kyselina p-toluensulfonova; K-Cure 1040; Toluen-4-sulfonsaeure; K-Cure 040; HSDB 2026; Toluene-p-sulfonate; NSC 167068; p-toluene sulphonic acid; para-toluenesulfonic acid; Eltesol TSX; EINECS 203-180-0; UNII-QGV5ZG5741; BRN 0472690; p-toluensulfonic acid; QGV5ZG5741; DTXSID0026701; CHEBI:27849; AI3-26478; p-Toluene-sulfonic acid; NSC-2167; para-toluenesulphonic acid; ACTIVATOR-100T3; TAYCATOX-300; NSC-167068; DRYER-900; NACURE-1040; 4-Toluene sulfonic acid; CHEMBL541253; CYZAC-4040; DTXCID406701; TSA-95; 4-TOLUENE-SULFONIC ACID; EC 203-180-0; 4-11-00-00241 (Beilstein Handbook Reference); AD-3302W; KC-1040; TsOH; C-250; WLN: WSQR D1; p-TSA; Toluenesulfonic acid (VAN); TSU; LISINOPRIL IMPURITY B (EP IMPURITY); LISINOPRIL IMPURITY B [EP IMPURITY]; 2(Or 4)-toluenesulphonic acid; ANASTROZOLE IMPURITY F (EP IMPURITY); ANASTROZOLE IMPURITY F [EP IMPURITY]; P-TOLUENESULFONIC ACID (EP IMPURITY); P-TOLUENESULFONIC ACID [EP IMPURITY]; SULTAMICILLIN IMPURITY B (EP IMPURITY); SULTAMICILLIN IMPURITY B [EP IMPURITY]; toluene-p-sulfonic acid; Kyselina p-toluensulfonova [Czech]; Kyselina p-toluenesulfonova [Czech]; paratoluene sulphonic acid; para toluene sulfonic acid; TIZANIDINE HYDROCHLORIDE IMPURITY I (EP IMPURITY); TIZANIDINE HYDROCHLORIDE IMPURITY I [EP IMPURITY]; TosicAcid; 4-sulphotoluene; pTsOH; TosOH; p-toluenesulfonicacid; P-Toluene Sulfonic acid(monohydrate); p-TsOH; Tos-OH; p-toluenesufonic acid; 4-Toluenesulfonicacid; p-toluene sulfonicacid; p-toluene-sulfonicacid; p-toluensulphonic acid; paratoluensulfonic acid; 25231-46-3; Ts-OH; p-toluen sulfonic acid; p-toluenesuiphonic acid; p-toluenylsulfonic acid; paratoluenesulfonic acid; 4-toluenesulphonic acid; p -toluenesulfonic acid; p- toluenesulfonic acid; p-tolu-enesulfonic acid; p-toluyl sulphonic acid; toluene p-sulfonic acid; para-toluensulfonic acid; rho-toluenesulfonic acid; paratoluenesulphonic acid; p-toluene-sulphonic acid; toluene 4-sulfonic acid; toluene p-sulphonic acid; toluene-p-sulphonic acid; para toluenesulfonic acid; paratoluene sulfonic acid; paratoluene-sulfonic acid; SCHEMBL34; 4-toluene sulphonic acid; 4-toluene-sulphonic acid; rho-toluene sulfonic acid; para toluenesulphonic acid; para-toluene sulfonic acid; para-toluene-sulfonic acid; 4methylbenzenesulfonic acid; 4-methylphenylsulfonic acid; para toluene sulphonic acid; para-toluene sulphonic acid; 4-methylphenylsulphonic acid; NCIOpen2_002932; NCIOpen2_003096; 4-methylbenzenesulphonic acid; 4-methyl-benzenesulfonic acid; 4-methylbenzene sulfonic acid; 4-methylbenzene-sulfonic acid; p-toluenesulfonic acid (ptsa); 4-methyl benzene sulfonic acid; 4-methyl-benzene sulphonic acid; 4-methyl-benzene-sulphonic acid; 4-methylbenzene-1-sulfonic acid; NSC2167; PTS-100; 4-Toluenesulfinic acid sodium salt; P-TOLUENESULFONIC ACID [MI]; Tox21_202364; AC-794; BDBM50294029; MFCD00064387; NSC167068; STL199173; AKOS008966288; AM90497; AT27303; CS-W019626; DB03120; NCGC00248146-01; NCGC00248146-02; NCGC00248146-03; NCGC00259913-01; AS-82150; BP-31081; CAS-104-15-4; SY011236; DB-050363; FT-0619532; FT-0648905; NS00010519; T0267; C06677; A800907; AE-848/00887005; Q285878; SR-01000944854; J-001117; Q-200514; SR-01000944854-1; F1908-0079; InChI=1/C7H8O3S/c1-6-2-4-7(5-3-6)11(8,9)10/h2-5H,1H3,(H,8,9,10"	.	.	.	6101	.	DB03120	.
DRG00307	Zidovudine monophosphate	Zidovudine monophosphate	.	"Zidovudine monophosphate; AZTMP; ZDVMP; Zdv 5'-monophosphate; Zidovudine 5'-monophosphate; 29706-85-2; AZT-MP; 3'-Azido-3'-deoxythymidine 5'-phosphate; 3'-Azido-3'-deoxythymidine 5'-Monophosphate Sodium Salt; 3'-Azido-2',3'-deoxythymidine 5'-monophosphate; azidothymidine monophosphate; 97YMU05VPJ; 5'-Thymidylic acid, 3'-azido-3'-deoxy-; [(2S,3S,5R)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl dihydrogen phosphate; 3'-azido-3'-deoxythymidine-5'-monophosphate; 128506-29-6; AzddTMP; 3'-azido-3'-deoxythymidine monophosphate; UNII-97YMU05VPJ; AZT-monophosphate; 3'-Azido-3'-deoxythymidine 5'phosphate; NSC742230; [(2S,3S,5R)-3-azido-5-(5-methyl-2,4-dioxo-pyrimidin-1-yl)tetrahydrofuran-2-yl]methyl dihydrogen phosphate; AZT 5'-MONOPHOSPHATE; CHEMBL257695; SCHEMBL15094301; DTXSID30183855; OIFWQOKDSPDILA-XLPZGREQSA-N; Zidovudine-monophosphate (AZT-MP); BDBM50478975; DB03666; NS00070697; 3'-Azido-2',3'-dideoxythymidine-5'-monophosphate; 3'-azido-3'-deoxythymidine 5'-(dihydrogen phosphate); Q27272049"	.	.	.	65374	D0A2IQ	DB03666	.
DRG00308	Edcme	Edcme	.	"EDCME; 41164-36-7; Estradiol-3-O-carboxymethyl ether; 3-O-(Carboxymethyl)estradiol; 2-[[(8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl]oxy]acetic acid; ((17beta-hydroxyestra-1,3,5(10)-trien-3-yl)oxy)acetic acid; {[17beta-hydroxyestra-1,3,5(10)-trien-3-yl]oxy}acetic acid; E23CME; SCHEMBL4823383; DTXSID70961472; CHEBI:138727; B-ESTRADIOL 3-CARBOXYMETHYL ETHER; 17beta-estradiol 3-O-carboxymethyl ether; {[17-Hydroxyestra-1(10),2,4-trien-3-yl]oxy}acetic acid; {[(17beta)-17-hydroxyestra-1,3,5(10)-trien-3-yl]oxy}acetic acid; Acetic acid, (((17beta)-17-hydroxyestra-1,3,5(10)-trien-3-yl)oxy)-"	.	.	.	66392	.	.	.
DRG00309	17beta-Estradiol hemisuccinate	17beta-Estradiol hemisuccinate	.	"beta-Estradiol 17-hemisuccinate; 7698-93-3; 17beta-Estradiol hemisuccinate; ESTRADIOL HEMISUCCINATE; MLS000028612; beta-Estradiol-17beta-hemisuccinate; beta-Estradiol-17-beta-hemisuccinate; 4-[[(8R,9S,13S,14S,17S)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl]oxy]-4-oxobutanoic acid; VQV5064VG6; 1,3,5(10)-Estratriene-3,17beta-diol 17-hemisuccinate; SMR000058687; 17BETA-ESTRADIOL 17-HEMISUCCINATE; 93939-81-2; 4-{[(14beta,17alpha)-3-Hydroxyestra-1,3,5(10)-Trien-17-Yl]oxy}-4-Oxobutanoic Acid; Estra-1,3,5(10)-triene-3,17-diol 17-(hydrogen succinate); UNII-VQV5064VG6; Eutocol (TN); Opera_ID_1469; MLS001077317; SCHEMBL1903732; Estradiol 17 beta-hemisuccinate; CHEMBL1233274; beta -Estradiol 17-hemisuccinate; DTXSID00227770; HMS2235C22; BCP09313; EX-A4652; EINECS 300-371-1; (c)micro-Estradiol 17-hemisuccinate; MFCD00056186; Estra-1,3,5(10)-triene-3,17-diol (17beta)-, 17-(hydrogen butanedioate); DB07891; ESTRADIOL HEMISUCCINATE [WHO-DD]; ESTRADIOL 17.BETA.-HEMISUCCINATE; TS-10019; HY-148586; 17.BETA.-ESTRADIOL 17-HEMISUCCINATE; CS-0643525; FT-0636571; NS00069753; D07919; SUCCINIC ACID, 17-MONOESTER WITH ESTRADIOL; Q24884541; 3,17beta-Hydroxy-1,3,5(10)-estratriene 17-hemisuccinate; ESTRA-1,3,5(10)-TRIENE-3,17.BETA.-DIOL 17-(HYDROGEN SUCCINATE); ESTRA-1,3,5(10)-TRIENE-3,17-DIOL (17.BETA.)-, 17-(HYDROGEN BUTANEDIOATE); 1,3,5(10)-Estratrien-3-[(17beta)-diol]-17-hemisuccinate; (17beta-Estradiol)-17-hemisuccinate; HE7"	.	.	.	66440	.	DB07891	.
DRG00310	Rhodamine B	Rhodamine B	.	"RHODAMINE B; 81-88-9; Basic Violet 10; Brilliant Pink B; Tetraethylrhodamine; Rhodamine O; Calcozine Red BX; Symulex Magenta F; Rhodamine S; Rheonine B; Rhodamine FB; Rhodamine B chloride; Rhodamine; Geranium lake N; Rhodamine BA; Rhodamine BF; Rhodamine BL; Rhodamine BN; Rhodamine BS; Rhodamine BX; Rhodamine BXL; Rhodamine BXP; Basic Rose Red; Rhodamine Lake Red B; Symulex Pink F; ADC Rhodamine B; Edicol Suppa Rose BS; Rhodamine FB CL; Acid Brilliant Pink B; Ikada Rhodamine B; Rhodamine B Extra; Certiqual Rhodamine; Iragen Red L-U; Aizen Rhodamine BH; Akiriku Rhodamine B; Eriosin Rhodamine B; Takaoka Rhodamine B; Mitsui Rhodamine BX; Rhodamine BA Export; Aizen Rhodamine BHC; Basonyl Red 545; Diabasic Rhodamine B; Elcozine Rhodamine B; Edicol Supra Rose B; Rhodamine B Extra S; C.I. Basic Violet 10; Food Red 15; D and C Red No. 19; Rhodamine, Blue shade; Edicol Supra Rose BS; CI Food Red 15; Rhodamine, tetraethyl-; Cerise Toner X1127; Calcozine Rhodamine BXP; C.I. 45170; Rhodamine B500; Cogilor Red 321.10; Hexacol Rhodamine B Extra; Violet zasadita 10; Basonyl Red 540; Red No. 213; D&C Red 19; Rhodamine B 20-7470; Rhodamine B Extra M 310; Basonyl Red 545FL; FD and C Red No. 19; Symulex Rhodamine B Toner F; CI Basic Violet 10; Rhodamine B500 hydrochloride; D&C red no.19; 11411 Red; Basazol Red 71P; C.I. Food Red 15; Sicilian Cerise Toner A-7127; 9-(2-Carboxyphenyl)-3,6-bis(diethylamino)xanthylium chloride; FD&C Red No. 19; D&C Red No. 19; D & C Red No.19; C.I. No. 45170; Cosmetic Brilliant Pink Bluish D conc; CCRIS 3985; Cerise Toner X 1127; HSDB 5244; UNII-K7G5SCF8IL; CI 45170; K7G5SCF8IL; Xanthylium, 9-(2-carboxyphenyl)-3,6-bis(diethylamino)-, chloride; EINECS 201-383-9; NSC 10475; Rhodamine B 500; DTXSID6042369; Tetraethyldiamino-o-carboxyphenyl xanthenyl chloride; CHEBI:52334; Rhodamine B (C.I. 45170); Xanthylium, 9-(2-carboxyphenyl)-3,6-bis(diethylamino)-, chloride (1:1); MFCD00011931; NSC-10475; 9-O-Carboxyphenyl-6-diethylamino-3-ethylimino-3-isoxanthene, 3-ethochloride; AKA213; DTXCID4022369; ROSE B W 3005; AKA-213; (9-(o-Carboxyphenyl)-6-(diethylamino)-3H-xanthen-3-ylidene) diethylammonium chloride; Ethanaminium, N-(9-(2-carboxyphenyl)-6-(diethylamino)-3H-xanthen-3-ylidene)-N-ethyl-, chloride; Ethanaminium, N-(9-(2-carboxyphenyl)-6-(diethylamino)-3H-xanthen-3-ylidene)-N-ethyl-,chloride; D&C RED NO. 19 (DELISTED); FD&C RED NO. 19 (DELISTED); Basic Violet 10;Brilliant Pink B;Rhodamine O;Tetraethylrhodamine; RHODAMINE B (IARC); RHODAMINE B [IARC]; Ammonium, (9-(o-carboxyphenyl)-6-(diethylamino)-3H-xanthen-3-ylidene)diethyl-, chloride; N-(9-(2-carboxyphenyl)-6-(diethylamino)-3H-xanthen-3-ylidene)-N-ethylethanaminium chloride; Rhodamine S [Russian]; N-[9-(2-carboxyphenyl)-6-(diethylamino)-3H-xanthen-3-ylidene]-N-ethylethanaminium chloride; Ethanaminium, N-[9-(2-carboxyphenyl)-6-(diethylamino)-3H-xanthen-3-ylidene]-N-ethyl-, chloride; Violet zasadita 10 [Czech]; D&C RED NO. 19 (DELISTED) (II); D&C RED NO. 19 (DELISTED) [II]; NSC41837; FD&C RED NO. 19 (DELISTED) (II); FD&C RED NO. 19 (DELISTED) [II]; Rodamina B; [9-(o-Carboxyphenyl)-6-(diethylamino)-3H-xanthen-3-ylidene] diethylammonium chloride; Calcozine Rhodamine BL; Calcozine Rhodamine BX; Ethanaminium, N-(9-(2-carboxyphenyl)-6-(diethylamino)-3H-xanthen-3-ylidene)-N-ethyl-; RHODAMINE B [MI]; RHODAMINE B [HSDB]; SCHEMBL16280; D+C RED NO 19; D & C Red No. 19; D AND C RED NO 19; CHEMBL428971; FD AND C RED NO 19; RED NO 213; AMY3544; HY-Y0016; NSC10475; Tox21_301450; CI 749; NSC-41837; AKOS000283060; CCG-269534; CS-7637; [9-(2-carboxyphenyl)-6-(diethylamino)xanthen-3-ylidene]-diethylazanium;chloride; CAS-81-88-9; N-(9-(2-Carboxyphenyl)-6-(diethylamino)-3H-xanthen-3-ylidene)-N-e- thylethanaminium chloride; NCGC00255803-01; AS-17153; C.I. 749; CL 45170; Ethanaminium, N-(9-(2-carboxyphenyl)-6-(diethylamino)-3H-xanthen-3-ylidene)-N-e- thyl-, chloride; SY010955; Diethyl-m-aminophenolphthalein hydrochloride; FT-0622587; NS00113691; R0014; R0040; C19517; D88566; Q429022; DIETHYL-M-AMINO-PHENOLPHTHALEIN HYDROCHLORIDE; TETRAETHYLDIAMINO-O-CARBOXY-PHENYL-XANTHENYL CHLORIDE; 9-(2-carboxyphenyl)-3,6-bis(diethylamino) xanthylium chloride; 9-(2-carboxyphenyl)-3,6-bis(diethylamino)xanthenium chloride; 9-(2-Carboxyphenyl)-3,6-bis(diethylamino)xanthyliumchloride; WLN: T C666 BO EYJ EUK2&2 IR BVQ& MN2&2 &Q &G; Ethanaminium, N-(9-(2-carboxyphenyl)-6-(diethylamino)-3H-xanthen-3-ylidene)-N-e-thyl-, chloride; N-(9-(2-Carboxyphenyl)-6-(diethylamino)-3H-xanthen-3-ylidene)-N-e-thylethanaminium chloride"	.	.	.	6694	.	DB16853	.
DRG00311	"2,6-Dimethoxyquinone"	"2,6-Dimethoxyquinone"	.	"2,6-Dimethoxy-1,4-benzoquinone; 530-55-2; 2,6-Dimethoxy-p-benzoquinone; 2,6-Dimethoxyquinone; 2,6-dimethoxycyclohexa-2,5-diene-1,4-dione; 2,6-Dimethoxybenzoquinone; 2,6-Dimethoxy-p-quinone; 2,5-Cyclohexadiene-1,4-dione, 2,6-dimethoxy-; NSC 24500; 2,6-Dimethoxysemiquinone anions; p-Benzoquinone, 2,6-dimethoxy-; EINECS 208-484-7; 2,6-Dimethoxy-2,5-cyclohexadiene-1,4-dione; NSC-56336; UNII-1Z701W789S; 2,6-Dimethoxybenzo-1,4-quinone; 2,6-Dimethoxysemiquinone radicals; NSC24500; NSC-24500; ghl.PD_Mitscher_leg0.4; 1Z701W789S; MLS002207260; MFCD00016368; NSC 56336; 26547-64-8; SMR001306787; p-Benzoquinone,6-dimethoxy-; 2,4-dione, 2,6-dimethoxy-; DIMETHOXYBENZOQUINONE,6-; 3,5-Dimethoxy-1,4-benzoquinone; 3,5-Dimethoxybenzoquinone; NSC 24500; 2,6-DMBQ; Spectrum_000723; 2, 6-Dimethoxyquinone; Maybridge1_002628; Spectrum2_000781; Spectrum3_000177; Spectrum4_001608; Spectrum5_000335; Quinone, 2,6-dimethoxy-; 2,6-Dimetoxy-p-benzoquinone; 2-6-DIMETHOXYQUINONE; BSPBio_001673; KBioGR_001955; KBioSS_001203; SPECTRUM200413; cid_68262; DivK1c_001380; SCHEMBL570683; SPBio_000882; 2, 6-Dimethoxy-p-benzoquinone; CHEMBL448515; BDBM80763; HMS548P10; KBio2_001203; KBio2_003771; KBio2_006339; KBio3_001173; OLBNOBQOQZRLMP-UHFFFAOYSA-; 2,6-dimethoxy[1,4]benzoquinone; DTXSID80862128; 3,5-Dimethoxy-1,4-benzoquinone; HMS1922P16; 2, 6-Dimethoxy-1,4-benzoquinone; 2,6-dimethoxy-[1,4]benzoquinone; DIMETHOXYBENZOQUINONE,2,6-; 2,6-DIMETHOXYQUINONE [MI]; HY-N1677; NSC56336; CCG-40159; AKOS015851594; FS-4243; SDCCGMLS-0066389.P001; CDS1_000340; 2,6-Dimethoxy-1,4-benzoquinone, 97%; NCGC00095215-01; NCGC00095215-02; NCGC00095215-03; NCGC00095215-04; NCI60_001958; PD002219; SY048603; DB-020224; CS-0017339; D2706; FT-0610674; NS00006663; D90101; A829370; SR-05000002399; Q4596807; SR-05000002399-1; 2,5-Cyclohexadiene-1,4-dione, 2,6-dimethoxy- (9CI); 2,5-Cyclohexadiene-1,4-dione, 2,6-dimethoxy-, radical ion(1-); InChI=1/C8H8O4/c1-11-6-3-5(9)4-7(12-2)8(6)10/h3-4H,1-2H3; KIA"	.	.	.	68262	.	.	CHEMBL448515
DRG00312	Leurubicin	Leurubicin	.	"Leurubicin; 70774-25-3; leucyl-doxorubicin; Leurubicin [INN]; 1Z20MGK851; (2S)-2-amino-N-[(2S,3S,4S,6R)-3-hydroxy-2-methyl-6-[[(1S,3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-2,4-dihydro-1H-tetracen-1-yl]oxy]oxan-4-yl]-4-methylpentanamide; Leurubicina; Leurubicine; Leurubicinum; N-Leucyldoxorubicin; (S)-2-amino-N-((2S,3S,4S,6R)-3-hydroxy-2-methyl-6-(((1S,3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl)oxy)tetrahydro-2H-pyran-4-yl)-4-methylpentanamide; N-leucyl-doxorubicin; N-L-leucyldoxorubicin; N-L-leucyl-doxorubicin; Leurubicine [INN-French]; Leurubicinum [INN-Latin]; Leurubicina [INN-Spanish]; UNII-1Z20MGK851; Doxogenix L; LEU-DOX; L-ADR; SCHEMBL1231191; CHEMBL3989596; DTXSID50991030; HROXIDVVXKDCBD-ZUWKMVCBSA-N; AKOS040747057; RP-39937; CT-012002; NS00122043; E-88/032; Q27253246; (8S,10S)-10-((3-((S)-2-AMINO-4-METHYLVALERAMIDO)-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-8-GLYCOLOYL-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-1-METHOXY-5,12-NAPHTHACENEDIONE; (8S,10S)-10-((3-((S)-2-Amino-4-methylvaleramido)-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; 3,5,12-Trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-[(2-amino-1-hydroxy-4-methylpentylidene)amino]-2,3,6-trideoxyhexopyranoside"	.	.	.	68897	D0T5XN	.	.
DRG00313	9-Fluorenone-2-carboxylic acid	9-Fluorenone-2-carboxylic acid	.	"9-Fluorenone-2-carboxylic acid; 784-50-9; 9-oxofluorene-2-carboxylic acid; 9-Oxo-9H-fluorene-2-carboxylic acid; Fluorenone-2-carboxylic acid; 9-Oxofluoren-2-carboxylic acid; 9H-Fluorene-2-carboxylic acid, 9-oxo-; 9-Oxo-2-fluorenecarboxylic acid; MFCD00001156; 9-Fluorenone-2-carboxylicacid; EINECS 212-317-3; SCHEMBL292802; BJCTXUUKONLPPK-UHFFFAOYSA-; DTXSID50229062; 9-oxo-2-fluorene carboxylic acid; 9-oxo-fluorene-2-carboxylic acid; AMY32672; NSC81258; NSC 81258; NSC-81258; NSC113321; AKOS001325046; 9-Fluorenone-2-carboxylic acid, 98%; AC-4882; CCG-314871; CS-W013069; NSC 113321; NSC-113321; 9-Oxo-9H-fluorene-2-carboxylic acid #; AS-38202; SY050752; F0263; FT-0621650; NS00037987; EN300-26713; J-009414; Q-101170; Z228460224; InChI=1/C14H8O3/c15-13-11-4-2-1-3-9(11)10-6-5-8(14(16)17)7-12(10)13/h1-7H,(H,16,17)"	.	.	.	69913	.	.	.
DRG00314	9-Aminoacridine	9-Aminoacridine	.	"9-AMINOACRIDINE; 90-45-9; Acridin-9-amine; Aminacrine; Aminoacridine; 9-Acridinamine; Aminacrin; Izoacridina; Monacrin; 10-Amino-5-azaanthracene; 9-Acridinylamine; Acridine, 9-amino-; Aminoacridina; Aminoacridinum; 9-Aminoakridin; 9AA; NSC 13000; Acridin-9-ylamine; MFCD00037839; NSC-13000; 78OY3Z0P7Z; 9-AA; NSC 7571; CHEBI:74789; Aminopt; Mykocert; 9-Aminoacridin; 9-amino acridine; WLN: T C666 BNJ IZ; 9-Aminoakridin [Czech]; MLS000780068; Aminoacridine [INN:BAN]; NSC7571; 8AD; CCRIS 748; 65944-23-2; SMR000420251; EINECS 201-995-6; BRN 0141171; iminoacridan; UNII-78OY3Z0P7Z; Aminoacrid; AI3-51012; 110166-26-2; 9-Amino-acridin; 4bds; 9-Amino-acridine; acridin-9-yl-amine; Quench (Salt/Mix); Mycosert (Salt/Mix); Spectrum_001108; AMINACRINE [MI]; SpecPlus_000861; 9-Aminoacridine, 97%; Spectrum2_001112; Spectrum3_000617; Spectrum4_000580; Spectrum5_001498; 9-Aminoacridine free base; AMINACRINE [VANDF]; AMINOACRIDINE [INN]; Acramine Yellow (Salt/Mix); SCHEMBL14999; BSPBio_002154; KBioGR_001020; KBioSS_001588; BIDD:GT0816; CHEMBL43184; DivK1c_006957; SPECTRUM1500810; SPBio_001244; AMINOACRIDINE [WHO-DD]; DTXSID2024456; BDBM72700; cid_2723598; KBio1_001901; KBio2_001588; KBio2_004156; KBio2_006724; KBio3_001654; XJGFWWJLMVZSIG-UHFFFAOYSA-; HMS1921I16; HMS2092K22; HMS3715H04; Pharmakon1600-01500810; 9-acridinamine;hydrate;hydrochloride; ALBB-020726; BCP25849; HY-B1422; NSC13000; NSC28747; AC2194; CCG-39037; NSC-28747; NSC757794; s4303; STK387428; AKOS000120447; acridin-9-ylamine;hydrate;hydrochloride; CS-4915; DB11561; NSC-757794; NCGC00094857-01; NCGC00094857-02; NCGC00094857-03; 7AD; 9-Aminoacridine (purified by sublimation); AS-17405; SY039786; SBI-0051612.P002; DB-026983; DB-220082; FT-0621612; NS00005526; SW219793-1; EN300-17076; AB00052180_09; AB00052180_10; CS-003/03975023; Q513937; SR-01000760844; CU-01000012501-2; SR-01000760844-2; BRD-K00535541-001-02-2; BRD-K00535541-311-04-1; 9-Aminoacridine, matrix substance for MALDI-MS, >=99.5% (HPLC); InChI=1/C13H10N2/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13/h1-8H,(H2,14,15)"	.	.	.	7019	.	.	CHEMBL43184
DRG00315	"(2,2,8-trimethyl-4H-[1,3]dioxino[4,5-c]pyridin-5-yl)methanol"	"(2,2,8-trimethyl-4H-[1,3]dioxino[4,5-c]pyridin-5-yl)methanol"	.	"1136-52-3; (2,2,8-trimethyl-4H-[1,3]dioxino[4,5-c]pyridin-5-yl)methanol; 4H-1,3-Dioxino[4,5-c]pyridine-5-methanol, 2,2,8-trimethyl-; 2,2,8-Trimethyl-4H-1,3-dioxino[4,5-c]pyridine-5-methanol; WDX5WR58LW; MLS000026774; 2,2,8-Trimethyl-4H-1-3-dioxino(4,5-c)pyridin-5-ylmethanol; ALPHA 4,3-O-ISOPROPYLIDENE PYRIDOXINE; MFCD00233509; NSC-103697; 2,2,8-Trimethyl-4H-1,3-dioxino(4,5-c)pyridine-5-methanol; SMR000011096; (2,2,8-Trimethyl-4H-[1,3]dioxino[4,5-c]pyridin-5-yl)-methanol; {2,2,8-trimethyl-2H,4H-[1,3]dioxino[4,5-c]pyridin-5-yl}methanol; ; A4,3-O-Isopropylidene Pyridoxine; ChemDiv2_000100; {2,2,8-TRIMETHYL-4H-[1,3]DIOXINO[4,5-C]PYRIDIN-5-YL}METHANOL; 4H-1,3-DIOXINO(4,5-C)PYRIDINE-5-METHANOL, 2,2,8-TRIMETHYL-; EINECS 214-498-4; NSC 103697; UNII-WDX5WR58LW; NCIOpen2_007208; Oprea1_175959; Oprea1_802156; cid_70818; ISOPROPYLIDENE PYRIDOXINE; CHEMBL1595224; SCHEMBL11012435; BDBM30672; DTXSID70150480; a4,3-O-Isopropylidene Pyridoxine; ?4,3-O-Isopropylidene Pyridoxine; HMS1369E12; HMS2484D09; NSC103697; STL227166; AKOS000550096; 3,4'-O-ISOPROPYLIDENE PYRIDOXINE; AS-70529; SY345814; DB-239416; CS-0153419; FT-0670525; NS00005902; D83575; EN300-1212410; SR-01000392000; SR-01000392000-1; BRD-K16027286-001-08-8; Z3038435425; 5-Hydroxymethyl-2,2,8-trimethyl[1,3]dioxano[4,5-c]pyridine; (2,2,8-Trimethyl-4H-[1,3]dioxino-[4,5-c]pyridin-5-yl)-methanol"	.	.	.	70818	.	.	.
DRG00316	"Spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one, 4,5,6,7-tetrachloro-3',6'-dihydroxy-2',4',5',7'-tetraiodo-, dipotassium salt"	"Spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one, 4,5,6,7-tetrachloro-3',6'-dihydroxy-2',4',5',7'-tetraiodo-, dipotassium salt"	.	"632-68-8; Aizen Rose Bengal; Food Red 105; Bengal Rose B; Spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one, 4,5,6,7-tetrachloro-3',6'-dihydroxy-2',4',5',7'-tetraiodo-, dipotassium salt; Bengal Red B; Food red dye 105; Bengal Pink B; Rose Bengal GR; dipotassium;4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-3-oxospiro[2-benzofuran-1,9'-xanthene]-3',6'-diolate; Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 4,5,6,7-tetrachloro-3',6'-dihydroxy-2',4',5',7'-tetraiodo-, dipotassium salt; Simacid Rose Bengal; Aizen Rose Bengal B; Triacid Bengal Rose B; Aizen Food Red 105; UNII-1ZPG1ELY14; Red No. 232; EINECS 211-182-8; Spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one, 4,5,6,7-tetrachloro-3',6'-dihydroxy-2',4',5',7'-tetraiodo-, potassium salt (1:2); Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one,4,5,6,7-tetrachloro-3',6'-dihydroxy-2',4',5',7'-tetraiodo-, dipotassium salt; Tetrachlorotetraiodofluorescein dipotassium salt; SCHEMBL1649956; DTXSID00110057; VQHHOXOLUXRQFQ-UHFFFAOYSA-L; NS00020325"	.	.	.	71553	.	.	.
DRG00317	"4,7,13,16,21,24-Hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane"	"4,7,13,16,21,24-Hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane"	.	"23978-09-8; 4,7,13,16,21,24-Hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane; Kryptofix 222; Cryptand 222; Cryptating agent 222; Cryptofix 222; Kriptofix 222; Cryptate 222; Ligand 222; Kryptand 222; Cryptand C 222; 2,2,2-Cryptand; Cryptand 2.2.2; 2,2,2-Crypt; Crypt-2,2,2; Cryptand-222; C18H36N2O6; NSC 264495; Kryptofix Merck 222; MFCD00005111; 4,7,13,16,21,24-Hexaoxa-1,10-diazabicyclo(8.8.8)hexacosane; 18V22YHN6G; 13,16,21,24-Hexaoxa-1,10-diazabicyclo-(8,8,8)-hexacosane; NSC-264495; EINECS 245-962-4; BRN 0620282; UNII-18V22YHN6G; Kryptofix-222; 2,2-Cryptand; [2.2.2]cryptand; SCHEMBL27017; 2,2,2-CRYPTATE; CRYPTAND 222 [MI]; (2,2,2)CRYPAND; AMY5255; DTXSID00178697; BBL028994; NSC264495; STK530369; AKOS005463220; AKOS015854436; CS-W011776; DS-5217; HY-W011060; SY010940; FT-0617280; H0932; NS00020283; A51055; A-(222); A817018; J-015297; Q4596986; 4,13,16,21,24-Hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane; 4,7,13,16,21,24-hexaoxa-1,10-diaza-bicyclo[8.8.8]hexacosane; 4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo-[8.8.8]hexacosane; 4,7,13,16,21,24-Hexaoxa-1,10-diazabicyclo[8.8.8.]hexacosane; 4,7,13,16,21,24-Hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane, 98%; 4,7,13,16,21,24-Hexaoxa-1,10-diazabicyclo[8.8.8]-hexacosane (Kryptofix 2.2.2); 4,7,13,16,21,24-hexaoxa-1,10-diazoniabicyclo[8.8.8]hexacosane;4,7,13,16,21,24-Hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane"	.	.	.	72801	.	.	.
DRG00318	"1-[1-[4-(Iodomethyl)phenyl]ethoxy]-2,2,6,6-tetramethylpiperidine"	"1-[1-[4-(Iodomethyl)phenyl]ethoxy]-2,2,6,6-tetramethylpiperidine"	.	.	.	.	.	86032744	.	.	.
DRG00319	"cis,cis-9,12-Octadecadienoic acid, 2-benzyl-hydrazide"	"cis,cis-9,12-Octadecadienoic acid, 2-benzyl-hydrazide"	.	"JEIDZKDINMIZJM-HZJYTTRNSA-N; cis,cis-9,12-octadecadienoic acid, 2-benzyl-hydrazide"	.	.	.	86737276	.	.	.
DRG00320	Nitrilotriacetic acid	Nitrilotriacetic acid	.	"NITRILOTRIACETIC ACID; 139-13-9; 2,2',2''-nitrilotriacetic acid; Triglycollamic acid; N,N-Bis(carboxymethyl)glycine; Aminotriacetic acid; NTA; Nitrilotriacetate; Trilon A; 2-[bis(carboxymethyl)amino]acetic acid; Glycine, N,N-bis(carboxymethyl)-; Komplexon I; Titriplex I; Versene NTA acid; Nitrilotriessigsaeure; Hampshire NTA acid; Tri(carboxymethyl)amine; Nitrilo-2,2',2''-triacetic acid; Acetic acid, nitrilotri-; 2-(bis(carboxymethyl)amino)acetic acid; CHEL 300; Tris(carboxymethyl)amine; NCI-C02766; MFCD00004287; Nitrilotriacetic acid (NTA); alpha,alpha',alpha''-Trimethylaminetricarboxylic acid; DTXSID6020939; CHEBI:44557; KA90006V9D; NSC-2121; Nitriloacetate; Nitrilotriaceticacid; DTXCID20939; 49784-42-1; CAS-139-13-9; CCRIS 436; Aminotriethanoic acid; N,N-Bis(carboxymethyl)glysine; HSDB 2853; Kyselina nitrilotrioctova [Czech]; Kyselina nitrilotrioctova; NSC 2121; EINECS 205-355-7; BRN 1710776; UNII-KA90006V9D; AI3-52483; Nitrilotriacetic Acid; 2-[Bis(carboxymethyl)amino]acetic acid; NTA; H3nta; Potassium cadmium nitrilotriacetate; EINECS 256-488-2; WLN: QV1N1VQ1VQ; EC 205-355-7; Cambridge id 5122183; NitrilotriessigsA currencyure; N(CH2-COOH)3; NTA (Nitrilotriacetic acid); SCHEMBL20409; Triglycine; Triglycine; NTA; 4-04-00-02441 (Beilstein Handbook Reference); 80751-51-5; MLS000069464; BIDD:ER0361; Glycine,N-bis(carboxymethyl)-; Nitrilo-2,2''-triacetic acid; CHEMBL1234848; NSC2121; HMS2232K17; NITRILOTRIACETIC ACID [MI]; CCG-2133; STR02791; NITRILOTRIACETIC ACID [HSDB]; Nitrilotriacetic acid, p.a., 99%; Tox21_202195; Tox21_300156; BBL002469; NITRILO-N,N,N-TRIACETIC ACID; STK387109; AKOS005441655; NITRILOTRIACETIC ACID [USP-RS]; DB03040; HY-W030778; NCGC00091141-01; NCGC00091141-02; NCGC00091141-03; NCGC00091141-04; NCGC00254116-01; NCGC00259744-01; BP-30104; Cadmate(1-), (N,N-bis((carboxy-kappaO)methyl)glycinato(3-)-kappaN,kappaO)-, potassium (1:1), (T-4)-; Cadmate(1-), (N,N-bis((carboxy-kappaO)methyl)glycinato(3-)-kappaN,kappaO)-, potassium, (T-4)-; SMR000054748; 2-[bis(carboxymethyl)amino]essigsure; DB-042463; CS-0074802; FT-0631809; N0098; Nitrilotriacetic acid, Sigma Grade, >=99%; NS00001715; EN300-19833; Nitrilotriacetic acid, ACS reagent, >=99.0%; Nitrilotriacetic acid, BioUltra, >=99.0% (T); .alpha.,.alpha.''-Trimethylaminetricarboxylic acid; A,A',A''-TRIMETHYLAMINETRICARBOXYLIC ACID; DISODIUM EDETATE IMPURITY A [EP IMPURITY]; Q425340; J-007239; F1905-6980; SODIUM CALCIUM EDETATE IMPURITY A [EP IMPURITY]; Z104475690; Nitrilotriacetic acid, United States Pharmacopeia (USP) Reference Standard; Potassium (N,N-bis(carboxymethyl)glycinato(3-)-N,O,O',O'')cadmate(1-); Nitrilotriacetic acid, Pharmaceutical Secondary Standard; Certified Reference Material"	.	.	.	8758	D03ZSY	DB03040	CHEMBL1234848
DRG00321	3-Benzyloxyaniline	3-Benzyloxyaniline	.	"3-Benzyloxyaniline; 1484-26-0; 3-(benzyloxy)aniline; Benzenamine, 3-(phenylmethoxy)-; 3-phenylmethoxyaniline; 3-(benzyloxy)benzenamine; 3-[(phenylmethyl)oxy]aniline; 3-Benzyloxy-phenylamine; MFCD00007784; 3-Aminophenyl benzyl ether; IAB1VDA972; CHEMBL1642680; EINECS 216-056-6; Aniline, m-(benzyloxy)-; UNII-IAB1VDA972; 3-(phenylmethoxy)phenylamine; AI3-52570; 3-benyloxyaniline; m-benzyloxy-aniline; O1D; 3-benzyloxy aniline; 3-benzyloxyphenylamine; 3-Benzyloxyaniline, 98%; M-(BENZYLOXY)ANILINE; NCIOpen2_004385; SCHEMBL291445; (3-phenylmethyloxyphenyl)amine; (3-phenylmethoxy-phenyl)-amine; 3-(BENZYLOXY)PHENYLAMINE; DTXSID9022156; M-AMINOPHENYL BENZYL ETHER; HMS3741I11; BCP21762; BDBM50334273; STL067389; AKOS000132828; CS-W002033; PS-6048; NCGC00325909-01; BP-10087; SY007822; DB-003369; A3250; AM20060409; B4197; FT-0633599; NS00024858; EN300-52995; AB00375952-03; W-108103; Q27280632; F3377-0293; Z239127534"	.	.	.	92892	.	.	.
DRG00322	tert-Butylchlorodiphenylsilane	tert-Butylchlorodiphenylsilane	.	"tert-Butylchlorodiphenylsilane; 58479-61-1; tert-Butyldiphenylchlorosilane; TBDPSCl; tert-Butyl(chloro)diphenylsilane; Silane, chloro(1,1-dimethylethyl)diphenyl-; t-Butyldiphenylchlorosilane; tert-butyl-chloro-diphenylsilane; t-butylchlorodiphenylsilane; tert-butyldiphenyl chlorosilane; TERT-BUTYLDIPHENYLSILYL CHLORIDE; t-butyldiphenylsilyl chloride; TBDPS-Cl; 132183-16-5; MFCD00000497; 3BEU48UI4E; NSC-617386; Benzene, 1,1'-(chloro(1,1-dimethylethyl)silylene)bis-; C16H19ClSi; UNII-3BEU48UI4E; tert-butylchloro-diphenylsilane; tert-butylchlorodiphenyl silane; TBDPS chloride; TBDPS-chloride; tert-butyl-chloro-diphenyl-silane; (tert-Butyl)(chloro)diphenylsilane; EINECS 261-282-0; NSC617386; TBDPSCI; T-BUPH2SICL; terbutyldiphenylchlorosilane; t-butyldiphenylsilylchloride; chloro t-butyldiphenylsilane; t-butyl chlorodiphenylsilane; t-butyl-chlorodiphenylsilane; t-butylchlorodiphenyl silane; t-butyldiphenyl chlorosilane; t-butyldiphenylchloro silane; SCHEMBL4241; tert-butylchorodiphenylsilane; t-butyldiphenyl-silylchloride; tert-Butydiphenylchlorosilane; tertbutyldiphenylsilylchloride; chloro t-butyl diphenylsilane; chloro(t-butyl)diphenylsilane; t-butyl -chlorodiphenylsilane; t-butyl chlorodiphenyl silane; t-butyl-diphenyl-chlorosilane; tert-butyidiphenylchlorosilane; t-butyl diphenylsilyl chloride; t-butyl-diphenylsilyl chloride; tert-butyldiphenylsilylchloride; tertbutyldiphenylsilyl chloride; tert- butyldiphenylchlorosilane; tert-butydiphenylsilyl chloride; tert-butyl diphenylchlorosilane; tert-butyl-chlorodiphenylsilane; tert-butyl-diphenylchlorosilane; tert-butylchlorodiphenyl-silane; tert-butyldiphenyl-chlorosilane; tert-butyldiphenysilyl chloride; tert.-butylchlorodiphenylsilane; diphenyl tert-butylsilylchloride; tert-butyl diphenylsilylchloride; tert-butyl-diphenylsilylchloride; tert-butyldiphenyl-silylchloride; chloro(tert-butyl)diphenylsilane; tert-Butyidiphenylsilyl chloride; tert-butyl diphenyl-chlorosilane; tert-butyl-diphenyl-chlorosilane; DTXSID5069259; tert-butyl diphenylsilyl chloride; tert-butyl(diphenyl)silylchloride; tert-butyl-diphenylsilyl chloride; tert-butyldiphenyl-silyl chloride; chloro-tert-butyl(diphenyl)silane; MHYGQXWCZAYSLJ-UHFFFAOYSA-; tert-butyl (chloro)diphenylsilane; tert-butyldiphenylsilanyl chloride; Chloro-tert-butyl-diphenyl-silane; tert-butyl diphenyl silyl chloride; tert-butyl(diphenyl)silyl chloride; tert.butyl diphenyl silyl chloride; tert-butyl-chloro-di(phenyl)silane; AMY39325; tert-butyl (diphenyl)silyl chloride; CB2805; AKOS008901066; 1,1-dimethylethyldiphenylsilyl chloride; tert-Butyl(chloro)diphenylsilane, 98%; 1,1-dimethyl-ethyl-diphenylchlorosilane; 1,1-dimethyl-ethyldiphenyl-chlorosilane; chloro(1,1-dimethylethyl)diphenylsilane; 1,1-dimethyl-ethyl-diphenyl-chlorosilane; AS-11826; BP-21169; TERT-BUTYLDIPHENYLCHLOROSILANE [MI]; DB-009817; diphenyl-(2-methylprop-2-yl)silyl chloride; B1223; CS-0017207; FT-0640528; NS00053234; EN300-39946; D72524; A934169; J-524842; Q27257003; 1,1'-(CHLORO(1,1-DIMETHYLETHYL)SILYLENE)BISBENZENE; tert-Butyl(chloro)diphenylsilane, for GC derivatization, >=98.0% (GC); InChI=1/C16H19ClSi/c1-16(2,3)18(17,14-10-6-4-7-11-14)15-12-8-5-9-13-15/h4-13H,1-3H3"	.	.	.	94078	.	.	.
DRG00323	Norgalanthamine	Norgalanthamine	.	"N-Desmethyl Galanthamine; Norgalanthamine; 41303-74-6; N-Desmethylgalantamine; Norgalantamine; N-Norgalanthamine; N-Desmethylgalanthamine; N-Demethylgalanthamine; UNII-2BPQ4IVQ21; 2BPQ4IVQ21; CHEMBL1385; CHEBI:31919; (1S,12S,14R)-9-methoxy-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-ol; N-Desmethyl galantamine; (-)-N-Demethylgalanthamine; Galanthamine, 10-demethyl-; 6H-Benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-, (4aS,6R,8aS)-; Galanthamine, 10-demethyl-; (4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol; 6H-Benzofuro[3a,3,2-ef][2]benzazepin-6-; Stephaoxocanidine derivative; SCHEMBL5740733; GALANTAMINE METABOLITE 8; AIXQQSTVOSFSMO-RBOXIYTFSA-N; HY-N7612; BDBM50166809; AKOS030242087; Norgalanthamine (N-Demethylgalanthamine); MS-23881; CS-0134789; FT-0666162; NS00094200; F82742; Q27114718; GALANTAMINE HYDROBROMIDE IMPURITY E [EP IMPURITY]; GALANTAMINE HYDROBROMIDE IMPURITY, N-DESMETHYLGALANTAMINE- [USP IMPURITY]; (4aS,6R,8aS)-3-Methoxy-4a,5,9,10,11,12-hexahydro-6H-benzo[2,3]benzofuro[4,3-cd]azepin-6-ol; (4AS,6R,8AS)-3-METHOXY-5,6,9,10,11,12-HEXAHYDRO-4AH-(1)BENZOFURO(3A,3,2-EF)(2)BENZAZEPIN-6-OL; 6H-BENZOFURO(3A,3,2-EF)(2)BENZAZEPIN-6-OL, 4A,5,9,10,11,12-HEXAHYDRO-3-METHOXY-, (4AS,6R,8AS)-"	.	.	.	9838394	.	.	.
DRG00324	"O-(N-acetyl-4,7,8,9-tetra-O-acetyl-1-methyl-&alpha;-neuraminosyl)-(2-3)-O-2,4-di-O-acetyl-6-O-(phenylmethyl)-&beta;-D-galactopyranosyl-(1-4)-O-[6-deoxy-2,3,4-tris-O-(phenylmethyl)-&alpha;-L-galactopyranosyl-(1-3)]-2-(acetylamino)-2-deoxy-6-O-(phenylmethyl)-&beta;-D-glucopyranosylamine"	.	.	.	.	.	.	.	.	.	.
DRG00325	"1H-Imidazole-2-carboxamide, N-[1-(3-aminopropyl)-5-[[[5-[[[4-[[2-[[[5-[[[5-[[[5-[[[3-[[3-(dimethylamino)propyl]amino]-3-oxopropyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-imidazol-4-yl]amino]-4-oxobutyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1H-pyrrol-3-yl]-1-methyl-4-[[(1-methyl-1H-imidazol-2-yl)carbonyl]amino]"	.	.	.	.	.	.	.	.	.	.
DRG00326	Maleimide derivative of doxorubicin	.	.	.	.	.	.	.	.	.	.
DRG00327	"(T-4)-[2-[4-azido-1-(4-iodo-3,5-dimethyl-2H-pyrrol-2-ylidene-&kappa;N)butyl]-4-iodo-3,5-dimethyl-1H-pyrrolato-&kappa;N]difluoro-boron"	.	.	.	.	.	.	.	.	.	.
DRG00328	5-FAM (Hydroxyfluorescein) dye	.	.	.	.	.	.	.	.	.	.
DRG00329	Protoporphyrin IX derivative	.	.	.	.	.	.	.	.	.	.
DRG00330	"(8S,10S)-10-[(3-amino-2,3,6-trideoxy-&alpha;-L-lyxo-hexopyranosyl)oxy]-8-(1-hydrazonoethyl)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-Naphthacenedione"	.	.	.	.	.	.	.	.	.	.
DRG00331	"(T-4)-[4-[(3,5-dimethyl-1H-pyrrol-2-yl-&kappa;N)(3,5-dimethyl-2H-pyrrol-2-ylidene-&kappa;N)methyl]phenolato]difluoro-boron"	.	.	.	.	.	.	.	.	.	.
DRG00332	"Platinum-(SP-4-2)-[2-(3-aminopropyl)propanedioato(2-)-&kappa;O1,&kappa;O3]diammine"	.	.	.	.	.	.	.	.	.	.
DRG00333	Meso-porphyrin derivative	.	.	.	.	.	.	.	.	.	.
DRG00334	Firefly luciferin derivative	.	.	.	.	.	.	.	.	.	.
DRG00335	(9Z)-9-Octadecenoic acid hydrazide	.	.	.	.	.	.	.	.	.	.
DRG00336	"Cholest-5-en-3-ol (3&beta;)-, 3-(hydrazinecarboxylate)"	.	.	.	.	.	.	.	.	.	.
DRG00337	"3-Methoxyestra-1,3,5(10),16-tetraeno[17,16-d]pyrimidin-2-amine"	.	.	.	.	.	.	.	.	.	.
DRG00338	"3-(Phenylmethoxy)estra-1,3,5(10),16-tetraeno[17,16-d]pyrimidin-2-amine"	.	.	.	.	.	.	.	.	.	.
DRG00339	"(1R,3R,4aS,4bR,6aS,8S,10aS,10bS,12aS)-1-[1H]phenanthro[2,1-c]pyran]-3-carboxylic acid, octadecahydro-8-methoxy-10a,12a-dimethyl-Spiro[furan-2(3H)"	.	.	.	.	.	.	.	.	.	.
DRG00340	"4-[(1E)-2-[2,5-dibutoxy-4-[(1E)-2-[3,4,5-tris(dodecyloxy)phenyl]ethenyl]phenyl]ethenyl]-benzoic acid"	.	.	.	.	.	.	.	.	.	.
DRG00341	"N-[2-[2-oxo-2-[[4-(10,15,20-triphenyl-21H,23H-porphin-5-yl)phenyl]amino]ethoxy]acetyl]-L-Aspartic acid"	.	.	.	.	.	.	.	.	.	.
DRG00342	"3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-sulfonic acid"	.	.	.	.	.	.	.	.	.	.
DRG00343	"N-[(1,1-Dimethylethoxy)carbonyl]-3-[(3-nitro-2-pyridinyl)dithio]-L-alanine"	.	.	.	.	.	.	.	.	.	.
DRG00344	"4-(10,15,20-Tri-4-pyridinyl-21H,23H-porphin-5-yl)benzaldehyde"	.	.	.	.	.	.	.	.	.	.
DRG00345	"4-[1-[(2,2,6,6-tetraethyl-4-methoxy-1-piperidinyl)oxy]ethyl]-benzenemethanol"	.	.	.	.	.	.	.	.	.	.
DRG00346	"1-[(5R,6R,8R,9R)-4-amino-9-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-6-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2,2-dioxido-1,7-dioxa-2-thiaspiro[4.4]non-3-en-8-yl]-3-(3-aminopropyl)-5-methyl-2,4(1H,3H)-pyrimidinedione"	.	.	.	.	.	.	.	.	.	.
DRG00347	"(3&alpha;,5&beta;,7&alpha;,12&alpha;)-7-(acetyloxy)-12-[[(1,1-dimethylethoxy)carbonyl]amino]-3-[[(2-propen-1-yloxy)carbonyl]amino]-cholan-24-oic acid"	.	.	.	.	.	.	.	.	.	.
DRG00348	"L-Serine-N-(2,3-dihydroxybenzoyl)-O-[N-(2,3-dihydroxybenzoyl)-O-[N-(5-&beta;-D-glucopyranosyl-2,3-dihydroxybenzoyl)-L-seryl]-L-seryl]-(3-13)-lactone"	.	.	.	.	.	.	.	.	.	.
DRG00349	Paclitaxel derivative	.	.	.	.	.	.	.	.	.	.
DRG00350	"4-amino-&alpha;-methyl-1H-pyrazolo[3,4-d]pyrimidine-1-acetic acid"	.	.	.	.	.	.	.	.	.	.
DRG00351	6-[[[5-(Dimethylamino)-1-naphthalenyl]sulfonyl]amino]hexanoic acid	.	.	.	.	.	.	.	.	.	.
DRG00352	"1H-Pyrazole-5-carboxylic acid, 3-amino-1-[(4-methoxyphenyl)methyl]-methyl ester"	.	.	.	.	.	.	.	.	.	.
DRG00353	"O-6-deoxy-2,3,4-tris-O-(phenylmethyl)-&alpha;-L-galactopyranosyl-(1-3)-O-[6-O-(phenylmethyl)-&beta;-D-galactopyranosyl-(1-4)]-2-(acetylamino)-2-deoxy-6-O-(phenylmethyl)-&beta;-D-glucopyranosyl azide"	.	.	.	.	.	.	.	.	.	.
DRG00354	Fullerene (C60) derivitavie 	.	.	.	.	.	.	.	.	.	.
DRG00355	Fluorescein isothiocyanate (FITC) AND derivative	.	.	.	.	.	.	.	.	.	.
DRG00356	O-&beta;-D-Galactopyranosyl-(1-3)-O-&beta;-D-galactopyranosyl-(1-4)-&beta;-D-glucopyranose	.	.	.	.	.	.	.	.	.	.
DRG00357	"2H-1-Benzopyran-6-sulfonic acid, 3,4-dihydro-2,2,5,7,8-pentamethyl"	.	.	.	.	.	.	.	.	.	.
DRG00358	1-(1-Methylethyl)-2-(trifluoromethyl)-1H-benzimidazole-5-carboxylic acid	.	.	.	.	.	.	.	.	.	.
DRG00359	2-[(6-Chloro-2-phenyl-1H-benzimidazol-1-yl)oxy]acetic acid	.	.	.	.	.	.	.	.	.	.
DRG00360	L-Arginyl-L-arginyl-N-[3-(phenylmethoxy)phenyl]-L-leucinamide	.	.	.	.	.	.	.	.	.	.
DRG00361	4-(2-Thioxo-1-imidazolidinyl)benzoic acid	.	.	.	.	.	.	.	.	.	.
DRG00362	5-O-Phosphonoadenylyl-(2-5)-adenylyl-(2-5)-adenosine	.	.	.	.	.	.	.	.	.	.
DRG00363	"2-Morpholinemethanol, 6-(6-amino-9H-purin-9-yl)-4-(3-azidopropyl)-, 2-phosphinephosphate, (2S,6R)"	.	.	.	.	.	.	.	.	.	.
DRG00364	"2H-Pyrido[3,4-b]indole-2,3-dicarboxylic acid, 1,3,4,9-tetrahydro-1-(4-hydroxy-3,5-dimethoxyphenyl)-, 2-(1,1-dimethylethyl) ester, (3S)"	.	.	.	.	.	.	.	.	.	.
DRG00365	Phorphirine derivative	.	.	.	.	.	.	.	.	.	.
DRG00366	"N-[5-[(6-chloro-2-methoxy-9-acridinyl)amino]pentyl]-4-[(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)methyl]-cyclohexanecarboxamide"	.	.	.	.	.	.	.	.	.	.
DRG00367	"N-[5-[[3-[(6-chloro-2-methoxy-9-acridinyl)amino]-1-oxopropyl]amino]pentyl]-4-[(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)methyl]-cyclohexanecarboxamide"	.	.	.	.	.	.	.	.	.	.
DRG00368	"N-[5-[[12-[(6-chloro-2-methoxy-9-acridinyl)amino]-1-oxododecyl]amino]pentyl]-4-[(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)methyl]-cyclohexanecarboxamide"	.	.	.	.	.	.	.	.	.	.
DRG00369	"N-[2-[[12-[(6-chloro-2-methoxy-9-acridinyl)amino]-1-oxododecyl]amino]ethyl]-4-[(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)methyl]-cyclohexanecarboxamide"	.	.	.	.	.	.	.	.	.	.
DRG00370	"1H-Imidazol-1-yloxy, 2-[4-(2-ethoxy-2-oxoethoxy)phenyl]-4,5-dihydro-4,4,5,5-tetramethyl-, 3-oxide"	.	.	.	.	.	.	.	.	.	.
DRG00371	"2-[(3,6-Dihydroxy-2,4-dimethoxyphenyl)thio]acetic acid"	.	.	.	.	.	.	.	.	.	.
DRG00372	"3,3,3,4-tetrahexyl-[2,2:5,2:5,2-quaterthiophene]-5-carboxylic acid"	.	.	.	.	.	.	.	.	.	.
DRG00373	"(3&alpha;,5&beta;,7&alpha;,12&alpha;)-3,7,12-Triaminocholan-24-ol"	.	.	.	.	.	.	.	.	.	.
DRG00374	"7-(2-Bromoacetyl)-10-methylbenzo[g]pteridine-2,4(3H,10H)-dione"	.	.	.	.	.	.	.	.	.	.
DRG00375	"Diaqua[N2,N2-bis[(carboxy-&kappa;O)methyl]-L-lysinato(3-)-&kappa;N2,&kappa;O]-nickelate(1-)"	.	.	.	.	.	.	.	.	.	.
DRG00376	Porfirin derivative	.	.	.	.	.	.	.	.	.	.
DRG00377	"Adenosine 5-(trihydrogen diphosphate), P-anhydride with phosphorothioic acid"	.	.	.	.	.	.	.	.	.	.
DRG00378	4-[(3-Methyl-2(3H)-benzothiazolylidene)methyl]quinoline	.	.	.	.	.	.	.	.	.	.
DRG00379	"3,5,6,7-tetrahydro-6-octyl-1,3,5,7-tetraoxo-benzo[1,2-c:4,5-c]dipyrrole-2(1H)-acetic acid"	.	.	.	.	.	.	.	.	.	.
DRG00380	"2-[10,15,20-Tris(4-methylphenyl)-21H,23H-porphin-5-yl]benzenamine"	.	.	.	.	.	.	.	.	.	.
DRG00381	"Ruthenium(2+), bis(2,2-bipyridine-&kappa;N1,&kappa;N1)(dipyrido[3,2-a:2,3-c]phenazine-&kappa;N4,&kappa;N5)-, (OC-6-21)"	.	.	.	.	.	.	.	.	.	.
DRG00382	"2-[(11aS)-1,3,4,11a-tetrahydro-6-oxo-2H-benzo[b]quinolizin-11(6H)-ylidene]-, (2Z)-acetic acid"	.	.	.	.	.	.	.	.	.	.
DRG00383	"2-[(3S)-2,3-dihydro-3-methyl-1-oxo-4(1H)-isoquinolinylidene]-, methyl ester, (2Z)-acetic acid"	.	.	.	.	.	.	.	.	.	.
DRG00384	"3,6-Diamino-9(10H)-acridinone"	.	.	.	.	.	.	.	.	.	.
DRG00385	Anthraquinone derivative	.	.	.	.	.	.	.	.	.	.
DRG00386	Irofulven derivative	.	.	.	.	.	.	.	.	.	.
DRG00387	9-(Phenylamino)-4-acridinecarboxylic acid	.	.	.	.	.	.	.	.	.	.
DRG00388	"3H-Indolium, 5-carboxy-2-[7-[1,3-dihydro-3,3-dimethyl-1-(4-sulfobutyl)-2H-indol-2-ylidene]-1,3,5-heptatrien-1-yl]-3,3-dimethyl-1-(4-sulfobutyl)-, inner salt"	.	.	.	.	.	.	.	.	.	.
DRG00389	Tetraphenyl porphyrin (TPP) derivative	.	.	.	.	.	.	.	.	.	.
DRG00390	Methyl 3-(aminocarbonyl)-5-nitrobenzoate	.	.	.	.	.	.	.	.	.	.
DRG00391	"25,26,27,28-tetrabutoxy-pentacyclo[19.3.1.13,7.19,13.115,19]octacosa-1(25),3,5,7(28),9,11,13(27),15,17,19(26),21,23-dodecaene-5,11,17,23-tetracarboxylic acid"	.	.	.	.	.	.	.	.	.	.
DRG00392	60-Fulleroacetic acid	.	.	.	.	.	.	.	.	.	.
DRG00393	"[3S-(3&alpha;,5&alpha;,9&beta;,11a&beta;)]-5-acetyloctahydro-7-oxo-3,6-Methano-1H,3H-pyrrolo[2,1-c][1,4,7]thiadiazonine-9-carboxylic acid"	.	.	.	.	.	.	.	.	.	.
DRG00394	Sinomenine	Sinomenine	Anti-inflammatory agent	"Sinomenine; 115-53-7; Kukoline; Cucoline; Coculine; Sabianine A; CCRIS 1550; SINOMENIN; morphinan-6-one, 7,8-didehydro-4-hydroxy-3,7-dimethoxy-17-methyl-, (9alpha,13alpha,14alpha)-; CHEBI:9163; CHEMBL248095; 63LT81K70N; (1R,9S,10R)-3-Hydroxy-4,12-dimethoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5,11-tetraen-13-one; (1R,9S,10S)-3-hydroxy-4,12-dimethoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5,11-tetraen-13-one; (9alpha,13alpha,14alpha)-7,8-Didehydro-4-hydroxy-3,7-dimethoxy-17-methylmorphinan-6-one; SR-05000002170; EINECS 204-094-6; BRN 0095280; UNII-63LT81K70N; Sinomenine,(S); Sinomenine (Cucoline); SINOMENINE [MI]; Spectrum2_001242; Spectrum3_001134; Spectrum4_001981; Spectrum5_001621; UPCMLD-DP085; 7,8-Didehydro-4-hydroxy-3,7-dimethoxy-17-methyl-9-alpha,13-alpha,14-alpha-morphinan-6-one; SINOMENINE [WHO-DD]; BSPBio_002627; KBioGR_002508; 5-21-13-00516 (Beilstein Handbook Reference); SCHEMBL363812; SPECTRUM1505253; SPBio_001144; NP51; UPCMLD-DP085:001; BCBcMAP01_000195; KBio3_002127; DTXSID00871595; BDBM224031; ALBB-020908; BCP20032; BDBM50241298; CCG-39100; NSC785175; s2359; AKOS000265568; AKOS015960539; AKOS016023715; AC-8025; NSC-785175; 9-alpha,13-alpha,14-alpha-Morphinan-6-one, 7,8-didehydro-4-hydroxy-3,7-dimethoxy-17-methyl-; SMP1_000273; NCGC00161641-01; NCGC00161641-02; NCGC00161641-04; NCGC00161641-05; BS-42101; HY-15122; Sinomenine 100 microg/mL in Acetonitrile; SNM; CS-0003778; NS00018030; SW219295-1; C09643; Sinomenine, 0.3 mol chloroform of crystallization; Q7524904; SR-05000002170-2; SR-05000002170-3; BRD-K83459933-001-02-1; BRD-K83459933-001-05-4; 7,8-didehydro-4-hydroxy-3,7-dimethoxy-17-methylmorphinan-6-one; MORPHINAN-6-ONE, 7,8-DIDEHYDRO-4-HYDROXY-3,7-DIMETHOXY-17-METHYL-, (9.ALPHA.,13.ALPHA.,14.ALPHA.)-; morphinan-6-one, 7,8-didehydro-4-hydroxy-3,7-dimethoxy-17-methyl-, (9alpha,13alpha,14alpha)-, hydrochloride"	.	.	.	5459308	D0F9WF	DB16892	.
DRG00395	Amatoxins	.	Cytotoxic drugs	.	.	.	.	.	.	.	.
DRG00396	5-Amino-2-Methyl-N-[(1r)-1-Naphthalen-1-Ylethyl]benzamide	.	SARS PLpro inhibitor	"GRL0617; 1093070-16-6; GRL-0617; 5-Amino-2-Methyl-N-[(1r)-1-Naphthalen-1-Ylethyl]benzamide; SQH4947NDN; 5-Amino-2-methyl-N-(1R-naphthalen-1-yl-ethyl)-benzamide; UNII-SQH4947NDN; (-)-GRL-0617; GRL 0617; 5-Amino-2-methyl-N-((1R)-1-(1-naphthalenyl)ethyl)benzamide; 5-Amino-2-methyl-N-[(1R)-1-(1-naphthalenyl)ethyl]benzamide; 5-amino-2-methyl-N-[(1R)-1-(naphthalen-1-yl)ethyl]benzamide; Benzamide, 5-amino-2-methyl-N-((1R)-1-(1-naphthalenyl)ethyl)-; 5-Amino-2-methyl-N-[(R)-1-(1-naphthyl)ethyl]benzamide; (R)-5-amino-2-methyl-N-(1-(naphthalen-1-yl)ethyl)benzamide; CHEMBL549695; SCHEMBL1319181; BDBM31524; GTPL11078; DTXSID10660795; CHEBI:167176; UVERBUNNCOKGNZ-CQSZACIVSA-N; EX-A4032; s6845; AKOS015840255; AKOS015924263; DB08656; compound 25 [PMID: 19645480]; NCGC00188640-01; AC-36473; BS-48457; Naphthalene and Benzamide Derivative, 25; HY-117043; CS-0063568; NS00072489; E73459; Q27097846; 5-Amino-2-methyl-N-[2-(naphthalen-1-yl)ethyl]benzamide"	.	.	.	24941262	D5I3MF	.	CHEMBL549695
DRG00397	Cabazitaxel	Cabazitaxel	Cytotoxic drugs	"CABAZITAXEL; Jevtana; 183133-96-2; Taxoid XRP6258; Xrp6258; Cabazitaxelum; XRP-6258; kabazitaxel; Jevtana Kit; TXD 258; Cabazitaxel Injection; Jevanta; TXD258; XRP 6258; NSC-761432; CHEBI:63584; UNII-51F690397J; RPR 116258A; Jevtana (TN); 51F690397J; DTXSID40171389; TXD-258; NSC 761432; CABAZITAXEL (MART.); CABAZITAXEL [MART.]; Benzenepropanoic acid, beta-[[(1,1-dimethylethoxy)carbonyl]amino]-alpha-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4,6-dimethoxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (alphaR,betaS)-; Cabazitaxel (Jevtana); (((tertbutoxy)carbonyl)amino)-2-hydroxy-3-phenylpropanoate1-hydroxy-7beta,10beta-dimethoxy-9-oxo-5beta,20-epoxytax-11-ene-2alpha,4,13alpha-triyl 4-acetate 2-benzoate 13-((2R,3S)-3-; (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(acetyloxy)-15-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1-hydroxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2-yl benzoate; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-acetoxy-9-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-11-hydroxy-4,6-dimethoxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxet-12-yl benzoate.; 1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-ene-2,4,13-triyl 4-acetate 2-benzoate 13-((2R,3S)-3-(((tertbutoxy)carbonyl)amino)-2-hydroxy-3-phenylpropanoate); cabazitaxel acetonate; CABAZITAXEL ACETONATE [JAN]; Cabazitaxel [USAN:INN]; C45H57NO14; (2alpha,5beta,7beta,10beta,13alpha)-4-acetoxy-13-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; (2alpha,5beta,7beta,10beta,13alpha)-4-acetoxy-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; RPR-116258A; XRP6258;RPR-116258A;taxoid XRP6258; CABAZITAXEL [MI]; CABAZITAXEL [INN]; Cabazitaxel (USAN/INN); CABAZITAXEL [USAN]; CABAZITAXEL [VANDF]; CABAZITAXEL [WHO-DD]; SCHEMBL179674; CABAZITAXEL [EMA EPAR]; GTPL6798; CHEMBL1201748; DTXCID1093880; AMY4317; CABAZITAXEL [ORANGE BOOK]; EX-A838; L01CD04; BMQGVNUXMIRLCK-OAGWZNDDSA-N; MFCD18827611; NSC761432; NSC794609; s3022; AKOS032947285; CCG-270519; CS-0972; DB06772; NSC-794609; NCGC00346704-01; NCGC00346704-03; 4-acetoxy-13-((3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; AS-75355; HY-15459; C3390; A25044; D09755; AB01273971-01; AB01273971_02; EN300-22232477; Q412963; SR-01000941585; J-011721; J-519981; SR-01000941585-1; (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(acetyloxy)-15-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1-hydroxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0(3),(1)?.0?,?]heptadec-13-en-2-yl benzoate; (2AR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-acetoxy-9-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-11-hydroxy-4,6-dimethoxy-4a,8,13,1; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-acetoxy-9-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-11-hydroxy-4,6-dimethoxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxet-12-yl benzoate; [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1-hydroxy-15-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate; 1-HYDROXY-7.BETA.,10.BETA.-DIMETHOXY-9-OXO-5.BETA.,20-EPOXYTAX-11-ENE-2.ALPHA.,4,13.ALPHA.-TRIYL 4-ACETATE 2-BENZOATE 13-((2R,3S)-3-(((TERT-BUTOXY)CARBONYL)AMINO)-2-HYDROXY-3-PHENYLPROPANOATE); 1-HYDROXY-7beta,10beta-DIMETHOXY-9-OXO-5beta,20-EPOXYTAX-11-ENE-2alpha,4,13alpha-TRIYL 4-ACETATE 2-BENZOATE 13-((2R,3S)-3-(((TERT-BUTOXY)CARBONYL)AMINO)-2-HYDROXY-3-PHENYLPROPANOATE); 1-hydroxy-7beta,10beta-dimethoxy-9-oxo-5beta,20-epoxytax-11-ene-2alpha,4,13alpha-triyl 4-acetate 2-benzoate 13-((2R,3S)-3-(((tertbutoxy)carbonyl)amino)-2-hydroxy-3-phenylpropanoate)"	TAR10017	Microtubule (MT)	.	9854073	D02HSB	DB06772	.
DRG00398	D-Glucose	D-Glucose	GLUT1 specific binding molecule	"D-Glc; D-Glucopyranose; D-Glucopyranoside; D-Glucose; Glc; Glucopyranose; Glucopyranoside; Glucose; 2280-44-6; Grape sugar; (3R,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol; D-Glcp; Traubenzucker; 54-17-1; Glucopyranose, D-; Glucosum, anhydrous; CHEBI:4167; GLUCOSE, ALPHA-D-; rel-(3R,4S,5S,6R)-6-(Hydroxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetraol; Corn sugar; DTXSID901015217; (+)-Glucose; (3R,4S,5S,6R)-6-(Hydroxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetraol; Glucodin; Goldsugar; Meritose; Vadex; Clintose L; D-gluco-hexose; CPC hydrate; Roferose ST; a-D-Glucose; Clearsweet 95; a-D-Glucopyranose; Staleydex 95M; Staleydex 111; Cerelose 2001; Tabfine 097(HS); UNII-5J5I9EB41E; 2h-pyran-2,3,4,5-tetraol; D-Glucopyranose, anhydrous; DTXSID30197710; Liquid glucose; glc-ring; EINECS 207-757-8; Cartose Cerelose; D-aGlucopyranose; D-glucose-ring; Glucose injection; D-Glucopyranose; Glucopyranose; NSC 287045; Dextrose (Closed Ring); Glucose 40; Staleydex 130; EINECS 218-914-5; Glc-OH; Meritose 200; nchembio867-comp4; Glucose (JP17); starbld0000491; 6-(hydroxymethyl)tetrahydropyran-2,3,4,5-tetraol; Anhydrous Glucose ,(S); Purified glucose (JP17); Epitope ID:142342; D-(+)-DEXTROSE; GTPL4536; CHEMBL1222250; BDBM34103; CHEBI:37661; DTXCID90120201; DTXCID201473543; DTXSID501015215; 26655-34-5; D-Glucose 1000 microg/mL in Water; AKOS025147374; NSC 287045; D-Glucose 1000 microg/mL in Methanol; NCGC00166293-01; BS-48662; G0048; (3R,4S,5S,6R)-6-(hydroxymethyl)tetrahydro-; C00031; D00009; F71542; Q37525; Q23905964; N_FULL/O_FULL_10000000000000_GS_656; D-glucose (closed ring structure, complete stereochemistry); WURCS=2.0/1,1,0/(a2122h-1a_1-5)/1/; 1023302-86-4"	.	.	.	5793	D0C1FY	DB01914	CHEMBL1222250
DRG00399	"3-(4-Oxo-3,4-dihydroquinazolin-2-yl)propanoic acid"	.	Antibacterial	"5368-37-6; 3-(4-oxo-3,4-dihydroquinazolin-2-yl)propanoic acid; 3-(4-Oxo-3,4-dihydro-quinazolin-2-yl)-propionic acid; 3-(4-oxo-1H-quinazolin-2-yl)propanoic acid; CHEMBL1892587; 3,4-Dihydro-4-oxo-2-quinazolinepropionic Acid; MFCD03955531; 3,4-Dihydro-4-oxo-; NSC251919; Enamine_004755; 3-(4-hydroxyquinazolin-2-yl)propanoicacid; 2-Quinazolinepropanoic acid, 1,4-dihydro-4-oxo-; MLS000775861; SCHEMBL2718160; SCHEMBL19953232; DTXSID00312256; HYSISEGNFBAVMJ-UHFFFAOYSA-N; HMS1407I03; HMS2754F07; ALBB-030898; AMY25856; BBL030181; BDBM50234922; MFCD12015470; STL374134; STL521303; AKOS000669520; AKOS005202394; AKOS028111280; NSC-251919; 2-(2-carboxyethyl)quinazolin-4(3h)-one; BS-14054; DA-42158; SMR000370984; CS-0213162; EN300-04546; G37826; SR-01000353582; 3-(4-HYDROXYQUINAZOLIN-2-YL)PROPANOIC ACID; 3-(4-oxo-3,4-dihydroquinazolin-2-yl)propanoicacid; SR-01000353582-1; 1,4-DIHYDRO-4-OXO-2-QUINAZOLINEPROPANOIC ACID; 3-(4-Oxo-1,4-dihydroquinazolin-2-yl)propanoic acid; 3-(4-OXO-3H-QUINAZOLIN-2-YL)PROPANOIC ACID; Z56869288; 3-(4-oxo-3,4-dihydro-quinazolin-2-yl)-propionic acid, AldrichCPR"	.	.	.	135449434	.	.	CHEMBL1892587
DRG00400	N-(4-acetylphenyl)-5-chloro-2-hydroxybenzamide	.	Antibacterial	CHEMBL3604890; SCHEMBL18341044; AKOS000202582	.	.	.	28370604	.	.	.
DRG00401	5-formyl-2-hydroxy-N-[4-(trifluoromethyl)phenyl]benzamide	.	Antibacterial	CHEMBL5269985; TWEKINRRQYBGSQ-UHFFFAOYSA-N; OCID190132366247	.	.	.	162613323	.	.	.
DRG00402	2-(2-Nitro-1H-imidazol-1-yl)acetic acid	.	Radionucleotides	"2-(2-Nitro-1H-imidazol-1-yl)acetic acid; 22813-32-7; 2-(2-Nitroimidazol-1-yl)acetic acid; NSC302988; MLS003115771; MFCD12022607; NSC-302988; 1H-Imidazole-1-acetic acid, 2-nitro-; NCIStruc1_000016; NCIStruc2_000181; SCHEMBL3914305; CHEMBL1741825; DTXSID20316397; TYDGDUVFDYKZMY-UHFFFAOYSA-N; XAA81332; (2-nitro-imidazol-1-yl)acetic acid; CCG-38321; NCGC00014673; NCI302988; (2-nitro-imidazol-1-yl) acetic acid; AKOS006317718; NCGC00014673-02; NCGC00097776-01; AS-63970; NCI60_002558; SMR001831337; SY358306; (2-NITROIMIDAZOL-1-YL)ACETIC ACID; 2-(2-Nitro-1H-imidazol-1-yl)aceticacid; 2-(2-nitro-1H-imidazol-1-yl)-acetic acid; CS-0155608; C74175; A925486; (2-(hydroxy(oxido)amino)-1H-imidazol-1-yl)acetic acid"	.	.	.	327544	.	.	.
DRG00403	Fluconazole	Fluconazole	Anti-infection drug	"fluconazole; 86386-73-4; Diflucan; Triflucan; Biozolene; Elazor; Fluconazol; Biocanol; Zoltec; Fluconazolum; Flucazol; Flucostat; Fungata; difluconazole; Flukezol; Flunizol; Pritenzol; Alflucoz; Cryptal; Dimycon; Oxifugol; Baten; Canzol; Forcan; Mutum; Syscan; Zemyc; 2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol; 2-(2,4-DIFLUOROPHENYL)-1,3-DI(1H-1,2,4-TRIAZOL-1-YL)PROPAN-2-OL; UK 49858; Flunazol; UK-49858; Alkanazole; Triconal; Fluconazolum [Latin]; DRG-0005; 2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1-yl)propan-2-ol; Fluconazoli; CCRIS 7211; HSDB 7420; DIFLUCAN IN SODIUM CHLORIDE 0.9%; UNII-8VZV102JFY; 123631-92-5; 8VZV102JFY; Fluconazole in sodium chloride 0.9%; NSC-758661; Fluconazole [USAN]; 1H-1,2,4-Triazole-1-ethanol, alpha-(2,4-difluorophenyl)-alpha-(1H-1,2,4-triazol-1-ylmethyl)-; DTXSID3020627; CHEBI:46081; DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER; UK-49,858; BAYT006267; BAYT-006267; Fluconazole in dextrose 5% in plastic container; MFCD00274549; Zonal; CHEMBL106; 2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)-2-propanol; 2,4-Difluoro-alpha,alpha-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol; DTXCID10627; Fluconazole in sodium chloride 0.9% in plastic container; DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER; 2-(2,4-Difluorophenyl)-1,3-di-1H-1,2,4-triazol-1-ylpropan-2-ol; Fluzon (Antifungal); Fluzon [Antifungal]; alpha-(2,4-Difluorophenyl)-alpha-(1H-1,2,4-triazol-1-ylmethyl)-1H-1,2,4-triazole-1-ethanol; Fluconazolum (Latin); NSC 758661; Fluconazole [USAN:USP:INN:BAN:JAN]; NCGC00095089-01; Fluconazol [Spanish]; Loitin; FLUCONAZOLE (MART.); FLUCONAZOLE [MART.]; C13H12F2N6O; FLUCONAZOLE (USP-RS); FLUCONAZOLE [USP-RS]; FLC; Diflazon; FLUCONAZOLE (EP MONOGRAPH); FLUCONAZOLE [EP MONOGRAPH]; Fuconal; Trican; FLUCONAZOLE (USP MONOGRAPH); FLUCONAZOLE [USP MONOGRAPH]; 2-(2,4-DIFLUORFENYL)-1,3-BIS(1H-1,2,4-TRIAZOOL-1-YL)PROPAAN-2-OL; Fluconazole (USAN:USP:INN:BAN:JAN); Diflucan (TN); SMR000471882; CAS-86386-73-4; FLCZ; Fluconazole & hGCSF; SR-01000765440; fluconazolo; Biozole; Flucoral; Fluconazole & MC-510,011; Fluconazole (f); Fluconazole,(S); Expel-F; Fluconazole- Bio-X; KS-1059; AF01 - Antifungals; Fluconazole in combination with MGCD290; Spectrum_001654; FLUCONAZOLE [MI]; Spectrum2_001607; Spectrum3_001912; Spectrum4_000090; Spectrum5_001277; FLUCONAZOLE [INN]; FLUCONAZOLE [JAN]; F0677; FLUCONAZOLE [HSDB]; MGCD290 and Fluconazole; FLUCONAZOLE [VANDF]; cid_3365; MG-3290 and Fluconazole; SCHEMBL3151; Fluconazole, Sodium Chloride; BSPBio_003504; FLUCONAZOLE [WHO-DD]; FLUCONAZOLE [WHO-IP]; KBioGR_000360; KBioSS_002134; MLS001066394; MLS001165780; MLS001195645; MLS001304713; MLS001306492; MLS006011884; BIDD:GT0799; DivK1c_001030; SPECTRUM1503975; Fluconazole in Sodium Chloride; SPBio_001613; Fluconazole (JP17/USP/INN); BDBM25817; HMS503M21; KBio1_001030; KBio2_002134; KBio2_004702; KBio2_007270; KBio3_003009; D01AC15; FLUCONAZOLE [ORANGE BOOK]; J02AC01; NINDS_001030; HMS1922O10; HMS2090I20; HMS2093M21; HMS2230O22; HMS3259H13; HMS3373I19; HMS3654P15; HMS3715F21; HMS3748G19; Pharmakon1600-01503975; FLUCONAZOLI [WHO-IP LATIN]; AMY23415; BCP28522; Fluconazole 2.0 mg/ml in Methanol; HY-B0101; 1,2,4-triazol-1-yl)propan-2-ol; Tox21_111419; Tox21_202240; Tox21_300581; 2-(2,4-Difluoro-phenyl)-1,3-bis-[1,2,4]triazol-1-yl-propan-2-ol; AC-428; BBL005614; CCG-39065; DL-407; Fluconazole & Human recombinant granulocyte colony stimulating factor; NSC754343; NSC758661; s1331; STK619301; AKOS000280854; Tox21_111419_1; CS-1835; DB00196; Fluconazole, >=98% (HPLC), powder; NC00650; NSC-754343; IDI1_001030; NCGC00095089-02; NCGC00095089-04; NCGC00095089-05; NCGC00095089-06; NCGC00095089-07; NCGC00095089-08; NCGC00095089-09; NCGC00095089-10; NCGC00095089-11; NCGC00254412-01; NCGC00259789-01; 1ST10047; 2-(2,4-difluorophenyl)-1,3-di(1H-; BF164466; Fluconazole 100 microg/mL in Acetonitrile; SBI-0051880.P002; UK-049858; NS00000281; SW199616-2; EN300-53634; C07002; D00322; AB00052399-07; AB00052399-08; AB00052399_09; AB00052399_10; A841625; Q411478; Q-201120; SR-01000765440-2; SR-01000765440-4; SR-01000765440-8; UK-49858;UK 49858;UK49858; BRD-K05977355-001-02-6; BRD-K05977355-001-09-1; BRD-K05977355-001-18-2; BRD-K05977355-001-19-0; BRD-K05977355-001-23-2; F2173-0496; Z235354561; Fluconazole, European Pharmacopoeia (EP) Reference Standard; 2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1-yl)-2-propanol; Fluconazole, United States Pharmacopeia (USP) Reference Standard; 2-[2,4-bis(fluoranyl)phenyl]-1,3-bis(1,2,4-triazol-1-yl)propan-2-ol; Fluconazole, Pharmaceutical Secondary Standard; Certified Reference Material; 2,4-DIFLUORO-1',1'-BIS(1H-1,2,4-TRIAZOL-1-YLMETHYL)BENZYL ALCOHOL; a-(2,4-Difluorophenyl)-a-(1H-1,2,4-triazol-1- ylmethyl)-1H-1,2,4-triazole-1-ethanol; Fluconazole for peak identification, European Pharmacopoeia (EP) Reference Standard; .alpha.-(2,4-Difluorophenyl)-.alpha.-(1H-1,2,4-triazol-1-ylmethyl)-1H-1,2,4-triazole-1-ethanol; 1H-1,2,4-Triazole-1-ethanol, .alpha.-(2,4-difluorophenyl)-.alpha.-(1H-1,2,4-triazol-1-ylmethyl)-; 1H-1,2,4-TRIAZOLE-1-ETHANOL, 1-(2,4-DIFLUOROPHENYL)-1-(1H-1,2,4-TRIAZOL-1-YLMETHYL)-"	TAR10058	Lanosterol 14-alpha demethylase (ERG11)	P10613	3365	D09LNI	DB00196	CHEMBL106
DRG00404	13-Aminomethyl-15-thiomatrin	.	Anti-osteoporosis drugs	.	.	.	.	.	.	.	.
DRG00405	10-Hydroxycamptothecin	10-Hydroxycamptothecin	Cytotoxic drugs	"10-Hydroxycamptothecin; 19685-09-7; (S)-10-Hydroxycamptothecin; Hydroxycamptothecin; 10-hydroxycamptothecine; 10-Hydroxy camptothecin; (S)-4-Ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; Hydroxycamptothecine; (4S)-4-Ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; Camptothecin, hydroxy-; Camptothecine, 10-hydroxy-; 10-HCPT; 10-Hydroxy-Camptothecin; NSC107124; NSC-107124; CHEMBL273862; CHEBI:81395; 9Z01632KRV; Hydroxy camptothecine; MFCD02093100; (S)-4-ethyl-4,9-dihydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione; Camptothecin, 10-hydroxy-; (20S)-4-Ethyl-4,9-dihydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione; (S)-4-Ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione ((S)-10-Hydroxycamptothecin); NSC 107124; (S)-10-Hydroxycamptothecin hydrate; UNII-9Z01632KRV; CAMPTOTHECIN, 10-HYDROXY; 10-Hydroxy-CPT; Spectrum_001639; (+)-(S)-10-HYDROXYCAMPTOTHECIN; SpecPlus_000763; Spectrum2_001660; Spectrum3_001621; Spectrum4_001815; Spectrum5_000549; ethyl(dihydroxy)[?]dione; SCHEMBL25875; BSPBio_003281; KBioGR_002454; KBioSS_002119; 1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4,9-dihydroxy-, hydrate, (S)-; DivK1c_006859; SPECTRUM1504123; SPBio_001819; KBio1_001803; KBio2_002119; KBio2_004687; KBio2_007255; KBio3_002501; DTXSID00941444; EX-A988; BCP01385; HY-N0095; (+)-10-HYDROXYCAMPTOTHECIN; BDBM50008922; CCG-38770; s2423; s3898; AKOS015919293; AC-5502; BCP9000058; CS-5193; DB12385; 10-HYDROXYCAMPTOTHECIN [WHO-DD]; NCGC00095986-01; NCGC00095986-02; NCGC00095986-03; NCGC00095986-04; NCGC00178165-01; 1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione-,4-ethyl-4,9-dihydroxy-, (S)-; AC-13221; AS-13196; NCI60_000173; SY010687; H1463; NS00018317; A25382; C17939; EN300-19810684; SR-05000002620; Q-100241; SR-05000002620-1; BRD-K63784565-001-02-1; BRD-K63784565-001-03-9; BRD-K63784565-001-05-4; BRD-K63784565-001-06-2; Q27155328; Z3093896188; 4-Ethyl-4,9-dihydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione; (19S)-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione; (19S)-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione; (S)-10-Hydroxycamptothecin;-;(+/-)-4-ethyl-4,9-dihydroxy-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4h,12h)-dione; (S)-4-Ethyl-4,9-dihydroxy-1H-pyrano[3 inverted exclamation mark ,4 inverted exclamation mark :6,7]indolizino[1,2-b]quinoline-3,14-(4H,12H)-dione; (S)-4-Ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14-(4H,12H)-dione; 1H-PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLINE-3,14(4H,12H)-DIONE, 4-ETHYL-4,9-DIHYDROXY-, (4S)-; 1H-Pyrano[3',7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione-,4-ethyl-4,9-dihydroxy-, (S)-; 4-Ethyl-4,10-dihydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione; 4-Ethyl-4,9-dihydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione (10-hydroxycamptothecin)"	TAR10008	DNA topoisomerase 1 (TOP1)	P11387	97226	D07ILP	.	CHEMBL273862
DRG00406	Monastrol	Monastrol	Cytotoxic drugs	"monastrol; 329689-23-8; 254753-54-3; DL-Monastrol; ETHYL 4-(3-HYDROXYPHENYL)-6-METHYL-2-THIOXO-1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBOXYLATE; 4-(3-Hydroxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydro-4H-pyrimidin-5-carboxylic Acid Ethyl Ester; ethyl 4-(3-hydroxyphenyl)-6-methyl-2-sulfanylidene-3,4-dihydro-1H-pyrimidine-5-carboxylate; CHEBI:75382; ethyl 4-(3-hydroxyphenyl)-6-methyl-2-sulfanylidene-1,2,3,4-tetrahydropyrimidine-5-carboxylate; (+/-)-Monastrol; 5-Pyrimidinecarboxylic acid,1,2,3,4-tetrahydro-4-(3-hydroxyphenyl)-6-methyl-2-thioxo-, ethyl ester; SR-01000357662; Monastrol?; ()-Monastrol; MFCD00813077; ( inverted exclamation markA)-Monastrol; (A+/-)-Monastrol; Probes1_000001; Probes1_000042; Probes1_000312; Probes2_000257; Probes2_000376; Lopac0_000821; Oprea1_487786; BSPBio_001273; CBDivE_015834; KBioGR_000613; KBioSS_000613; MLS006011746; C18H23NO3S; F3284-6466; SCHEMBL3168349; BCBcMAP01_000162; KBio2_000613; KBio2_003181; KBio2_005749; KBio3_001085; KBio3_001086; DTXSID10388124; CHEBI:143544; LOBCDGHHHHGHFA-UHFFFAOYSA-N; BDBM175356; Bio1_000459; Bio1_000948; Bio1_001437; Bio2_000467; Bio2_000947; DTXSID501317756; GLXC-04725; HMS1362O15; HMS1792O15; HMS1990O15; HMS3267N03; HMS3403O15; HMS3412E20; HMS3676E20; BCP06757; BCP19385; EX-A1988; EX-A4169; GR-322; HB2551; MFCD06762956; NSC716782; NSC829695; s8439; STK386781; ZINC00297106; Monastrol, >=98% (HPLC), solid; AKOS000295413; AKOS002264887; AKOS016068396; AKOS016315550; CCG-267397; CS-6183; HY-101071A; NSC-716782; NSC-829695; IDI1_002222; SMP1_000197; UPCMLD0ENAT5762435:001; NCGC00025103-01; NCGC00025103-02; NCGC00025103-03; NCGC00025103-04; AC-33010; AS-74678; NCI60_040353; SMR004703468; DB-048305; D84039; M 8515; EN300-1266062; A902103; J-016007; Q6898425; SR-01000357662-1; SR-01000357662-2; BRD-A78377521-001-02-2; BRD-A78377521-001-03-0; BRD-A78377521-001-05-5; Z57061994; 5-[[4-[(1-Methylcyclohexyl)methoxy] phenyl]methyl]-2,4-thiazolidinedione; Ethyl 4-(3-hydroxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydro-4H-pyrimidin-5-carboxylate; ethyl 4-(3-hydroxyphenyl)-6-methyl-2-thioxo-3,4-dihydro-1H-pyrimidine-5-carboxylate; ethyl 6-(3-hydroxyphenyl)-2-mercapto-4-methyl-1,6-dihydropyrimidine-5-carboxylate; ethyl 6-methyl-4-(3-hydroxyphenyl)-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate; rac-ethyl 4-(3-hydroxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate; 6-Methyl-4-(3-hydroxyphenyl)-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid ethyl ester; Ethyl 4-(3-hydroxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (11)"	TAR10059	Kinesin-like protein KIF11 (KIF11)	P52732	2987927	D0ZK2G	DB04331	CHEMBL236789
DRG00407	Combretastatin A4	Combretastatin A4	Cytotoxic drugs	"Combretastatin A4; 117048-59-6; Combretastatin A-4; Combrestatin A4; (Z)-2-METHOXY-5-(3,4,5-TRIMETHOXYSTYRYL)PHENOL; Combretastatin 4; Combretastatin-A4; CA-4; 2'-deoxycombretastatin A1; NSC-613729; 2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenol; Crc 87-09; CHEMBL67; MFCD03453309; 3,4,5-Trimethoxy-3'-hydroxy-4'-methoxystilbene; NSC-817373; 16U6OP69RQ; Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-; CA4; 2-Methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenol; 2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)vinyl]phenol; 2-Methoxy-5-[(Z)-2-(3,4,5-trimethoxy-phenyl)-vinyl]-phenol; Phenol, 2-methoxy-5-(2-(3,4,5-trimethoxyphenyl)ethenyl)-, (Z)-; NSC 817373; Crc-98-09; UNII-16U6OP69RQ; combretastin A4; Combrestatin A-4; Combretastin A-4; combretastatin-A-4; Combretastastin A-4; NSC 609397; NSC 613729; 2-methoxy-5-(3,4,5-trimethoxystyryl)phenol; Z-Combretastatin A-4; 2-Methoxy-5-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-phenol; SCHEMBL18945; combretastatin A-4, (CSA4); CA 4; GTPL8854; COMBRETASTATIN A-4 [MI]; CHEBI:181391; DTXSID101025983; GLXC-02861; HMS3650G11; AMY24892; COMBRETASTATIN A4 [WHO-DD]; EX-A4207; HY-N2146; BDBM50005480; s7783; AKOS015950727; AC-5280; CCG-265026; CS-6023; DB14680; DS-5860; Phenol,4,5-trimethoxyphenyl)ethenyl]-; ST-1986; C2520; Combretastatin A4, >=98% (HPLC), powder; NS00116331; 5-(3,4,5-trimethoxystyryl)-2-methoxyphenol; C20268; 3'-Hydroxy-3,4,4',5-tetramethoxy-cis-stilbene; EN300-1587417; (Z)-5-(3,4,5-trimethoxystyryl)-2-methoxyphenol; SR-01000946784; (Z)-3''-hydroxy-3,4,4'',5-tetramethoxystilbene; Q5150955; SR-01000946784-1; BRD-K61195623-001-01-4; Z2312943638; [3,4,5-trimethoxy-3'-hydroxy-4'-methoxy-(z)-stilbene]; 2-Methoxy-5-[(Z)-2-(3,4,5-trimethox y-phenyl)-vinyl]-phenol; (combretastin A-4)2-Methoxy-5-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-phenol; 5-[(S)-2-Hydroxy-2-(3,4,5-trimethoxy-phenyl)-ethyl]-2-methoxy-phenol; (combretastatin A-4)2-Methoxy-5-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-phenol; 1-(3,4,5-Trimethoxyphenyl)-2-(3'-hydroxy-4'-methoxyphenyl) ethane 3,4,5-trimethoxy-3'-hydroxy-4'-methoxystilbene"	TAR10017	Microtubule (MT)	.	5351344	.	.	CHEMBL67
DRG00408	Salinomycin	.	Cytotoxic drugs	.	.	.	.	.	.	.	.
DRG00409	"3-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanoic acid"	.	Albumin coupling agent	.	TAR10061	Human serum albumin	.	.	.	.	.
DRG00410	Gefitinib	.	Cytotoxic drugs	"Gefitinib; 184475-35-2; Iressa; ZD1839; Irressat; N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; ZD 1839; ZD-1839; gefitinib (zd1839); N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine; gefitinibum; CCRIS 9011; UNII-S65743JHBS; Gefitinib (GMP); NSC-759856; N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; S65743JHBS; DTXSID8041034; CHEBI:49668; 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; MFCD04307832; CHEMBL939; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine; DTXCID6021034; NSC715055; NSC 759856; Gefitinib [USAN]; NCGC00159455-02; GEFITINIB (MART.); GEFITINIB [MART.]; N-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; 3-Chloro-4-Fluoro-N-[(4z)-7-Methoxy-6-(3-Morpholin-4-Ylpropoxy)quinazolin-4(1h)-Ylidene]aniline; C22H24ClFN4O3; GEFITINIB (EP MONOGRAPH); GEFITINIB [EP MONOGRAPH]; 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-; Iressa(TM); IRE; Iressa (TN); CAS-184475-35-2; SR-00000000262; Gefitinib (JAN/USAN/INN); Gefitinib [USAN:INN:BAN]; Gefitini; Iressa; 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine; Iressa (AstraZeneca); nchembio866-comp14; Kinome_3321; Kinome_3322; GEFITINIB [INN]; GEFITINIB [JAN]; GEFITINIB [MI]; GEFITINIB [VANDF]; Gefitinib (ZD1839)?; GEFITINIB [WHO-DD]; SCHEMBL7866; Gefitinib,ZD-1839,Iressa; GEFITINIB [EMA EPAR]; KBioSS_002241; MLS003899193; CU-00000000396-1; BDBM5447; cid_123631; GTPL4941; GEFITINIB [ORANGE BOOK]; Gefitinib, >=98% (HPLC); L01XE02; BCPP000221; HMS2089B19; HMS3244M21; HMS3244M22; HMS3244N21; HMS3295A21; HMS3413H08; HMS3654A07; HMS3677H08; HMS3714A05; HMS3748E17; Pharmakon1600-01502274; BCP01365; Tox21_111683; HY-50895G; NSC759856; NSC800105; s1025; STK621310; AKOS000280752; Tox21_111683_1; AB20814; AC-1556; BCP9000718; CCG-220642; CS-0124; DB00317; KS-1204; NSC-715055; NSC-800105; 4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-(3-morpholinopropoxy)quinazoline; 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-4-morpholin)propoxy)-; 6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine; NCGC00159455-03; NCGC00159455-04; NCGC00159455-05; NCGC00159455-06; NCGC00159455-08; NCGC00159455-09; NCGC00159455-14; BCB03_000781; BG164498; HY-50895; SMR002204119; SY002154; AM20090619; CS-0622782; G0546; NS00006312; SW199108-4; D01977; EN300-123024; G-4408; K00240; AB01273954-01; AB01273954-02; AB01273954-03; AB01273954_04; A812870; Q417824; Q-201149; SR-00000000262-2; SR-00000000262-3; BRD-K64052750-001-16-7; BRD-K64052750-001-17-5; BRD-K64052750-001-22-5; BRD-K64052750-001-23-3; Gefitinib, EuropePharmacopoeia (EP) Reference Standard; Z1546610485; 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)-quinazoline; Gefitinib for system suitability, EuropePharmacopoeia (EP) Reference Standard; (3-CHLORO-4-FLUORO-PHENYL)-[7-METHOXY-6-(3-MORPHOLIN-4-YL-PROPOXY)-QUINAZOLIN-4-YL]-AMINE"	TAR10004	Epidermal growth factor receptor (EGFR)	P00533	123631	D09XZB	.	.
DRG00411	"5-(4-Hydroxy-phenyl)-10,15,20-triphenylporphyrin"	.	Cytotoxic drugs	.	.	.	.	.	.	.	.
DRG00412	Ortho carborane	.	Cytotoxic drugs	.	.	.	.	.	.	.	.
DRG00413	Etoposide	.	Cytotoxic drugs	"etoposide; VePesid; 33419-42-0; Toposar; trans-Etoposide; (-)-Etoposide; Lastet; Zuyeyidal; Etoposidum; Etoposido; Etoposidum [INN-Latin]; VP-16; Etoposide (VP16); VP 16 (pharmaceutical); Sintopozid; Vepesid J; VP-16-213; VP 16-213; Etoposido [INN-Spanish]; 4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside; NK 171; CCRIS 2392; NSC-141540; DTXSID5023035; HSDB 6517; UNII-6PLQ3CP4P3; EINECS 251-509-1; 6PLQ3CP4P3; 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside); EPEG; CHEBI:4911; Epipodophyllotoxin VP-16213; Etoposide (VP-16); VP 16; 4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin; CHEMBL44657; Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside); Epipodophyllotoxin-beta-D-ethyliden-glucoside, 4'-demethyl-; Eposide; DTXCID601473876; Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside; 4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside); NSC 141540; Etoposide [USAN:USP:INN:BAN:JAN]; Etosid; ETOPOSIDE (IARC); ETOPOSIDE [IARC]; Etoposidum (INN-Latin); Etoposido (INN-Spanish); ETOPOSIDE (MART.); ETOPOSIDE [MART.]; ETOPOSIDE (USP-RS); ETOPOSIDE [USP-RS]; (5S,5aR,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside; Etopophos (phosphate salt); ETOPOSIDE (EP IMPURITY); ETOPOSIDE [EP IMPURITY]; ETOPOSIDE (EP MONOGRAPH); ETOPOSIDE (USP IMPURITY); ETOPOSIDE [EP MONOGRAPH]; ETOPOSIDE [USP IMPURITY]; ETOPOSIDE (USP MONOGRAPH); ETOPOSIDE [USP MONOGRAPH]; Etopol; Prestwick 211; Demethylepipodophyllotoxin-beta-D-ethylideneglucoside; VP 16213; MFCD00869325; NSC141540; Etoposide (USAN:USP:INN:BAN:JAN); (10R,11R,15R,16S)-16-{[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-hexahydro-2H-pyrano[3,2-d][1,3]dioxin-6-yl]oxy}-10-(4-hydroxy-3,5-dimethoxyphenyl)-4,6,13-trioxatetracyclo[7.7.0.0^{3,7}.0^{11,15}]hexadeca-1(9),2,7-trien-12-one; 9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one; SMR000112002; VePESID (TN); 4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside; Demethyl Epipodophyllotoxin Ethylidine Glucoside; Etoposide,(S); NCGC00016821-01; (5R,5aR,8aR,9S)-9-(((4aR,6R,7R,8R,8aS)-7,8-Dihydroxy-2-methylhexahydropyrano[3,2-d][1,3]dioxin-6-yl)oxy)-5-(4-hydroxy-3,5-dimethoxyphenyl)-5,5a,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(8H)-one; (5S,5aR,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol -5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside; EVP; Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 9-[[4,6-O-(1R)-ethylidene-.beta.-D-glucopyranosyl]oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-, (5R,5aR,8aR,9S)-; CAS-33419-42-0; Etoposide; VP-16; CPD000112002; ETOPOSIDE [INN]; ETOPOSIDE [JAN]; ETOPOSIDE [MI]; ETOPOSIDE [HSDB]; ETOPOSIDE [USAN]; Prestwick3_000396; ETOPOSIDE [VANDF]; 4'-Demethylepipodophyllotoxin ethylidene-beta-D-glucoside; ETOPOSIDE [WHO-DD]; ETOPOSIDE [WHO-IP]; SCHEMBL4259; BSPBio_000611; 9-((4,6-O-Ethylidene-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one, (5R-(5alpha,5abeta,8aalpha,9beta(R*)))-; 9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4- hydroxy-3,4-dimethyloxyphenyl)furo (3',4'':6,7) naptho-(2,3-d)-1,3-dioxol-6 (5aH)-one; MLS000049957; MLS001074951; MLS001424283; MLS002153463; MLS002207239; MLS002222184; Etoposide (JP17/USP/INN); BPBio1_000673; GTPL6815; ETOPOSIDE [ORANGE BOOK]; L01CB01; ETOPOSIDUM [WHO-IP LATIN]; HMS2052N05; HMS2089F14; HMS2096O13; HMS2232L03; HMS3713O13; (5R,5aR,8aR,9S)-9-[[4,6-O-(1R)-Ethylidene-beta-D-glucopyranosyl]oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one; EPE; EX-A1207; Tox21_110630; Tox21_302201; BDBM50127140; s1225; Etoposide - CAS 33419-42-0; AKOS007930275; BCP9000669; CCG-101165; CS-1774; DB00773; Etoposide, synthetic, >=98%, powder; NC00415; SDCCGSBI-0050405.P002; 4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside; NCGC00179504-02; NCGC00255126-01; (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one; AS-35312; BE164434; Furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one, 9-((4,6-O-(1R)-ethylidene-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-, (5R,5aR,8aR,9S)-; Furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one-, 9-((4,6-O-ethylidene-beta-D-glucopyranosyl)oxy)5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl), (5R-(5alpha,5abeta,8aalpha,9beta(R*)))-; HY-13629; ETOPOSIDE IMPURITY C (EP IMPURITY); SBI-0051910.P002; AB00438905; NS00009585; EN300-97099; C01576; D00125; AB00438905-17; AB00438905-18; AB00438905_19; Q418817; SR-01000763196; SR-01000763196-3; BRD-K37798499-001-02-5; BRD-K37798499-001-05-8; BRD-K37798499-001-10-8; BRD-K37798499-001-14-0; BRD-K37798499-001-18-1; BRD-K37798499-001-21-5; BRD-K37798499-001-22-3; BRD-K37798499-001-25-6; BRD-K37798499-001-27-2; -5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside; Etoposide, British Pharmacopoeia (BP) Reference Standard; Z1304065033; Etoposide, European Pharmacopoeia (EP) Reference Standard; Etoposide, United States Pharmacopeia (USP) Reference Standard; 4''-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside); 4'-DEMETHYLEPIPODOPHYLLOTOXIN 9-(4,6-O-(R)-ETHYLIDENE-.BETA.-D-GLUCOPYRANOSIDE); Etoposide for system suitability, European Pharmacopoeia (EP) Reference Standard; (5R,5AR,8aR,9S)-9-(((2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methylhexahydropyrano[3,2-d][1,3]dioxin-6-yl)oxy)-5-(4-hydroxy-3,5-dimethoxyphenyl)-5,5a,8a,9-tetrahy; (5R,5aR,8aR,9S)-9-(((2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methylhexahydropyrano[3,2-d][1,3]dioxin-6-yl)oxy)-5-(4-hydroxy-3,5-dimethoxyphenyl)-5,5a,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(8H)-one; (5R,5AR,8AR,9S)-9-((4,6-O-((1R)-ETHANE-1,1-DIYL)-.ALPHA.-D-GLUCOPYRANOSYL)OXY)-5-(4-HYDROXY-3,5-DIMETHOXYPHENYL)-5,8,8A,9-TETRAHYDRO(2)BENZOFURO(5,6-F)(1,3)BENZODIOXOL-6(5AH)-ONE; (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxy-phenyl)-5a,6,8a,9-tetrahydro-5H-isobenzofuro[5,6-f][1,3]benzodioxol-8-one; (5S,5aR,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3'',4'':6,7]naphtho[2,3-d][1,3]dioxol-5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside; 121471-01-0; 9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3'',4'''':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one; FURO(3',4':6,7)NAPHTHO(2,3-D)-1,3-DIOXOL-6(5AH)-ONE-, 9-((4,6-O-ETHYLIDENE-.BETA.-D-GLUCOPYRANOSYL)OXY)5,8,8A,9-TETRAHYDRO-5-(4-HYDROXY-3,5-DIMETHOXYPHENYL), (5R-(5.ALPHA.,5A.BETA.,8A.ALPHA.,9.BETA.(R*)))-"	TAR10002	DNA topoisomerase 2-alpha (TOP2A)	P11388	36462	D0B7EB	.	.
DRG00414	Vivotag 680 XL	.	Fluorescent dye	.	.	.	.	.	.	.	.